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ABSTRACT 
 Cellular immortality is one of the ten hallmarks of human cancer and has been shown to 
be an essential prerequisite for malignant progression (Hanahan and Weinberg., 2011, Newbold 
et al., 1982, Newbold and Overell., 1983). In contrast, normal human somatic cells proliferate 
for a limited number of population doublings before entering permanent growth arrest known as 
replicative senescence. This is thought to be due to the progressive shortening of telomeric 
sequences with each round of cell division. Over 90% of human tumours, but not the majority 
of human somatic cells, have been found to express telomerase activity (Kim et al., 1994). The 
rate-limiting component of the human telomerase enzyme is the telomerase reverse transcriptase 
subunit, which is encoded by the hTERT gene. Transfection of hTERT cDNA into normal 
human fibroblasts and epithelial cells may sometimes be sufficient to confer cellular 
immortality (Newbold., 2005, Stampfer and Yaswen., 2002). Therefore, de-repression of hTERT 
and telomerase re-activation are thought to be critical events in human carcinogenesis and is the 
predominant mechanism by which cancer cells maintain their proliferative capacity.  
 Previously, our group has shown that introduction of a normal, intact copy of human 
chromosome 3 into the 21NT primary breast cancer cell line by microcell-mediated 
monochromosome transfer (MMCT), is associated with strong telomerase repression and 
induction of cell growth arrest within the majority of hybrid clones (Cuthbert et al., 1999). 
Structural mapping of chromosome 3 within telomerase-positive revertent clones revealed two 
regions of deletion: 3p21.3-p22 and 3p12-p21.1, thought to harbour the putative telomerase 
repressor sequence(s). Subsequent studies showed that the chromosome 3p-encoded telomerase 
repressor sequence(s) mediates its function by means of transcriptional silencing of hTERT, in 
part, through chromatin remodelling of two sites within intron 2 of the hTERT gene (Ducrest et 
al., 2001, Szutorisz et al., 2003). Attempts to achieve positional cloning of hTERT repressor 
sequences on chromosome 3p identified two interesting candidates; the histone 
methyltransferase SETD2 and an adjacent long non-coding RNA (lncRNA) sequence known as 
FLJ/KIF9-AS1 (Dr. T. Roberts, unpublished data). Through MMCT-mediated introduction of 
intact chromosomes 3 and 17 into the 21NT cell line, I have demonstrated that at least two as 
yet unidentified telomerase repressor sequences (one located on each of these two normal 
chromosomes) may function to repress telomerase activity within the same breast cancer cell 
line, which suggests that multiple, independent telomerase regulatory pathways may be 
inactivated within the same cancer type. Furthermore, by examining the consequences of forced 
SETD2 and FLJ expression within the 21NT cell line, together with siRNA-mediated 
knockdown of SETD2 within a single telomerase-repressed 21NT-chromosome 3 hybrid, I have 
provided evidence to show that neither of these two candidate genes may function as a regulator 
of hTERT transcription. Through interrogation of relevant literature, a set of four candidate 
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telomerase regulatory genes (BAP1, RASSF1A, PBRM1 and PARP-3) were selected for further 
investigation based on their location within the 3p21.1-p21.3 region together with their 
documented role in the epigenetic regulation of target gene expression. Using mammalian 
expression vectors containing candidate gene cDNA sequences, my colleague Dr. T. Roberts 
and I demonstrated that forced overexpression of BAP1 and PARP-3 within the 21NT cell line is 
associated with consistent, but not always sustained, repression of hTERT transcriptional 
activity and telomerase activity. It is therefore possible that at least two sequences may exist on 
chromosome 3p that function collectively to regulate hTERT expression within breast cancer 
cells. 
 Finally, using an in vitro model of human mammary epithelial cell (HMEC) 
immortalization, involving the targeted abrogation of two pathologically relevant genes, p16 
and p53 to generate a series of variant clones at different stages of immortal transformation 
(developed by my colleague Dr. H. Yasaei), I have shown that single copy deletions on 
chromosome 3p are a frequent, clonal event, specifically associated with hTERT de-repression 
and immortal transformation. Subsequent high-density single nucleotide polymorphism (SNP) 
array analysis of immortal variants carried out by Dr. H. Yasaei, identified a minimal common 
region of deletion localized to 3p14.2-p22. Together, these findings provide additional evidence 
to show that chromosome 3p may harbour critical hTERT repressor sequences, that are lost as 
an early event during breast carcinogenesis.         
 
  
4 
 
TABLE OF CONTENTS 
Abstract ........................................................................................................................................ 2 
Table of Contents ........................................................................................................................ 4 
List of Figures .............................................................................................................................. 8 
List of Tables ............................................................................................................................. 15 
Acknowledgements ................................................................................................................... 17 
Abbreviations ............................................................................................................................ 18 
1 General Introduction ........................................................................................................ 21 
1.1 Anatomy and Function of the Female Breast ............................................................... 21 
1.2 Breast Cancer ............................................................................................................... 22 
1.2.1 Subtypes and Classification ................................................................................ 22 
1.2.2 Disease Classification ......................................................................................... 27 
1.2.3 Epidemiology and Risk Factors .......................................................................... 31 
1.2.4 Symptoms, Screening and Diagnosis .................................................................. 40 
1.2.5 Treatment ............................................................................................................ 42 
1.3 Targeting Cellular Immortality as an Anti-Cancer Mechanism ................................... 47 
1.3.1 Replicative Lifespan of Normal and Tumour cells ............................................. 47 
1.3.2 Cellular Senescence as a Barrier to Immortality ................................................. 48 
1.3.3 Telomeres, Senescence and Cancer .................................................................... 50 
1.3.4 Telomerase and Cancer ....................................................................................... 59 
1.3.5 Regulation of Human hTERT ............................................................................. 61 
1.3.6 Telomeres, Telomerase and Breast Cancer ......................................................... 78 
1.3.7 Conflicting Views on the Origins of Telomerase in Cancer ............................... 86 
1.3.8 Telomerase-Independent Pathways of Telomere Maintenance in Cancer .......... 89 
1.3.9 Therapeutic Strategies for Targeting Telomerase ............................................... 93 
Aims and Objectives ................................................................................................................. 97 
2 General Materials and methods ....................................................................................... 98 
2.1 Cell Culture Manipulation ........................................................................................... 98 
2.1.1 General equipment for cell culture ...................................................................... 98 
2.1.2 Cell lines and  Culture conditions ....................................................................... 98 
2.1.3 Serial Sub-Cultivation of Cell Lines (Passaging) ............................................. 101 
2.1.4 Cryopreservation and Recovery of Cells .......................................................... 101 
2.1.5 Isolation and Propagation of Individual Cell Colonies/Clones ......................... 102 
2.1.6 Cell Number and Viability Estimation .............................................................. 102 
2.2 Genomic DNA Isolation and Quantification.............................................................. 103 
5 
 
2.3 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) ............................. 104 
2.3.1 RNA Extraction and Quantification .................................................................. 104 
2.3.2 Elimination of DNA from RNA Extracts.......................................................... 104 
2.3.3 Reverse Transcription of RNA to Complementary DNA (cDNA) ................... 105 
2.3.4 Gene Expression Analysis by qRT-PCR ........................................................... 105 
2.3.5 Gene Expression Quantification ....................................................................... 107 
2.4 Determination of Telomerase Activity ...................................................................... 108 
2.4.1 Protein Extraction and Quantification ............................................................... 108 
2.4.2 Telomere Repeat Amplification Protocol (TRAP) Assay ................................. 109 
2.4.3 Quantification of Telomerase Activity.............................................................. 110 
2.5 Gene Copy Number Variation (CNV) Analysis ........................................................ 112 
2.6 Cloning ....................................................................................................................... 114 
2.6.1 Transformation of Chemically-Competent E.coli with Plasmid Vectors.......... 114 
2.6.2 Preparation of Bacterial Glycerol Stocks .......................................................... 114 
2.6.3 Propagation of transformed E.coli .................................................................... 114 
2.6.4 Extraction and purification of plasmid DNA constructs from E.coli ................ 115 
2.7 Transfection of Target Genes Within the 21NT Cell Line ........................................ 115 
2.7.1 Transfection Procedure ..................................................................................... 115 
2.7.2 Transfection Efficiency ..................................................................................... 116 
2.7.3 Colony Forming Unit (CFU) Assay .................................................................. 117 
2.8 Statistical Formulae ................................................................................................... 118 
2.8.1 Population Doublings (PD) ............................................................................... 118 
3 The Use of Microcell-Mediated Monochromosome Transfer (MMCT) Techniques to 
Determine the Existence of Telomerase Repressor Sequences Located on Chromosomes 3 
and 17 within the 21NT Breast Cancer Cell Line ................................................................ 119 
3.1 Introduction ................................................................................................................ 119 
3.2 Materials and methods ............................................................................................... 122 
3.2.1 Microcell-Mediated Monochromosome Transfer (MMCT) Procedure ............ 122 
3.2.2 Telomerase Activity of 21NT-Hybrid and 21NT Cell Colonies ....................... 125 
3.2.3 Cell Growth and Replicative Potential .............................................................. 126 
3.3 Results and Discussion .............................................................................................. 127 
3.3.1 Telomerase Activity of 21NT-Neo3 and 21NT-HyTK17 hybrid colonies ....... 128 
3.3.2 The Relationship Between 21NT-Neo3 and 21NT-Hytk17 Hybrid Proliferation 
and Telomerase Activity ................................................................................................... 132 
3.4 Summary .................................................................................................................... 140 
4 Functional Investigation of the 3p21-linked sequences, SETD2 and FLJ, as 
Telomerase Repressor Genes in Breast Cancer cells ........................................................... 145 
4.1 Introduction ................................................................................................................ 145 
6 
 
4.2 Materials and Methods ............................................................................................... 149 
4.2.1 Characterisation of Breast Cancer Cell Lines and HMEC Cell Strains ............ 149 
4.2.2 SETD2 and FLJ Copy Number Variation (CNV) Analysis .............................. 151 
4.2.3 Over-Expression of SETD2 Within the 21NT Cell Line .................................. 152 
4.2.4 Transfection of FLJ into the 21NT Cell Line .................................................... 155 
4.2.5 siRNA-Mediated Knockdown of SETD2 ......................................................... 156 
4.2.6 Gene Expression Analysis of Treated 21NT cells ............................................ 157 
4.2.7 Determination of Telomerase Activity.............................................................. 157 
4.2.8 Chromosome 3 Arm-Specific Painting by Fluorescence in situ Hybridization 157 
4.3 Results and Discussion .............................................................................................. 159 
4.3.1 Exploring the Functional Role of SETD2 and FLJ in Breast Cancer Cells ...... 159 
4.3.2 Forced Overexpression of SETD2 within the 21NT Breast Cancer Cell Line . 169 
4.3.3 Knockdown of SETD2 Expression within a Single 21NT-Chromosome 3 Hybrid 
Clone (H3.5) ..................................................................................................................... 176 
4.3.4 Analysis of a Two Stable 21NT-FLJ Transfection Clones ............................... 183 
4.4 Summary .................................................................................................................... 186 
5 Exploring the Role of Tumour Suppressor Genes within the Chromosome 3p21.1-
p21.3 Region as Candidate Regulators of Telomerase in Breast Cancer ........................... 192 
5.1 Introduction ................................................................................................................ 192 
5.1.1 BAP1 ................................................................................................................. 193 
5.1.2 RASSF1A ......................................................................................................... 196 
5.1.3 PBRM1/BAF180 ............................................................................................... 200 
5.1.4 PARP-3 ............................................................................................................. 204 
5.2 Materials and Methods ............................................................................................... 206 
5.2.1 Gene Copy Number Variation Analysis (CNV) ............................................... 206 
5.2.2 Gene Expression Analysis ................................................................................ 206 
5.2.3 Transfection of Target Genes into the 21NT Breast Cancer Cell Line ............. 207 
5.2.4 Telomerase Activity .......................................................................................... 213 
5.3 Results and Discussion .............................................................................................. 214 
5.3.1 Candidate Gene Copy Number Variation and Expression Analysis within Normal 
HMEC Strains and Breast Cancer Cell Lines ................................................................... 214 
5.3.2 BAP1 as a Candidate Telomerase Repressor and Tumour Suppressor Gene in 
Breast Cancer Cells ........................................................................................................... 219 
5.3.3 RASSF1A as a Candidate Telomerase Repressor and Tumour Suppressor Gene 
in Breast Cancer Cells ....................................................................................................... 230 
5.3.4 PBRM1 as a Candidate Telomerase Repressor and Tumour Suppressor Gene in 
Breast Cancer Cells ........................................................................................................... 236 
5.4 Summary .................................................................................................................... 245 
7 
 
5.4.1 BAP1 ................................................................................................................. 245 
5.4.2 RASSF1A ......................................................................................................... 249 
5.4.3 PBRM1 ............................................................................................................. 252 
5.4.4 PARP-3 ............................................................................................................. 255 
6 Investigating Chromosome 3p Structure During the Multi-Step Process of Normal 
Human Mammary Epithelial Cell (HMEC) Immortalization ............................................ 259 
6.1 Introduction ................................................................................................................ 259 
6.2 Materials and Methods ............................................................................................... 263 
6.2.1 Cell Lines/Strains .............................................................................................. 263 
6.2.2 Gene Expression Analysis ................................................................................ 265 
6.2.3 Copy Number Variation (CNV) Analysis ......................................................... 265 
6.3 Results ........................................................................................................................ 266 
6.3.1 Characterization of HMEC 184D and Immortal Derivatives............................ 266 
6.3.2 Physical Mapping of Chromosome 3p Structure at Different Stages of HMEC 
Immortal Transformation .................................................................................................. 270 
6.4 Discussion .................................................................................................................. 274 
7 General Discussion and Future Work ........................................................................... 278 
7.1 Summary and Conclusion .......................................................................................... 286 
7.2 Future Work ............................................................................................................... 288 
7.2.1 Investigating the Role of SETD2 in Breast Cancer .......................................... 288 
7.2.2 Narrowing the Search for hTERT Repressor Sequences on Chromosome 3p in 
Breast Cancer Cells ........................................................................................................... 290 
8 References ........................................................................................................................ 293 
 
 
 
 
  
8 
 
LIST OF FIGURES  
Figure 1.1: Female mammary gland structure including the terminal ductal-lobular unit (TDLU) 
and the multi-layer architecture of the mammary ductal system.................................................21 
Figure 1.2: A cross-sectional view of the breast ductal lumen at various stages during the 
progression of invasive ductal carcinoma (IDC) and common molecular changes that occur....24 
Figure 1.3: Age-standardized incidence and mortality rates/100,000 females of breast cancer 
worldwide in 2012........................................................................................................................31 
Figure 1.4: Age-standardized mortality rates (per 100,000 females) for women in more 
developed and less developed regions between 1950-2012.........................................................33 
Figure 1.5: Breast cancer five-year relative survival rates for women in the USA between 2005-
2011 according to stage of disease at diagnosis...........................................................................35 
Figure 1.6: European age-standardized incidence and mortality rates/100,000 for (A) females 
and (B) males in the UK between 1975 and 2011. Average age-specific incidence rates for (C) 
females and (D) males in the UK between 2009 and 2011.....................................................36-37 
Figure 1.7: Schematic representations of (A) T-loop formation by invasion of the 3'-single 
stranded (ss) overhang into the double-stranded (ds) telomeric sequence to form a D-loop 
through base-pairing with the complementary C-rich strand. (B) Shelterin complex members 
and an example of their organization on the repetitive telomeric DNA sequence.......................50 
Figure 1.8: Schematic representations of (A) the structure of the hTERT protein subunit of 
telomerase showing the TEN (telomerase essential N-terminal domain), TRBD (telomerase 
RNA-binding domain), RT (reverse transcriptase), CTE (C-terminal extension) domains and 
conserved sequence motifs, (B) the human telomerase holoenzyme complex and (C) a 
simplified model for processive telomere elongation by telomerase...........................................53  
Figure 1.9: Schematic representation of the hTERT promoter and the approximate positions of 
activating and repressing cis-acting elements with known interacting proteins/factors..............62 
Figure 1.10: The structure of the human TERT (hTERT) gene with approximate positions of the 
TEN, TRBD, RT and CT functional domains. The open reading frames (ORF) of the full-length 
transcript and four splice variants α, β, INS3 and INS4, which have exons 6 and 7-8 deleted and 
intron 14 inserted respectively are indicated................................................................................74 
9 
 
Figure 1.11: Schematic representations of two models of alternative lengthening of telomeres 
(ALT) (A) unequal telomere sister chromatid exchange (T-SCE) and (B) homologous 
recombination (HR)-dependent DNA replication........................................................................91  
Figure 2.1: Standard calibration curve of BSA protein (2mg/ml) diluted in CHAPS lysis 
buffer..........................................................................................................................................108 
Figure 2.2: Representative amplification and standard curve plots of control samples and 
standards included in each qRT-PCR-based telomere repeat amplification protocol assay 
(TRAP). Baseline-corrected normalized relative fluorescence signals (ΔRn) of (A) Telomerase-
positive wild-type 21NT and normal human control samples, (B) heat-treated samples and 
CHAPs only non-template control (NTC), (C) serial-dilution standards of telomerized PC-3-
hTERT. (D) A typical standard curve plot of Ct values obtained from PC-3-hTERT serial 
dilution standards........................................................................................................................111  
Figure 2.3: Determination of transfection efficiency. Representative fluorescence microscopy 
images (x20 magnification) of three individual P60 dishes of 21NT cells (seeded at 2.5 x 10
5
 
cells/dish) 48 hours after they were transfected with a lentiviral vector-green fluorescent protein 
(LNV-GFP) plasmid vector construct using the Mirus Transfection Reagent protocol............117 
Figure 3.1: Representative photomicrographs of human: rodent monochromosome hybrid donor 
cells 48 hours after incubation with colcemid (x100 magnification). (A) A9-Neo3 hybrids 
incubated with 0.1µg/ml colcemid. (B) A9-Hytk17 hybrids incubated with 0.075µg/ml 
colcemid.....................................................................................................................................123   
Figure 3.2: Representative photomicrographs (magnification x100) of two 21NT-Hytk17 and 
one 21NT-Neo3 hybrid clone (s) harvested in situ, that displayed morphological characteristics 
of senescence..............................................................................................................................128 
Figure 3.3: Telomerase activity within (A) 21NT-Neo3 and (B) 21NT-Hytk17 hybrid clones 
generated, expressed as a percentage of parental 21NT cells. (C) Telomerase activity within 
nine individual 21NT clones relative to PC-3-hTERT (100%)...........................................130-131 
Figure 3.4: Average telomerase activity expressed as a percentage of wild-type 21NT cells 
within 21NT-Neo3 and 21NT-Hytk17 hybrid clones that entered growth arrest (either in situ or 
after they were picked) or proliferated continuously for 12-15PD after they were picked........133  
Figure 3.5: (A) Representative photomicrograph images of three 21NT-Neo3 and one 21NT-
Hytk17 hybrid(s) that entered growth arrest after they were picked. (B) Telomerase activity of 
all hybrids that entered growth arrest both in situ or after they were picked, expressed as a 
percentage of wild-type 21NT cells...........................................................................................135  
10 
 
Figure 3.6: Representative photomicrographs showing the cellular morphologies of (A) parental 
21NT cells, (B) one 21NT-Neo3 and one 21NT-Hytk17 continuously proliferating hybrid 
colony within similar growth rates to parental 21NT cells, (C) proliferating 21NT-Neo3 and 
21NT-Hytk17 hybrid colonies with a significant reduction in growth rate compared with 
parental 21NT cells. (D) The mean PD time over five serial passages and the relative telomerase 
activity of proliferating 21NT-Neo3 and 21NT-Hytk17 hybrid colonies...........................136-137  
Figure 3.7: Scatter plots showing the relationship between the mean population doubling time 
and relative telomerase activity of continuously proliferating (A) 21NT-Neo3 and (B) 21NT-
Hytk17 hybrid clones.................................................................................................................139  
Figure 4.1: A line graph showing the average expression stability (geNorm M) of seven 
endogenous control genes within normal human mammary epithelial cell (HMEC) strains and 
breast cancer cell lines following step-wise exclusion of the lease stable endogenous control 
gene.............................................................................................................................................151 
Figure 4.2: Physical map of the pCMVNeo vector (OriGene)...................................................152 
Figure 4.3: The position of DraIII restriction enzyme cleavage sites within pCMVNeo and 
pCMVNeo-SETD2 circular plasmid vector constructs..............................................................153 
Figure 4.4: Gel electrophoresis of DraIII-digested and undigested pCMVNeo-SETD2 vector 
constructs....................................................................................................................................154 
Figure 4.5: A physical map of the SETD2 transcript sequence and the relative positions of UTR 
sequences targeted by four siRNA constructs developed by Qiagen, 
NL...............................................................................................................................................156  
Figure 4.6: The normalized relative quantities (NRQ) of (A) SETD2 and (B) FLJ mRNA within 
a panel of eight breast cancer cell lines and three normal HMEC cell strains. (C) A scatter graph 
showing the relationship between SETD2 and FLJ expression levels within breast cancer cell 
lines (excluding BT474)......................................................................................................161-162 
Figure 4.7: (A) Copy number variation (CNV) analysis of SETD2 and FLJ gene loci within nine 
breast cancer cell lines and three normal HMEC strains. Mean NRQ values of (B) SETD2 and 
(C) FLJ mRNA within HMEC cell strains and breast cancer cell lines grouped by overall copy 
number at the SETD2-FLJ gene locus................................................................................165-166 
Figure 4.8: (A) Telomerase activity within HMEC cell strains and breast cancer cell lines 
relative to a telomerized prostate cancer cell line PC-3-hTERT. Scatter plots showing the 
relationship between (B) SETD2 NRQ values, (C) FLJ NRQ values and (D) allele copy number 
within the SETD2-FLJ locus within breast cancer cell lines examined..............................167-168  
11 
 
Figure 4.9: The NRQ of (A) SETD2 and (B) hTERT mRNA within stable 21NT-pCMVNeo and 
21NT-pCMVNeo-SETD2 colonies relative to the mean expression levels of two untreated 21NT 
cell samples. (C) Telomerase activity within stable 21NT-pCMVNeo and 21NT-pCMVNeo-
SETD2 clones expressed as a percentage of untreated 21NT cells.....................................170-171  
Figure 4.10: The NRQ of (A) SETD2 and (B) hTERT mRNA within 21NT cells 2-5 days 
following transient transfection of 21NT cells with pCMVNeo and pCMVNeo-SETD2 vector 
constructs, relative to untreated 21NT cells harvested on the same day. (C) A scatter plot 
showing the relationship between SETD2 and hTERT gene expression levels within 21NT cells 
transiently transfected with the pCMVNeo-SETD2 plasmid..............................................173-174 
Figure 4.11: (A) Photographs of eight P60 dishes containing fixed and stained stable (i) control 
21NT-pCMVNeo and (ii) target gene 21NT-pCMVNeo-SETD2 colonies that arose following 
two weeks of neomycin selection. (B) The mean number of 21NT-pCMVNeo and 21NT-
pCMVNeo-SETD2 colonies present across four individual dishes for each plasmid 
construct.....................................................................................................................................175 
Figure 4.12: The NRQ of hTERT mRNA within the HMEC 184 cell strain, pre-crisis H3.5E and 
post-crisis H3.5L hybrid clones relative to parental 21NT cells................................................177 
Figure 4.13: Representative fluorescence images (x100 magnification) of (A. i, ii) HMEC 184, 
(B. i, ii) 21NT, (C. i, ii) H3.5E and (D. i, ii) H3.5L cell lines/strain metaphase spreads 
hybridized with a chromosome 3 p-arm (green) and q-arm (red)-specific probes and 
counterstained with DAPI (blue)................................................................................................178  
Figure 4.14: (A) The NRQ of SETD2 mRNA within pre-crisis H3.5E and post-crisis H3.5L 
hybrid clones relative to parental 21NT cells. (B) CNV analysis of the SETD2-FLJ genomic 
locus within HMEC 184, parental 21NT cells, H3.5E and H3.5L hybrid clones......................180 
Figure 4.15: The NRQ of (A) SETD2 and (B) hTERT mRNA 48-96 hours post-transfection of 
H3.5E hybrid clones with non-targeting (NT) or a mixture of four SETD2-siRNA construct 
molecules relative to untreated (UT) H3.5E hybrids harvested on the day of transfection.......182 
Figure 4.16: The NRQ of FLJ mRNA within pre-crisis H3.5E and post-crisis H3.5L hybrid 
clones relative to parental 21NT cells........................................................................................183 
Figure 4.17: The NRQ of (A) FLJ and (B) hTERT mRNA within two stable 21NT-pCMVNeo 
and two stable 21NT-pCMVNeo-FLJ clones relative to untreated 21NT cells. (C) Telomerase 
activity within all stable empty vector control and target gene clones relative to untreated 21NT 
cells.............................................................................................................................................184 
12 
 
Figure 4.18: Kaplan-Meier relapse-free survival (RFS) analysis depending on SETD2 
expression of (A) all breast cancer subtypes (B) Estrogen receptor (ER)-negative breast cancers 
with p53 mutations and (C) ER-negative, progesterone receptor (PgR)-negative and human 
epidermal growth factor receptor 2 (HER2)-positive breast cancers.........................................190  
Figure 5.1: Gel electrophoresis of DNA fragments following restriction digest of (A) 
pCMV6AC-BAP1 with XhoI and EcoRI, (B) pcDNA3.1(+)-RASSF1A with HindIII and EcoRI. 
(C) (i) Relative positions of NotI and EcoRI restriction sites determined using the NEBcutter 
software program and expected fragment lengths (ii) Gel electrophoresis of DNA fragments 
following digestion of pBABEpuro-BAF180 with EcoRI and NotI...................................210-211  
Figure 5.2: Estimation of stable clone diameter. Representative photomicrograph images at 2.5x 
magnification of (A) 10mm reticule and (B) a single stable 21NT-pBABEpuro-BAF180 clone 
fixed and stained with Methyl Blue............................................................................................213 
Figure 5.3: Graphical representation of the approximate positions of selected candidate genes 
RASSF1A, PARP-3, BAP1, PBRM1 within the 3p21.1-p21.3 region of human chromosome 3 
and their locations relative to the SETD2-FLJ genomic locus...................................................214  
Figure 5.4: The NRQ of candidate genes (A) BAP1, (B) RASSF1 (C) PBRM1 and (D) PARP-3 
mRNA levels within a panel of nine breast cancer cell lines and three normal HMEC 
strains..................................................................................................................................216-217 
Figure 5.5: The NRQ of (A) BAP1 and (B) hTERT mRNA within stable empty vector control 
21NT-pCMVNeo and target gene 21NT-pCMVNeo-BAP1 transfection clones relative to the 
mean ± SD (standard deviation) of three untreated 21NT cell samples. (C) Telomerase activity 
within stable 21NT-pCMVNeo and 21NT-pCMVNeo-BAP1 transfection clones relative to 
untreated 21NT cells...........................................................................................................221-222 
Figure 5.6: (A) Cumulative number of population doublings (PD) of untreated 21NT cells, 
stable 21NT-pCMVNeo transfection clones 4 and 8 and stable 21NT-pCMVNeo-BAP1 
transfection clones 6 and 8 over five serial passages. (B) The mean PD time (hours) for all 
samples across five serial passages. (C) Representative photomicrograph images (x40 or x100 
magnification) of untreated 21NT cells, stable empty vector 21NT-pCMVNeo and 21NT-
pCMVNeo-BAP1 transfection clones.................................................................................223-224 
Figure 5.7: (A) The NRQ of BAP1 mRNA within two stable 21NT-pCMVNeo and two stable 
21NT-pCMVNeo-BAP1 transfection clones relative to three individual untreated 21NT cell 
samples at passage 1 and following five serial passages. (B) Telomerase activity within the 
same samples relative to untreated 21NT cells...................................................................226-227 
13 
 
Figure 5.8: (A) Photographs of P60 dishes containing fixed and stained stable (i) negative 
control 21NT-pCMVNeo and (ii) target gene 21NT-pCMVNeo-BAP1 colonies that emerged 
(post-transfection) following two weeks of neomycin selction. (B) The mean number of 
negative control and BAP1 target gene stable colonies present across four individual P60 dishes 
for each plasmid construct. (C) Representative photomicrographs (2.5x magnification) of fixed 
and stained stable (i) 21NT-pCMVNeo and (ii) 21NT-pCMVNeo-BAP1 clones that emerged 
(post-transfection) following two weeks of neomycin selection. (D) The average diameter (mm) 
of 11-13 individual 21NT-pCMVNeo and 21NT-pCMVNeo-BAP1 clones......................228-229  
Figure 5.9: The NRQ of (A) RASSF1 (B) hTERT mRNA within stable empty vector control 
21NT-pcDNA and target gene 21NT-pcDNA-RASSF1A transfection clones relative to the mean 
± SD NRQ values of three untreated 21NT cell samples. (C) Telomerase activity within stable 
21NT-pcDNA and 21NT-pcDNA-RASSF1A transfection clones relative to untreated 21NT 
cells.....................................................................................................................................231-232  
Figure 5.10: (A) Photographs of P60 dishes containing fixed and stained stable (i) negative 
control 21NT-pcDNA and (ii) target gene 21NT-pcDNA-RASSF1A  colonies that emerged 
(post-transfection) following two weeks of neomycin selection. (B) The mean number of 
negative control and RASSF1A target gene stable colonies present across four individual P60 
dishes for each plasmid construct. (C) Representative photomicrographs (2.5x magnification) of 
fixed and stained stable (i) 21NT-pcDNA and (ii) 21NT-pcDNA-RASSF1A clones that emerged 
(post-transfection) following two weeks of neomycin selection. (D) The average diameter (mm) 
of 11-17 individual 21NT-pcDNA and 21NT-pcDNA-RASSF1A clones...........................233-235 
Figure 5.11: The NRQ of (A) PBRM1 and (B) p21 mRNA within stable empty vector control 
21NT-pBABE and target gene 21NT-pBABE-PBRM1 transfection clones relative to the mean ± 
SD NRQ values of three untreated 21NT cell samples. The relationship between PBRM1 and 
p21 expression levels within (C) 21NT-pBABE and (D) 21NT-pBABE-PBRM1 clones relative 
to untreated 21NT cells. (E) The NRQ of hTERT mRNA within the same samples relative to the 
mean ± SD NRQ values of three untreated 21NT cell samples. (F) Telomerase activity within 
stable 21NT-pBABE and 21NT-pBABE-PBRM1 transfection clones relative to untreated 21NT 
cells.....................................................................................................................................238-240 
Figure 5.12: Representative photomicrographs (magnification x200) of untreated 21NT cells 
and a subset of stable control 21NT-pBABE and target gene 21NT-pBABE-PBRM1 transfection 
clones...................................................................................................................................241-242  
Figure 5.13: Photographs of P60 dishes containing fixed and stained stable (i) negative control 
21NT-pBABE and (ii) target gene 21NT-pBABE-PBRM1 colonies that emerged (post-
transfection) following two weeks of puromycin selection. (B) The mean number of negative 
14 
 
control and target gene stable colonies present across four individual P60 dishes for each 
plasmid construct. (C) Representative photomicrographs (2.5x magnification) of fixed and 
stained stable (i) 21NT-pBABE and (ii) 21NT-pBABE-PBRM1 clones that emerged (post-
transfection) following two weeks of puromycin selection. (D) The average diameter (mm) of 
13 individual 21NT-pBABE and 21NT-pBABE-PBRM1 clones.......................................243-245 
Figure 6.1: Model of the barriers to indefinite proliferation encountered by normal human 
mammary epithelial cells (HMEC) and how these are bypassed/overcome..............................260 
Figure 6.2: A model showing the derivation of HMEC 184D cell strains/lines used during this 
study...........................................................................................................................................264 
Figure 6.3: The NRQ of (A) p16, (B) p53 and (C) hTERT mRNA within nickel chloride-treated 
post-stasis 184D-Ni cells, immortalized 184D-hT1, spontaneously immortalized 184-p16sh and 
184D-p53sh clones and the 21NT breast cancer cell line relative to the pre-stasis 184D cell 
strain....................................................................................................................................268-269 
Figure 6.4: Copy number variation (CNV) analysis of six genes spanning the length of human 
chromosome 3p (3p12.1-p26.1) within pre- and post-stasis HMEC 184D strains, stable 
immortal 184D-Nip53sh clones, immortal 184D-p16sh and 184D-hT1 cell line derivatives and 
the 21NT breast cancer cell line.................................................................................................271 
Figure 6.5: Single nucleotide polymorphism (SNP) array analysis of chromosome 3 within (A) 
pre- and post-stasis HMEC 184D strains, six immortal 184D-Nip53sh clones, the immortalized 
184D-hT1 cell line and the 21NT breast cancer cell line. (B) Alignment of chromosome 3p 
deletions within four immortal 184D-Nip53sh clones...............................................................273 
 
 
 
  
15 
 
LIST OF TABLES 
Table 1.1: The incidence and histopathological features of invasive breast lesions....................26 
Table 1.2: Current Union for International Cancer Control (UICC) criteria for clinical and 
pathological Tumour/Node/Metastasis (TNM) classification system of breast tumours.............28 
Table 1.3: Known genes/genomic loci associated with increased breast cancer risk..................38 
Table 1.4: Adjuvant systemic treatment recommendations for each intrinsic molecular breast 
cancer subtype..............................................................................................................................45 
Table 1.5: Summary of chromosomes found to repress hTERT expression and/or induce 
senescence pathways within different cancer cell lines...............................................................70 
Table 2.1: Origin and features of each human cell line/strain utilized.........................................99 
Table 2.2: Individual human cell line growth media and 
supplements................................................................................................................................100 
Table 2.3: Primer and probe sequences and transcript accession numbers................................106 
Table 2.4: Primer-specific thermal cycling parameters and final reaction primer and probe 
concentrations.............................................................................................................................107 
Table 2.5: Primer sequences used in the qRT-PCR TRAP assay...............................................109 
Table 2.6: Details of the size and genomic region targeted by pre-designed CNV primers (ABI, 
US)..............................................................................................................................................112 
Table 3.1: Conditions used for micronucleation of human: rodent donor hybrid cells..............122 
Table 3.2: Summary of hybrid colonies generated and the number of colonies that senesced and 
entered growth arrest in situ.......................................................................................................127 
Table 3.3: The proportion of 21NT-Neo3 and 21NT-Hytk17 hybrid colonies recovered that 
showed an increase or decrease in telomerase activity outside the normal range of 21NT 
interclonal variability, including those that exhibited a greater than 90% reduction.................132  
Table 3.4: The frequency of 21NT-Neo3 and 21NT-Hytk17 hybrids that entered growth arrest 
or proliferated continuously.......................................................................................................133 
Table 4.1: Details of the endogenous control genes evaluated for expression stability across 
HMEC strains and breast cancer cell lines.................................................................................150 
16 
 
Table 4.2: Characteristics of all breast cancer cell lines employed during this study................160 
Table 5.1: Details of mammalian expression vectors used to overexpress BAP1, RASSF1A and 
PBRM1 within 21NT breast cancer cells....................................................................................207 
Table 5.2: Restriction enzyme digest reaction conditions used to release target gene cDNA from  
plasmid vector backbone............................................................................................................209  
Table 5.3: Candidate gene copy number (CN) variation analysis within normal HMEC strains 
and a panel of nine breast cancer cell lines................................................................................215  
Table 6.1: Details of target genes/region selected for physical chromosome 3p mapping by CNV 
analysis.......................................................................................................................................265 
Table 6.2: A summary of HMEC cell strains, immortal derivatives and breast cancer cell lines 
employed for the purposes of this study.....................................................................................267  
 
  
17 
 
ACKNOWLEDGEMENTS 
 I would firstly like to thank my principle supervisor, Professor Robert Newbold, for 
sharing his expertise and knowledge with me throughout this project, and also for his kind 
words of encouragement. A big thank you also to my second supervisor Dr. Amanda Harvey for 
her support and for sharing her knowledge and opinions with me. Thank you also to Professor 
Kefah Mokbel and the Breast Cancer Hope (BCH) charity for the opportunity to carry out this 
project and for the generous funds. Professor Mokbel's dedication to fighting breast cancer on so 
many fronts is truly inspiring.  
 I would also like to thank Dr. Terry Roberts and Dr. Hemad Yasaei for their help and 
advice in the laboratory. Thank you to Mrs. Alison Marriott for sharing her expertise in tissue 
culture with me. A special thank you to Dr. Jessica Pickles, whose approach to her research has 
shown me what hard work can really achieve.  
 I would also like to acknowledge all of the hard working colleagues and friends I had 
the opportunity to meet and work with throughout this project.  
 Last, but by no means least, I would like to thank my family for their love, support, 
patience and guidance. I am also deeply grateful to Mrs. Margaret Grant for her support and 
friendship.   
 
AUTHOR'S DECLARATION 
All of the work presented in this thesis is my own unless stated. Any work of others is 
appropriately referenced. 
Hannah Louise Linne, August 2015 
 
 
  
18 
 
ABBREVIATIONS 
ADH  Atypical Ductal Hyperplasia 
ALT  Alternative Lengthening of Telomeres 
BAP1  BRCA1 associated protein-1 
CADM2 Cell adhesion molecule 2 
cDNA  Complementary DNA 
CFU  Colony Forming Unit 
CMV  Cytomegalovirus 
CNV  Copy Number Variation 
COSMIC Catalogue of Somatic Mutations in Cancer 
CSC  Cancer stem cell 
Ct  Cycle threshold 
DCIS  Ductal Carcinoma in situ 
DNMT  DNA methyltransferase 
DSB  Double strand break 
EBV  Epstein Barr Virus 
ER  Estrogen receptor 
FISH  Fluorescence in situ hybridization 
FLJ/ 
KIF9-AS1 KIF9 antisense RNA 1   
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
HAT   Histone acetyltransferase OR Hypoxanthine aminopterin thymidine 
HDAC  Histone deacetylase 
HER2/Neu/ 
ERBB2  erb-b2 receptor tyrosine kinase 2  
HMEC  Human mammary epithelial cell 
19 
 
HPV  Human papillomavirus 
HR  Hormone receptor 
HRT  Hormone replacement therapy 
hTERT  Human telomerase reverse transcriptase 
hTR  Human telomerase RNA component 
Hytk  Hy, hygromycin phosphotransferase; tk, thymidine kinase 
IDC  Invasive ductal carcinoma 
ILC  Invasive lobular carcinoma 
IS  in situ 
LCIS  Lobular carcinoma in situ 
LOH  Loss of heterozygosity 
MMCT  Microcell-mediated monochromosome transfer 
Neo  Neomycin 
NRQ  Normalised relative quantities 
OIS  Oncogene-induced senescence 
PARP-3 Poly (ADP-ribose) polymerase family, member 3  
PBRM1 Polybromo 1 
PD  Population doubling 
PgR  Progesterone receptor 
PI3KCA Phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha  
qRT-PCR Quantitative real time-polymerase chain reaction 
RAR-β  Retinoic acid receptor, beta 
RASSF1 Ras association (RalGDS/AF-6) domain family member 1 
SETD2  SET domain containing 2 
SIPS  Stress-induced premature senescence 
20 
 
SUMF1 Sulfatase modifying factor 1 
SV40-LT Simian vacuolating virus 40- large T antigen 
TDLU  Terminal ductal-lobular unit 
TNM  Tumour/Node/Metastasis 
TOP1  Topoisomerase (DNA) 1 
TRAP  Telomere repeat amplification protocol 
TRF  Telomere restriction fragment 
UDH  Usual ductal hyperplasia 
YWHAZ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
  zeta 
 
 
 
  
21 
 
        CHAPTER 1  
1 GENERAL INTRODUCTION 
1.1 ANATOMY AND FUNCTION OF THE FEMALE BREAST 
 The female breast is made up of three main structures (i) milk-producing glands known 
as lobes and lobules, (ii) Lactiferous ducts, responsible for facilitating the transport of milk to 
the nipple, and (iii) connective tissue/stroma that surrounds the ducts and lobules, which 
contains blood, lymphatic vessels and adipose tissue (Figure 1.1) (Pocock and Richards, Human 
Physiology., 2006). The functional unit responsible for milk production is known as the 
terminal ductal-lobular unit (TDLU). From these terminal acinar units to the nipple, the ductal 
system consists of an outer basement membrane, a basal cell layer comprising of contractile 
myoepithelial cells, progenitor stem cells and an inner secretory luminal epithelial cell layer 
(Figure 1.1, Gusterson et al., 2005).  
 
 
 
 
 
 
 
 
Figure 1.1 - Female mammary gland structure including the terminal ductal-lobular unit 
(TDLU) and the multi-layer architecture of the mammary ductal system. Figure obtained from 
Dimri et al., (2005). 
 The primary function of the female breast is to synthesize, secrete and eject milk, 
known as lactation (reviewed by Ellis and Mahadevan, 2013). During puberty, the production of 
oestrogen and progesterone causes ductal cell proliferation, which results in the development of 
a lobular network in order to prepare for lactation. The process of lactation begins during the 
third trimester of pregnancy, when human placental lactogen (hpL) is released from the 
placenta. Following gestation, the simultaneous production of prolactin from the anterior 
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pituitary gland and a reduction of circulating oestrogen, progesterone and hpL in the blood 
stream, initiates the process of lactation (Ellis and Mahadevan, 2013).  
 
1.2 BREAST CANCER 
1.2.1 SUBTYPES AND CLASSIFICATION 
 Breast cancer is characterized by the abnormal proliferation of cells within the breast 
ducts, lobules and rarely within the connective tissues (American Cancer Society, Types of 
Breast Cancers; www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf‎). It is 
the most common cancer diagnosed in females world-wide and comprises of a large 
heterogeneous group of diseases that exhibit different pathological, histological and molecular 
features (Stewart and Wild, World Cancer Report., 2014).  
 The majority of breast cancers arise from epithelial cells lining the breast ducts and 
lobes and are known as breast carcinomas or adenocarcinomas (epithelial cells of glandular 
tissues) (Stewart and Wild., 2014). The development of malignant tumours within connective 
tissues of the breast such as fat, muscle or blood vessels, are known as sarcomas. According to 
the recent World Health Organization (WHO) Classification of Tumours of the Breast (Lakhani 
et al., 2012), there are over 20 different breast cancer subtypes.  
1.2.1.1 In Situ Breast Lesions   
 The clonal proliferation of cells with malignant features within the terminal duct-lobular 
unit of the breast, which have not infiltrated the basement membrane, are known as pre-invasive 
or in situ breast lesions (Beckman et al., 1997). These are sub-divided into lobular carcinoma in 
situ (LCIS) and ductal carcinoma in situ (DCIS) depending on their cytological and architectural 
features (Stewart and Wild., 2014). 
 DCIS represents around 25% of all diagnosed breast cancer cases and can present 
clinically as a palpable mass, nipple discharge or mammary Paget's disease (a rare breast cancer 
type that involves the nipple and the areola) (Virnig et al., 2009, Tillman and Klimberg., 2000). 
DCIS encompasses a spectrum of diseases that are classified according to cytonuclear 
differentiation, architectural features and the presence or absence of comedonecrosis (central 
luminal inflammation with devitalized cells) (Burstein et al., 2004, Fabri et al., 2007). Low-
grade DCIS lesions consist of well-differentiated cells with monomorphic nuclei and a clinging, 
cribiform, papillary or micropapillary growth pattern (Fabri et al., 2007). Cells within 
intermediate-grade DCIS lesions demonstrate some architectural differentiation, with 
pleomorphic nuclei and can also display comedonecrosis. Around two-thirds of patients with 
low and intermediate grade DCIS present with multi-focal disease, with up to 1cm gaps between 
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individual foci (Burstein et al., 2004). On the other hand, high-grade DCIS commonly presents 
as a continuous lesion containing cells with pleomorphic nuclei, necrosis and with a micro-
papillary, solid or pseudo-cribriform (a particular histological tissue architecture characterised 
by the presence of multiple perforations) growth pattern. Women diagnosed with high-grade 
DCIS have an increased risk of developing invasive breast cancer recurrence following surgical 
removal of the lesion (lumpectomy) compared to women diagnosed with intermediate or low-
grade DCIS (Kerlikowske et al., 2003). The presence of comedonecrosis within DCIS lesions is 
associated with an increased risk of local recurrence following lumpectomy and poorer disease 
free survival compared to those without comedonecrosis (Poller et al., 1995). The majority of 
low-grade DCIS lesions have been found to express oestrogen (ER) and progesterone receptors 
(PgR), whereas high-grade lesions frequently overexpress the epidermal growth factor (EGF) 
receptor tyrosine kinase 2 (ERBB2 or HER2/neu
+
) (Burstein et al., 2004). Breast tumours 
positive for hormone receptors are generally associated with a good response to endocrine 
therapy and a favourable prognosis (Osborne et al., 1980). On the other hand, patients 
diagnosed with DCIS lesions overexpressing HER2 are associated with worse disease prognosis 
(reviewed by Eccles., 2001). 
 DCIS lesions of the breast are commonly thought to represent an intermediate stage 
between atypical hyperplasia and invasive ductal carcinoma (IDC) (Figure 1.2, Stewart and 
Wild., 2014). High-grade DCIS lesions have been associated with disruption of myoepithelial 
cell layers and the basal lamina surrounding the breast lumen leading to stromal invasion, which 
is a typical feature of breast IDC (Figure 1.2, Damiani et al., 1999). Betsill et al., (1979), found 
that six out of ten (60%) untreated female patients initially diagnosed with low-grade DCIS, 
were found to develop invasive carcinoma within the same breast after an average of around 10 
years. In further support of this model, molecular features of breast tumorigenesis present within 
invasive breast lesions can be observed within pre-invasive hyperplastic and DCIS lesions 
(Burstein et al., 2004). According to the Catalogue of Somatic Mutations in Cancer database 
(COSMIC, Forbes et al., 2015) the two most frequently mutated genes within atypical 
hyperplasia, DCIS and IDC lesions include the phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA) and tumour protein 53 (TP53/p53) gene, which demonstrates a 
clonal evolutionary relationship. From ductal hyperplasia without atypia to IDC of the breast, an 
increase in the number of chromosomal gains and losses have also been observed with 
increasing histological grade (Figure 1.2, Aubele et al., 2000).  
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Figure 1.2 - A cross-sectional view of the breast ductal lumen at various stages during the 
progression of invasive ductal carcinoma (IDC) and common molecular changes that occur. 
Adapted from Burstein et al., (2004). 
 Lobular carcinoma in situ (LCIS) is a rare type of lobular neoplasia (LN) that is usually 
identified incidentally as a result of a breast biopsy carried out for another reason (Tillman and 
Klimberg., 2000). The majority of LCIS lesions cannot be detected using mammographic 
screening methods, and therefore the true incidence of LCIS within the general population is 
difficult to ascertain. However, institution-based and population-based studies indicate that up 
to 3.8% of the population may be affected by LCIS (reviewed by Oppong and King., 2012). The 
majority of LCIS lesions are multi-focal and are characterized by the abnormal proliferation of 
large, monomorphic cells between the epithelium and basement membrane of the terminal 
ducto-lobular unit and usually involves multiple lobular acini (Haagensen et al., 1978, Beute et 
al., 1991, Hussain and Cunnick., 2011). A distinguishing feature of LCIS lesions is complete 
loss of transmembrane glycoprotein E-cadherin expression, which is present within DCIS and 
IDC tissue samples (Acs et al 2001). Unlike DCIS, LCIS lesions do not generally exhibit 
features of necrosis and around 50% of patients have been found to present with bilateral 
disease (Beute et al., 1991). Furthermore, LCIS is not considered to be an obligate pre-
cancerous lesion, but is associated with around a 7% increased risk of developing invasive 
cancer in either breast, within ten years of diagnosis (Chuba et al., 2005). Patients diagnosed 
with LCIS rarely require further intervention with chemo-preventative treatments or surgery, but 
are offered lifelong surveillance by regular mammographic screening and breast examinations 
(Oppong and King., 2012).  
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1.2.1.2 Invasive Breast Lesions 
 Invasive breast carcinoma (IBC) is the most common type of breast cancer and is 
characterized by the stromal infiltration of malignant epithelial cells and an increased propensity 
for metastasis to distant sites (Figure 1.2, Fabri et al., 2007). The largest subset of IBC is 
infiltrating/invasive‎ ductal‎ carcinoma‎ (IDC)‎ ‘no special type/not otherwise specified’ 
(NST/NOS), which represents 40-75% of all breast cancer cases (Table 1.1). This 
heterogeneous group of tumours vary in size and architecture and constituent cells present with 
no specific morphological features (Stewart and Wild., 2014). The remaining subset of IBC 
lesions consist of 'special type' carcinomas, which exhibit different histological types and 
prognoses and are grouped according to morphological features such as lobular, mucinous, 
medullary, papillary, apocrine and metaplastic (Table 1.1). Infiltrating lobular carcinoma (ILC) 
is the second most frequent IBC lesion and accounts for 5-15% of all breast cancer cases. 
Unlike IDC, ILC is frequently multifocal and bilateral and is not commonly associated with the 
formation of palpable tumours that can be easily detected by mammographic screening methods 
(Helvie et al., 1993, Lesser et al., 1982). In addition, lobular and mixed ductal/lobular breast 
lesions are more likely to be hormone receptor positive (ER and PR) than IDC lesions. 
However, lobular and ductal/lobular lesions are more likely to be diagnosed at an advanced 
stage and are therefore not associated with a more favourable clinical outcome compared with 
breast IDC (Li et al., 2005, Arpino et al., 2004). Using Surveillance, Epidemiology and End 
Results Program data from over 135,000 patients diagnosed with invasive breast cancer between 
1992 and 2001, Li et al., (2005) demonstrated that different histological breast cancer subtypes 
exhibit a marked variation in clinical features and prognoses. Unlike mucinous, papillary and 
tubular IBC lesions, inflammatory and medullary carcinoma cases were associated with more 
aggressive clinical features, such as high tumour grade and absence of hormone receptors. Other 
ER negative tumour subtypes include adenoid cystic and metaplastic carcinomas (Weigelt et al., 
2008). However, many 'special type' IBC lesions including lobular, mucinous, medullary, 
papillary and tubular carcinomas have been associated with an increased survival rate compared 
to IDC lesions (Li et al., 2003c).  
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Table 1.1 - The incidence and histopathological features of invasive breast lesions 
Type Growth Pattern Incidence Features Reference(s) 
Invasive Ductal 
Carcinoma No 
Special Type 
(NST)/Not 
Otherwise 
Specified (NOS) 
Mixed 
40-75% 
IDC NOS accompanied by another 
morphological subtype e.g. lobular. 
Fabri et al., 
2007 
Pleomorphic 
Usually high-grade, characterized by 
pleomorphic and giant cells. 
Silver and 
Tavassoli., 
2000 
With osteoclastic 
giant cells 
Characterized by pleomorphic malignant 
giant cells of epithelial cell origin. 
Gupta et al., 
1996 
Special Type 
Acinic cell 
carcinoma 
- Clinicopathological features of acinic cell 
differentiation seen in salivary gland 
tumours. 
Damiani et al., 
2000 
Adenoid cystic 
carcinoma 
0.1% Typically observed in salivary glands. 
Present as irregular, heterogeneous 
masses. Associated with good prognosis 
and rare metastases. 
Glazebrook et 
al., 2010 
Apocrine 
carcinoma 
0.3-4% Cells exhibit features of apocrine cells; 
eosinophillic cytoplasm with prominent 
nucleoli. 
Frable and 
Kay., 1968 
Glycogen-rich 
clear cell 
carcinoma 
1-3% Cells have clear cytoplasm due to the 
presence of large quantities of particulate 
glycogen. 
Hull et al., 
1981 
Inflammatory 
carcinoma 
1-2% Characterized by a large mass with rapid 
growth and lymphatic infiltration. 
Usually associated with poor prognosis. 
Yasumura et 
al., 1997 
 
Invasive 
cribiform 
carcinoma 
0.8-3.5% 
Small tumour cells with low or 
intermediate degree of nuclear 
pleomorphism. Associated with a good 
prognosis. 
Fabri et al., 
2007 
Invasive lobular 
carcinoma (ILC) 
5-15% Small, non-cohesive tumour cells with 
oval nuclei and a thin layer of cytoplasm. 
Fabri et al., 
2007 
Lipid-rich 
carcinoma 
- Around 90% of tumour cells contain 
cytoplasmic lipids. 
Dina and 
Eusebi., 1997 
Medullary 
carcinoma 
1-7% Characterized by poorly differentiated 
cells with pleomorphic nuclei and 
lymphoplasmacytic stromal infiltrate. 
Fabri et al., 
2007 
Metaplastic 
carcinoma 
<1% Heterogeneous mixture of non-glandular, 
spindle, mesenchymal and squamous cell 
differentiation. 
Greenberg et 
al., 2004 
Micropapillary 
carcinoma 
<2% 
Characterized by mircopapillae separated 
by fibrocollagenous/fibrovascular stroma. 
Siriaunkgul 
and Tavassoli., 
1993 
Mucinous 
carcinoma 
2% Uniform round tumour cells with 
eosinophillic cytoplasm, surrounded by 
mucin. 
Fabri et al., 
2007 
Neuroendocrine 
carcinoma 
2-5% Tumour cells express neuroendocrine 
markers. Associated with poor prognosis 
Wei et al., 
2010 
Papillary 
carcinoma 
1-2% Tumours characterized by fibrovascular 
stalks and a myoepithelial cell layer. 
Usually associated with IDC. 
Fabri et al., 
2007 
Tubular 
Carcinoma 
<2% Small, regular cancer cells with some 
nuclear pleomorphism. Usually 
associated with DCIS and LCIS. 
Patchefsky et 
al., 1977 
  
Incidence rates obtained from Fabri et al., (2007) and Wei et al., (2010). 
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1.2.2 DISEASE CLASSIFICATION 
 Breast cancer is a heterogeneous disease that displays a wide variety of clinical, 
histological and molecular features. Therefore, routine clinical management of breast cancer is 
dependent on a variety of histopathological features including cytological appearance (grade), 
tumour size, presence/absence of hormone receptors, HER2/neu
+
 status and anatomical features 
such as lymph node stage and presence/absence of metastases (Stewart and Wild., 2014). Some 
of these factors alone or in combination have been shown to be valuable prognostic 
determinants and can be used to facilitate the selection of suitable therapeutic options and assess 
treatment progress.  
1.2.2.1 Histopathological and Biological 
 The most widely used histological grading system employed for the clinical 
management of breast cancer patients in Europe is the semi-quantitative Elson-Ellis 
modification of the Scarff-Bloom-Richardson grading system (Bloom and Richardson., 1957, 
Elston and Ellis., 1991). This involves the numerical scoring (1-3) of three cytological 
parameters: (i) architectural differentiation (tubule and gland formation), (ii) nuclear 
pleomorphism and (iii) proliferation (mitoses). Overall tumour grade is calculated by adding 
each score together. Tumours are then classified as grade 1 (3-5, low), grade 2 (6-7, 
intermediate) or grade 3 (8-9, high). This method of tumour grading was shown to be a useful 
indicator of patient survival in a retrospective study of 630 breast cancer patients, with a high 
tumour grade associated with worse patient prognosis (Sundquist et al., 1999). 
 Tumour histologic grade is also combined with pathological primary tumour size and 
lymph node stage (the number of tumour cell-positive nodes and degree of nodal involvement), 
to calculate the Nottingham Prognostic Index (NPI, Galea et al., 1992). As with histologic grade 
alone, each parameter is assigned an appropriate value and entered into the formula: NPI = [0.2 
x tumour size(cm)] + lymph node stage (1 -tumour free, 2 -up to three auxiliary nodes, or 3-four 
or more nodes/apical node involvement) + grade. The score is positively correlated with patient 
survival. This classification system combines time-dependent (lymph node and tumour size) and 
biological (tumour grade) factors and has been shown to provide a reliable estimation of patient 
prognosis in a prospective study of 320 patients diagnosed with primary breast cancer (Galea et 
al., 1992, Todd et al., 1985). 
 The Union for International Cancer Control (UICC) Tumour/Node/Metastasis (TNM) 
classification system for malignant tumours is the current global standard for breast cancer 
staging (Sobin et al., 2011). As shown in Table 1.2, this system involves the clinical and 
histopathological assessment of the anatomic stage of disease by grading three main 
components: (i) extent of primary tumour (T), (ii) presence/absence and extent of lymph node 
metastases (N) and (iii) presence/absence of distant metastases (M). TNM staging is used to 
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provide an indication of patient prognosis, establish suitable treatment options, evaluate the 
effects of treatment and provide an internationally recognised system that enables the exchange 
of information between different treatment centres (Sobin et al., 2011).  
Table 1.2 - Current Union for International Cancer Control (UICC) criteria for clinical and 
pathological Tumour/Node/Metastasis (TNM) classification system of breast tumours  
Classification Subgroup Clinical (pre-treatment) Pathological (post-surgery) 
Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis DCIS/LCIS/Paget's disease 
T1 
Tumour‎is‎<2cm‎in‎greatest‎dimensions;‎T1mi‎(Microinvasion,‎≤0.1cm),‎
T1a (>0.1 to 0.5cm), T1b (>0.5 to 1cm), T1c (>1 to 2cm). 
T2 Tumour is >2 to 5cm in greatest dimension 
T3 Tumour is >5cm in greatest dimension 
T4 
T4a (extension to chest wall), T4b (ulceration, ipsilateral satellite skin 
nodules, skin oedema), T4c (both 4a and 4b), T4d (inflammatory 
carcinoma). 
Node 
NX Cannot be assessed 
N0 No lymph node metastases 
N1 
Metastasis in movable ipsilateral 
level 1, 2 ALN 
pN1mi (micrometastasis >0.2 to 
2mm in greatest dimensions or 
>200 cells), pN1a (1-3 ALN 
including one >2mm in greatest 
dimesions), pN1b (IMLN), pN1c 
(1-3 ALN and IMLN). 
N2 
N2a (ALN fixed or matted to each 
other or to another structure), N2b 
(IMLN and in absence of ALN). 
N2a (4-9 ALN including at least 
one >2mm), N2b (IMLN in absence 
of ALN). 
N3 
N3a (ILN), N3b (IMLN and ALN), 
N3c (SLN) 
N3a (10 or more ALN or ILN), N3b 
(ipsilateral IMLN and ALN/more 
than 3 ALN and IMLN). 
Metastasis 
M0 No distant metastases N/A 
M1 
Distant metastases Distant metastases confirmed 
microscopically. 
Classification criteria obtained from Sobin et al., (2011). Abbreviations: ALN (auxiliary lymph 
node), IMLN (internal mammary lymph node), ILN (infraclavicular lymph node), SLN 
(supraclavicular lymph node).  
 In addition to histopathological classification, invasive and in situ breast tumours are 
also routinely assessed by immunohistochemical (IHC) and in situ hybridization (ISH) for the 
presence/absence of hormone receptors (ER and PgR) and the over-expression of the epidermal 
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growth factor receptor HER2 (Hammond et al., 2010, Wolff et al., 2007). According to the 
results of a systematic literature review carried out by an expert panel from the American 
Society for Clinical Oncology (ASCO) and College of American Pathologists (CAP), the 
presence of both ER and PgR within invasive breast lesions is positively associated with 
increased overall survival, time to disease recurrence and response to endocrine therapy 
(Hammond et al., 2010). Over 70% of breast cancers are hormone receptor positive (Barnes et 
al., 1996). Studies have shown that oestrogen stimulates the growth rate of hormone-responsive 
breast cancer cells in vitro, whereas anti-estrogens can have the opposite effect on cell growth 
(Katzenellenbogen et al., 1987, Atiken and Lippman., 1985). Therefore, hormone receptor 
status is a useful prognostic indicator and can be used to assess patient suitability for endocrine 
therapy. On the other hand, HER2 is amplified in approximately 20% of human breast cancers 
(Wolff et al., 2007). In 1987, Slamon et al., demonstrated a strong association between an 
increase in HER2 gene copies and lymph node status, tumour size, reduced time to disease 
relapse and decreased overall survival. Aside from a prognostic indicator, breast tumours over-
expressing HER2 are also associated with resistance or sensitivity to some endocrine therapies 
and chemotherapeutic agents (Konecny et al., 2003, Pritchard et al., 2006). Furthermore, a 
greater increase in time to disease progression has been observed within patients with HER2-
overexpressing tumours than those without, following treatment with trastuzumab (Herceptin) 
in conjunction with the chemotherapeutic agent docetaxel and platinum salts (Pegram et al., 
2004). Therefore HER2 receptor status is a valuable factor for determining effective patient 
treatment plans. 
1.2.2.2 Molecular Profiling 
 As determined by the most recent collaborative analysis of critical gaps in current breast 
cancer research (Eccles et al., 2013), our understanding of the molecular drivers behind breast 
cancer subtypes and tumour heterogeneity remains incomplete. Independent studies have 
demonstrated the reliability of histopathological and biological classification systems in 
estimating disease prognosis (see above). However, it is thought that these methods may not be 
sufficient to define or understand the vast array of clinical behaviours of breast cancer (Rakha et 
al., 2010). For example, breast tumours are known to display both inter and intra-tumour 
heterogeneity, which may not be taken into account using current histological grading methods 
(Stewart and Wild., 2014). Patients with similar breast tumour grades may have different 
clinical outcomes or responses to therapy and concerns have been raised about the inter-
observer variability of histopathological assessments (Rakha et al., 2010). Over the last fifteen 
years, microarray, array comparative genomic hybridization (aCGH) and next generation 
sequencing (NGS) technologies have facilitated the characterization of transcriptomic and 
genomic landscapes of breast cancer and have enabled the identification of molecular subtypes 
(Sorlie et al., 2001, Chin et al., 2007, Stephens et al., 2012). It is thought that, by defining new 
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molecular classification systems we can increase our understanding of the genetic drivers of 
breast carcinogenesis, identify new therapeutic targets and move towards the development of 
more personalized treatment plans (Dawson et al., 2013).   
 Through microarray analysis and hierarchical clustering of gene expression patterns 
within breast tumour samples, five distinct intrinsic molecular subtypes comprising ER-positive 
(luminal A and B) and ER-negative (basal-like, HER2-overexpressing, and normal breast-like) 
groups have been identified (Perou et al., 2000, Sorlie et al., 2001, Sorlie et al., 2003). A 
subsequent study demonstrated that early-stage breast tumours can also be classified into 
luminal and basal-like subtypes based on their relative gene expression profiles. These studies 
provide evidence to show that breast tumours comprise distinct biological entities that may 
originate from different epithelial cell types (luminal or basal) (Sorlie et al., 2006). Biological 
pathway analyses revealed that basal-like breast tumours exhibit increased expression of genes 
involved in the G1/S cell cycle transition, cell proliferation and differentiation, and p21-
mediated pathways, whereas luminal A subtypes display higher expression levels of genes 
involved in ER-signalling and fatty acid metabolism. These molecular subtypes have also been 
found to exhibit significant differences in clinical outcome (Sorlie et al., 2001, 2003). Both 
basal-like and HER2-overexpressing tumours have been associated with shorter relapse-free and 
overall survival compared with other subtypes. Other studies have shown that around 11% of all 
breast cancers and 25% of IDC NOS tumours fall within the basal-like group, which consist of 
mainly 'triple-negative' (ER/PgR/HER2 negative) tumour cells (Dent et al., 2007, Banerjee et 
al., 2006). This particular group was associated with increased likelihood of distant recurrence 
and death within five years of diagnosis compared with other breast cancer types.   
 In 2012, The Cancer Genome Atlas (TCGA) network published results from a 
comprehensive genome, transcriptome and proteome analysis of primary breast tumours using 
DNA methylation, gene copy number, exome sequencing, mRNA, miRNA and reverse-phase 
protein arrays (Cancer Genome Atlas Network., 2012). In concordance with the mRNA-
subtypes defined by Sortie et al., (2001, 2003), analysis of combined platforms using a multi-
platform data matrix, demonstrated that breast cancers can be divided into four molecular 
subtypes: luminal A, luminal B, basal-like and HER2-overexpressing. Over 10% of all breast 
cancers harboured somatic mutations in p53, PIK3CA or GATA3. However, gene mutations, 
protein expression and copy number alterations common to each subtype were also observed, 
which provides a greater understanding of the genomic drivers underlying the main breast 
cancer subtypes and identifies therapeutic drug targets. Luminal breast tumours were found to 
harbour the highest frequency of PIK3CA mutations, therefore this group may respond to 
inhibitors of active PIK3CA or signalling pathway members. Basal-like breast tumours were 
found to exhibit similar genomic aberrations as serous ovarian cancer including mutations in 
p53, BRCA1, BRCA2, ATM and amplification of MYC.  
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1.2.3 EPIDEMIOLOGY AND RISK FACTORS 
1.2.3.1 Global Variation in Breast Cancer Incidence and Mortality 
 In 2012 around 1.7 million new breast cancer cases were diagnosed and an estimated 
521,817 women died of breast cancer globally (International Agency for Research on Cancer, 
IARC, Ferlay et al., 2013). Breast cancer is the second most frequently diagnosed cancer in the 
world and is the most common cancer diagnosed in women (25% of all female cancers). It is 
also ranked as the fifth cause of global cancer-related death. For women in less developed 
regions, breast cancer is the most common cause of cancer-related death but falls second to lung 
cancer for women living in more developed regions (IARC, Ferlay et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 - Age-standardised incidence and mortality rates/100,000 females of breast cancer 
worldwide in 2012. Data obtained from GLOBOCAN (Ferlay et al., 2013). Image adapted from 
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx 
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 The global age-standardized incidence rates for female breast cancer were 43.3/100,000 
female population in 2012 (IARC, Ferlay et al., 2013). There is an approximate 4-fold variation 
in female breast cancer incidence rates between different regions worldwide, with the highest 
incidence rates observed within Europe and northern America, and the lowest rates occurring in 
eastern and central Asia and Africa (Figure 1.3). The highest breast cancer incidence rates 
worldwide occur in Belgium (111.9/100,000 females), Denmark (105) and France (104.5), 
while Bhutan (4.6), Lesotho (9), and Mongolia (9.4) have the lowest incidence rates (IARC, 
Ferlay et al., 2013). The large variation in global breast cancer incidence rates is reportedly due 
to differences in hormonal and reproductive factors together with the availability of 
mammographic screening services (Jemal et al., 2010, 2011).  Reproductive factors that have 
been associated with increased breast cancer incidence rates in more developed regions include 
null parity, late child-bearing, early menarche, or exposure to external estrogens through the use 
of menopausal hormone therapy and oral contraceptives. The binding of estrodiol to oestrogen 
receptors is thought to promote breast carcinogenesis by initiating mitogenic signalling 
pathways leading to increased mammary cell proliferation (Cavalieri and Rogan., 2006). It is 
also thought that cellular metabolism of estrodiol results in the production of electrophilic 
metabolites, which react with genomic DNA causing the formation of adducts.  
 International variations in female breast cancer incidence rates are also thought to be 
due to differences in diet and alcohol consumption (Althius et al., 2005). A meta-analysis of 
cohort and case-control studies revealed that a positive correlation exists between alcohol 
consumption and breast cancer risk (Longnecker., 1993). An increase in plasma estrogens such 
as estradiol and estrone sulphate in pre- and post-menopausal women following alcohol 
consumption is thought to be responsible for the increased risk of breast cancer development 
(Hankinson et al., 1995, Willet., 2001). A positive correlation between global economic 
development and fat consumption has been observed (Willet., 2001). An association between 
per capita fat intake and mortality from breast cancer has been observed, which may explain 
why more developed regions have the highest breast cancer incidence rates (Armstrong and 
Doll., 1975). However, a review of prospective studies has revealed that high energy intake, but 
not fat consumption alone, is associated with increased breast cancer risk (Willet., 2001). High 
energy intake is thought to contribute to early onset of menstruation and increased attained 
height and weight, which have also been found to be positively correlated with increased breast 
cancer risk. A high body mass index (BMI) is associated with elevated serum estrodiol, which is 
thought to promote breast carcinogenesis (Lamar et al., 2003). Interestingly, high body weight 
has only been associated with increased breast cancer risk in post-menopausal women but an 
inverse relationship exists between body weight and breast cancer risk in pre-menopausal 
women (Willet., 2001). This is thought to be due to the observation that heavier pre-menopausal 
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women are more likely to have irregular menstrual cycles, which confers less exposure to 
endogenous estrogens (Rich-Edwards et al., 1994).  
 Female breast cancer incidence rates in European countries, Australia and the USA 
have increased since late 1980 and have remained stable or decreased since early 2000 (Jemal et 
al., 2010, 2011). The observed decline in incidence rates within these countries since the 
beginning of the millennia is reportedly due to a reduction in the use of menopausal hormone 
therapy known as hormone replacement therapy (HRT) (Parkin., 2009, Cronin et al., 2008). 
Elevated serum levels of oestrogen and androgen sex hormones within post-menopausal 
women, have been associated with an increased risk in breast cancer development (Lamar et al., 
2003). Randomized studies have shown that use of combined oestrogen and progesterone 
hormone therapy in post-menopausal women is associated with a significant increase in breast 
cancer risk, which also increases with duration of treatment (reviewed by Cogliano et al., 2005). 
Since 2002, the use of HRT in the USA alone was reduced by 50%, which is thought to be 
responsible for the observed decline in breast cancer incidence rates.    
 
 Figure 1.4 - Age-standardized mortality rates (per 100,000 females) for women in more 
developed (MD) and less developed (LD) regions between 1950-2012. Data obtained from 
IARC, GLOBOCAN cancer mortality database (http://www-dep.iarc.fr/WHOdb/WHOdb.htm). 
 Global, age-standardized female mortality rates for breast cancer in 2012 were 
12.9/100,000 females (IARC, Ferlay et al., 2013). As shown in Figure 1.3, global mortality 
rates vary much less than incidence rates, which is due to improved survival in more developed 
regions. Regions within Melanesia and western Africa including Fiji (28.4/100,000 women), 
Nigeria (25.9) and the Solomon Islands (24.4) were found to display the highest global female 
breast cancer mortality rates. The lowest rates of breast cancer-associated death in women 
0
5
10
15
20
25
30
35
1
9
5
0
1
9
5
5
1
9
6
0
1
9
6
5
1
9
7
0
1
9
7
5
1
9
8
0
1
9
8
5
1
9
9
0
1
9
9
5
2
0
0
0
2
0
0
5
2
0
1
0
R
a
te
/1
0
0
,0
0
0
 F
em
a
le
s 
Year 
Age-standardized female mortality rates in selected countries 1950-
2012 (GLOBOCAN) 
Belgium (MD)
Brazil (LD)
China: selected areas (LD)
Egypt (LD)
Guatemala (LD)
Mexico (LD)
Republic of Korea (LD)
United Kingdom (MD)
United States of America
(MD)
34 
 
worldwide were observed in eastern Asia and central America including Bhutan (1.8/100,000 
females), Guatemala (5) and China (5.4). In contrast to the USA and northern European 
countries, breast cancer incidence and mortality rates within Asian, African and Central 
American countries such as China, Korea, Egypt, Mexico and Guatemala, have been rising 
(Figure 1.4, Jemal et al., 2011). The observed reduction in mortality rates in the USA and 
northern Europe since the late 1980's is likely to be due to earlier detection and improved 
treatment strategies. It is thought that rising incidence rates within Asian, African and central 
American countries may be due to the adoption of traits associated with 'westernization' such as 
physical inactivity, obesity and cultural changes such as late child-bearing or having fewer 
children. An obesity pandemic is reportedly spreading from the USA and Europe to urban areas 
of less-developed countries, which are unable to cope with the rise of associated non-
communicable diseases due to inadequate health-care services (Prentice., 2005). These factors, 
together with the lack of early detection services and treatment strategies is thought to underlie 
the increasing breast cancer mortality rates within less developed countries (Figure 1.4, Jemal., 
2010).  
 Similarly to incidence rates, a large variation in global female breast cancer survival 
rates have been observed, with five-year relative survival rates of around 12% within African 
regions to around 90% in the USA and UK (Youlden et al., 2012). Disparities in global survival 
rates are largely thought to be due to differences in access to treatment services and early 
detection. Over the last forty years, five-year breast cancer survival rates in the UK have 
increased from around 50% in 1970 to over 80% in 2011 (CRUK). Similar trends have been 
observed in more developed countries due to the introduction of mammographic screening 
programs and the use of adjuvant therapies (Youlden et al., 2012). Breast cancer survival is 
dependent on both age and stage of disease at diagnosis (CRUK). According to five-year net 
survival rates of women in the UK between 2007-2011, women aged 40-69 years have the best 
survival rates of around 90%, compared with 84.8% and 64.1% for women aged 15-39 and 80-
99 respectively (CRUK). As shown in Figure 1.5, women diagnosed with localized disease or 
regional lymph node metastases have the highest five-year relative survival rates compared with 
patients diagnosed with distant metastases or unknown tumour stage (Survival, Epidemiology, 
and End Results Program, SEER).     
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Figure 1.5 - Breast cancer five-year relative survival rates for women in the USA between 
2005-2011 according to stage of disease at diagnosis. Data obtained from Surveillance, 
Epidemiology, and End Results Program (SEER) of the National Cancer Institute 
(http://seer.cancer.gov/statfacts/html/breast.html).  
 In contrast to females, male breast cancer constitutes less than 1% of all cancers 
diagnosed in men and incidence rates are around 1-1.2/100,000 male population in Western 
countries (Rizzolo et al., 2013, Speirs and Shaaban., 2008). Between 1988-2002, the highest 
incidence rates of male breast cancer were observed in Israel (1.24/100,000 males), the 
Philippines (0.99), Italy (0.8) and France (0.75) (Ly et al., 2012). Similarly to female breast 
cancer, regions within eastern Asia such as Thailand (0.14), Japan (0.17) and Singapore (0.19) 
were found to display the lowest male breast cancer incidence rates within the same time-
period. The high incidence of male breast cancer in Israel is thought to be due to the increased 
frequency of mutations within breast cancer susceptibility genes BRCA1 and BRCA2 observed 
within Ashkenazi Jewish populations (Struewing et al., 1997).    
 Similarly to females, male age-standardized breast cancer incidence rates have 
increased from the early 1970's in many regions worldwide, but have reached a plateau since the 
beginning of the millennia (Anderson et al., 2010, Ly et al., 2012). The observed similarity to 
female incidence trends could suggest that men and women may be exposed to common breast 
cancer risk factors. For example, obesity and physical inactivity have been associated with an 
increased risk of breast cancer for both males and females (Ly et al., 2012). However, male 
breast cancer incidence rates in European countries have remained fairly stable since the early 
1970s (Miao et al., 2011). An example of this can be seen in Figure 1.6A and B, which shows a 
72% increase in age-standardized female breast cancer incidence rates in the UK from 1975-
2011, but a relatively stable male breast cancer incidence rate of less than 1/100,000 male 
population within the same time-period (Cancer Research UK, CRUK). Therefore, sex-specific 
risk factors such as hormonal and reproductive factors, are responsible for the observed 
differences in breast cancer incidence trends for males and females. It is also thought that these 
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differences may also reflect changes in the availability of mammographic screening services for 
women, especially within more developed regions (Ly et al., 2012). A review of SEER 
population data revealed that both male and female breast cancer mortality rates in the USA 
have declined between 1973 and 2005. As shown in Figure 1.6A and B, a similar trend was 
observed in the UK. It is thought that improved adjuvant systemic therapy such as Tamoxifen, 
may have contributed to the decline in male breast cancer mortality rates within these countries 
(Anderson et al., 2010).  
 Breast cancer incidence in men and women is strongly associated with age, with around 
24% and 36% of breast cancer cases diagnosed in females and males aged over 75 years 
between 2009-2011 in the UK respectively (Figure 1.4C and D, CRUK). For men, age-specific 
incidence rates increase steadily from the age of 35, whereas incidence rates for women increase 
from the age of 30 until 50 years, where they plateau until the age of 60 when they begin to 
increase. Female breast cancer incidence rates then decrease slightly between the ages of 70-74, 
but increase again at ages 75 and over (Figure 1.4C and D, CRUK). A bi-modal age distribution 
in female breast cancer incidence patterns have also been observed following analysis of SEER 
program data, with peak incidences at around age 50 (early-onset, premenopausal) and 70 years 
(late-onset, post-menopausal) (Anderson et al., 2006). This study also found that early-onset 
breast cancers were associated with more aggressive molecular subtypes including basal-like 
and HER2-overexpressing, while late-onset breast cancers were more likely to be ER-positive 
(luminal A and B). In contrast, age-dependent incidence frequencies for male breast cancer are 
uni-modal, with the highest incidence rates observed at age 71 (Anderson et al., 2004). 
Interestingly, male breast cancers have been found to share common molecular features with 
late-onset female breast cancers such as ER and PR-positivity and low nuclear grade (Anderson 
et al., 2004). These findings suggest that late-onset female and male breast cancers may share a 
common aetiology and risk exposures that are distinct from early-onset female breast cancers.  
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Figure 1.6 - European age-standardized incidence and mortality rates/100,000 for (A) females 
and (B) males in the UK between 1975 and 2011. Average age-specific incidence rates for (C) 
females and (D) males in the UK between 2009 and 2011. Data obtained from Cancer Research 
UK (CRUK: http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/?script=true).  
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1.2.3.2 Familial Predisposition   
 Women with one or more first degree relatives diagnosed with breast cancer are at an 
increased risk of also developing the disease (Collaborative Group on Hormonal Factors in 
Breast Cancer., 2001). The assessment of breast cancer risk in groups of monozygotic and 
dizygotic twins has demonstrated that familial clustering of breast cancer cases is due to genetic 
factors and not common environmental exposures (Lichtenstein et al., 2000). Through genome-
wide association studies (GWAS), linkage analysis and mutational candidate gene screening 
studies, multiple breast cancer susceptibility genes have been identified (reviewed by Turnbull 
and Rahman., 2008 and Zhang et al., 2011). Susceptibility genes are currently grouped by their 
associated risk profiles, which include high (>10% risk), intermediate (2-4% risk) and low 
(<1.5% risk) penetrance (Table 1.3). The breast cancer susceptibility genes identified to date are 
estimated to account for only 50% of inherited breast cancer cases; therefore more have yet to 
be uncovered (Cybulski et al., 2015).  
Table 1.3 - Known genes/genomic loci associated with increased breast cancer risk 
High 
Penetrance 
Intermediate 
Penetrance 
Low Penetrance Alleles (Putative Causal Genes) 
Unknown 
Penetrance 
17q21 - 
BRCA1 
 
13q12 - 
BRCA2 
 
17p13 - p53 
(Li Fraumeni 
Syndrome) 
 
10q23 - PTEN 
(Cowden 
Syndrome) 
22q12 - 
CHEK2 
 
11q22-q23 - 
ATM 
 
17q22 - BRIP1 
 
16p12.2 - 
PALB2 
 
 
2q33 - CASP8, TRAK2, 
ALS2CR12, ALS2CR2, 
ALS2CR11, 
LOC389286, 
LOC729191 
2q35 
3p24 - SLC4A7, NEK10 
5p12 - MRPS30 
5q11 - MAP3K1, 
MGC33648, MIER3 
6q22 - ECHDC1, 
RNF146 
6q25 - ESF1, C60rf97 
8q24 
9p21 - CDKN2A/2B 
10p15 - ANKRD16, 
FBXO1810q21 - 
ZNF365 
10q22 - ZMIZ1 
10q26 - FGFR2 
11p15 - LSP1, TNNT3, 
MRPL23, H19, 
LOC728008 
11q13 
12p12 - RECQL 
14q24 - RAD51L1 
16q12 - TNRC9, 
LOC643714 
17q22 - COX11 
19p13 - ABHD8, 
ANKLE1, C19orf62 
19p13 - STK11 
(Peutz-Jehgers 
Syndrome) 
 
16q22 - CDH1 
(Hereditary 
diffuse gastric 
cancer 
syndrome) 
 
Data obtained from Turnbull and Rahman., (2008), Zhang et al., (2011) and Cybulski et al., 
(2015). 
 The BRCA1 and BRCA2 high penetrance breast and ovarian cancer susceptibility genes 
were identified by linkage analysis and positional cloning during the early 1990's (Hall et al., 
1990, Miki et al., 1994, Wooster et al., 1995). Only 0.11 and 0.12% of women in the general 
population carry germline mutations in BRCA1 and BRCA2 respectively (Peto et al., 1999). 
However, BRCA1/2 mutation carriers confer a 65% and 45% average cumulative risk of 
developing breast cancer by the age of 70 years respectively (Antoniou et al., 2003). The 
relative risk of breast cancer development in women carrying BRCA1 mutations reduces with 
advancing age, with the highest relative risk of >30-fold at under 40 years, which declines to 
around 14-fold at over 60 years of age. On the other hand, a positive correlation between 
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relative breast cancer risk and age exists within females harbouring germline BRCA2 mutations 
(Antoniou et al., 2003). These findings are consistent with those presented by Krainer et al., 
(1997), demonstrating that mutations in BRCA1 confer a greater risk of developing early-onset 
breast cancer than BRCA2 mutations. Overall, BRCA1/2 mutations account for approximately 
20% of all familial breast cancer cases (Turnbull and Rahman., 2008). In contrast to females, 
males carrying germline BRCA2 mutations have a higher average cumulative risk of developing 
breast cancer by 70 years (6.8%) compared with those that carry BRCA1 mutations (1.2%) (Tai 
et al., 2007). The majority of breast cancer-associated BRCA1 and BRCA2 mutations involve 
insertions, deletions, and nonsense mutations that lead to loss of protein function through 
premature protein truncation (Gudmundsdottir and Ashworth., 2006). However, founder 
mutations have been observed at a higher frequency within certain ethnic groups such as 
BRCA1-185delAG and BRCA2-6174delT within Ashkenazi Jewish populations (Tonin et al., 
1996).     
 Li Fraumeni syndrome is a rare autosomal dominant disorder that is associated with the 
development of multiple early-onset malignancies including breast carcinoma, osteosarcoma, 
soft tissue sarcomas, adrenocortical carcinomas, brain tumours, Wilms' tumour, and phyllodes 
tumour (Birch et al., 2001). Around 50% of affected individuals have been found to carry 
germline mutations in the p53 tumour suppressor gene (Hisada et al., 1998). p53 is a 
transcription factor that plays an important functional role in mediating the cellular response to 
DNA damage by regulating the activity of genes involved in cell cycle arrest (Kastan et al., 
1991). Interestingly, intermediate penetrance breast cancer genes (CHEK2, ATM, BRIP1, 
PALB2), which account for around 2.3% of inherited breast cancer risk, are involved in the p53 
and/or BRCA1/2-mediated DNA damage response pathway (Turnbull and Rahman., 2008). In 
response to irradiation-induced DNA damage, both ATM and CHK2 protein kinases 
phosphorylate and activate BRCA1 and p53 proteins to initiate DNA DSB repair pathways and 
cell cycle arrest (Gudmundsdottir and Ashworth., 2006). Individuals carrying germline, 
monoallelic, ataxia-telangiectasia-associated mutations in ATM, have been found to be at an 
increased risk of developing breast cancer, with an estimated relative risk of around 2.37 
(Renwick et al., 2006). A review of ten case-control studies involving over 10,800 breast cancer 
patients, revealed that those harbouring the protein-truncating CHEK2-1100delC mutation are at 
an increased risk (estimated odds ratio of 2.34) of developing breast cancer (CHEK2 Breast 
Cancer Case-Control Consortium., 2004). Monoallelic truncating mutations within the BRIP1 
gene, which encodes a BRCA1-interacting helicase enzyme, have been observed within 0.74% 
of breast cancer patients with families negative for BRCA1/2 mutations and were associated 
with an increased relative risk of breast cancer of 2.0 (Seal et al., 2006). Furthermore, the 
relative risk of breast cancer within individuals harbouring monoallelic germline mutations in 
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PALB2, which encodes a protein that interacts with and stabilizes BRCA2,  is estimated to be 
2.3 (Rhaman et al., 2007).  
 Low-penetrance breast cancer susceptibility genes, which confer a <1.5 relative risk 
have so far been identified through genome wide association studies (GWAS) and candidate 
gene approaches (Turnbull and Rahman., 2008). For example, Easton et al., (2009) screened 
227,876 single nucleotide polymorphisms (SNPs) in around 22,000 invasive and in situ breast 
carcinoma patients and controls from 22 case-control studies and identified five loci and four 
putative causal genes including 5q11(MAP3K1), 8q24, 10q26 (FGFR2), 11p15 (LSP1), 16q12 
(TNRC9) (Table 1.3). A recent population-based, whole-exome sequencing study involving 
breast cancer patients from Poland and Quebec with a family history of the disease, identified 
rare recurrent mutations in the RECQL gene (Cybulski et al., 2015). Interestingly, this gene 
encodes the RECQL helicase enzyme that plays important functional roles in gene expression, 
DNA recombination and, similarly to other breast cancer susceptibility genes, promotes genome 
stability through stabilization and re-initiation of stalled DNA replication forks thereby 
preventing DSB breaks (Berti et al., 2013).  
 
1.2.4 SYMPTOMS, SCREENING AND DIAGNOSIS 
 The most common symptoms associated with breast cancer include a palpable lump(s), 
swelling or thickening of the breast, a change in shape of the breast or nipple (inversion or 
sinking into the breast), haematic nipple discharge, breast pain, auxiliary adenopathy or 
spontaneous skin retraction (CRUK, Di Maggio., 2007). Inflammatory breast cancer symptoms 
may include swelling of the breast and a porous-like breast skin texture. The development of a 
red, eczematous rash around the nipple is usually associated with Paget's disease. 
 Since the 1980s, over thirty countries worldwide have implemented national or regional 
mammographic screening programs for women between the ages of 40 and 75 years (Youlden 
et al., 2012). The overall aim of breast screening is to detect cancer at a early stage within 
asymptomatic women, in order to improve prognosis and survival and decrease mortality. As 
shown in Figure 1.5, an important factor for breast cancer survival is stage at diagnosis, with 
localized and regional disease stages associated with better survival rates. For many breast 
cancers there is a positive correlation between tumour size and lymph node involvement 
(Foulkes et al., 2010). Therefore, early diagnosis is a critical factor in improving survival 
outcomes for breast cancer patients (Youlden et al., 2012). Mammography is currently the most 
effective and sensitive method of identifying early-stage breast cancer (Di Maggio., 2007). This 
particular screening modality can be used to obtain whole-breast images and identify features 
associated with breast neoplasia including, structural distortions, nodular opacities and 
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microcalcifications. In this way, non-palpable breast lesions can be discovered and the 
location(s) and dimensions of breast tumours can be recorded for downstream treatment 
purposes. However, some breast lesions, such as lobular breast carcinomas, present with 
minimal stromal involvement and a largely intact glandular architecture, which are difficult to 
detect using mammographic screening methods. Furthermore, due to the incidence of false-
negative readings, the use of mammography for women with dense breast tissue may be less 
sensitive and other imaging techniques such as ultrasound or magnetic resonance imaging 
(MRI), may be used to identify breast lesions (Crystal et al., 2002). A review of the NHS Breast 
Screening Program conducted in 2012, found that an estimated 1,300 breast cancer-associated 
deaths may be prevented each year as a result of the screening program (Independent UK Panel 
on Breast Screening., 2012). Similarly, studies carried out in Australia, Denmark, the 
Netherlands and Sweden have reported a 19%-32% decrease in mortality rates due to 
mammographic screening programs (reviewed by Youlden et al., 2012). However, a major 
drawback is the over-diagnosis and treatment of breast cancers that would not have otherwise 
progressed or become clinically apparent throughout the women's lifetime. As a consequence of 
this, women undergo unnecessary surgical procedures, radiotherapy or drug regimens 
(Independent UK Panel on Breast Screening., 2012). The magnitude of over-diagnosis is 
difficult to ascertain, however, population-based studies estimate that between 1%-54% of 
patients may be over-diagnosed as a result of screening (de Gelder et al., 2011). Despite these 
observations, there is a general consensus that the survival benefits of mammographic screening 
programs outweigh the potential harms (Youlden et al., 2012). However, whether the benefits of 
mammographic screening outweigh the harms is still under debate. A recent review of Swedish 
randomised mammographic screening trials, demonstrated that the risk reduction in breast 
cancer death due to mammographic screening was overestimated due to the use of 
unconventional statistical methods (Autier et al., 2015). 
 The diagnosis of breast cancer typically involves a combination of clinical tests, 
imaging procedures and pathological assessments (Senkus et al., 2013). A medical professional 
will first examine the breasts for typical extramammary signs of breast cancer and also 
determine the presence of loco-regional lesions through bimanual palpation of the breasts, 
surrounding lymph nodes and assess for distant metastases within the bones, brain, liver and 
lungs. A complete personal medical history is also taken to determine familial risk factors and 
to assess menopausal status. The principal imaging modality used to determine the presence, 
location and size of breast tumours is a bilateral mammography (Mariani and Gianni., 2007). To 
determine the degree of regional lymph node involvement an ultrasound may also be 
undertaken. Magnetic resonance imaging (MRI) is employed only if conventional imaging 
methods produce inconclusive results, if individuals have a family history of the disease or if 
multi-centric or multi-focal lesions are suspected from breast mammography (Schnall and Orel., 
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2006). Based on results of imaging procedures, pathological assessment of the breast lesion(s) is 
then carried out (Senkus et al., 2013). To do this, a manual or ultrasound-guided core needle 
biopsy or fine need aspirate (FNA) of the primary tumour and suspicious lymph nodes (sentinel 
lymph node biopsy) is undertaken. Tumour samples obtained from biopsies or surgical 
specimens are then classified according to histopathological criteria (Chapter 1.2.2.1), including 
histological sub-type, tumour grade and the assessment of ER, PgR and HER2 receptor status by 
immunohistochemistry (IHC) or in situ hybridization (ISH). The WHO tumour, node, 
metastasis (TNM) classification system (Table 1.2 and Lakhani et al., 2012) is used to 
characterize the stage of disease within each patient following clinical (cTNM) or post-operative 
(pTNM) pathological assessment of the primary tumour and lymph nodes. If a patient is found 
to have a large tumour(s) (>5cm in greatest dimensions), auxiliary lymph node involvement or 
clinical symptoms indicative of distant metastases, additional imaging modalities such as chest 
computed tomography (CT), bone scans, abdominal and liver ultrasounds or a 
fluorodeoxyglucose positron emission tomography (FDG-PET) scan may be used to confirm the 
sites and extent of metastatic spread (Senkus et al., 2013).  
 
1.2.5 TREATMENT 
 The choice of breast cancer treatment strategy depends on multiple factors including (i) 
anatomical features such as the number of lesions, tumour size, location and the number and 
extent of lymph node infiltration (ii) biological factors such as histopathological classification 
and the presence/absence of hormone receptors (HR) and HER2 overexpression, (iii) the age 
and general health of the patient and (iv) patient preferences.  
1.2.5.1 Surgery 
 There are two main surgical options for patients with invasive or in situ breast lesions; 
breast conserving surgery (BCS) and complete mastectomy. Independent trials have shown that 
in certain instances, BCS followed by radiotherapy for patients with infiltrating breast 
carcinoma confers similar survival, loco-regional and distant disease recurrence rates, to radical 
or modified radical mastectomy (Sarrazin et al., 1989, reviewed by Guarneri et al., 2007). An 
estimated 60%-80% of breast cancers are therefore considered to be treatable by BCS and 
radiation therapy (Senkus et al., 2013). However, a mastectomy is usually recommended for 
patients that present with multi-focal disease, a large tumour(s), have positive tumour surgical 
margins as a result of BCS or due to patient preferences. In addition, a prophylactic bilateral 
mastectomy is generally offered to high risk patients, such as BRCA1/BRCA2 mutation carriers, 
which has been associated with a 95% reduction in breast cancer risk (Rebbeck et al., 2004). 
Patients presenting with a large uni-focal breast tumour can undergo neoadjuvant systemic 
therapy prior to breast surgery to reduce tumour size, avoid a mastectomy and improve cosmetic 
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outcomes following BCS (Senkus et al., 2013). BCS generally involves a wide local excision of 
the tumour with a minimum 1mm histological margin for invasive lesions and a >2mm margin 
for in situ lesions. Oncoplastic procedures during BCS aim to promote acceptable cosmesis for 
all patients, particularly those with large breasts or high tumour-to-breast size ratios. In addition, 
the insertion of a clip during BCS can be carried out to mark the cancer site and direct post-
operative radiotherapy treatment.  
 Following mastectomy procedures, patients can either undergo immediate, delayed or 
no breast reconstructive surgery depending on cancer type or patient preferences. Immediate 
reconstructive surgery is not recommended for inflammatory breast cancer as some studies have 
shown that this may limit radiation coverage to the affected breast tissue and, where appropriate, 
regional lymph nodes (Dawood et al., 2011). Out of the two major reconstructive surgery 
techniques, autologous tissue flaps have been associated with more favourable cosmesis and 
fewer complications following post-surgical radiotherapy when compared with prosthesis 
(Senkus-Konefka et al., 2004). Sources of autologous tissue flaps include the transverse rectus 
abdominis and latissimus dorsi muscles from the patients abdomen and back respectively 
(Senkus et al., 2013).  
 As part of the disease staging process and to determine long-term patient prognosis, 
assessment of regional lymph node metastases by auxiliary lymph node dissection can be 
carried out during breast surgery (Senkus et al., 2013). However, a major contraindication 
associated with auxiliary clearance and post-operative radiotherapy is disruption of the 
lymphatic drainage system within the breast leading to lymphoedema (Guarneri et al., 2007). 
Therefore, in order to reduce the extent of breast surgery, a preceding sentinel lymph node 
biopsy (SNLB) is usually carried out to determine the degree of regional lymph node 
involvement and whether auxiliary clearance is required (SinghRanger and Mokbel., 2003).    
1.2.5.2 Radiotherapy 
 Randomized trials have shown that radiation therapy for patients following BCS or 
mastectomy is associated with a 17%-19% risk reduction of loco-regional recurrence within 5-
10 years and a 3.8-5.4% reduction in breast cancer mortality risk within 15 years (Early Breast 
Cancer Trialists' Collaborative Group., 2006, 2012). Over a period of 3-7 weeks following 
surgery, patients can undergo local/regional adjuvant external beam radiotherapy treatment 
which usually involves up to 28 fractions of around 2.0Gy providing a total radiation dose of 
45-50Gy (Senkus et al., 2013). In addition to conventional radiation treatment, a boost radiation 
dose of 10Gy or 16Gy has been associated with a greater risk reduction of ipsilateral breast 
relapse within patients initially diagnosed with invasive breast carcinoma and treated with local 
excision and BCS (Romestaing et al., 1997, van Werkhoven et al., 2011). Boost radiation doses 
may be offered to patients with high-grade tumours, vascular invasion, or patients that have 
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undergone BCS. Side effects associated with breast radiotherapy include inflammation, 
reddening of the skin, lymphoedema (commonly associated with auxiliary node clearance) and 
fatigue (CRUK). Furthermore, a positive correlation between mean radiation dose and risk for 
ischaemic heart disease has been observed in patients that have received radiotherapy for breast 
cancer (Darby et al., 2013).  
 Around 90% of local breast cancer recurrences have been found to occur within the 
immediate vicinity of the primary breast tumour (Vaiyda et al., 2010). Therefore, in order to 
reduce harmful side effects and target treatment to the affected area, accelerated partial breast 
irradiation (APBI) techniques including intra-operative radiotherapy and brachytherapy (see 
below) have been developed. Intra-operative radiotherapy involves the delivery of a single 
radiation dose of around 20Gy to the surface of the tumour bed during surgery. Results from the 
TARGIT-A (targeted intraoperative radiotherapy) randomised phase 3 trial, showed that 
invasive breast carcinoma patients treated with intra-operative radiotherapy or post-surgical 
whole-breast external beam radiotherapy, displayed similar 4-year local recurrence rates 
(Vaiyda et al., 2010). A more recent review of TARGIT-A trial data demonstrated that intra-
operative radiotherapy was associated with a 2% higher ipsilateral breast recurrence rate 
compared with whole breast irradiation (Vaiyda et al., 2012). The brachytherapy form of APBI, 
which involves the targeted delivery 34Gy of radiation over 10 fractions through interstitial 
single lumen catheters, has been shown to yield comparable 5-year ipsilateral breast recurrence 
rates, toxicity levels (fat necrosis, infections and seromas) and cosmesis as whole-breast 
irradiation (Shah et al., 2013). Long-term local recurrence or survival rates for breast cancer 
patients treated with brachytherapy compared with whole-breast radiotherapy are currently 
unknown, but are expected within the next 10 years.  
1.2.5.3 Adjuvant Systemic Therapy 
 Aside from or in addition to surgery, adjuvant systemic treatments such as 
chemotherapeutic agents and targeted biological agents including endocrine therapies or HER2-
inhibitors, can be used to improve disease-free survival and overall survival of breast cancer 
patients (Senkus et al., 2013). The choice of adjuvant systemic therapy treatment for individual 
patients depends on the intrinsic molecular breast cancer subtype (Table 1.4), as well as age, 
general health, menopausal status and patient preferences (Goldhirsch et al., 2013, Senkus et al., 
2013). Breast tumours positive for ER and PgR receptors (particularly luminal cancers) are 
treated with endocrine therapies such as selective oestrogen receptor modulators (SERMs, 
tamoxifen and raloxifane), aromatase inhibitors (letrozole), or gonadotropin-releasing hormone 
(GnRH) agonists. Tamoxifen is a partial, non-steroidal, oestrogen agonist that binds to the ER 
causing ligand-dependent conformational changes and disruption of growth factor signalling 
pathways (Wakeling., 2000). GnRH agonists function to suppress ovarian function, whereas 
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aromatase inhibitors are a group of steroidal or non-steroidal inhibitors that bind to and disrupt 
aromatase enzyme function, which leads to reduced serum estrodiol levels (Lumachi et al., 
2011). Aromatase is responsible for catalyzing the aromatization of androgens to estrogens. 
Tamoxifen is considered to be the standard endocrine therapy for pre-menopausal breast cancer 
patients, but GnRH agonists in combination with aromatase inhibitors may also be considered in 
the event of tamoxifen-associated contraindications (such as endometrial cancer) (Senkus et al., 
2013). A combination of aromatase inhibitors and tamoxifen are usually considered for post-
menopausal breast cancer patients. Compared with luminal A, luminal B molecular subtypes 
have a higher Ki-67 proliferative index, are less endocrine sensitive and are associated with 
poorer disease prognosis. Therefore, this particular subtype may be treated with a combination 
of endocrine therapy and chemotherapy (Table 1.4). Multi-gene expression assays, such as the 
21-gene recurrence score assay, have been shown to define a particular subgroup of luminal 
cancers that are associated with higher recurrence rates and an improved response to 
chemotherapeutic agents (Goldhirsch et al., 2013).  
Table 1.4 - Adjuvant systemic treatment recommendations for each intrinsic molecular breast 
cancer subtype 
Clinico-Pathological Surrogate Intrinsic 
Phenotype 
Features 
Systemic 
Treatment 
Luminal A-like 
ER (+), PgR (+), HER2 (-), Ki67 
(low), MGEA (low risk) 
ET 
Luminal B-like HER2 (-) 
ER (+) and PgR (-/low) or Ki67 
(high), MGEA (high risk) 
ET+CT 
Luminal B-like HER2 (+) ER (+), PgR (+/-), Ki67 (high/low) 
ET+CT+Anti-
HER2 
HER2-positive (non-luminal) ER (-), PgR (-), HER2 (+) CT+Anti-HER2 
Basal-like ER (-), PgR (-), HER2 (-) CT 
Special Types A (Cribiform, Mucinous and 
Tubular) 
ER (+), PgR (+) ET 
Special Subtypes B (Metaplastic, Apocrine, 
Adenoid Cystic, Medullary) 
ER (-), PgR (-) CT 
Data obtained from St Gallen International Expert Consensus on the Primary Therapy of Early 
Breast Cancer (Goldhirsch et al., 2013). Abbreviations: ER (oestrogen receptor), PgR 
(Progesterone Receptor) HER2 (Human epidermal growth factor receptor 2), ET (endocrine 
therapy), CT (cytotoxic therapy), MGEA (Multi-gene expression assay) 
 HER2-overexpressing breast tumours and metastases are treated with the monoclonal 
antibody (MAb) trastuzumab (herceptin), directed against the HER-2 protein. Through direct 
binding to the HER-2 receptor, it is thought that trastuzumab blocks downstream PI3-kinase 
(PI3K) and MAP-kinase (MAPK) signalling pathways leading to cell cycle arrest in G1 and 
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induction of apoptosis (Nahta and Esteva., 2005). Trastuzumab has also been found to suppress 
angiogenesis in vivo through downregulation of pro-angiogenic factors such as vascular 
endothelial growth factor (VEGF) and up-regulation of anti-angiogenic factors such as 
thrombospondin-1 (TSP-1) (Izumi et al., 2002).   
 Cytotoxic chemotherapy is prescribed to patients with HR-negative/poor, HER2-
positive or high grade tumours and those with locally advanced, metastatic disease or recurrence 
(Senkus et al., 2013). Common chemotherapy regimens for breast cancer usually comprise 4-8 
cycles of treatment lasting up to 8 months and generally involve the intravenous administration 
of a combination of anthracyclines (doxorubicin or epirubicin) with cyclophosphamide and an 
anti-metabolite (methotrexate or fluorouracil) and in some cases, an additional microtubule 
agent (docetaxel). Older patients and those with pre-existing heart conditions may be offered 
regimens that do not contain anthracyclines, such as CMF (cyclophosphamide, methotrexate, 
fluorouracil), due to the increased risk of cardiomyopathy and congestive heart failure (Cortes-
Funes and Coronado., 2007). However, anthracycline-containing chemotherapy regimens are 
associated with a significant improvement in 10-year recurrence and overall mortality rates for 
older and younger patients, when compared to CMF regimens (EBCTCG., 2005).  
1.2.5.4 Resistance 
 Around 5% of breast cancer patients present with detectable metastatic disease at initial 
diagnosis, but up to 40% will go on to develop metastatic disease despite undergoing surgical 
and/or systemic therapy (Guarneri et al., 2007). In addition, around 30% of patients diagnosed 
with early-breast cancer will develop recurrent disease, either locally or at distant sites 
(Gonzalez-Angulo et al., 2007). One of the major contributing factors for disease recurrence in 
breast cancer patients is resistance to adjuvant systemic agents. Patients with HER2-positive 
breast tumours initially respond to herceptin-containing treatment regimens but undergo disease 
progression within the first year (Slamon et al., 2001). Furthermore, only around one third of 
patients diagnosed with ER-positive metastatic breast cancer, have objective tumour regression 
following endocrine therapy (Osborne and Schiff., 2011). After an initial response, the majority 
of cancer patients treated with chemotherapeutic agents develop progressive disease (Liu et al., 
2009).  
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1.3 TARGETING CELLULAR IMMORTALITY AS AN ANTI-CANCER 
MECHANISM 
 Cancer development and progression is a multi-step process that relies on the 
accumulation of multiple somatic mutations and epigenetic changes, which confer survival 
advantages over neighbouring cells through an increased ability to proliferate, migrate and 
survive within foreign tissues or hostile environments and evade detection by the immune 
system. This step-wise process is thought to depend on a Darwinian evolutionary system, 
known as 'clonal evolution,' which is characterized by the continual process of clonal expansion, 
acquisition of a rare somatic-cell genetic/epigenetic alteration and clonal selection (Greaves and 
Maley., 2010). At least five or six successive cycles of genetic/epigenetic alteration and clonal 
expansion are thought to be required for the development of most common human carcinomas 
(Newbold., 2005). The initiation of cancer by clonal evolution must therefore require an initial 
step that permits extended cell proliferation over neighbouring cells, a higher level of 
genetic/epigenetic variability and the capacity for indefinite, unfettered cell growth. 
 Complex multi-cellular organisms are made up of both mitotic cells such as epithelial, 
endothelial (vascular), stromal (fibroblasts), haematopoietic, stem and progenitor cells and post-
mitotic differentiated cells including specialized muscle cells and neurons (Campisi and 
Fagagna., 2007). The proliferative capacity of mitotic cells facilitates the process of tissue 
repair/regeneration, which is essential for organism survival. However, proliferating cells 
acquire more genetic/epigenetic alterations than non-dividing cells (Busuttil et al., 2006). 
Therefore, with increasing age, molecular gain-of-function changes occur that allow abnormal 
cellular proliferation (hyperplasia), which results in the acquisition of further molecular 
alterations that can lead to clonal evolution and cancer development. Cancer is an age-related 
disease, with incidence rates increasing almost exponentially from the mid-point of an 
organisms lifespan (Campisi., 2013).  
 Multi-cellular organisms with tissue renewal capabilities have evolved stringent tumour 
suppressive mechanisms that inhibit the proliferation of potential cancer cells. One such 
mechanism is cellular senescence, which is characterized by the irreversible growth arrest of 
mitotic cells in response to potentially oncogenic stimuli. 
 
1.3.1 REPLICATIVE LIFESPAN OF NORMAL AND TUMOUR CELLS 
 Cellular senescence was first described by Hayflick and colleagues over 50 years ago, 
when normal human fibroblasts were found to undergo an initial period of active proliferation in 
vitro before gradually decreasing in mitotic activity and entering a period of permanent but 
viable growth arrest, despite the availability of nutrients, growth factors and space (Hayflick and 
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Moorhead., 1961, Hayflick., 1965). In complete contrast, human cancer cells that are 
established in culture proliferate indefinitely. At this time, the immortal phenotype exhibited by 
cancer cells in vitro, was thought to be a cell culture artefact and not a characteristic feature of 
cancer cells. However, later studies involving normal diploid rodent fibroblasts, demonstrated 
that malignant transformation, either spontaneously or following carcinogen treatment or 
transfection with oncogenes (such as Ha-rasV12), could only occur within cells that had been 
previously immortalized (Newbold et al., 1982, Newbold and Overell., 1983). Transfection of 
normal rodent cells and primary human fibroblasts with the Ha-rasV12 oncogene, was found to 
induce premature cellular senescence (Newbold and Overell., 1983, Serrano et al., 1997). 
Furthermore, spontaneous immortalization of normal human somatic cells (fibroblasts or 
epithelial cells) has never been found to occur in vitro (Stampfer and Yaswen., 2002). Only after 
treatment with human oncogenes, viral oncoproteins or powerful carcinogens, have rare 
immortal variants been found to emerge (Newbold et al., 1982, Stampfer and Bartley., 1985). 
These findings demonstrate the importance of cellular immortality in mammalian 
carcinogenesis, which is now recognized as one of the hallmarks of human cancer (Hanahan and 
Weinberg., 2011). Moreover, these findings demonstrate the existence of intrinsic and stringent 
tumour suppressive mechanisms within mammalian cells that function to prevent cellular 
immortalization and cancer development upon exposure to oncogenic stimuli.  
 
1.3.2 CELLULAR SENESCENCE AS A BARRIER TO IMMORTALITY 
1.3.2.1 Mortality Barriers to Cellular Immortality 
 In support of the notion that cellular senescence represents a critical tumour suppressive 
mechanism, in vitro studies involving transfection of DNA tumour virus early oncogenes, such 
as those encoding the simian vacuolating virus 40 (SV40) large T-antigen (SV40-LT) and 
human papilloma virus (HPV) E6 and E7 proteins, into normal diploid human fibroblasts, 
provided evidence of a two-step mechanism of cellular immortalization that involved 
senescence bypass (Wright et al.,1989, Wright and Shay., 1992, Ozer et al., 1996, Newbold., 
2005). Normal human diploid fibroblasts undergo 50-80 population doublings (PD) in vitro 
before entering replicative senescence, termed Mortality 1 (M1). However, following 
introduction of SV40-LT or HPV E6 and E7 viral oncoproteins, fibroblasts enter a period of 
extended vigorous cell growth of around 20-30 PD, before slowing and entering a 'crisis' period 
known as Mortality 2 (M2), which is characterized by slow cell turnover and extensive cell 
death. Rarely, a clone of rapidly dividing cells emerges from crisis at a frequency of 10
-5
 to 10
-8
, 
which can proliferate indefinitely (Wright and Shay 1992, Newbold., 2005). These findings 
demonstrate that bypass of replicative senescence pathways, through introduction of viral 
oncoproteins, leads to an increased propensity for cellular immortalization.  
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 SV40-LT and HPV E6 and E7 proteins are known to bind and sequester the p53 tumour 
suppressor protein and disrupt the pRb-E2F complex. Taking into account the observations 
made by viral immortalization studies, these proteins must therefore function as important 
effectors of cellular senescence pathways (Jha et al., 1998). p53 activates the expression of 
p21
CIP1/WAF1
, a cyclin-dependent kinase inhibitor (CDKI) that prevents cyclin E/CDK2-mediated 
phosphorylation (and inactivation) of pRb, which forms a complex with E2F and represses the 
transcription of target genes involved in cell cycle progression through the G1/S transition and 
S-phase (reviewed by Campisi and Fagagna., 2007). Two major pathways are known to control 
activation of p53; DNA-damage response (DDR) and ARF (p14) (reviewed by Ben-Porath and 
Weinberg., 2005). In response to DNA damage such as DSB, ATM/ATR and Chk1/Chk2 
proteins phosphorylate and stabilize p53. The ARF protein is encoded by an alternative splice 
variant of the INK4A/CDKN2A locus, which also encodes the p16
INK4A
 gene. ARF and p16 are 
under the control of two separate promoters and are translated from different but overlapping 
open reading frames. ARF expression is activated in response to stressful stimuli or following 
ectopic expression of oncoproteins such as E2F1, c-Myc and Ras (Lowe and Sherr., 2003). 
Through inhibition of the E3 ubiquitin ligase HDM2, which targets p53 for proteolytic 
degradation, ARF promotes the stabilization of p53. Therefore, p53 and pRb function as key 
mediators of cellular senescence in response to potentially oncogenic stimuli such as DNA 
damage and oncoproteins.  
 The p16 gene has also been implicated as an important effector of cellular senescence in 
mammalian cells (Newbold., 2005). p16 encodes a CDKI that inhibits cyclin D/CDK4, 6 
complexes resulting in hypophosphorylation and activation of pRb. It is thought that p16 is 
responsible for activating a premature senescence pathway, termed Mortality 0 (M0), in 
response to accumulated stress in vitro (for example, supra-physiological or inadequate growth 
conditions) or in vivo (for example, ageing) (Campisi and Fagagna., 2007). Furthermore, 
induction of p16 expression and premature senescence has been observed following exposure to 
oncogenic RAS, which is known as oncogene-induced senescence (OIS). p16 is solely 
responsible for mediating stress-associated premature senescence (SIPS) within normal human 
mammary epithelial cells (HMEC) and keratinocytes (Stampfer and Yaswen., 2002). 
Inactivation of p16, but not p53, through epigenetic silencing or deletion of the p16 locus, is 
associated with bypass of premature senescence in vitro, which allows continued proliferation 
until the p53/p21/pRb-dependent M1 senescence barrier is reached. Interestingly, p16 is 
frequently inactivated in many human cancers (Herman et al., 1995). It is believed that, in 
addition to p53/p21/pRb-mediated replicative senescence pathways, p16/pRb-mediated 
premature senescence in response to stress or oncoproteins, provides an additional barrier 
against cellular immortalization, clonal evolution and malignant progression.  
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1.3.3 TELOMERES, SENESCENCE AND CANCER 
1.3.3.1 Telomere Structure and the End Replication Problem 
 Early genetic studies carried out over 70 years ago, found that chromosomes with 
damaged termini were unstable and formed ring or dicentric chromosomes through end-to-end 
fusions, which caused loss of genetic material during subsequent mitoses (Muller., 1938, 
McClintock., 1941). Chromosome ends were found to possess specialized structures, termed 
telomeres, that were thought to function to protect chromosome integrity. Telomeres are now 
known to be highly conserved, specialized nucleoprotein complexes located at the terminal ends 
of linear eukaryotic chromosomes that consist of short, repetitive DNA sequences and 
associated proteins including the shelterin complex (Blackburn., 1999, de Lange., 2005). 
Among different organisms, the number of telomeric sequence repetitions varies from a few 
kilobases (kb) to greater than 100kb (Gomez et al., 2012). However, the number of telomeric 
repetitions can also vary among individuals of the same species and also between tissues and 
chromosomes of the same organism. Human germ-line and adult somatic cells have an average 
telomere length of around 10kb (Blackburn., 1999, White et al., 2001).  
  
Figure 1.7 - Schematic representations of (A) T-loop formation by invasion of the 3'-single 
stranded (ss) overhang into the double-stranded (ds) telomeric sequence to form a D-loop 
though base-pairing with the complementary C-rich strand. (B) Shelterin complex members and 
an example of their organization on the repetitive telomeric DNA sequence. Images obtained 
and adapted from de Lange et al., (2005).  
 The human repetitive telomeric DNA sequence (TTAGGG)n, is always oriented 5'-3' 
towards chromosome termini and consists of a large double-stranded tract and a 3'-single-
stranded overhang that protrudes around 200 nucleotides beyond the complementary C-rich 
strand (Figure 1.7A), which can form complex G-quadruplex structures that disrupt DNA 
replication or telomere elongation by the telomerase enzyme (Makarov et al., 1997, Blackburn., 
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1999). In order to sequester the telomere end, single-stranded 3'-DNA overhangs invade the 
double-stranded telomeric DNA segments to form telomere loops (T-loop), which are stabilized 
through displacing G-rich strands and base-pairing with C-rich strands to form triple-stranded 
displacement loops (D-loop) (Figure 1.7A). T-loop formation and stabilization is mediated by 
members of the Shelterin complex, which consist of six telomere-specific protein units; TRF1, 
TRF2, RAP1, TIN2, POT1 and TPP1 (Figure 1.7B, Griffith et al., 1999, de Lange., 2005). 
Other telomere-associated proteins include DNA helicases, tankyrases and DNA damage 
sensors such as Rad50. Inhibition of shelterin component members, such as TRF2, results in 
telomere 'uncapping,' chromosomal end-to-end fusions and activation of the ATM/ATR-
mediated canonical DNA damage response pathway, leading to cell cycle arrest, apoptosis or 
senescence (Griffith et al., 1999, de Lange., 2005). It is therefore thought that t-loop structures 
function to maintain chromosome integrity and prevent exposure of chromosome ends to DNA 
damage sensors and subsequent activation of inappropriate DNA damage repair pathways. 
 Telomeres also provide a solution to the 'end replication problem', which describes the 
incomplete replication of linear chromosome ends within eukaryotic cells (Watson., 1972, 
Olovnikov., 1973). During DNA replication, DNA primase enzymes synthesize RNA primer 
molecules (approximately 10 nucleotides in length) at 200bp-intervals along the lagging strand 
of the replication fork, which are extended by DNA polymerase to form Okazaki fragments 
(Okazaki et al.,1968). Following removal of RNA primers, DNA ligase and DNA polymerase 
enzymes seal the Okazaki fragments together to form a continuous DNA strand (Wynford-
Thomas and Kipling., 1997). However, removal of the last RNA primer leaves a small region at 
the chromosome terminal, for which no complementary strand can be synthesized. Therefore, 
due to incomplete DNA replication and in the absence of compensatory telomere elongation 
mechanisms, telomeric DNA sequences are lost with each round of cell division. In humans this 
is equivalent to approximately 150-200bp/chromosome terminal with each cell division 
(Smorgorzewska and de Lange., 2004).  
1.3.3.2 Telomere Maintenance by Telomerase 
 The de novo synthesis of most eukaryotic telomeres is carried out by the reverse 
transcriptase ribonucleoprotein enzyme, telomerase, which was first discovered within the 
Tetrahymena thermophila ciliate protozoa by Greider and Blackburn (1989). The human 
telomerase enzyme is composed of a reverse transcriptase catalytic subunit (hTERT), an RNA  
template component (hTR) and integral accessory proteins, which together function to catalyze 
the addition of telomeric repeat sequences (TTAGGG) to the single-stranded 3'-end of telomeric 
DNA (reviewed by Wyatt., 2010).  
 The hTERT protein subunit is encoded by the hTERT gene located on chromosome 
5p15.33, which is around 40kb in length and comprises 16 exons and 15 introns (Daniel et al., 
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2012). This gene encodes a 1132 amino acid protein, which contains a long N-terminal 
extension, a central catalytic reverse transcriptase component and and a shorter C-terminal 
extension (Wyatt., 2010). Within the N-terminal conserved sequence motif TEN (telomerase 
essential N-terminal domain), is the DAT (dissociates activities of telomerase) region, which 
has been shown to play an important role in binding the hTR subunit (Figure 1.8A, Friedman 
and Cech., 1999). Adjacent to the TEN domain is the TRBD (telomerase RNA-binding 
domain), which contains three conserved RNA binding sequences CP, QFP and T-motif that  
are involved in positioning the hTR subunit within the hTERT active site (Figure 1,8A, Nicholls 
et al., 2011). The central reverse transcriptase (RT) domain forms the catalytic core of hTERT 
and contains conserved sequence motifs, which are involved in positioning the single-stranded 
3'-telomeric end within the TERT active site and catalyzing the addition of telomeric sequences. 
The active site contains a catalytic triad of three conserved aspartic acid residues, which 
facilitate the sequential addition of nucleotides through a two-metal ion mechanism (Autexier 
and Lue., 2006, Gillis et al., 2008). The TERT C-terminal extension exhibits the least sequence 
conservation, but mutations within this region have been shown to influence the subcellular 
localization of telomerase, enzyme processivity and telomere length maintenence (reviewed by 
Wyatt et al., 2010).  
 The hTR component of telomerase is encoded by the hTR gene (also known as hTERC), 
which is located on chromosome 3q26 and is 451bp in length (Nicholls et al., 2011). hTR 
consists of three conserved domains; (i) the template core domain (or pseudoknot), which 
contains an 11bp-RNA template strand (5'-CUAACCCUAAC-3') that encodes the telomeric 
repeat sequence, (ii) conserved regions 4 and 5 (CR4/CR5) and (iii) a box H/ACA domain, 
which is responsible for tethering telomere-associated proteins, maintaining hTR stability and 
nuclear localization (Gomez et al., 2012, Wyatt., 2010). Aside from hTERT, hTR has been 
found to interact with and facilitate the activation of hnRNP A1 (heterogeneous nuclear 
ribonucleoprotein A1), which functions to direct binding of the telomerase holoenzyme 
complex to telomere sequences (Nicholls et al., 2011).    
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Figure 1.8 - Schematic representations of (A) the structure of the hTERT protein subunit of 
telomerase showing the TEN (telomerase essential N-terminal domain), TRBD (telomerase 
RNA-binding domain), RT (reverse transcriptase), CTE (C-terminal extension) domains and 
conserved sequence motifs (adapted from Nicholls et al., 2011), (B) the human telomerase 
holoenzyme complex (image obtained from Gomez et al., 2012) and (C) a simplified model for 
processive telomere elongation by telomerase (adapted from Autexier and Lue., 2006). 
Abbreviations: RNP (ribonucleoprotein), hTERT (human telomerase reverse transcriptase), 
hTR (human telomerase RNA). 
 Following hTERT mRNA transcription and cytoplasmic translation, hTERT peptides 
are translocated into the nucleus through interaction with 14-3-3 signaling proteins and NFκB 
p65, where it is then recruited to Cajal bodies (Wojtyla et al., 2011). Trimethylguanosine 
(TMG)-capped, pre-cursor hTR mRNA is modified and converted into mature hTR through 
binding of the RNA-dependent NTPase RHAU and dyskerin to 5'- and 3'-ends of the mRNA 
respectively (reviewed by Podlevsky and Chen., 2012). TCAB1 (telomerase Cajal body protein 
1) then binds to the H/ACA motif and transports mature hTR to Cajal bodies for assembly of the 
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telomerase ribonucleoprotein complex. Inhibition of TCAB1 has been associated with 
prevention of telomerase component assembly, disruption of telomerase-telomere interactions 
and telomere synthesis (Venteicher et al., 2009). Analysis of affinity-purified telomerase from 
the cervical cancer-derived HeLa cell line by mass spectrometry demonstrated the presence of 
several other telomere-associated proteins including NOP10, NHP2, GAR1, pontin and reptin, 
which play essential roles in the biogenesis, stabilization and nuclear localization of telomerase 
(Figure 1.8B, Venteicher et al., 2008). The highly conserved nucleolar protein dyskerin, 
together with two closely related ATPase enzymes reptin and pontin, function to assemble the 
telomerase ribonucleoprotein complex through recruitment and stabilization of the hTR subunit. 
Dyskerin binds to the hairpin subunit of the H/ACA motif of hTR, along with NOP10, NHP2 
and GAR1 proteins, which have been shown to be required for stability and accumulation of 
hTR in vivo (Fu and Collins., 2007). The human telomerase enzyme comprises a 1:1 
stoichiometric ratio of hTERT and hTR and has been shown, through single-particle electron 
microscopy, to display a bi-lobal structure (Sauerwald et al., 2013). It is thought that telomerase 
is a dimeric complex consisting of two hTERT and two hTR dimers, which has the capacity to 
extend two telomeric substrates simultaneously. This has been proposed to allow telomerase to 
bind and extend sister chromatid telomeres in tandem. Following assembly of the dimeric 
telomerase complex within Cajal bodies, the hnRNA A1 protein binds to the hTR subunit and 
directs telomerase to telomere ends within the nucleolus (Wojtyla et al., 2011). Confocal 
microscopy analysis of normal human fibroblasts containing a green fluorescent protein (GFP)-
hTERT fusion protein, demonstrated that telomerase is released from the nucleolus into the 
nucleoplasm to extend telomere lengths during S/G2 phase of the cell cycle (Wong et al., 2002). 
In contrast, tumour cells were found to display high levels of telomerase within the nucleoplasm 
during all phases of the cell cycle, which demonstrates that cell cycle-dependent nucleolar 
association/dissociation of telomerase is dysregulated in cancer cells leading to increased access 
to telomeric substrates.  
 The synthesis and elongation of telomeric repeat sequences by telomerase involves the 
sequential addition of deoxynucleotide triphosphates (dNTPs) to the 3'-hydroxyl group of 
telomeric ssDNA overhang (Wyatt et al., 2010). The process begins with binding of the 
telomerase enzyme to anchor sites within the 5'-ssDNA sequence and alignment of the 3'-
ssDNA sequence with the template strand located with the hTR component (Figure 1.8C). The 
hTERT RT domain then catalyzes the addition of dNTPs to the 3'-ssDNA through reverse 
transcription of the hTR template strand. Once the 5'-template boundary element is reached, 
telomerase undergoes a translocation reaction whereby the enzyme repositions to the new 5'-
ssDNA anchor site and aligns the hTR template strand to initiate another round of dNTP 
addition. This process of sequential dNTP incorporation is known as nucleotide addition 
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processivity, which is unique to the telomerase enzyme and can result in the addition of 
numerous telomere repeats before telomerase disassociates from the telomere.   
1.3.3.3 Telomere Dysfunction and Replicative Senescence  
 In 1990, Harley et al., discovered that telomeric DNA lengths within normal human 
fibroblasts decrease with increasing passage. However, within immortal human cell lines, such 
as the HeLa cell line, telomere elongation mechanisms appeared to counteract progressive 
telomere shortening. Gradual telomere shortening within a yeast strain defective in the est1 
(ever shorter telomeres) gene, was associated with induction of a senescent-like growth arrest, 
similar to that observed within higher eukaryotic cells (replicative senescence). It was therefore 
proposed that telomeres act as a 'mitotic clock' to limit the replicative lifespan of normal human 
somatic cells in vitro and in vivo. Furthermore, due to the known role of telomeres in stabilizing 
chromosome termini and protecting against end-to-end fusions, loss of telomeric sequences was 
thought to explain the higher frequency of dicentric chromosomes observed within senescent 
human fibroblasts (Harley., 1991).  
 Using a highly sensitive biochemical assay for measuring the levels of telomerase 
activity within human cells, Kim et al., (1994) demonstrated that 98% of immortal human cell 
lines derived from 18 different human tumour types and over 90% of tumour tissue biopsy 
samples from 12 different tumour types, were positive for telomerase activity, whereas normal 
human cell strains and noncancerous tissue biopsy samples derived from the same tissues were 
negative. These findings demonstrate a strong association between cellular immortality and the 
activation of telomere maintenance mechanisms, which strengthens the hypothesis that 
progressive telomere shortening within telomerase-deficient, normal human somatic cells, may 
act as a critical tumour suppressive barrier to cellular immortalization by limiting cellular 
replicative potential. Subsequent studies using more sensitive methods of telomerase detection 
have revealed that normal stem/progenitor cells residing within the highly proliferative tissues 
such as the bone marrow (haematopoietic), skin (hair follicle), and gastrointestinal tract (crypt 
epithelium) as well as cells within reproductive organs (ovary and testes), germ cells and 
activated lymphocytes, exhibit detectable levels of telomerase activity (reviewed by Artandi and 
DePinho., 2010). However, telomerase activity levels within these stem/progenitor cells does 
not appear to be sufficient to maintain telomere lengths with increasing age (Broccoli et al., 
1995).   
 Definitive proof of a causal relationship between progressive telomere shortening and 
induction of replicative senescence was provided by Bodnar et al., (1998), who demonstrated 
that ectopic expression of the gene encoding the telomerase reverse transcriptase subunit 
(hTERT) within telomerase-negative primary human fibroblasts and epithelial cells, was 
associated with telomere elongation and continued cell division beyond the replicative lifespan 
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exhibited by negative controls, which displayed progressive telomere shortening and entered 
replicative senescence. However, hTERT-expressing cells were found to display a normal 
karyotype and did not exhibit any morphological features of transformed cells (for example loss 
of contact inhibition), indicating that telomerase activity alone was insufficient to confer 
malignant transformation of normal cells. 
 Taking these observations into account, together with viral transforming gene studies, it 
is thought that p53 functions as a key mediator of replicative senescence (M1) induction in 
response to critically shortened telomeres (Newbold., 2002). In support of this, normal human 
fibroblasts have been found to exhibit increasing levels of DNA damage response factors such 
as γ-H2AX, ATM, ATR, 53BP1, BRCA1, Mre11 and ATRIP localized to telomeres, indicating 
that telomere shortening induces a DNA damage response (Herbig et al., 2004). Co-localization 
of DNA damage response factors and telomeres, known as telomere-dysfunction induced foci 
(TIF), have also been identified following inhibition of the telomere-associated TRF2 protein 
within human fibroblasts (Takai et al., 2003). Disruption of TRF2 binding resulted in telomere 
uncapping, chromosome-end fusions and rapid activation of ATM/p53-mediated DNA damage 
response pathways leading to apoptosis. Interestingly, Herbig et al., (2004) found that the 
telomere-associated TRF2 protein was absent from the majority of TIF in senescent fibroblasts, 
which demonstrates that destabilization of the protective cap occurs when telomeres become 
critically shortened. Furthermore, in some senescent cells, single TIF were found to be 
associated with multiple telomeres, indicating that chromosomal end-associations (a 
characteristic feature of telomere dysfunction) may also trigger a DNA damage response. There 
is evidence to suggest that, in any given cell, only one or two critically shortened telomeres are 
sufficient to produce γ-H2AX foci and initiate a DNA damage checkpoint response (Hemann et 
al., 2001, Shay and Wright., 2005). Damaged telomeres within senescent fibroblasts were found 
to activate ATM/Chk1/Chk2/p53/p21 signalling pathway, leading to cell cycle arrest in G1 
phase (Herbig et al., 2004). This provides evidence that dysfunctional telomeres are recognized 
by DNA damage response machinery and are responsible for initiating p53-mediated replicative 
senescence or pro-apoptotic pathways.  
 Disruption of p53 function, either by mutation or introduction of SV40 LT antigen 
prevents p53-mediated growth arrest in response to critical telomere shortening (Newbold., 
2005). As a result, DNA damage checkpoint responses are mitigated and cells continue to 
divide. An increasing number of telomeres become critically shortened, leading to chromosomal 
end-to-end fusions (dicentric chromosomes), chromosome breakage-fusion-bridge (BFB) cycles 
and loss of vital genetic material. Cells then enter crisis (M2), where most cells remain and 
where cell growth is balanced by cell death due high levels of genomic instability. Rare 
immortal clones that emerge from crisis acquire mechanisms that maintain or extend telomere 
lengths, allowing them to divide continuously. This is thought to be a critical step in human 
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carcinogenesis. The majority of these immortal clones maintain telomere lengths through 
reactivation of telomerase, which is thought to be due to loss of stringent telomerase regulatory 
mechanisms during crisis (Meyerson et al., 1997, Kim et al.,1994, Newbold., 2005). Having 
acquired a selective growth advantage over neighbouring cells, these immortal variants are 
predicted to undergo clonal evolution leading to malignant progression.  
1.3.3.3.1 Coevolution of Telomerase Activity, Replicative Senescence and Body Mass  
 As any single cell may undergo malignant transformation, the need for additional 
lifetime cell divisions within large, long-lived species may confer a greater risk for the 
development of spontaneous tumours compared with small, short-lived species. However, no 
correlation between body size and risk of cancer development has been found to exist (Caulin 
and Maley., 2011). Therefore, large, long-lived species are believed to have evolved tumour 
suppressive mechanisms that counteract the increased risk for spontaneous tumour 
development.  
 Induction of replicative senescence pathways in response to critical telomere shortening 
is thought to have evolved as a powerful tumour suppressor mechanism that limits the 
replicative capacity of cells and prevents malignant transformation (Campisi., 2001). Aside 
from normal human somatic cells, replicative senescence has also been found to occur within 
fibroblasts from Anthropoids such as New World Primates (squirrel monkey and spider 
monkey) and Old World Primates (rhesus monkey, orangutan and pigmy chimpanzee), and 
Ungulates such as sheep, cow and horse (Steinert et al., 2002, Gorbunova and Seluanov., 2009). 
Fibroblasts derived from these species were also found not to express detectable levels of 
telomerase. In complete contrast, many somatic tissues of small, short-lived rodents such as the 
hamster, mouse and rat, have been found to express telomerase activity and enter a telomere 
length-independent growth arrest termed stress-induced premature senescence (SIPS) 
(Newbold., 2005). Exposure of mouse somatic cells to supraphysiological levels of oxygen 
(20%) is associated with slowed growth after around 12-15PD followed by the emergence of 
immortal clones after a few days. Normal human somatic cells also possess the premature 
senescence pathway that is activated in response to stress or oncoproteins (see Chapter 1.3.2.1), 
however spontaneous immortalization of human somatic cells has never been found to occur in 
vitro (Stampfer and Yaswen., 2003). Therefore, replicative senescence is thought to provide an 
additional mechanism that protects against cancer development within human somatic tissues 
and those of other large, long-lived species. These observations suggest that significant 
differences exist between the barriers to immortal transformation and cancer within small, short-
lived species and large, long-lived species. 
 The differences between the telomere biology of humans and mice could be due to 
differences in lifespan or body mass (Gorbunova and Seluanov., 2009). In order to explore the 
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evolutionary relationship between telomerase activity, organism lifespan and body mass, 
Seluanov and colleagues examined telomerase activity within seven somatic tissues of 
individuals from a set of 15 different rodent species, representing a range of different sizes and 
lifespans (Seluanov et al., 2007). Interestingly, while the majority of rodent tissues were found 
to express telomerase activity, tissues from small, but longer-lived rodents such as the grey 
squirrel and naked mole rat, were also found to express telomerase activity. On the other hand, 
tissues from the two largest rodent species (beaver and capybara), were not found to express any 
detectable telomerase activity. Overall, a negative correlation was observed between telomerase 
activity and body mass, but no correlation was observed between telomerase activity and rodent 
lifespan. A subsequent study, which examined the proliferation rate and capacity of fibroblasts 
derived from each of the rodent species, revealed that larger rodent fibroblasts entered 
replicative senescence in culture, whereas fibroblasts from small, short-lived rodents 
proliferated continuously (Seluanov et al., 2008). Interestingly, telomerase-positive fibroblasts 
from small, longer-lived rodents were found to exhibit a slow proliferation rate compared with 
small, short-lived rodent species. This suggests that small, long-lived species may have evolved 
alternative mechanisms that protect against tumour development. 
 Based on these observations, it has been proposed that telomerase repression and 
replicative senescence are adaptive tumour suppressive mechanisms that have coevolved with 
an increase in organism body mass, as larger animals contain more cells and therefore have a 
greater risk for cancer development (Gorbunova and Seluanov., 2009).  
1.3.3.4 Telomere Dysfunction and Cancer 
 It is generally accepted that genetic instability, such as DNA copy number alterations, 
drives malignant transformation and leads to the development of advanced disease. The 
initiation of DNA damage pathways in response to one or two uncapped telomeres or 
chromosome end-associations, is thought to be a powerful barrier to tumour development. 
However, telomere dysfunction in conjunction with loss of DNA damage signalling checkpoints 
is believed to be a major mechanism underlying genomic amplifications and deletions in human 
cancers (Artandi and De Pinho., 2010). The acquisition of telomere maintenance mechanisms 
during crisis is thought to prevent ongoing telomere dysfunction and genomic instability so that 
cells remain viable, but retain some level of instability for clonal evolution and malignant 
progression. This hypothesis is consistent with the observation that telomere lengths within pre-
invasive and invasive carcinomas such as breast, pancreatic or prostate cancers, are generally 
significantly shorter than normal epithelial cell counterparts, which suggests that a period of 
telomere shortening occurs early in the development of multiple epithelial cell cancers (Meeker 
et al., 2002, 2004). Concomitant with telomere shortening, pre-invasive colon cancer lesions 
exhibit high levels of genomic instability, including anaphase bridges (a hallmark of telomere 
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dysfunction). Up-regulation of telomerase occurs during later stages of colon cancer 
development, which is thought to promote telomere stability and a reduce the rate of 
chromosomal alterations during invasive and metastatic stages (Chadeneau et al., 1995, Artandi 
and De Pinho., 2010). Therefore, telomere dysfunction plays an important tumour suppressive 
role by limiting the proliferative capacity of human cells, but can also be responsible for 
initiating chromosomal instability, which is a key driver of malignant progression.  
 
1.3.4 TELOMERASE AND CANCER 
 The observations made by Kim and colleagues in 1994, demonstrated a specific 
association between cancer cell immortality and telomerase activity (Kim et al., 1994). 
Functional proof of this relationship was demonstrated a few years later, after genes encoding 
the human reverse transcriptase enzyme component (hTERT) and the human telomerase RNA 
subunit (hTR) were cloned (Meyerson et al., 1997, Kilian et al., 1997, Feng et al., 1995). 
Northern analysis of hTR expression levels within normal human primary and pre-crisis human 
cell strains and immortalized cells revealed that hTR transcripts could be detected within both 
telomerase-positive immortal cell lines and telomerase-negative primary and pre-crisis cell 
strains (Avillon et al., 1996). Despite observing slightly higher hTR levels within human tumour 
samples compared with normal tissue samples, a positive correlation between hTR expression 
and telomerase activity was not observed. These findings demonstrate that an increase in hTR 
expression is unlikely to be responsible for the level of telomerase activity observed within 
human tumour cells.  
 On the other hand, studies have shown that telomerase-positive cancer cell lines, 
primary tumours and normal telomerase-positive human tissues such as the intestine and testes 
exhibit high levels of hTERT expression, whereas telomerase-negative, mortal fibroblast strains 
or normal human tissues such as the prostate, heart, brain and skeletal muscles do not 
(Meyerson et al., 1997, Kilian et al., 1997). Using an in vitro model of cellular immortalization 
involving the transformation of normal human lymphocytes and embryonic kidney cells with 
the Epstein-Barr virus (EBV) and the SV40-T antigen respectively, Meyerson et al., (1997) 
demonstrated that hTERT expression was specifically associated with emergence from crisis and 
telomerase activation. These findings demonstrate a strong correlation between hTERT 
expression and telomerase activity within normal human tissues, tumours and immortal cell 
lines, and suggest that de-repression of hTERT may be required for telomerase expression 
within tumour cells. In further support of this, ectopic expression of hTERT alone is sufficient to 
confer immortal transformation of normal human fibroblasts in vitro (Counter et al., 1998, 
Bodnar et al., 1998). In addition, expression of a dominant-negative hTERT mutant within 
telomerase-positive human tumour cells was associated with telomere shortening and cell death 
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in vitro, and elimination of tumour formation in vivo (Hahn et al.,1999). These findings not only 
provide evidence to suggest that the major rate-limiting component of telomerase activity within 
tumour cells is hTERT, but also demonstrate that inhibition of telomerase is sufficient to restore 
a limited cellular lifespan and inhibit tumour cell growth.  
 In further support of the notion that hTERT de-repression is a critical step for telomerase 
reactivation during human carcinogenesis, the high-risk human papilloma virus 16 (HPV16) E6 
and E7 oncoproteins have been found to immortalise primary human keratinocytes through 
induction of hTERT transcription and activation of telomerase activity (Klingelhutz et al., 1996, 
Liu et al., 2008). HPV16 has been linked to cervical, anal and head and neck carcinoma 
aetiology (zur Hausen., 2002, Gillison et al., 2001). E6 binds directly with hTERT regulatory 
molecules c-Myc, NFX-1 and the E6AP ubiquitin ligase to mediate activation of hTERT 
expression and there is evidence to suggest that E6 also interacts with the hTERT protein to 
increase telomerase activity through a post-transcriptional mechanism (Liu et al., 2008, 2009).  
 Using a quantitative real-time polymerase chain reaction (RT-PCR)-based technique, 
Ducrest et al., (2001) demonstrated that both pre-spliced and post-spliced hTERT transcripts 
could be detected within telomerase-positive tumour-derived cell lines, but not within 
telomerase-negative human fibroblasts. On average, telomerase-positive cancer cell lines were 
found to contain 0.2-6 molecules of post-spliced hTERT mRNA per cell. A strong correlation 
between the number of nuclear, pre-spliced hTERT transcripts and the number of cytoplasmic, 
post-spliced hTERT transcripts was observed within all telomerase-positive and negative cells 
analyzed. These findings provide evidence to suggest that telomerase activity within normal and 
cancer cells is dependent on the transcriptional control of hTERT. Using a reporter construct 
containing sequences upstream of hTERT, Cong et al., (1999) demonstrated that the hTERT 
promoter is inactive within normal human cells, but is activated during cellular immortalization. 
This suggests that telomerase reactivation during cellular immortalization may be due to 
transcriptional de-repression of hTERT. It has therefore been proposed that emergence from 
crisis and telomerase reactivation may be due to acquisition of a rare genetic or epigenetic 
change that results in the functional loss of critical hTERT transcriptional repressor genes 
(Newbold., 2005, Stampfer and Yaswen., 2002). The low frequency of spontaneous emergence 
from crisis (<10
-6
) indicates that stringent mechanisms of hTERT transcriptional repression exist 
within normal human somatic cells. This has prompted researchers to investigate the 
mechanisms responsible for mediating hTERT transcriptional repression within normal human 
cells and which of these may be disrupted to confer immortal transformation.  
1.3.4.1 Extra-Telomeric Functions of Telomerase 
 Aside from the established functional role of telomerase to extend telomeric repeat 
sequences, there is new evidence to suggest that extra-telomeric functions of telomerase exist to 
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promote tumour growth (reviewed by Mocellin et al., 2013). Constitutive activation of the 
Wnt/β-catenin signalling has been found to promote tumorigenesis of the breast, skin and bone 
marrow (Fodde and Brabletz, 2013). This is due to the downstream transcriptional activation of 
a variety of target genes involved in proliferation and differentiation, which is thought to play a 
major role in both cancer development and metastasis. The telomerase reverse transcriptase 
subunit (TERT), has been found to interact with the chromatin-remodelling protein BRG1, and 
form part of the β-catenin transcription complex, that functions to modulate the expression of 
target genes (Park et al., 2009).  In addition, it has been found that under periods of cell stress, 
TERT is excluded from the nucleus and localizes to the mitochondria, where it protects 
mitochondrial DNA (mtDNA) and prevents the induction of mitochondrial apoptotic pathways 
(Ahmed et al., 2008). TERT down-regulation has been shown to cause activation of the pro-
apoptotic factor Bax, which leads to induction of apoptosis (Martinez and Blasco., 2011). These 
observations provide evidence that telomerase plays a critical role, not only in the early events 
of cancer development, but also in disease progression.  
 
1.3.5 REGULATION OF HUMAN HTERT 
 Studies have shown that the major rate-limiting component of the human telomerase 
enzyme, hTERT, is regulated at the transcriptional level by a variety of transcription factors, 
oncogenes, tumour suppressor genes, hormones and unknown sequences present within the 
genome (reviewed by Kyo et al., 2008 and Daniel et al., 2012). Epigenetic alterations such as 
DNA methylation and histone modifications are thought to provide another level of regulation 
by modulating access of the hTERT promoter to activating/repressing factors. Splicing patterns 
and alternative splice variants of the hTERT gene have also been implicated regulating hTERT 
by maintaining an optimal level of hTERT expression, which is essential for cell survival. Post-
translational modifications of hTERT, such as phosphorylation and ubiquitination, are important 
for modulating hTERT protein stability and nuclear localization, which are critical for 
telomerase-dependent telomere length maintenance mechanisms within human cancer cells.     
1.3.5.1 Characterization of the hTERT Promoter 
 The 5'-promoter region of hTERT was cloned by several groups in 1999 (Cong et al., 
1999, Takakura et al., 1999, Horikawa et al., 1999). Using a 1.7kb fragment comprising 
upstream sequences of hTERT to control the expression of the firefly luciferase reporter gene, 
Horikawa et al., (1999) demonstrated that only cancer cell lines (SiHa and RCC23) but not 
normal human cells (SUSM-1) exhibited high levels of luciferase activity, which provides 
additional evidence that hTERT gene expression is controlled primarily at the transcriptional 
level. The hTERT promoter does not contain detectable TATA or CAAT boxes but is rich is 
CpG dinucleotides and contains a variety of transcription factor binding sites and hormone 
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response elements spanning at least -2670bp upstream of the transcription start site (TSS) 
(Figure 1.9, Kyo et al., 2008).  
 
Figure 1.9 - Schematic representation of the hTERT promoter and the approximate positions of 
activating and repressing cis-acting elements with known interacting proteins/factors (Adapted 
from Kyo et al., 2008). Abbreviations: ERE (oestrogen responsive element), ER (oestrogen 
receptor), RXR (retinoid X receptor), DR3' (degenerated vitamin D3 receptor/retinoid X 
receptor binding site), WT-1 (Wilms' tumour 1). 
 The minimal/core promoter region of hTERT is positioned -330bp upstream to +361bp 
downstream of the TSS and contains two E-box binding elements (-165bp to -160bp and +44bp 
to +49bp), five zinc finger transcription factor Sp1 binding sites (within 110bp upstream of 
TSS), two juxtaposed Ets transcription factor binding sites (-22bp to -14bp), an E2F 
transcription factor binding site (-174bp to -170bp) and a Wilms' tumour suppressor 1 (WT-1) 
binding site (-283bp to -273bp) (reviewed by Janknecht., 2004). E-box elements (CACGTG) are 
binding sites for the c-Myc/Max/Mad family of basic helix-loop-helix zipper (bHLHZ) 
transcription factors. Upstream of the hTERT core promoter are several other transcription 
factor binding sites such as four myeloid-specific zinc finger protein 2 (MZF-2) binding sites 
(spanning -687bp to -507bp), several activating protein 1 (Ap1/JUN) proto-oncogene binding 
sites (at -1655bp and -718bp) and a nuclear factor-kappa-B (NFκB) transcription factor complex 
binding site (Junknecht., 2004, Kyo et al., 2008). Two oestrogen receptor (ER) binding sites are 
also present upstream of the core hTERT promoter sequence (-873bp to -859bp and -2677bp to -
2665bp), one of which is a ER half-site coupled with a canonical Sp1 binding site. A vitamin D 
and retinoic acid nuclear hormone receptor response element DR3' (-2530bp to -2516bp) is 
positioned adjacent to the most distal ER binding site (Figure 1.9). The presence of multiple 
binding sites for several transcription factors and hormone receptors that are important effectors 
for vast array of signalling pathways, suggests that hTERT transcription may be controlled and 
regulated in response to a variety of different stimuli. 
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1.3.5.2 Transcriptional Regulation   
1.3.5.2.1 Transcriptional Activators 
1.3.5.2.1.1 Transcription Factors 
 The bHLHZ transcription factor c-Myc is responsible for regulating a variety of normal 
cellular functions including proliferation and differentiation (Daniel et al., 2012). Abrogation of 
c-Myc function, either through mutation or overexpression as a result of gene translocation or 
amplification, has been implicated in multiple cancer types. Several groups have shown that c-
Myc forms a heterodimer complex with Max and binds to E-box elements within the hTERT 
promoter to activate transcription (reviewed by Kyo et al., 2008). However, many of these 
studies used recombinant c-Myc and exogenous c-Myc overexpression to demonstrate 
transcriptional activation of hTERT through binding of c-Myc to the hTERT promoter, which 
may not reflect the function of endogenous c-Myc in vivo (Kyo et al., 2008). Furthermore, 
studies have reported no correlation between hTERT and c-Myc expression levels within some 
cancer cell types, including breast cancer (Kyo et al., 2008, Kirkpatrick et al., 2003). However, 
Xu et al., (2001) demonstrated that endogenous c-Myc binds to E-box elements within the 
hTERT promoter within exponentially proliferating but not differentiated HL60 human 
promyelocytic leukaemia cells. Therefore, it is unclear whether deregulation of endogenous c-
Myc expression plays a critical role in the transcriptional activation of hTERT during 
carcinogenesis in vivo. 
 In 2003, Goueli and Janknecht demonstrated that bHLHZ upstream transcription factors 
(USF) 1 and 2 bind more readily to E-box elements within the hTERT promoter than c-
Myc/Max within both hTERT-positive and negative cells. An increase in hTERT promoter 
activity was observed within cancer cells following joint expression of USF1 and USF2, 
compared with expression of each one alone, indicating that these proteins may function 
collectively to induce hTERT transcription within cancer cells. Exogenous expression of the 
USF coactivator protein p300, was associated with enhanced hTERT promoter activity within 
hTERT-expressing human embryonic 293T cells, whereas inhibition of the p38-MAP kinase (an 
activator of USF proteins), reduced hTERT promoter activity. These findings demonstrate that 
several upstream signalling pathways modulate USF1 and USF2-mediated activation of hTERT 
transcription. Goueli and Janknecht., (2003) propose that increased proliferative signalling 
pathways may lead to increased p38-MAP kinase or p300 activity and USF-mediated induction 
of hTERT during human carcinogenesis. However, exogenous overexpression of p38-MAP 
kinase within hTERT-negative normal human fibroblasts was not associated with induction of 
hTERT expression and telomerase activity, which suggests that activation of USF proteins may 
not be responsible for hTERT de-repression during human carcinogenesis. 
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 The zinc finger transcription factor Sp1, has been shown to bind five GC-boxes located 
on the hTERT promoter and activate hTERT transcription (Kyo et al., 2000). Substitution 
mutations within each Sp1 binding site was associated with a slight reduction in hTERT 
transcriptional activity within different cancer cell lines, whereas mutations within all Sp1 
binding sites resulted in a greater than 90% loss in hTERT promoter activity, even when c-
Myc/Max binding elements were intact. Furthermore, examination of Sp1 and c-Myc protein 
levels within human fibroblasts at various stages during the process of immortal transformation, 
revealed that Sp1 and c-Myc expression was up-regulated within hTERT and telomerase-
positive cell clones that had overcome the replicative senescence barrier. These findings 
indicate that binding of Sp1 to GC-boxes within the hTERT promoter maintains transcriptional 
activation of hTERT within cancer cells in vitro and also suggest that Sp1 and c-Myc may 
cooperate to induce hTERT transcription during cellular immortalization. In addition, Sp1 has 
been shown to cooperate with the nuclear factor of activated T cells (NFAT) to induce hTERT 
expression within activated lymphocytes (Chebel et al., 2009). Silencing of NFAT1 within 
MCF-7 breast cancer and Jurkat leukaemia cell lines was associated with reduced hTERT 
expression levels. However, Sp1 has been found to be expressed ubiquitously within normal 
human cells (Kyo et al., 2008). Furthermore, transcriptional repression of hTERT by an 
unknown repressor sequence(s) on human chromosome 3 within RCC23 renal cell carcinoma 
cells, was not associated with significant changes in Sp1 binding on the hTERT promoter 
(Horikawa et al., 2002). Therefore, Sp1 alone is unlikely to be responsible for mediating 
transcriptional activation of hTERT during immortal transformation.  
 Studies have shown that members of the Ets family of transcription factors play a 
functional role in hTERT transcriptional regulation (reviewed by Gladych et al., 2011). The Ets 
family comprises at least thirty members, which share a common erythroblast transformation-
specific (ETS) domain. Knockdown of Ets-2, but not Ets-1, within the MCF-7 breast cancer cell 
line, was associated with a significant reduction in hTERT expression and telomerase activity 
and increased cell death (Dwyer and Liu., 2009). Reconstitution of hTERT was found to rescue 
this effect, indicating that loss of telomerase activity was responsible for induction of cell death. 
Binding of Ets-2 to two Ets binding sites within the hTERT promoter (Figure 1.9) was found to 
be responsible for Ets-2-mediated induction of hTERT expression, as mutation of either site was 
associated with telomerase repression. Other Ets members including, ER81, PEA2 and FLI1 
have also been implicated in telomerase regulation through binding to Ets sites within the 
hTERT promoter within Ewing's sarcoma cell lines (Takahashi et al., 2003). It has therefore 
been proposed that hTERT transcription is regulated by the competitive binding of activating 
and repressing Ets members. As such, constitutive expression of activating Ets members, such 
as Ets-2, may be responsible for inducing hTERT transcription during carcinogenesis. In 
addition to gain-of-function mutations, constitutive activation of hTERT-inducing Ets 
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transcription factors may also be due to deregulation of upstream growth factor signalling 
pathways. Activation of the epidermal growth factor receptor (EGFR) and the epidermal growth 
factor receptor (EGFR)-related receptor tyrosine kinase HER2, has been associated with 
induction of hTERT transcription through activation of the mitogen activated protein kinase 
(MAPK) pathway and binding of Ets members to the hTERT promoter (Goueli and Janknecht., 
2004, Kyo et al., 2008). Therefore increased growth factor signalling may also contribute to 
Ets-mediated hTERT transcription in cancer cells. 
1.3.5.2.1.2 Hormones 
 As shown in Figure 1.9, the hTERT promoter contains two oestrogen response elements 
(ERE) located upstream of the hTERT TSS. The oestrogen steroid hormone has been found to 
up-regulate telomerase activity within breast and prostate cancer cells (Daniel et al., 2012). 
Studies have shown that ligand-activated oestrogen receptor α (ERα) binds to ERE within the 
hTERT promoter to mediate transcriptional activation of hTERT (reviewed by Kyo et al., 2008). 
There is also evidence to suggest that oestrogen induces telomerase activity within human 
ovarian cancer cells via Akt-dependent phosphorylation of hTERT (Kimura et al., 2004). 
Therefore, oestrogen activates telomerase through transcriptional and post-transcriptional 
regulation of hTERT.  
 The androgen steroid hormone has also been shown to up-regulate hTERT transcription 
within androgen-sensitive LNCap prostate cancer cells (Guo et al., 2003). Using an in vivo 
model of prostate cancer, androgen deprivation was associated with a reduction in hTERT 
mRNA levels and telomerase activity. In 2010, Nourbakhsh and colleagues demonstrated that 
exposure of ovarian adenocarcinoma cells to androgen hormones testosterone and 
androstenedione, was associated with a significant increase in hTERT expression, hTERT 
phosphorylation and telomerase activity. Androgen-induced hTERT expression was abolished 
following treatment of cells with phosphotidylinositol 3-kinase (PI3K) inhibitors. Therefore, 
unlike oestrogen, androgen hormones stimulate hTERT expression through an indirect 
mechanism. Androgen receptors (AR) have been found on the surface of ovarian and prostate 
cancer cells and can mediate androgen-dependent and androgen-independent growth of prostate 
cancer cells (Nourbakhsh et al., 2010, Haag et al., 2005). Androgens are also thought to play an 
important role in the pathogenesis of ovarian cancer, as exposure of normal human ovarian 
epithelial cell growth to the synthetic androgen mibolerone is associated with increased cell 
proliferation and inhibition of cell death (Edmonson et al., 2002). Therefore, androgen-
dependent up-regulation of hTERT expression and telomerase activity may contribute to 
tumorigenesis within androgen-sensitive tissues.  
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1.3.5.2.2 Transcriptional Repressors 
1.3.5.2.2.1 Transcription Factors 
 Using a genetic screening approach to identify genes responsible for mediating 
repression of hTERT transcription within normal human somatic cells, Oh et al., (2000) isolated 
the Mad1 bHLHZ transcription factor. The Mad1/Max heterodimer was shown to bind the 
hTERT promoter at the same E-box elements within the hTERT promoter as c-Myc/Max 
heterodimers. Abrogation of E-box elements by site-directed mutagenesis was associated with a 
significant increase in hTERT promoter activity within normal human diploid fibroblasts, 
indicating that Mad1 may be responsible for mediating repression of hTERT transcription within 
normal human cells (Oh et al., 2000). Furthermore, exogenous expression of Mad1 was found 
to suppress hTERT transcription within immortalized human kidney cells (293). This effect was 
reversed upon mutation of E-box binding elements or through increasing amounts of co-
transfected c-Myc expression plasmid. These findings suggest that Mad1 and c-Myc compete 
for the same binding site within the hTERT promoter sequence but have opposing effects on 
hTERT transcription. Interestingly, a switch from c-Myc/Max binding to Mad1/Max binding 
was observed when hTERT-expressing human promyelocytic leukaemia cells were induced to 
differentiate (Xu et al., 2001). Furthermore, exogenous expression of Mad1 within human 
bladder cancer cells was associated with transcriptional repression of hTERT (Daniel et al., 
2012). Oh et al., (2012) found that immortalized 293 kidney cells and HeLa cervical carcinoma 
cells exhibited higher levels of c-Myc protein than normal human kidney cells and fibroblasts, 
whereas Mad1 protein levels were found to be higher within normal human cells than immortal 
cell lines. Therefore increased c-Myc expression is thought to contribute to transcriptional 
activation of hTERT during carcinogenesis by causing a shift in Mad1/Max dimerization to c-
Myc/Max dimerization. However, studies have shown that some cancer types demonstrate no 
correlation between c-Myc and hTERT expression levels (see above), which indicates that 
induction of c-Myc expression cannot account for transcriptional activation of hTERT within all 
human cancer cells. 
 The CCCTC binding factor (CTCF) is a member of the BORIS (Brother of the regulator 
of Imprinted Sites) and CTCF gene family that contains eleven highly conserved zinc finger 
domains and functions as a transcriptional regulator of multiple target genes (Daniel et al., 
2012). CTCF has been shown to bind to CCCTC binding sites located within exons 1 and 2 of 
hTERT within telomerase-negative normal human cells but not within telomerase-positive 
tumour cell lines, which suggests that CTCF may function as a repressor of hTERT within 
normal human cells (Renaud et al., 2007). The ability of CTCF to bind to 5'-exonic regions of 
hTERT was found to be dependent on methylation of CpG sites within the core promoter. 
Treatment of telomerase-positive tumour cells with the demethylating agent 5'-aza-2'-
deoxycytidine (5-azadC) resulted in increased CTCF binding to hTERT exonic regions and 
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transcriptional repression. These findings suggest that changes in DNA methylation patterns 
around the hTERT promoter during tumorigenesis, may play an important role in de-repression 
of hTERT transcription by preventing access of CTCF.  
1.3.5.2.2.2 Tumour Suppressor Genes 
 The Menin tumour suppressor gene, encoded by the gene MEN-1 (multiple endocrine 
neoplasia 1), has been found to play a critical role in the transcriptional repression of hTERT 
(Lin and Elledge., 2003). Overexpression of Menin was associated with reduced hTERT 
expression within hTERT-positive HeLa cervical cancer cells, whereas depletion of Menin 
within hTERT-negative ALT-positive U2OS osteosarcoma cells was associated with increased 
hTERT expression levels. Importantly, short hairpin-RNA (shRNA)-mediated depletion of 
Menin within normal human BJ fibroblast cells led to increased telomerase activity and 
immortal transformation. Menin is thought to mediate hTERT transcriptional repression by 
interacting with AP1 and NFκB binding sites (Figure 1.9), thereby preventing access of 
transcriptional activators JunD and NFκB to the hTERT promoter respectively. These findings 
suggest that loss of Menin may contribute directly to activation of hTERT expression during 
tumour development. In support of this, individuals carrying germline MEN-1 mutations have 
multiple endocrine neoplasia type 1 syndrome, which is characterized by the development of 
neoplastic lesions within endocrine glands such as the pancreas or pituitary. Somatic mutations 
in the MEN-1 gene are prevalent within sporadic endocrine cancer types including parathyroid 
tumours (54%), gastrinoma (33%), pancreatic neuroendocrine tumours (44%) and insulinoma 
(17%) (Marx et al., 1999, Jiao et al., 2011). However, MEN-1 mutations have been identified 
within less than 1% of breast and ovarian cancer types (catalogue of somatic mutations in 
cancer, COSMIC, Forbes et al., 2015), therefore, functional loss of Menin cannot account for 
transcriptional activation of hTERT within all cancer types.   
 The Wilms' tumour 1 (WT-1) transcription factor is an important regulator of cell 
growth, development, differentiation and apoptosis and has been found to exhibit both tumour 
suppressive and oncogenic roles in tumorigenesis (Driessche et al., 2012). In 1999, Oh and 
colleagues demonstrated that WT-1 suppresses hTERT transcription and telomerase activity 
within immortalized human kidney cells (293), but not HeLa cervical carcinoma cells, through 
binding to a WT-1 binding sequence within the hTERT promoter (Oh et al., 1999). Disruption 
of the WT-1 binding site within the hTERT promoter was found to increase hTERT promoter 
activity within 293 cells, but not HeLa cervical carcinoma cells. Therefore, WT-1 may have cell 
type-specific effects on hTERT expression regulation. Sitaram et al., (2010) found that 
overexpression of WT-1 within clear cell renal cell carcinoma (ccRCC) cells was also 
associated with downregulation of hTERT expression and telomerase activity. Interestingly, 
WT-1 was found to mediate transcriptional repression of hTERT within ccRCC cells, not only 
through direct binding to the hTERT promoter, but also by activating the expression of negative 
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regulators of hTERT such as SMAD3 and ETS1, and repressing the expression of positive 
hTERT regulators including c-Myc and NFX1 (Sitaram et al., 2010). Therefore WT-1 may 
repress hTERT expression through direct and indirect mechanisms. However, the effects of WT-
1-mediated hTERT transcriptional repression on cell growth were not reported in either study, 
therefore it is unclear whether reconstitution of WT-1 alone is sufficient to confer hTERT 
repression and restore a limited cellular replicative potential. Furthermore, the lack of WT-1-
mediated hTERT transcriptional repression within HeLa cells, suggests that loss of WT-1 does 
not account for activation of hTERT expression within all cancer types. 
 Overexpression of wild type p53 has been shown to down-regulate telomerase activity 
within multiple cancer cell lines through transcriptional repression of hTERT (reviewed by 
Daniel et al., 2012). The p53 tumour suppressor protein regulates the expression of a variety of 
target genes to mediate cell cycle arrest or apoptosis in response to stressful stimuli and is the 
most frequently mutated gene in human cancer (Muller and Vousden., 2014). Abrogation of Sp1 
binding sites within the core hTERT promoter region, was found to prevent p53-mediated 
transcriptional repression of hTERT within human cervical squamous cell carcinoma cells 
(Kanaya et al., 2000). A similar study demonstrated that endogenous wild type p53 interacts 
with and sequesters Sp1, thereby preventing Sp1 from binding to the hTERT promoter within 
MCF-7 breast cancer cells (Xu et al., 2000). Interestingly, abrogation of the atypical E2F 
transcription factor binding site located within the hTERT core promoter, was associated with 
complete elimination of p53-mediated hTERT transcriptional repression within the same cell 
line, indicating that p53 regulates hTERT transcription via two independent pathways (Shats et 
al., 2004). Knockdown of the cyclin-dependent kinase inhibitor (CDKI) p21, which is a 
transcriptional target of p53, together with Rb family members was also found to reduce p53-
mediated transcriptional repression of hTERT. It was proposed that hTERT repression by 
endogenous p53 within MCF-7 cells is mediated through activation of the p21/pRb/E2F 
pathway and recruitment of histone deacetylases (HDAC) to the hTERT promoter. However, 
studies have shown that abrogation of p53 function, through transduction with the SV40 Large 
T-Antigen, within normal human fibroblasts and post-stasis (p16-silenced) normal human 
mammary epithelial cells (HMEC), leads to crisis (M2) and the very rare emergence of 
immortal clones (Gao et al., 1996, Gollahan and Shay., 1996, Van Der Haegen and Shay., 1993, 
Stampfer and Yaswen., 2003). This suggests that, loss of p53 alone is insufficient to confer 
telomerase re-activation within normal human somatic cells, and a second genetic or epigenetic 
event must occur during crisis to cause hTERT de-repression and telomerase re-activation.  
 Won et al., (2004) demonstrated that pRb-pocket protein (pRb/p107/p130)-E2F 
complex-mediated recruitment of HDACs is critical for regulating hTERT transcription within 
normal cycling human fibroblasts. Inhibition of HDAC recruitment to pRb-pocket protein-E2F 
complexes using the CGK1026 small molecule inhibitor or expression of a dominant-negative 
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E2F mutant, was associated with hTERT de-repression and telomerase re-activation. It has been 
proposed that increased p16 and p21 expression, which occurs with progressive cell divisions, 
results in an accumulation of hypophosphorylated pRb-pocket proteins that bind to E2F to 
mediate hTERT transcriptional repression during senescence. In this way, p16 and p53/p21-
mediated activation of the pRb pathway is a powerful tumour suppressive mechanism that 
prevents hTERT de-repression and spontaneous immortalization of normal human cells (Won et 
al., 2004). Disruption of this pathway may therefore contribute to de-repression of hTERT 
expression during carcinogenesis. 
1.3.5.2.2.3 Normal Human Chromosomes 
 Studies have shown that multiple oncogenes, tumour suppressor genes, transcription 
factors and hormones, that are de-regulated within different human cancer types, have been 
found to play a functional role in regulating hTERT transcription either directly or indirectly. 
However, a clear explanation for the tumour-specific expression of telomerase is still lacking. 
Whole somatic cell fusion of virally transformed or tumour-derived immortal cell lines with 
normal human cells has been found to produce telomerase-repressed hybrids with a finite 
replicative capacity, which indicates that telomerase activity and the capacity for indefinite 
growth behaves as a recessive trait (Pereira-Smith and Smith., 1983). These observations 
suggest that mechanisms of telomerase repression exist within normal human somatic cells that 
may be lost/inactivated to confer telomerase re-activation and cellular immortalization during 
carcinogenesis. In further support of this, monochromosome transfer studies have shown that 
the introduction of single normal chromosome copies within tumour cell lines, is sufficient to 
confer hTERT and telomerase repression (reviewed by Ducrest et al., 2002).  
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Table 1.5 - Summary of chromosomes found to repress hTERT expression and/or induce 
senescence pathways within different cancer cell lines 
hTERT-Repressive 
Chromosome 
Cancer 
Cell Line 
Cell Type 
Chromosomes 
Transferred 
Reference 
3 
21NT Breast carcinoma 3, 8, 12, 20 Cuthbert et al., (1999) 
RCC23 RCC 3, 7, 11 Horikawa et al., 1998 
KC12 RCC (VHL) 3, 11 Tanaka et al., 1998 
HeLa Cervical carcinoma 3, 4, 6,11 Backsch et al., 2001 
4 HeLa Cervical carcinoma 3, 4, 6, 11 Backsch et al., 2001 
6 
FK16A 
Immortalized 
keratinocyte 
6, 11 
Steenbergen et al., 
2001 
SiHa Cervical carcinoma 6, 11 
Steenbergen et al., 
2001 
7 MeT5A 
SV40-transformed 
mesothelial cell 
7 
Nakabayashi et al., 
1999 
10 Li7HM 
Hepatocellular 
carcinoma 
2, 4, 5, 10, 16 Nishimoto et al., 2001 
17 BP1-E 
Immortalized breast 
epithelial cell 
11, 17 Yang et al., 1999 
None Tested 
TE85 Osteosarcoma 1* Hensler et al., 1994 
SiHa Cervical Carcinoma 
2*, 3, 6, 7, 9, 
11, 12 
Tanaka et al., 1999 
CC1 Choriocarcinoma 1, 2, 6, 7*, 9, 11 Tanaka et al., 1999 
JTC-32 Bladder Carcinoma 7, 11* Tanaka et al., 1999 
*Denotes chromosomes that induced senescence within those cell lines in the absence of 
hTERT/telomerase repression. 
 Using the microcell-mediated monochromosome transfer (MMCT) technique and 
human: mouse monochromosomal hybrid panels, independent studies have shown that 
chromosomes 3, 4, 6, 7, 10, 17 are able to repress telomerase activity within different cancer 
types (Table 1.5, Oshimura and Barrett., 1997, Ducrest et al., 2002, Tanaka et al., 2005). For 
instance, chromosome 3 has been found to repress telomerase activity and restore cellular 
senescence pathways within breast and head and neck cancer, renal cell carcinoma and cervical 
carcinoma-derived cell lines (Cuthbert et al., 1999, Tanaka et al., 1998, Horikawa et al., 1999, 
Backsch et al., 2001). Horikawa et al., (1999) and Tanaka et al., (1999) observed progressive 
telomere shortening within renal cell carcinoma cell-chromosome 3 hybrids prior to induction 
of growth arrest. Through deletion mapping of revertant renal cell carcinoma (KC12)-
chromosome 3 hybrids that had escaped senescence and microcell transfer of sub-chromosomal 
chromosome 3 fragments into RCC23 renal cell carcinoma cells, Tanaka et al., (1998) identified 
a putative repressor sequence within the 3p14.2-p21.1 region. Similarly, deletion mapping of 
revertant breast cancer (21NT)-chromosome 3 hybrids by Cuthbert et al., (1999) identified two 
commonly deleted regions localized to 3p12-p21.1 and 3p21.3-p22, one of which overlapped 
with the commonly deleted region identified by Tanaka et al., (1999). These findings suggest 
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that a sequence(s) exists on the short arm of chromosome 3, that functions to repress telomerase 
activity within a variety of cancer types. However, using a genetic complementation approach, 
Tanaka et al., (2005) demonstrated that whole cell fusion of the 21NT breast cancer cell line 
with KC12 and RCC23 renal cell carcinoma cell lines (21NTxKC12 and 21NTxRCC23) 
produced telomerase-repressed hybrids whereas whole cell fusion of both renal cell carcinoma 
cell lines (KC12xRCC23) produced hybrids exhibiting a similar level of telomerase activity to 
parental cells (Tanaka et al., 2005). This suggests that at least two sequences may be present on 
chromosome 3p that function to repress telomerase activity in different cell types. Interestingly, 
introduction of chromosome 3 into the SiHa cervical carcinoma cell line (expressing HPV 16, 
E6 and E7 oncoproteins) was found to have no effect on telomerase activity (Tanaka et al., 
1999). Furthermore, introduction of chromosome 6 into the HeLa cervical carcinoma cell line, 
or chromosome 4 into the Li7HM hepatocellular carcinoma cell line, was found to have no 
effect on telomerase activity or hybrid growth potential, whereas both chromosomes were 
shown to repress telomerase within SiHa and HeLa cervical carcinoma cell lines respectively 
(Table 1.5). On the other hand, a 28.9cM region within chromosome 10p15 was found to be 
responsible for mediating telomerase repression within the Li7HM hepatocellular carcinoma 
cell line (Nishimoto et al., 2001). Moreover, introduction of chromosome 7 into the MeT5A 
SV40-immortalized mesothelial cell line was associated with telomerase repression, whereas 
choriocarcinoma CC1-chromosome 7 hybrids were found to enter cellular senescence without 
telomerase repression (Nakabayashi et al., 1999, Tanaka et al., 1999). These findings suggest 
that different sequences exist throughout the genome that function to repress telomerase activity 
in a tissue-specific manner, which may be lost during carcinogenesis. However, not all 
chromosomes have been tested within all cancer types. Therefore, it remains possible that 
common telomerase regulatory sequences exist that function ubiquitously across all tissue types, 
which have not yet been identified.  
 Microcell transfer of chromosomes 3, 6, 7 and 10 has been shown to mediate a 
reduction in telomerase activity through repression of hTERT gene expression within a variety 
of cancer cell lines (Ducrest et al., 2001, Horikawa et al., 1998, Steebergen et al., 2001, 
Nakabayashi et al., 1999, Nishimoto et al., 2001). This provides further evidence to suggest that 
the major determinant of telomerase activity is hTERT, which is controlled primarily by the rate 
of transcription. De-repression of hTERT expression through loss of a critical regulatory 
sequence(s) that functions in trans either directly or indirectly via a cis-acting element within 
the hTERT gene, is therefore thought to be responsible for telomerase reactivation during 
carcinogenesis. Results from monochromosome transfer studies show that inhibition of hTERT 
transcription is sufficient to confer telomerase repression and restore the cellular senescence 
program within multiple cancer types, which demonstrates that targeting cellular immortality is 
an effective anticancer strategy.  
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1.3.5.3 Epigenetic Regulation 
 Epigenetic mechanisms play a major role in regulating the expression of genes within 
eukaryotic cells by modulating the chromatin structure around gene regulatory regions 
(reviewed by Jaenisch and Bird., 2003). A major mechanism of epigenetic gene regulation 
involves methylation of cytosine residues within CpG islands by DNA methyltransferase 
(DNMT) enzymes. This particular molecular alteration is generally associated with stable 
repression of target gene expression. Another principle mechanism that influences chromatin 
structure is the post-translational modification of amino-terminal tails that protrude from 
histones H3 and H4, which includes acetylation, methylation, phosphorylation, ubiquitylation 
and sumoylation of particular amino acid residues (Bannister and Kouzarides., 2011). These 
modifications have important functional consequences for gene expression by recruiting 
activating/repressive enzymatic protein complexes and chromatin remodelling enzymes that 
reposition nucleosomes thereby altering the accessibility of factors that regulate gene 
expression.   
 Two large CpG islands have been identified within with hTERT promoter, which 
suggests that epigenetic mechanisms may play a role in the transcriptional regulation of hTERT 
(reviewed by Daniel et al., 2012). Consistent with the established role of DNA methylation in 
gene expression regulation, studies have shown that hTERT promoter hypermethylation is 
associated with hTERT gene repression within certain cancer cell types. Bechter et al., (2002), 
demonstrated that high levels of hTERT promoter methylation were associated with low levels 
of telomerase activity and vice versa, in patients with B-cell chronic lymphocytic leukaemia (B-
CLL). In contrast, other studies have reported no significant correlation, or a positive correlation 
between hTERT promoter methylation and hTERT expression levels (Daniel et al., 2012). 
Devereaux et al., (1999) examined hTERT promoter methylation through bisulfite genomic 
sequencing within 37 normal, immortalized and tumour-derived cell lines and found that the 
promoter was hypomethylated within normal hTERT-negative cells, but was either partially or 
totally methylated within the majority of hTERT-expressing cells. An inverse relationship 
between the degree of hTERT promoter methylation and hTERT expression has also been 
reported in gastric cancer and hepatocellular carcinoma (Gladych et al., 2011, Daniel et al., 
2012). A comprehensive analysis of hTERT promoter methylation patterns within telomerase-
positive breast, colon and lung cancer-derived cell lines by Zinn et al., (2007) demonstrated that 
the hTERT promoter was highly methylated within a region positioned 600bp upstream of the 
TSS, but unmethylated/partially methylated around the TSS. Furthermore, using chromatin 
immunoprecipitation-methylation-specific polymerase chain reaction (ChIP-MSP) assay, this 
group also demonstrated that histone modifications associated with active transcription, 
including histone 3 lysine 9 (H3K9) acetylation and histone 3 lysine 4 (H3K4) dimethylation, 
were associated with the unmethylated TSS of the hTERT promoter, whereas repressive H3K9 
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and H3K27 trimethyl chromatin marks were associated with methylated regions upstream of the 
TSS (Zinn et al., 2007). These findings suggest that the unmethylated region around the TSS of 
hTERT may be necessary for hTERT expression within cancer cells.  
 Consistent with these observations, Renaud et al., (2007) found that partial 
hypomethylation of the core promoter of hTERT was necessary for hTERT transcription and 
demonstrated that the CTCF transcription factor could only bind within exon 1 and repress 
hTERT transcription when this region was unmethylated. This was thought to explain why 
CTCF was found to bind to exon 1 within telomerase-negative normal human fibroblasts, but 
not within telomerase-positive HeLa and SW480 cervical and adenocarcinoma cell lines 
respectively. These findings suggest that DNA methylation of specific sites within the hTERT 
promoter may be responsible for the expression hTERT within some cancer cells by preventing 
access of critical hTERT repressors. Interestingly, Ge et al., (2010) found that Mad1 mediates 
transcriptional repression of hTERT through recruitment of the histone demethylase RBP2 to the 
hTERT promoter leading to H3K4 demethylation. Depletion of RPB2 was sufficient to confer 
hTERT expression within hTERT-negative normal human fibroblasts. Mad1 may therefore play 
a critical role in maintaining hTERT repression within normal human somatic cells through the 
recruitment of RPB2.  
 Methylation of specific H3 histone lysine residues has also been found to play an 
important role in regulating hTERT transcription. H3K4 trimethylation is associated with active 
hTERT transcription whereas methylation of H3K9 and H3K20 is associated with hTERT 
repression (Atkinson et al., 2005). The H3K4-specific di- and tri-methyltransferase enzyme 
SMYD3 has been shown to bind to specific sequences within the hTERT promoter and play a 
critical role in regulating hTERT expression (Liu et al., 2007). Ectopic expression of SMYD3 
was found to induce hTERT expression within telomerase-negative normal human fibroblasts. 
Conversely, knockdown of SMYD3 within human colorectal carcinoma and Hodgkin's 
lymphoma-derived cells was associated with a reduction in H3K4 trimethyl marks and loss of 
hTERT expression. H3K4 trimethylation by SMYD3 was shown to activate hTERT transcription 
through recruitment of histone acetyltransferases (HAT) to the hTERT promoter, which 
promotes binding of activating transcription factors Sp1 and c-Myc (Kyo et al., 2008). These 
findings are consistent with studies demonstrating that hyperacetylation of core histones within 
the hTERT promoter region is associated with hTERT expression (reviewed by Zhu et al., 2010). 
Treatment of normal human cells and telomerase-negative immortal cell lines with the histone 
deacetylase (HDAC) inhibitor trichostatin A (TSA), has been found to induce hTERT 
transcription and telomerase activity. Together, these observations suggest that a complex 
relationship exists between DNA methylation patterns, histone modifications and 
activating/repressing transcription factors, to control hTERT gene expression in human cells.  
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1.3.5.4 Alternative Splicing 
 There is strong evidence to suggest that expression of the hTERT gene is regulated 
primarily at the level of transcription. However, RNA processing has also been shown to play 
an important role in regulating hTERT expression (reviewed by Wong et al., 2014). Alternative 
splicing of gene transcripts is a common mechanism of gene expression regulation that 
amplifies the coding capacity of genes. The hTERT gene is 42kb in length and comprises 16 
exons (Figure 1.10). To date, 22 different splice variants of the hTERT gene have been 
identified, which contain exonic deletions and/or intronic insertions that affect the hTERT N-
terminal, reverse transcription (RT) or C-terminal domains. Only one isoform encodes the full-
length transcript while the remaining have lost one or more functional domains and are unable 
to form a functional telomerase complex for telomere elongation (Hrdlickova et al., 2012).   
 
Figure 1.10 - The structure of the human TERT (hTERT) gene with approximate positions of 
TEN (telomerase essential N-terminal domain), TRBD (telomerase RNA binding domain), RT 
(reverse transcriptase) and CT (C-terminal domain) functional domains. The open reading 
frames (ORF) of the full-length transcript and four splice variants α, β, INS3 and INS4 which 
have exons 6 and 7-8  deleted (Δ) and intron 14 (i14) inserted respectively, are indicated in the 
blue shaded regions. Red dots indicate the positions of stop codons and black rectangles 
represent intronic regions. Diagram adapted from (Hrdlickova et al., 2012).  
 The most well characterized alternative splice variants of hTERT include the minus 
alpha (-α)‎and‎the‎minus‎beta‎(-β)‎isoforms‎(Figure‎1.10,‎Wong‎et al., 2014). The minus alpha 
transcript isoform has an in-frame deletion of 36bp from exon 6 due to the use of an alternative 
3'-splice acceptor site, which is predicted to remove 12 amino acid residues from the RT 
domain. This isoform does not possess a functional reverse transcriptase activity, but has been 
shown to act as a dominant-negative inhibitor of endogenous telomerase activity that induces 
cellular senescence or apoptosis when overexpressed within telomerase-positive human cell 
lines (Colgin et al., 2000). Interestingly, two other hTERT transcript isoforms known as INS3 
75 
 
and INS4, have also been shown to act as dominant-negative inhibitors of telomerase activity 
within hepatocarcinoma cells (Figure 1.10, Zhu et al., 2014). Overexpression of both isoforms 
was associated with telomere shortening and cell growth inhibition. INS3 and INS4 isoforms 
contain a 159bp and 600bp insertion of sequences from intron 14 respectively, which leads to 
premature termination and loss of CTD-encoding sequences (Figure 1.10). hTERT is known to 
form a functional homodimer complex through interactions between the CTD and the N-
terminal RNA-interaction domain (RID1). It is thought that INS3 and INS4 proteins mediate 
telomerase inhibition by forming heterodimer complexes with wild-type hTERT, which disrupts 
association with hTR components and formation of a functional telomerase complex. Zhu et al., 
(2014) found that INS3 and INS4 isoforms could only be detected within telomerase-positive 
tumour-derived cell lines, but not within telomerase-negative primary human cells or ALT-
positive cells, which suggests that they may play a functional role in regulating telomerase 
activity within cancer cells (Zhu et al., 2014).  
 The minus beta isoform contains a 183bp region of deletion encompassing exons 7 and 
8, which leads to a frame-shift and a premature termination codon within exon 10 (Figure 1.10, 
Wong et al., 2014). As a result, the RT and CT domains are lost and the transcript is predicted 
to undergo nonsense-mediated mRNA decay (NMD). High expression levels of the minus beta 
splice variant have been observed within normal human stem cells and cancer cells. Listerman 
et al., (2013) demonstrated that the minus beta isoform is the most abundant hTERT isoform 
within breast cancer cells and provided evidence to show that it is translated into protein. 
Overexpression of the minus beta transcript within breast cancer cells caused inhibition of 
endogenous telomerase activity due to competitive binding for the hTR subunit. Conversely, 
ectopic overexpression of minus beta was also found to protect breast cancer cells from 
chemotherapy-induced apoptosis. Similarly, Hrdlickova et al., (2012) found that overexpression 
of a the human hTERT transcript‎ variant‎ termed‎ Δ4-13, which has undergone an in-frame 
deletion of exons 4 through 13, was associated with increased cellular proliferation through 
induction of Wnt signalling pathways. This shows that, aside from stabilizing telomere lengths, 
hTERT may play additional roles in cancer pathogenesis through alternative splicing.  
 Changes in alternative splicing patterns of the hTERT gene have been found to occur in 
a tissue and time-dependent manner during human foetal development (Ulaner et al., 2001). 
This involves a shift in the expression of full-length hTERT transcripts to alternative isoforms 
that lack a functional RT domain such as minus alpha and minus beta isoforms. Loss of full-
length hTERT expression correlates with loss of telomerase activity and progressive telomere 
shortening, which suggests that changes in alternative splicing patterns are responsible for 
down-regulating telomerase activity during the later stages of foetal tissue development. 
Interestingly, only a small proportion of total hTERT mRNA is spliced into the full-length 
isoform within telomerase-positive embryonic and adult tissue stem cells and cancer cells 
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(Wong et al., 2014). Analysis of hTERT splice variant expression levels within a panel of cancer 
cell lines revealed that only 5% of total hTERT transcripts were full-length, while the majority 
(80-90%) were the minus beta isoform (Yi et al., 2001). It is thought that the same program of 
hTERT splicing that occurs during human development is re-activated within cancer cells 
(Wong et al., 2014). The functional role of all alternative hTERT splice variants has not yet been 
elucidated, however it has been suggested that they may function to maintain the level of 
telomerase activity required to stabilize telomere lengths over progressive cell divisions. 
Insufficient levels of telomerase leads to telomere de-stabilization and genomic instability, 
whereas high levels of telomerase could result in excessive telomere elongation and cell growth 
inhibition. Therefore, maintaining telomerase activity at an optimal level is critical for cell 
survival. In support of this notion, overexpression of minus alpha, minus beta, INS3 and INS4 
hTERT transcript isoforms has been shown to inhibit telomerase activity within immortal human 
cell lines (Colgin et al., 2000, Zhu et al., 2014). It is also thought that the basal transcription 
machinery alone is unable to maintain optimal levels of hTERT expression and subsequent 
telomerase activity, therefore alternative splicing provides a mechanism to convert excess 
transcripts into non-catalytic isoforms (Wong et al., 2014).    
1.3.5.5 Post-Translational Regulation  
 In addition to transcriptional, epigenetic and alternative splicing mechanisms, post-
translational modifications of the hTERT peptide have also been implicated in the control of 
telomerase activity within human cells. Two major covalent modifications of hTERT, 
phosphorylation and ubiquitination, have been found to be involved in regulating hTERT 
protein stability, nuclear translocation and the formation of a functional telomerase complex for 
modulating telomere length homeostasis (Kim et al., 2001, Chung et al., 2012, Kim et al., 
2005). 
  The protein kinase C-alpha (PKC-α) enzyme has been found to interact with and 
phosphorylate hTERT, which was shown to be important for telomerase activity within human 
breast and cervical cancer cells (Li et al., 1998, Kim et al., 2001). Exposure of HeLa and 
CUMC-6 cervical cancer cells to the PKC-inhibitors bisindolylmaleimide I and Gö6978, was 
associated with elimination of telomerase activity (Kim et al., 2001). Similarly, PKC-α reversed 
the effects of protein phosphatase 2A (PP2A)-mediated inhibition of telomerase within breast 
cancer cells, suggesting a dynamic relationship between PP2A (de-phosphorylation) and PKC-α 
(phosphorylation) in telomerase regulation (Li et al., 1998). Breast cancer cells have been found 
to exhibit higher levels of nuclear PKC-α expression, therefore it is thought that up-regulation of 
PKC-α may contribute to telomerase activation during breast tumorigenesis. Interestingly, PKC 
has also been implicated in modulating telomerase activity during T-cell activation (Bodnar et 
al., 1996). Induction of telomerase was shown to occur during T-cell activation but was found 
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to be insufficient for maintaining constant telomere lengths within T-cells in long-term culture. 
Treatment of T-cells with the PKC-inhibitor bisindolylmaleimide was found to inhibit transient 
telomerase activation within activated T-cells. Conversely, treatment of peripheral blood 
mononuclear cells (PBMC), which have been found to express low levels of telomerase activity, 
with the PKC-activator phorbol myristate acetate (PMA) was associated with increased 
telomerase activity. Therefore, phosphorylation of hTERT by PKC enzymes is important for 
regulating telomerase activity within both normal T-cells and PBMCs and cancer cells.   
 hTERT has also been found to be a phosphorylation target of the Akt serine/threonine 
protein kinase, which is an important effector of the PI3K-signalling pathway (Kang et al., 
1999, Chung et al., 2012). Two putative Akt phosphorylation sites located within amino acid 
residues 220-229 and 817-826 have been identified within the hTERT peptide sequence (Kang 
et al., 1999). Purified Akt protein from human melanoma cell lysates was found to 
phosphorylate hTERT in vitro, which provides evidence that hTERT is a direct target of Akt. 
Furthermore, treatment of human melanoma cells with the specific PI3K-Akt inhibitor 
wortmannin resulted in a dose-dependent decrease in telomerase activity. On the other hand, 
treatment of cells with the PP2A inhibitor okadaic acid, resulted in Akt kinase activation and a 
dose-dependent increase in telomerase activity. These findings provide evidence to show that 
Akt-dependent phosphorylation of hTERT is important for maintaining telomerase activity 
within human cancer cells. In 2012, Chung et al., demonstrated that Akt-mediated 
phosphorylation of hTERT was critical for the immortal transformation of normal human 
fibroblast cells. Akt kinase was found to phosphorylate serine 227, located within a bipartite 
nuclear localization signal (NLS) within the hTERT peptide, which was required for mediating 
nuclear translocation of hTERT. As expected, treatment of telomerase-positive H1299 non-
small cell lung cancer (NSCLC) cells with wortmannin resulted in the accumulation of hTERT 
within the cytoplasm. Interestingly, normal human foreskin fibroblasts (HFF) transfected with 
mutant serine 227-hTERT exhibited similar levels of telomerase activity to those transfected 
with wild-type hTERT. However, unlike wild-type hTERT-HFFs, mutant serine 227-hTERT-
HFFs were found to undergo progressive telomere shortening and induction of senescence 
pathways, which suggests that Akt-mediated phosphorylation of serine 227 is required for 
efficient immortalization of human fibroblasts.  
 Consistent with the observation that phosphorylation is associated with positive 
regulation of hTERT and telomerase activity, overexpression of the serine/threonine protein 
phosphatase 2A (PP2A) holoenzyme has been shown to inhibit telomerase activity and disrupt 
nuclear translocation of hTERT (Xi et al., 2013). The PP2A scaffolding subunit PR65 was 
found to interact with the T-motif of hTERT and prevent binding of hTERT with 14-3-3θ,‎
which functions to direct nuclear localization of hTERT. In contrast to PKC and Akt kinases, 
the c-Abl protein tyrosine kinase has been shown inhibit hTERT activity through direct 
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interaction and phosphorylation of hTERT (Kharbanda et al., 2000). The functional importance 
of c-Abl-mediated hTERT inhibition was demonstrated by the observed telomere lengthening 
within c-Abl-deficient cells.  
 The Makorin RING finger protein 1 (MKRN1) E3 ubiquitin ligase has been found to 
interact with and ubiquitinate amino acid residues 946-1132 within the C-terminal domain of 
hTERT and promotes proteasome-mediated degradation of the hTERT peptide (Kim et al., 
2005). Overexpression of MKRN1 within HT1080 fibrosarcoma cells was associated with a 
significant reduction in hTERT protein levels, telomerase activity and telomere shortening 
compared with empty vector controls. This indicates that MKRN1 plays an important functional 
role in modulating telomere lengths within human cancer cells by influencing hTERT protein 
stability. Interestingly, Oh et al., (2010), also found that the HDM2 E3 ubiquitin ligase enzyme, 
responsible for targeting the p53 tumour suppressor protein for proteasome-mediated 
degradation, also interacts with and ubiquitinates five lysine residues within the N-terminal 
domain of hTERT. Depletion of HDM2 within HCT116 human colon carcinoma cells was 
associated with increased telomerase activity, whereas ectopic expression of HDM2 within 
H1299 human lung cancer cells increased proteasome-mediated degradation of hTERT and 
caused a reduction in telomerase activity. These findings suggest that HDM2 may function as a 
negative regulator of hTERT.  
 
1.3.6 TELOMERES, TELOMERASE AND BREAST CANCER 
1.3.6.1 Evidence for Telomere Dysfunction and Chromosome Instability in 
Breast Cancer 
 Similar to other epithelial cancers, breast cancer development can be characterized by 
the accumulation of multiple genetic and epigenetic alterations that facilitate progression from 
normal breast epithelium, to pre-malignant intermediates such as usual ductal hyperplasia 
(UDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) and finally to 
invasive and metastatic breast carcinoma (Figure 1.2, Heaphy et al., 2009). Chromosome 
instability (structural and numerical alterations) is a common feature of breast carcinomas, with 
allelic imbalances (AI) detectable within the earliest breast lesions such as ADH, DCIS and 
even within usual ductal hyperplasia (UDH) (O'Connell et al., 1997). For example, numerous 
studies have reported frequent loss of heterozygosity (LOH) on multiple chromosomes 
including 7q, 16q, 13q, 3p and 19p in breast cancer (reviewed by Miller et al., 2003). Telomere 
dysfunction is thought to be a major cause of genetic instability during human carcinogenesis 
(see Chapter 1.3.3.4) and there is evidence to suggest that telomere shortening may be at least 
partly responsible for the high level of genetic instability observed within human breast 
carcinomas (reviewed by Meeker and Argani., 2004).   
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 Using southern blot telomere restriction fragment (TRF) analysis, independent studies 
have shown that breast carcinomas possess shorter telomeres than normal breast tissue (Odagiri 
et al., 1993, Rogalla et al., 1996, Griffith et al.,1999). Odagiri et al.,(1993) observed a 
significant correlation between telomere length and histologic grade within a set of 41 breast 
carcinoma samples, with the shortest telomere lengths observed within Grade 3 breast 
carcinomas. These findings contrast those presented by Rogalla et al., (1996), who 
demonstrated no observable correlation between telomere length and tumour grade. Both 
studies reported no association between telomere length and tumour volume, hormone receptor 
(HR) status or lymph node status. Using a titration assay to quantify telomere DNA content 
within 49 invasive human breast carcinoma samples, Griffith et al., (1999) consistently 
demonstrated no association between telomere length and tumour volume, grade or stage, but 
found that tumours with the least telomeric DNA content were more likely to be aneuploid and 
metastatic. These findings suggest that there is no relationship between telomere lengths and 
clinicopathological features of breast cancer, however, shorter telomere lengths may be 
associated with increased genetic instability and metastatic potential. 
 Employing a telomere fluorescence in situ hybridization technique, which allows 
telomere length assessment of tissue sections at the single cell level, Meeker and colleagues 
found that over half of 114 invasive breast carcinoma samples exhibited significant telomere 
shortening (Meeker and Argani., 2004). 17.5% of samples were found to possess moderately 
shortened telomeres while around a quarter of samples exhibited normal telomere lengths (21%) 
or significantly elongated telomeres (5%). Interestingly, 78% of DCIS lesions were found to 
possess either significantly or moderately shortened telomere lengths, which indicates that 
telomere shortening occurs within early, pre-invasive breast lesions. In cases of DCIS with 
adjacent invasive breast lesions, telomere lengths were found to be similar within both lesions, 
indicating that progression to invasive disease and tumour expansion, was not accompanied by 
continued telomere shortening. Furthermore, a strong correlation was observed between the 
presence of short telomeres and chromosome instability, such as anaphase bridges (Meeker and 
Argani., 2004). Similarly, Heaphy et al., (2009) observed a gradual increase in altered telomeric 
DNA content and the number of sites of allelic imbalance within a continuum of breast lesions 
representing each stage of breast tumorigenesis (normal breast tissue, ADH, DCIS and invasive 
carcinoma). However, no significant changes in telomeric DNA content or allelic imbalance 
were observed beyond DCIS, indicating that levels of telomere dysfunction and genetic 
instability plateau at DCIS.  
 Interestingly, Meeker and Argani (2004) also observed moderate telomere shortening 
within normal luminal epithelial cells of the terminal duct lobular unit (TDLU). This was 
thought to be linked to the observations made by Holst et al.,(2003), which demonstrated that 
ductal and luminal cells within histologically normal breast epithelium, exhibit methylation (and 
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inactivation) of the p16 promoter. Promoter hypermethylation of p16 has been associated with 
spontaneous bypass of the stress-associated senescence barrier (termed stasis) within normal 
human mammary epithelial cells (HMECs) in vitro, leading to extended cell growth and 
continued telomere shortening until cells reach the telomere-dependent, replicative senescence 
barrier (Romanov et al., 2001). Together, these findings suggest that telomere shortening may 
play an important role in the early stages of breast cancer development.  
1.3.6.2 Telomerase Activity and hTERT Expression in Breast Cancer 
 By means of a highly sensitive polymerase chain reaction (PCR)-based telomerase 
detection assay, known as the telomere-repeat amplification protocol (TRAP) assay, 
independent studies have shown that over 90% of human breast carcinomas exhibit detectable 
levels of telomerase activity, whereas normal breast tissues do not (Hiyama et al., 1996, Clark 
and Osborne., 1997, Hoos et al., 1998, Poremba et al., 1998). These studies also demonstrate a 
correlation between telomerase activity and tumour stage, nodal metastases and decreased 
disease-free survival, which suggests that higher levels of telomerase activity is associated with 
a more aggressive disease. Poremba et al., (1998) found that, unlike invasive breast carcinomas, 
normal breast tissue and ADH lesions did not exhibit telomerase activity. Interestingly, 59% of 
DCIS lesions were found to exhibit detectable levels of telomerase activity, indicating that 
telomerase re-activation may occur at this stage of breast carcinogenesis. Others have reported 
that around 75% of in situ breast lesions and 88% of lobular and ductal carcinomas express 
detectable levels of telomerase activity, compared with only 5% of adjacent tissues (Shay and 
Bacchetti., 1887). DCIS lesions also exhibit telomere shortening and chromosomal instability 
(see above). It is thought that telomerase reactivation occurs during the DCIS stage of breast 
cancer development, which results in telomere stabilization and reduced chromosomal 
instability (Artandi., 2003). These findings support the notion that telomerase re-activation is a 
critical step during human carcinogenesis that provides a mechanism of overcoming the growth-
inhibiting effects of critical telomere shortening. 
 Using a real-time quantitative reverse transcription-PCR (qRT-PCR) assay to detect and 
quantify hTERT transcript levels, studies have reported increased but heterogeneous expression 
of hTR within pre-invasive ADH and DCIS lesions and invasive breast carcinomas relative to 
normal breast epithelium (Yashima et al., 1998, Poremba et al., 2002). Bieche et al., (2000) 
found that around 75% of invasive breast carcinomas expressed detectable levels of hTERT, 
whereas normal breast tissue samples showed complete absence of hTERT expression. 
Furthermore, increased levels of hTERT expression were associated with shorter relapse-free 
survival, higher histopathological tumour grade and absence of hormone receptors ER and PgR, 
indicating that hTERT expression also correlates with more aggressive disease. In contrast, 
studies have reported heterogeneous hTERT expression patterns within both normal breast 
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epithelium and malignant breast tumours, with a subset of normal epithelial cells displaying 
higher hTERT expression levels than tumour cells (Hines et al., 2005, Liu et al., 2004). These 
findings contradict the hypothesis that hTERT de-repression and telomerase re-activation are 
critical events during breast carcinogenesis and suggest that breast tumours may arise from 
hTERT-positive epithelial cells. Analysis of four different hTERT splice variants (full-length, α, 
β, α+β) within normal breast tissue specimens, benign breast lesions and breast cancers by 
Zaffaroni et al., (2002), demonstrated that expression of the full-length hTERT transcript was 
associated with the presence of active telomerase. While breast carcinoma samples were found 
to express the full-length variant as well as different combinations of other alternative splice 
variants, five out of six (83%) peri-tumoral normal breast tissue samples taken at a distance of 
3cm away from the malignant tumour, expressed the truncated β-hTERT isoform and three out 
of six (50%) normal breast tissue samples were found to express the full-length hTERT variant. 
Out of these, only one normal breast tissue sample was found to exhibit telomerase activity, 
which could suggest that full-length hTERT expression levels may have been too low to confer 
telomerase activity within the remaining samples. Furthermore, the majority (80%) of normal 
breast samples taken from breast tissue surrounding benign breast lesions (fibroadenomas, 
fibrocystic lesions and duct papillomatosis) were not found to express any detectable hTERT 
splice variants. These findings indicate that normal breast epithelial cells may express hTERT 
splice variants that encode catalytically inactive protein products, which could account for the 
high level of hTERT expression observed by Hines et al., (2005) and Liu et al., (2004) and 
provide an explanation for the lack of telomerase activity observed within normal breast tissues 
observed by others (see above). Furthermore, these findings suggest that alternative splicing 
patterns of hTERT may play an important role in regulating hTERT expression and telomerase 
activity in breast cancer cells.  
 Consistent with other human carcinomas, such as skin tumours, gastric, renal cell and 
ovarian carcinomas, a significant correlation between hTERT mRNA levels and telomerase 
activity has been observed within human breast carcinomas, which is consistent with the 
hypothesis that hTERT is the critical rate-limiting component of telomerase enzyme activity 
(Kirkpatrick et al., 2003). Furthermore, ectopic expression of hTERT within normal human 
mammary epithelial cells is sufficient to confer bypass of replicative senescence, immortal 
transformation‎ and‎ resistance‎ to‎ transforming‎ growth‎ factor‎ β‎ (TGF-β),‎ which‎ is‎ a‎ common‎
feature of malignancy in human carcinomas (Stampfer et al., 2000).  
1.3.6.3 hTERT regulation in Breast Cancer 
 Epidemiological and in vitro studies have demonstrated that oestrogen plays an 
important role in breast cancer aetiology, with certain established breast cancer risk factors, 
such as post-menopausal obesity, exogenous hormones (contraceptive pill, HRT) and early age 
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at menarche, associated with increased systemic exposure to oestrogen (reviewed by Althuis et 
al.,  2004). In 1999, Kyo and colleagues were the first to show that oestrogen is a direct and 
indirect transcriptional activator of hTERT within breast cancer cells. Following treatment with 
17β-estrodiol (E2), oestrogen receptor (ER)-positive MCF-7 breast cancer cells were found to 
exhibit increased levels of hTERT expression and telomerase activity. This was found to be due 
to direct, ligand-activated binding of the ER to the imperfect oestrogen responsive element 
(ERE) located approximately 2.7kb upstream from the hTERT core promoter region. In 
addition, oestrogen-induced transactivation of hTERT was found to be mediated by induction of 
c-Myc expression and binding of c-Myc/Max heterodimers to E-box elements within the hTERT 
core promoter (Kyo et al., 1999).  
 The importance of ligand-activated ER-signalling on the transcriptional regulation of 
hTERT in breast cancer cells was demonstrated by Marconett et al., (2011), who found that 
inhibition of E2-stimulated hTERT expression by indole-3-carbinol (I3L) was associated with 
cell cycle arrest in G1 and induction of cellular senescence pathways. I3L is a glycolysis 
product of glycobrassicin, which is a naturally occurring compound found within cruciferous 
vegetables such as broccoli and cabbage. I3L was found to inhibit E2-induced hTERT 
expression through stimulating both the degradation of ER-α and the production of threonine 
579 (Thr579)-phosphorylated Sp1, thereby disrupting the binding of both transcriptional 
regulators to an ERE-Sp1 composite element within the hTERT promoter. Treatment of MCF-7 
cells with the selective oestrogen receptor modulator raloxifene, was also found to inhibit E2-
induced transcriptional activation of hTERT by inhibiting ERE-induced hTERT expression, 
phosphorylation (and activation) of Akt, the PI3K/Akt/NFκB signalling cascade, hTERT 
phosphorylation and interaction with NFκB (Kawagoe et al., 2003). These findings demonstrate 
that oestrogen not only functions as a direct and indirect transcriptional activator of hTERT, but 
also influences post-translational modifications and interactions with factors that control the 
intracellular localization of hTERT. Treatment of MCF-7 cells and MCF-7 mouse xenograft 
models with melatonin was associated with a dose-dependent reduction in hTERT mRNA levels 
in vitro and a significant reduction in telomerase activity, tumour weight and metastatic 
potential in vivo (Leon-Blanco et al., 2003). A later study found that melatonin inhibits hTERT 
expression within MCF-7 cells by blocking E2 or xenoestrogen (cadmium)-ER induced hTERT 
transcription (Martinez-Campa et al., 2008). Therefore, the oncostatic effects of melatonin on 
tumour growth can be attributed, in part, to a significant reduction in hTERT expression and 
telomerase activity.  
 In addition to oestrogen, the progesterone sex steroid hormone has also been found to 
regulate hTERT expression within breast cancer cells (Wang et al., 2000). Transient exposure of 
breast cancer cells to progesterone was associated with rapid induction of hTERT expression, 
which peaked at around 12 hours after exposure before declining. Treatment of cells with a 
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MEK (serine/threonine kinase) inhibitor prevented progesterone-stimulated hTERT 
transcription, indicating that activation of the mitogen activated protein kinase (MAPK) 
pathway may be involved in mediating progesterone-induced hTERT transcriptional activity. In 
contrast, long-term exposure to progesterone (over 48 hours) was associated with inhibition of 
oestrogen-induced hTERT transcriptional activation, which was thought to be due to up-
regulation of p21 expression. These findings demonstrate that hTERT is a target of both 
oestrogen and progesterone steroid hormones, which display different effects on hTERT 
transcription within breast cancer cells.  
 Introduction of c-Myc, but not viral oncoproteins such as HPV16-E7 or cellular 
oncoproteins such as Ras, cyclin D1 or cdc25C/A, has been found to induce telomerase activity 
and extend the proliferative capacity of normal HMECs in vitro (Wang et al., 1998). Induction 
of hTERT expression following c-Myc transduction was rapid, with elevated hTERT mRNA 
levels observed within one passage. Telomere lengths within c-Myc-transduced HMECs were 
found to be stabilized, compared with negative control HMECs, which underwent progressive 
telomere shortening with each round of cell division. Telomere lengths within human tumour 
cells are generally short but stable. Therefore, transduction of c-Myc within normal HMECs, 
was associated with alterations in telomere dynamics similar to that observed within tumour 
cells (Wang et al., 1998). Studies have shown that c-Myc is amplified and  overexpressed within 
16% and 22% of breast cancers respectively (Deming et al., 2000, Bieche et al., 1999). 
Therefore, the results presented by Wang et al., (1998) suggest that de-regulation of c-Myc may 
contribute to breast tumorigenesis, in part, through induction of hTERT expression. c-Myc 
activates hTERT transcription through binding to two canonical E-box (CACGTG) elements 
located both upstream and downstream of the transcription start site (TSS) (see Chapter 
1.3.5.2.1.1). 
 c-Myc has also been found play a critical role in mediating Aurora-A kinase-induced 
transcriptional activation of hTERT within breast and ovarian epithelial cell lines (Yang et al., 
2004). Aurora-A is a serine/threonine kinase involved in regulating G2/M cell cycle control 
(reviewed by Anand et al., 2003). The Aurora-A gene is located within 20q13.2, which has been 
found to undergo frequent amplification in multiple human carcinomas such as colorectal, 
gastric, breast and ovarian. Specifically, Aurora-A has been shown to be overexpressed within 
up to 62% of human breast cancers, which is thought to be a major cause of spindle checkpoint 
dysfunction and aneuploidy during carcinogenesis. Ectopic expression of Aurora-A within 
MCF-10A breast epithelial cells, was found to induce telomerase activity through 
transcriptional activation of c-Myc, which led to binding of c-Myc to the upstream E-box 
element and activation of hTERT transcription (Yang et al., 2004). Therefore, aside from 
chromosome missegregation, Aurora-A may also contribute to breast carcinogenesis through 
induction of hTERT expression.  
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 Overexpression of the c-Myc-cooperating oncogene Bmi-1, originally identified as a 
driver of B-cell lymphomas in mice, has been found to induce telomerase activity and 
immortalize normal HMECs in vitro (Dimri et al., 2002). Bmi-1 is a member of the polycomb-
group (PcG) family of transcriptional repressors and controls cell proliferation through 
regulation of the INK4A locus, which encodes two tumour suppressor genes p16 and ARF 
(Jacobs et al., 1999). It is thought that Bmi-1 cooperates with c-Myc to drive tumorigenesis by 
blocking c-Myc-mediated induction of ARF, which allows HDM2-mediated degradation of p53 
and inhibition of apoptosis. Dimri et al., (2002) found that overexpression of Bmi-1 within two 
different post-stasis (bypassed M0 through p16 silencing) HMEC strains, resulted in extended 
replicative capacity, telomerase activation and immortal transformation through transcriptional 
activation of hTERT. In contrast, overexpression of Bmi-1 within normal human fibroblasts was 
insufficient to confer telomerase activation or immortalization, indicating cell-type specific 
differences in hTERT regulation between human epithelial cells and fibroblasts. Bmi-1-induced 
hTERT transcription did not appear to involve c-Myc, as mutation of c-Myc-binding sites within 
the hTERT promoter was associated with increased promoter activity. This suggests that binding 
of the c-Myc/Max competitor Mad1/Max, may be important for mediating transcriptional 
repression of hTERT within normal HMECs. Bmi-1 expression was also found to be higher 
within breast cancer cell lines and immortalized HMECs relative to a non-tumorigenic breast 
cell line (Dimri et al., 2002). Silva et al., (2007) demonstrated a strong correlation between 
plasma Bmi-1 expression and poor disease-free and overall survival within breast cancer 
patients. Therefore, deregulation of Bmi-1 may contribute to breast tumorigenesis through 
induction of hTERT expression and immortal transformation.     
 The epidermal growth factor receptor (EGFR)-related receptor tyrosine kinase HER2, 
which is overexpressed within 20-30% of human breast cancers, has also been shown to induce 
hTERT expression and telomerase activity within breast cancer cells (Goueli and Janknecht., 
2004). Breast tumour tissue specimens and cell lines overexpressing HER2 were found to 
display higher levels of hTERT expression and telomerase activity than HER2-negative 
specimens or cell lines. Upon exposure to the HER2-inhibitor AG825, HER2-overexpressing 
SKBR3 breast cancer cells were found to exhibit a significant reduction in telomerase activity. 
HER2 was shown to induce telomerase activity through activation of Ras and Raf downstream 
effector proteins and collaboration with the ERK transcription factor ER81, which binds to two 
Ets sites within the hTERT promoter leading to transcriptional activation. Therefore, HER2 
induces hTERT transcription by activating the MAPK signalling cascade. Co-transfection of the 
V664E oncogenic HER2 mutant and ER81 within telomerase-negative normal human 
fibroblasts was sufficient to confer induction of hTERT expression and telomerase activity. 
These findings suggest that induction of hTERT expression by oncogenic HER2 may be a 
contributing factor in the re-activation of telomerase during the development of many breast 
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tumours, as early pre-invasive DCIS lesions have been found to exhibit abnormal HER2 
expression (Burstein et al., 2004).  
 In addition to initiating the MAPK signalling cascade, HER2 has also been found to 
mediate transcriptional activation of hTERT through the PI3K/Akt/NFκB/c-Myc pathway 
(Papanikolaou et al., 2011). Irradiation of tumour cells derived from HER2-overexpressing 
breast cancer biopsies, resulted in increased radio-resistance and elevated expression of hTERT 
and telomerase activity due to increased binding of c-Myc/Max complexes to E-box elements 
within the hTERT promoter. In contrast, irradiation of tumour cells derived from HER2-negative 
breast tumours was associated with increased Mad1/Max binding to the hTERT promoter. HER2 
was found to induce c-Myc transcription through initiating the PI3K/Akt/NFκB pathway, 
thereby leading to indirect activation of hTERT expression. These findings demonstrate another 
mechanism by which HER2 activates hTERT transcription in breast cancer cells, which may be 
activated in response to radiotherapy and contribute to radio-resistance. Therefore HER2-
induced hTERT expression may not only contribute to breast cancer development but also 
therapeutic resistance. 
 Aside from growth factor and hormone receptors, transcription factors and oncogenes, 
epigenetic mechanisms have also been implicated in regulating hTERT gene expression within 
breast cancer cells. By examining the micrococcal nuclease (MNase) digestion pattern of a 
26.4kb region of the hTERT gene, encompassing around 10kb of 5'-flanking sequences and 
16kb of sequences downstream of the TSS, Szutorisz et al., (2003) investigated the chromatin 
structure around the hTERT gene within hTERT-repressed and hTERT-positive cells to identify 
cis-acting regulatory elements that may be responsible for tumour cell-specific expression of 
hTERT. Two discrete sites located within the first 1kb of intron 2 of the hTERT gene, were 
found to be susceptible to MNase-digestion within hTERT-positive tumour cells and an SV40-
immortalized human fibroblasts cell line, but not within hTERT-negative normal human 
fibroblasts or an SV40-immortalized human fibroblast cell line that uses an alternative 
lengthening of telomeres (ALT) pathway of telomere maintenance. Interestingly, no differences 
in the pattern of MNase sensitive sites were observed in the 5'-flanking region of hTERT-
positive cells and hTERT-negative cells. These findings suggest that an 'open' chromatin 
conformation around intron 2 may be responsible for tumour-specific hTERT expression. In 
support of this, introduction of a normal copy of chromosome 3 into the hTERT-positive 21NT 
breast cancer cell line produced hTERT-repressed hybrids that displayed a change in the 
MNase-sensitivity pattern around intron 2 of hTERT, which resembled normal human 
fibroblasts. The MNase-sensitivity pattern associated with active hTERT transcription was 
restored upon loss of the exogenous chromosome 3 copy, however not all segregants were 
found to re-express hTERT. These observations indicate that a sequence(s) present on 
chromosome 3 functions to repress hTERT transcription within breast cancer cells by altering 
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the chromatin conformation around intron 2 of the hTERT gene. It was proposed that functional 
loss of this repressor sequence during breast tumorigenesis may lead to an 'open' chromatin state 
that is required, but not sufficient, to confer hTERT expression and telomerase re-activation. 
These findings indicate that epigenetic events may play a critical role in hTERT de-repression 
and cellular immortalization during breast tumorigenesis.     
 
1.3.7 CONFLICTING VIEWS ON THE ORIGINS OF TELOMERASE IN CANCER 
 In 1994, Kim and colleagues demonstrated that the majority of human tumours possess 
active telomerase activity, whereas the majority of human somatic tissues, aside from the 
ovaries and testes, do not (Kim et al., 1994). It is now known that telomerase is active within 
developing embryonic tissues until around 21 weeks of gestation, at which point it is either 
down-regulated and maintained at low levels within stem/progenitor cells of self-renewing adult 
tissues including gastrointestinal crypt, hair follicle bulbs, lymphoid tissue and glandular 
prostate tissue, or repressed completely within certain adult tissue compartments, such as 
mesenchymal tissues (Forsyth et al., 2002). Unlike embryonic stem cells, which display high 
levels of telomerase activity and an immortal phenotype, tissue stem cells and their progeny 
(progenitor and transit amplifying stem cells), which reside within tissue micro-environmental 
niches, are not immortal and exhibit reduced self-renewal capacity (reviewed by Kong et al., 
2014). However, intestinal stem cells (ISC), which reside within intestinal crypts and function 
to replace epithelial cells shed from the epithelium every day, are in a constitutive state of 
activation and can undergo several thousand cellular divisions throughout a human's lifespan 
(Pech and Artandi., 2011). Similar to immortal human cell lines, human ISCs exhibit telomerase 
activity and do not appear to show a limited proliferative capacity. However, despite the 
presence of telomerase activity within many human tissue stem cell compartments, adult stem 
cells have been found to undergo progressive telomere shortening with increasing age (Shay and 
Wright., 2010). Therefore, despite the lack of sufficient telomerase to maintain stable telomere 
lengths, it is thought that low levels of telomerase activity within adult stem/progenitor cells 
delays the rate of telomere attrition to support rapid cell division and differentiation for the 
replacement of lost/damaged cells during tissue renewal or repair.      
 Studies involving the immortal transformation of normal human fibroblasts and 
epithelial cells using viral oncoproteins have demonstrated that the functional loss of genes p53, 
pRb and p16, which are abrogated in a significant proportion of human cancers, is associated 
with an increased propensity for immortal transformation (Newbold., 2005). The rare 
emergence (around one in ten million cells) of an immortal variant from crisis is almost always 
accompanied by de-repression of hTERT and telomerase re-activation (Newbold., 2005, Shay 
and Wright., 2010).  Based on these observations, it is thought that stringent mechanisms of 
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hTERT transcriptional repression exist within the majority of normal human somatic cells that 
provide a powerful barrier to cellular immortalization, clonal evolution and malignant 
progression. Therefore, the acquisition of an immortal phenotype during crisis is thought to be 
due to a rare mutational or epigenetic event that leads to functional loss of a critical hTERT 
repressor sequence(s). In support of this, chromosome transfer studies have shown that 
repression of hTERT transcription and telomerase activity can be achieved within different 
human cancer types, through introduction of single copies of normal human chromosomes (see 
Chapter 1.3.5.2.2.3). The observed effect on hTERT transcription is thought to be due to 
reconstitution of a hTERT repressor sequence(s) present on the introduced chromosome copy, 
that was lost during immortal transformation. 
 Despite these observations, a second hypothesis for the origin of telomerase activity 
within human cancers has also been proposed, which is that cancer cells arise from telomerase-
positive stem cell populations residing within self-renewing tissues (reviewed by Sell., 2004). 
Human tumours are known to display intra-tumoral heterogeneity, which is thought to be due to 
the acquisition of mutations or epigenetic alterations as tumour cells undergo clonal evolution. 
However, tumours also display non-genetic, heterogeneous patterns of differentiation, which 
reflect aspects of normal differentiation patterns that occur within the original tissue (reviewed 
by Reya et al., 2001). For example, breast tumour cells display variable expression patterns of 
normal differentiation markers such as the oestrogen receptor or milk proteins. Consequently, 
the degree of tumour 'de-differentiation' is an important prognostic marker that is used by 
pathologists to grade tumours and predict clinical outcomes. During the normal process of 
organogenesis, adult stem cells divide by asymmetric cell division to produce one daughter cell 
that retains the same stem cell properties, while the other becomes a more differentiated 
progenitor or transit amplifying cell that gives rise to a variety of functional cell types specific 
to that organ (Shay and Wright., 2010). Analogous to this process, it is thought that the variable 
degree of differentiation observed within human tumours originates from a deregulated process 
of organogenesis, initiated by a cancer stem cell (CSC) or tumour initiating cell. The degree of 
differentiation within the tumour is thought to reflect the stage of maturation at which the 
normal stem cell acquired a tumorigenic alteration and became a CSC (Sell., 2004). In support 
of the CSC hypothesis, Tomasetti and Vogelstein (2015) recently found a significant correlation 
between the total number of tissue stem cell divisions and the lifetime risk of developing cancer 
within that particular tissue in 25 different cancer subtypes. Due to inherent flaws in the process 
of DNA replication, around three mutations are predicted to occur each time a normal cell 
divides. Therefore, the accumulation of 'replicative mutations' within normal stem cells is 
thought to explain why certain tissue types give rise to human cancers more frequently than 
other tissue types.  
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 Unlike the clonal evolution theory of tumour formation, which suggests that the 
majority of the tumour cells possess self-renewing capacity, the CSC hypothesis proposes that 
tumours possess a hierarchical organization with only a small subpopulation of tumour cells 
capable of self-renewing and generating tumour cells (Visvader and Lindman., 2012). In 
support of the CSC theory, in vitro and in vivo studies have shown that the majority of tumour 
cells are incapable of initiating tumour formation (Shay and Wright., 2010, Reya et al., 2001). 
This was first reported by Park et al., (1971), who found that only 1 in 10
2
-10
4
 mouse myeloma 
cells could form colonies in an in vitro colony-forming assay. Furthermore, when transplanting 
human cancer cells into immuno-deficient mice, hundreds of thousands to millions of cells are 
required to form a tumour (Shay and Wright., 2010). These observations suggest that the 
majority of human tumour cells are unable to proliferate extensively, while only a small 
subpopulation of cells are clonogenic. Furthermore, CSCs or tumour initiating cells, which 
express stem/progenitor cell surface markers, have been identified within multiple cancer types 
including primary glioblastoma multiform (GBM), breast, prostate and multiple myeloma. 
Studies have shown that CSCs derived from breast, pancreatic glioblastoma, neuroblastoma and 
prostate cancers express hTERT mRNA and telomerase activity (Kong et al., 2014). A 
comparison of telomerase activity within CSC and non-CSC tumour populations derived from 
resected glioma specimens, revealed that only the CSC population possessed detectable levels 
of telomerase activity (Castelo-Branco et al., 2011). Interestingly, inhibition of telomerase using 
the telomerase inhibitor Imetelstat, was associated with DNA damage, growth arrest and cell 
maturation of neural CSCs and rapid inhibition of the clonogenic survival of CD138
-
 multiple 
myeloma CSCs (Castelo-Branco et al., 2011, Shay and Wright 2010). These findings not only 
indicate that CSCs rely on telomerase activity to maintain stable telomere lengths for self-
renewal, but also demonstrate that CSCs are sensitive to anti-telomerase therapies. This is 
consistent with the observation that CSCs derived from GBM and prostate cancers have been 
found to possess short telomere lengths (Shay and Wright., 2010). In many cases, cells within 
pre-neoplastic lesions have been shown to possess shortened telomere lengths (Meeker et al., 
2002). It has therefore been proposed that tumour initiating cells or CSCs originate from a 
subpopulation of transit amplifying cells located within tissue stem cell compartments, that have 
undergone telomere shortening, possibly as a result of chronic inflammation (Shay and Wright., 
2010). Analogous to the mortality barriers encountered by normal human fibroblasts and 
epithelial cells, these cells are predicted to bypass replicative senescence and enter crisis in the 
absence of p53. Immortal variants that emerge have indefinite self-renewing capacity due to up-
regulation or re-activation of telomerase activity and stabilization of telomere lengths.  
 These observations have important implications for the development of anti-telomerase 
therapies in the treatment of human cancers and pose important questions that remain to be 
answered. Namely, what genetic/epigenetic alterations are responsible for up-regulating 
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telomerase activity and maintaining stable telomere lengths within CSCs and are they different 
to those responsible for telomerase re-activation within normal human fibroblasts and epithelial 
cells? Do all human tumours originate from telomerase-positive tissue stem/progenitor cells, or 
do tumours arise from the immortalization and clonal expansion of telomerase-negative, 
functional cell types such as fibroblasts and epithelial cells?  
 
1.3.8 TELOMERASE-INDEPENDENT PATHWAYS OF TELOMERE MAINTENANCE IN 
CANCER 
 In order to examine the role of telomerase in cancer, Blasco and colleagues constructed 
a telomerase-knockout mouse strain by deleting the telomerase RNA component (mTR) from 
the mouse germline (Blasco et al., 1997). Rodents are known to possess active telomerase in 
adult tissues, which is active throughout the organisms lifespan (Greenberg et al.,1998). As a 
consequence, primary rodent cell cultures have long telomeres, which do not shorten over time 
with increasing cell divisions in vitro. mTR
-/-
 mice were found to lack detectable telomerase 
activity but survived for six generations, likely due to the presence of long telomeres in the 
original mouse strain (Blasco et al., 1997). Telomere lengths shortened at a rate of around 
4.8kp/generation and cells derived from generation 4 (G4) mice lacked detectable telomeric 
repeat sequences and were found to display multiple chromosome abnormalities such as 
chromosome end-to-end fusions. Telomere shortening and induction of replicative senescence 
pathways in normal human somatic cells is considered to be a powerful protective barrier to 
immortal transformation. Therefore, it was surprising to find that telomerase-deficient cells 
derived from all mTR
-/-
 mice generations could be transformed by viral oncogenes and produce 
tumours in athymic mice (Blasco et al., 1997). These findings indicate that telomerase-
independent telomere-maintenance mechanisms exist within mammalian cells.  
 The existence of alternative mechanisms of telomere maintenance in eukaryotic cells 
was first observed following inactivation of telomerase activity (through deletion of est-1) 
within the Saccharomyces cerevisisae yeast strain (Lundblad and Szostak., 1989). The majority 
of est-1 mutants were found to undergo telomere shortening and cell death, however a small 
population of immortal cells arose that maintained their telomere lengths through amplification 
and acquisition of sub-telomeric elements via a RAD52-mediated homologous recombination 
pathway (Lundblad and Blackburn., 1993). Evidence for the existence of telomerase-
independent telomere maintenance mechanisms in human cancer cells, stems from the 
observation that most, but not all, cancer cells possess active telomerase (Kim et al., 1994). In 
addition, Bryan et al., (1995) found that around 43% of DNA tumour virus (SV40 and HPV)-
transformed human fibroblasts were dependent on a telomerase-independent mechanism of 
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telomere maintenance. These cells were found to possess long but heterogeneous telomeres, 
ranging from very short (undetectable) to up to 50kb in length.  
 It is now known that around 15% of all human cancers maintain telomere lengths 
through a telomerase-independent mechanism involving homologous recombination (HR), 
known as alternative lengthening of telomeres (ALT) (reviewed by Cesare and Reddel., 2010). 
ALT-positive tumour cells can be distinguished from telomerase-positive and normal human 
cells by the presence of ALT-associated promyelocytic leukaemia (PML) bodies (APB), which 
are large round nuclear structures consisting of telomeric DNA, PML protein, telomere-binding 
proteins such as TRF1 and TRF2 and proteins involved in DNA recombination and synthesis 
including RAD51, RAD52 and replication factor A (Yeager et al., 1999). It is thought that 
APBs represent the site of ALT activity. In addition, ALT-positive cells exhibit very 
heterogeneous telomere lengths (which may change rapidly) and increased levels of 
recombination at telomeres. Furthermore, the ALT phenotype is associated with significantly 
higher levels of extrachromosomal telomeric DNA compared to telomerase-positive and normal 
human cells, which can take the form of linear double-stranded DNA (dsDNA), double or 
partially single-stranded telomeric circles (t-circles), G-rich strand circles (G-circles) or C-rich 
strand circles (C-circles) (Cesare and Reddel., 2010). Despite these unique characteristics, 
telomeres within ALT-positive cells still retain many typical features, such as the ability to form 
t-loops and the presence of shelterin complex protein components.    
 The ALT phenotype has been observed within a 5-15% of carcinomas such as breast, 
renal, bladder, endometrium and lung (Henson and Reddel., 2010). However, this phenotype is 
more common among sarcomas, such as liposarcomas and osteosarcomas, and central nervous 
system tumours such as glioblastoma multiform (an adult malignant brain tumour) and 
astrocytomas, compared with epithelial cell malignancies (Cesare and Reddel., 2010). A 
comprehensive survey of the ALT phenotype within over 6000 primary tumour specimens 
encompassing a wide range of human tumour types, demonstrated that a subset of 
adenocarcinomas from the prostate, small intestine, colon and pancreas do not exhibit any 
features of ALT, indicating that certain tumour types rely solely on telomerase activity for 
telomere length maintenance (Heaphy et al., 2011).   
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Figure 1.11 - Schematic representations of two models of alternative lengthening of telomeres 
(ALT): (A) unequal telomere sister chromatid exchange (T-SCE) and (B) homologous 
recombination (HR)-dependent DNA replication. Image adapted from Cesare and Reddel., 
(2010).  
 Physical evidence of homologous recombination-mediated telomere maintenance 
mechanisms within ALT-positive cells was provided by Dunham and colleagues in 2000. 
Plasmid tags inserted within telomeres were found to be copied to other chromosome ends 
within ALT-positive but not telomerase-positive cell lines, indicating that inter-telomeric 
templating and recombination may occur within ALT cells. Furthermore, telomere sister 
chromatid exchanges (T-SCEs) have been found to occur at a higher frequency within ALT-
positive cells compared with telomerase-positive or normal human cells (Cesare and Reddel., 
2010). Two hypothetical recombination-dependent models for telomere maintenance and 
elongation within ALT-positive cells have been proposed; unequal T-SCE exchange and HR-
dependent DNA replication (Figure 1.11A). It is thought that nicks within telomeric DNA 
sequences of ALT-positive cells, disrupt DNA replication and causes unequal T-SCE. In this 
model, exchange of telomeric DNA between sister chromatids results in the extension of one 
telomere at the expense of another. This would not result in any net gain in telomere length 
unless elongated and shortened telomeres were each segregated into two separate daughter cells 
(Figure 1.11A, Durant., 2012). Therefore, through non-random segregation, one generation 
would possess longer telomeres and an extended proliferative capacity. It has also been 
proposed that ALT may result from  HR-dependent DNA replication, which involves the 
synthesis of a new telomeric DNA sequence by inter-telomeric strand invasion of an adjacent 
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chromosomal telomere (Figure 1.11B). This method of telomere-templated DNA synthesis can 
involve other copy templates such as sister chromatid telomeres, where the 3'-ssDNA overhang 
from one chromatid invades the homologous sequence of the sister chromatid telomere to prime 
DNA replication. Alternatively, linear or circular extrachromosomal telomeric DNA sequences 
such as double-stranded DNA fragments, t-circles or C-circles, are thought to provide templates 
for HR-mediated telomeric DNA synthesis through strand-invasion or rolling-circle replication 
mechanisms (Cesare and Reddel., 2010).  
 Through genetic analyses, the MRE11-RAD50-NSB1 (MRN) complex has been found 
to play an important role in mediating telomere elongation within ALT-positive cells. In normal 
human cells MRN protein complex members have been found to interact with the telomere-
associated protein TRF2 during different cell cycle phases, and are thought to facilitate t-loop 
formation (Zhu et al.,2000). Furthermore, the MRN complex functions as a DNA damage 
sensor that recruits ATM to DSB  sites and facilitates resection of the DNA ends for repair by 
homologous recombination (Lee and Paull., 2007). RNA-interference (RNAi)-mediated 
disruption of RAD50, has been found to result in telomere erosion and induction of senescence 
pathways (Potts and Yu., 2007). It is thought that the MRN complex may promote HR-
dependent telomeric DNA replication within ALT cells by recruiting ATM and initiating a 
recombination process of DNA repair, whereby the 3'-ssDNA overhang invades a neighbouring 
telomeric DNA strand (adjacent/sister chromosome or extra-chromosomal sequence) and DNA 
polymerase catalyzes extension of the 3' sequence (Cesare and Reddel., 2010).  
  The mechanisms by which ALT pathways are suppressed within normal human cells 
and the events that occur during carcinogenesis that re-activate ALT pathways is unknown. 
Whole somatic cell fusion of ALT-positive and normal human cells was found to produce 
hybrids that displayed rapid telomere erosion and induction of a senescent-like phenotype, 
which indicates that normal human cells possess at least one mechanism that functions to 
repress ALT pathways (Perrem et al., 1999). Due to the high frequency of ALT-positive cells 
produced by SV40-LT immortalization, it is possible that functional loss of p53 may play a role 
in activation of ALT pathways during human carcinogenesis (Bryan et al.,1995, Newbold., 
2002). The existence of a telomerase-independent pathway of telomere maintenance and 
elongation in cancer, poses a potential problem to the application of anti-telomerase therapies. 
ALT-positive tumours are resistant to anti-telomerase therapies, which indicates that a 
proportion of carcinomas, sarcomas or central nervous system tumours may not respond to this 
treatment type (Heaphy et al., 2011). In addition, it is not known whether activation of ALT 
pathways presents a potential resistance mechanism to anti-telomerase therapies (Newbold., 
2002). Therefore, by understanding the mechanisms that repress ALT-pathways and hTERT 
transcription within normal human somatic cells, and monitoring the consequences of anti-
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telomerase therapies on tumour cell growth, we can develop more effective therapies that target 
both mechanisms of telomere maintenance that underlie cancer cell immortality. 
 
1.3.9 THERAPEUTIC STRATEGIES FOR TARGETING TELOMERASE 
 The telomerase ribonucleoprotein holoenzyme is responsible for maintaining stable 
telomere lengths within the majority of human cancers (Kim et al., 1994). By counteracting the 
effects of progressive telomere shortening, telomerase prevents recognition of eroded 
chromosome ends as double-stranded DNA breaks (DSB) by DNA repair machinery, 
subsequent activation of DNA damage response pathways and induction of senescence or 
apoptosis. In this way, telomerase is responsible for sustaining the indefinite growth capacity of 
cancer cells. Telomerase therefore represents an attractive anti-cancer target and has been the 
focus of the scientific community to develop strategies that inhibit its activity (Pal et al., 2015). 
A proof of principle of this approach was provided by Hahn et al., (1999), who demonstrated 
that inhibition of telomerase activity within human cancer cell lines by introducing a dominant-
negative hTERT mutant, was associated with telomere shortening and cell growth arrest in vitro 
and elimination of tumorigenicity in vivo.  
 Unlike cancer cells, the majority of normal human somatic cells do not express 
detectable levels of telomerase. However, as discussed earlier, some actively dividing normal 
somatic cells, such as stem/progenitor cells located within self-renewing tissues, require low 
levels of telomerase activity to facilitate tissue repair/regeneration (see Chapter 1.3.7). The 
importance of telomerase within adult stem cells has been demonstrated through the study of 
individuals with defective telomerase activity (Kong et al., 2014). Dyskeratosis congenita (DC) 
is a rare genetic disease either caused by inheritance of X-linked DKC1 mutations or autosomal 
dominant/recessive hTERT and hTR mutations (Vulliamy and Dokal., 2006). These genes 
encode important subunits and associated proteins that are essential for telomerase holoenzyme 
complex biogenesis, stability and function. In the absence of telomerase activity, the stem cells 
of DC individuals have defective telomere maintenance and undergo critical telomere 
shortening, which manifests pathologically as bone marrow failure, oral leukoplakia, nail 
dystrophy and increased risk of cancer. Therefore, telomerase plays an integral role in human 
tissue renewal. There is also some evidence to show that telomerase is active during S-phase of 
the cell cycle within primary human fibroblasts (Masutomi et al., 2003). Therefore, the 
development of therapeutic strategies that aim to inhibit telomerase activity within cancer cells, 
may have an adverse effect on the regulation of telomere structure within normal human cells, 
and the self-renewing capacity and function of normal adult stem cells. However, despite the 
presence of higher levels of telomerase activity, cancer cells have been found to possess shorter 
telomere lengths than normal human somatic cells (Shay and Wright., 2006). Therefore, normal 
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stem/progenitor cells would theoretically remain unaffected by telomerase inhibitors due to their 
lower-mitotic activity and longer telomere lengths. 
 An important limitation of targeting telomerase as a therapeutic anti-cancer strategy is 
the period of time required for short telomeres to become critically shortened and induce cell 
cycle arrest or apoptotic pathways (Shay and Wright., 2006). During this lag-phase, cancer cells 
would continue to divide and the tumour mass would increase before telomeres become 
critically shortened. On the other hand, treatment of cancers with chemotherapy and/or 
radiotherapy is associated with a rapid reduction in tumour burden. However, resistance to 
chemotherapeutic agents and disease relapse is an inevitable consequence of this treatment 
approach. Small subpopulations of cancer stem cells (CSC)/tumour initiating cells, which 
depend on telomerase activity for their indefinite self-renewal capacity, are thought to be 
responsible for mediating resistance to these anti-cancer therapies (Kong et al., 2014). 
Therefore, using telomerase inhibitors in combination with chemotherapeutic agents and/or 
radiotherapy has been proposed as a potential strategy to reduce the tumour burden and prevent 
therapeutic resistance simultaneously (Shay and Wright., 2006).  
 A variety of approaches have been developed to inhibit telomerase activity, the majority 
of which target the reverse transcriptase (hTERT) or telomerase RNA (hTR) components (Pal et 
al., 2015, Philippi et al., 2010). These include the use of: (1) nucleic acid-based biologicals such 
as small interfering RNA (siRNA) or anti-sense oligonucleotides (AS-ODN) that interfere with 
hTERT and hTR translation (2) ribozymes and hammerhead ribozymes that cleave hTERT and 
hTR components respectively, (3) Gene-directed pro-drug therapy (GDEPT) that exploits the 
high promoter activities of hTERT and hTR within cancer cells, to induce the expression of pro-
apoptotic 'suicide' genes, (4) nucleoside analogues such as azidothymidine triphosphate (AZT) 
(5) dominant-negative hTERT mutants, (6) G-quadruplex targeting agents that stabilize complex 
G-quadruplex secondary structures and prevent access of telomerase to the telomeric 3'-ssDNA 
overhang, (7) induction of antigen-presenting cells (T-lymphocytes or dendritic cells) against 
peptides derived from hTERT to stimulate an immune response against hTERT-positive cells.  
 Studies involving the inhibition of telomerase through the use of AS-ODNs that target 
template and non-template regions of the hTR subunit, have demonstrated a reduction in 
telomerase activity within cancer cells in vitro (reviewed by White et al., 2001). However, the 
majority of these studies did not report progressive telomere shortening as a result of continued 
treatment. Furthermore, some studies found that cells exhibited slowed growth or apoptosis in a 
shorter time period than would be expected if the AS-ODN had targeted telomerase specifically. 
Independent studies involving the use of hammerhead ribozymes to target the template region of 
hTR also showed a reduction of telomerase activity within endometrial and melanoma cells in 
vitro, but no change in cellular proliferative capacity (Yokoyama et al., 1998, Folini et al., 
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2000). In addition, studies have shown that treatment of cancer cell lines with the reverse 
transcriptase inhibitor 3'-azido-3'-deoxythymidine (AZT), was associated with telomerase 
inhibition but not telomere shortening or induction of cell growth arrest following prolonged 
exposure (White et al., 2001). These findings suggest that some telomerase inhibitors are non-
specific and have off-target effects that may lead to side effects in vivo. 
 The hTR template antagonist GRN163L, also known as imetelstat, is a promising agent 
that has been found to inhibit telomerase activity within cancer cells in vitro and in vivo 
(Herbert et al., 2005). GRN163L has been found to induce cell growth arrest, apoptosis and 
reduce colony formation and tumorigenicity within a variety of cancer cell lines including lung, 
breast, prostate, ovarian, cervical, glioblastoma, hepatoma and melanoma (reviewed by Ruden 
and Puri., 2013). Furthermore, GRN163L was found to restore sensitivity to trastuzumab within 
HER2-positive breast cancer cell lines (Goldblatt et al., 2009). Unlike typical AS-ODNs, which 
bind to and prevent translation of target mRNA sequences, GRN163L consists of a 5'-palmitoyl-
TAGGGTTAGACAA-3' oligonucleotide sequence that is complementary, and binds with high 
specificity, to the hTR template strand thereby preventing elongation of telomeric sequences by 
telomerase. The 5'-palmitoyl moiety makes the oligonucleotide sequence lipid-soluble, which 
facilitates transport across cell membranes. GRN163L has undergone (and is currently 
undergoing) several stage I/II clinical trials where it has been tested alone or in combination 
with other monoclonal antibodies and/or chemotherapeutic agents to assess dose limiting 
toxicities, pharmacokinetics and objective response rates for a variety of solid tumour 
malignancies, lymphoma and multiple myeloma (Ruden and Puri., 2013). A phase I clinical trial 
investigating GRN163L in patients with metastatic or recurrent breast cancer, in combination 
with paclitaxel and bevacizumab demonstrated an overall response rate of 53.8% (Kozloff et al., 
2010). A phase I clinical trial investigating the effect of GRN163L treatment on reversing 
trastuzumab resistance in HER2-positive breast cancer patients is currently ongoing (Clinical 
Trials Phase Identifier: NCT0126592).  
 Other promising strategies for telomerase inhibition include the use of telomerase-based 
immunotherapies, which are designed to stimulate an immune response against telomerase-
positive cancer cells through induction of CD4+ and CD8+ cytotoxic lymphocytes (CTL) 
(reviewed by Ruden and Puri., 2013). Telomerase-positive cancer cells express telomerase-
associated antigens (TAAs), such as hTERT peptides, on their surface through major 
histocompatibility complexes (MHC). A variety of telomerase targeting vaccines have been 
developed that aim to stimulate CTL-mediated elimination of these cells. These include 
GV1001 and GRNVAC1, which have been tested within phase I/II clinical trials and have been 
shown to stimulate CD4+ and CD8+ immune responses with minimal effects on normal cells 
(Ruden and Puri., 2013). GV1001 is an MHC class II-restricted vaccine containing sixteen 
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amino acids of the hTERT active site, while GRNVAC1 contains autologous dendritic cells that 
have been transfected ex vivo with the hTERT mRNA sequence.    
 The existence of a telomerase-independent telomere maintenance mechanism (ALT), 
presents a potential problem for the use of telomerase-targeting agents to inhibit cancer cell 
growth. Following telomerase inhibition, it is thought that re-initiation of telomere erosion and 
cell crisis during the lag-phase may facilitate the emergence of possible resistance mechanisms, 
such as activation of ALT (see Chapter 1.3.8). Using Atm
-/-
 knockout mouse engineered with an 
inducible mtert allele to model the effects of telomerase re-activation and inhibition in T-cell 
lymphoma, Hu et al., (2012) found that following telomerase extinction, the rate of tumour 
growth was reduced but soon increased due to the acquisition of ALT-mediated mechanisms of 
telomere maintenance. This was accompanied by the overexpression of PGC-1β (peroxisome 
proliferative activated receptor, gamma, coactivator 1 beta), which encodes an important 
regulator of mitochondrial function. Knockdown of PGC-1β or SOD2 (superoxide dismutase 2) 
was associated with a significant inhibition in ALT-positive tumour cell growth. Hu et al., 
(2012) proposed that, increased DNA damage signalling caused by ALT-mediated telomere 
maintenance mechanisms could lead to increased mitochondrial damage and a subsequent 
increase in intracellular reactive oxygen species (ROS). To counteract these potentially 
cytotoxic effects, ALT-positive cells up-regulate the expression of genes involved in 
maintaining mitochondrial function and reducing oxidative damage. These observations provide 
an insight into possible anti-telomerase resistance mechanisms in cancer cells and demonstrate 
how these may be counteracted by combination regimens that target the PGC pathway. 
However, in vitro studies suggest that activation of ALT pathways in response to anti-
telomerase inhibitors is rare in human cancers (Shay et al., 2012). Although, it is argued that in 
vitro experiments do not fully recapitulate clinically-relevant tumours in vivo due to limited cell 
numbers. Therefore, a greater understanding of whether and at what frequency ALT-positive 
human cancer cells arise in response to anti-telomerase therapies, and what pathways may be 
activated that constitute potential therapeutic targets for ALT inhibition, is required.  
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AIMS AND OBJECTIVES 
The aim of my project is to investigate the role of chromosome 17, chromosome 3 and single 
genes/sequences localised to chromosome 3p, in the regulation of hTERT transcription and 
telomerase activity within breast cancer cells.  
In order to achieve this aim, my objectives are as follows: 
I. To determine the existence of telomerase repressor sequences localized to chromosomes 3 
and 17 within a single breast cancer cell line using the microcell-mediated 
monochromosome transfer (MMCT) technique. 
 
II. To investigate the functional role of chromosome 3p-encoded genes SETD2, FLJ, BAP1, 
RASSF1, PARP-3 and PBRM1 as candidate repressors of hTERT transcription and 
telomerase activity in breast cancer cells. 
 
III. To investigate chromosome 3p structure during the multi-step process of normal human 
mammary epithelial cell (HMEC) immortalization. 
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        CHAPTER 2  
2 GENERAL MATERIALS AND METHODS 
2.1 CELL CULTURE MANIPULATION 
2.1.1 GENERAL EQUIPMENT FOR CELL CULTURE 
 Cell culture manipulation was carried out in a LaminAir HB2448 laminar flow safety 
cabinet (Heraeus Instruments, DE). All cell lines and strains were maintained in fully 
humidified (>95%) HeraCell incubators (Heraeus Instruments, DE) at 37ºC with either 5% or 
10% carbon dioxide (CO2). Visualization and monitoring of cell cultures was performed using 
an Olympus CK40 inverted phase contrast microscope and photomicrographs of cells were 
obtained using an Olympus 1X71 inverted microscope attached to a coolSNAP cf camera 
(Photometrics, US). Centrifugation of cell suspensions was carried out using a Sorvall Legend T 
swinging-bucket rotor bench-top centrifuge (ThermoScientific, UK).  
 Generally, all cell lines were maintained in sterile disposable plastic culture dishes with 
the following surface areas; 9.5cm
2
 (6-well plate), 9cm
2
 (P35), 21cm
2
 (P60) or 55cm
2
 (P100) 
(Sarstedt, DE). Pre-sterilized, individually wrapped serological pipettes (Sarstedt, DE) were 
used to transfer liquid volumes (2ml-35ml). Smaller volumes (<1ml) were transferred using 
Gilson pipettes with RNAse and DNAse-free sterile filter-tips (Sarstedt, DE or Starlabs, UK). 
Glass Pasteur pipettes were heat-sterilized (130ºC) before being used to aspirate waste liquid 
volumes. 
2.1.2 CELL LINES AND  CULTURE CONDITIONS 
 Both human and rodent-derived cell lines and strains were cultivated for the purposes of 
this project (Table 2.1 and Chapter 2.1.2.2). Growth medium was purchased as filter-sterilized 
500ml liquid stock solutions (Gibco, US or HyClone, GE Healthcare, UK) to which appropriate 
supplements were directly added, depending on the specific requirements of each cell line  
(Table 2.2). To ensure that complete media were free from contaminants, 5ml aliquots were 
incubated at 37ºC for at least 5 days and monitored for microbial or fungal growth. Complete 
media were stored at 4ºC until required. 500ml stock solutions of foetal bovine serum (FBS, 
Gibco, US) supplement, were aliquoted into 50ml Falcon tubes and stored at -20ºC. Depending 
on manufacturer's guidelines, supplements were either stored at 4ºC or -20ºC. 
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2.1.2.1 Human Cell Lines/Strains 
Table 2.1 - Origin and features of each human cell line/strain utilized. 
Cell Line 
Patient 
Details 
Cancer 
Type 
Tumour 
stage 
Cell Line 
Tissue Origin 
Tumorigenic Reference 
BT20 
C, F, 74 
years, 
Breast, IDC - Mammary gland Yes 
Lasfargues 
and Ozello, 
1978 
BT474 
C, F, 60 
years 
Breast IDC - Breast Duct 
Yes 
 
Lasfargues et 
al. 1978 
GI101 
F, 57 
years 
Breast IDC III Breast Duct Yes 
Hurst et al. 
1993 
HCC1143 
C, F, 52 
years 
Breast IDC IIA Breast Duct - 
Gazdar et al. 
1998 
H5S78T 
C, F, 74 
years 
Breast CS - 
Mammary 
Gland 
No 
Hackett et 
al., 1977 
HMEC 
LONZA* 
F 
Normal 
HMEC cell 
strain 
N/A 
 
Breast - 
Reduction 
Mammoplasty 
Tissue 
- 
Lonza Group 
Ltd 
HMEC 
184* 
F, 21 
years 
Stampfer and 
Bartley 1984 
HMEC 
240L* 
F, 19 
years 
Garbe et al., 
2009 
MCF7 
C, F, 69 
years 
Breast, AC IV Pleural Effusion No 
Soule et al., 
1973, Clarke 
et al., 1990 
MCF-10A 
C, F, 36 
years 
Breast FBD - Breast 
No, 
spontaneously 
immortalized 
Soule et al., 
1990 
MTSV - 
Normal 
Breast 
epithelium 
N/A Breast Lumen 
No, SV40-
immortalized 
Bartek et al., 
1991, 
D'Souza et 
al., 1993 
PC3-
hTERT 
M, 62 
years 
Prostate 
AC 
- Prostate 
Yes, Telomerized 
by Newbold 
group (Brunel 
University) 
Kaighn et al., 
1979 
21NT 
F, 36 
Breast, IDC 
and DCIS 
III 
Breast Yes Band et al., 
1990 21MT Pleural Effusion Yes 
(*) Denotes HMEC cell strains that were cultivated by Dr. Hemad Yasaei. Abbreviations: C 
(Caucasian), F (Female), M (Male), IDC (Infiltrating/Invasive Ductal Carcinoma), CS 
(Carcinosarcoma), AC (Adenocarcinoma) HMEC (Human Mammary Epithelial Cell), FBD 
(Fibrocystic Disease), DCIS (Ductal Carcinoma In Situ).  
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Table 2.2 - Individual human cell line growth media and supplements 
Cell Line Medium Supplements 
21NT, 21MT MEM-α‎(1X) 
10% FBS, 10mM HEPES, 0.1mM NEAA, 1µg/ml 
Insulin, 2.8µM Hydrocortisone, 12.5ng/ml EGF 
BT474, H5S78T, 
BT20 
DMEM/F12 (1:1, 
1X) 
10% FBS, 1% Glutamax 
MTSV 
DMEM/F12 (1:1, 
1X) 
10% FBS, 1% Glutamax, 0.5µg/ml Hydrocortisone 
MCF-10A 
DMEM/F12 (1:1, 
1X) 
10% FBS, 1% Glutamax, 5µg/ml Insulin, 1µg/ml 
Hydrocortisone, 10ng/ml EGF 
HCC1143 RPMI 1640 (1X) 10% FBS, 1mM Sodium Pyruvate, 10mM HEPES 
GI101 RPMI 1640 (1X) 10% FBS, 2mM Glutamine, 10µg/ml Insulin 
MCF-7 EMEM (1X) 10% FBS, 0.1mM NEAA, 1mM Sodium Pyruvate 
PC3-hTERT F12 (1X) 7% FBS, 1% Glutamax 
Abbreviations: FBS (foetal bovine serum), MEM (modified Eagle's medium), DMEM 
(Dulbecco's MEM), EMEM (Eagle's minimal essential medium), F12 (Ham's F12), HEPES (4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid), NEAA (non-essential amino acids), EGF 
(Epidermal Growth Factor). 
 The HMEC cell strains (LONZA, 184 and 240L) were cultured by Dr. Hemad Yasaei 
and were provided to me upon request, either as a semi-confluent monolayer or as a cell pellet.  
2.1.2.2 Rodent A92 and Human: Rodent Monochromosomal Hybrid Cells 
 The A92 cell line is a sub-clone of the A9 mouse fibroblast cell line, which in turn was 
derived from mouse L-cells (Littlefield, 1964). This cell line was cultured in DMEM (1X, 
Gibco, US) supplemented with 10% FBS and maintained at 37ºC with 5% CO2. 
 The human: rodent somatic cell hybrid A9-Hytk17 is a rodent fibroblast cell line (A9), 
carrying a single, intact copy of human chromosome 17. This hybrid was generated as part of a 
panel of 23 human: rodent hybrids, representing all 22 human autosomes and the X 
chromosome (Cuthbert et al., 1995). The normal human donor chromosomes are derived from a 
human male skin fibroblast cell strain (1BR.2); each human chromosome was tagged with a 
selectable hygromycin phosphotransferase-thymidine kinase (Hytk) fusion gene marker (Lupton 
et al. 1991). The Hytk marker comprises the E.coli hygromycin phosphatase gene (hph) and the 
Herpes Simplex virus thymidine kinase gene (HSVtk) (Lupton et al. 1991). Stable integration of 
the Hytk fusion gene within each human chromosome of the human: mouse hybrid panel allows 
the stable transfer of human monochromosomes into target mammalian cells using microcell-
mediated monochromosome (MMCT) techniques. In the presence of the hygromycin B (hygB) 
antibiotic, only hybrids containing the Hytk-tagged chromosome are resistant and able to 
survive. Selection for the loss of the tagged human chromosome from hybrids can be achieved 
through exposure of cells to ganciclovir (GCV), which is converted by the Hytk-encoded 
thymidine kinase enzyme into a cytotoxic nucleotide analogue. The A9-Hytk17 hybrid was used 
to study the effects of functional gene transfer during this project. This cell line was cultured in 
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DMEM (1X, Gibco, US), supplemented with 10% FBS and 400U/ml hygromycin B 
(Calbiochem, DE) and were maintained at 37ºC at 10% CO2. 
 The human: mouse monochromosome hybrid A9-Neo3 was also used as a donor of 
normal human chromosome 3 for the purposes of gene transfer during this project (Coriell Cell 
Repositories, Camden, NJ). The normal copy of human chromosome 3, within this hybrid, is 
derived from a female lung fibroblast cell line, and has been tagged with a neomycin (neo) 
antibiotic resistance gene. A9-Neo3 cells were cultured in DMEM (1X, Gibco, US), 
supplemented with 10% FBS and 400µg/ml geneticin (G418, Invitrogen, US).  
2.1.3 SERIAL SUB-CULTIVATION OF CELL LINES (PASSAGING) 
 All cell lines used within this study were cultured as anchorage-dependent cell 
monolayers and were subject to a standard protocol of serial sub-cultivation. This protocol was 
used to passage 70-90% confluent dishes containing cells growing in log-phase. First, all 
required reagents were warmed to 37ºC in a water-bath for at least 15 minutes prior to cell 
manipulation. Equipment and reagent bottles were cleaned and sterilized using 70% Industrial 
Methylated Spirits (IMS) diluted in de-ionized water. Following aspiration of cell culture 
media, 1-2ml of sterile 1X phosphate buffered saline solution (PBS, Severn Biotech, UK) was 
used to wash residual medium from the cell monolayer. Immediately after aspiration of PBS, 1-
2ml of sterile 1X TryPLE Express Enzyme solution (Gibco, US) was added. Cells were then 
incubated at 37
o
C for 5-10 minutes and regularly observed under the microscope to monitor 
detachment from the dish surface. In order to avoid prolonged exposure to dissociation enzymes 
within the TryPLE Express solution, the side of the dish was firmly tapped to detach any cells 
remaining after this incubation period. Rarely, a sterile 16cm cell scraper (Sarstedt, DE) was 
used to detach cells that remained adherent even after incubation or agitation. The resulting cell 
suspension was transferred to a new culture vessel containing fresh complete medium. Cells 
were sub-cultured at a ratio of 1:2 to 1:10 depending on cell growth rate and downstream 
requirements.  
 To maintain a constant pH balance and supply of nutrients, cell monolayers were re-fed 
with fresh complete culture medium every 2-3 days. 
2.1.4 CRYOPRESERVATION AND RECOVERY OF CELLS 
 Stocks of each cell line were created for long-term storage in liquid nitrogen (-196ºC) 
Firstly, cells at 70-90% confluence, growing in log-phase, were detached from the dish surface 
using the aforementioned method and the resulting cell suspension was transferred to a 15ml 
Falcon tube. To obtain any residual adherent cells, the dish was washed once with complete 
medium and the solution added to the cell suspension. The mixture was then centrifuged at 
1500rpm for 5 minutes. After careful aspiration of the supernatant, the Falcon tube was tapped 
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firmly to loosen the cell pellet. Depending on the original dish size (and therefore cell yield), 
0.5-1ml of freezing mixture consisting of 90% FBS and 10% Dimethyl Sulfoxide (DMSO) was 
used to re-suspend the cell pellet. The cell solution was then transferred to a sterile plastic 
screw-top ampoule (Sarstedt, DE), placed in a metal rack and slowly cooled in the gaseous 
phase of a liquid nitrogen container (at a rate of ~1ºC per minute). The following day, the 
ampoule was transferred to the liquid nitrogen phase for long-term storage. 
 To re-establish cell lines in culture following storage in liquid nitrogen, ampoules were 
first rapidly thawed at 37ºC in a water bath. Cell suspensions were then transferred into 1 or 2 
culture vessels containing complete growth media, and incubated under normal growth 
conditions. The following day, the cell culture medium was refreshed to remove any traces of 
DMSO.  
2.1.5 ISOLATION AND PROPAGATION OF INDIVIDUAL CELL COLONIES/CLONES 
 A standard protocol was developed for the isolation and propagation of cell colonies 
arising from treated 21NT cells undergoing antibiotic selection for: (i) stable cell hybrids 
containing an intact copy of a single MMCT-transferred human chromosome and (ii) cells 
containing transfected human gene cDNA clones that had been virally integrated into the host 
genome. Selection and growth of antibiotic-resistant cell colonies was carried out using P100 
cell culture dishes, in order to maximize the distance between colonies that may arise on the 
same dish. Following microscopic identification of a cell colony, a permanent black marker pen 
was used to draw a circle around the colony on the underside of the culture dish, in order to 
indicate colony size and position. After aspiration of cell culture media, the dish was washed 
once with pre-warmed 1X PBS. Sterile forceps were used to press a sterile plastic cloning 
cylinder (Cole-Parmer, Scienceware) into a layer (approximately 5mm thick) of pre-sterilized 
Vaseline® to coat the underside rim of the cylinder. Using the same forceps, the cylinder was 
then transferred to the P100 culture dish and firmly pressed down upon the marked colony. The 
Vaseline® coating was used to seal the cloning cylinder to the dish surface. Depending on the 
size of the cloning cylinder, 100-200µl of pre-warmed 1X TryPLE Express was pipetted into the 
cylinder, before placing the dish in a 37ºC incubator for 5-10 minutes to enable cell detachment. 
The resulting cell suspension was retro-pipetted several times and transferred to a P35 dish 
containing 2ml of complete medium and the appropriate selection antibiotic. Fresh medium was 
applied to the dish after 48 hours.  
2.1.6 CELL NUMBER AND VIABILITY ESTIMATION  
 Cell number and viability was assessed using a Countess® Automated Cell Counter 
(Invitrogen, US), according to manufacturer's guidelines. Cells growing in log-phase were 
harvested and pelleted using the aforementioned procedure. Depending on the size of the culture 
dish and the observed level of confluence prior to cell detachment, cell pellets were resuspended 
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in 1-2ml of culture medium. 10µl of cell suspension were transferred to a sterile Eppendorf 
tube, followed by 10µl of 0.4% Trypan blue stain (Invitrogen, US). After thorough mixing, 10µl 
of the cell solution were transferred into a single chamber of a Countess® Cell Counting 
Chamber Slide. The slide was then immediately placed into the automated cell counter and both 
the cell number (number of cells/ml) and viability (viable cells/ml) were ascertained and 
recorded.  
 
2.2 GENOMIC DNA ISOLATION AND QUANTIFICATION 
 Cell monolayers growing in log-phase (70-90% confluent) were harvested and 
centrifuged to obtain cell pellets as mentioned previously. After aspiration of the supernatant, 
1ml of pre-warmed 1X PBS was used to wash pellets and remove residual growth media. 
Following aspiration of the supernatant cell pellets were immediately stored at -80ºC until 
required. 
 DNA extraction was carried out using the Wizard® Genomic DNA Purification Kit 
(Promega) according to the manufacturer's guidelines. Cell pellets were first removed from 
storage and thawed on ice. 600µl of Nuclei Lysis solution was then immediately added to the 
pellet and the solution retro-pipetted several times to facilitate complete cell lysis. Cell lysates 
were transferred to a sterile 1.5ml Eppendorf tube, followed by the addition of 3µl of RNAse A 
solution. The mixture was then incubated at 37ºC for 15-30 minutes in a pre-heated water bath. 
The cell lysate mixtures were then cooled to room temperature for 5 minutes before 200µl of 
Protein Precipitation solution was added. After vigorous vortexing for 20 seconds, samples were 
incubated on ice for 5 minutes to enable protein precipitation. Samples were then centrifuged at 
13,000 x g for 4 minutes at 4ºC. Sample supernatants, containing genomic DNA, were carefully 
transferred to fresh 1.5ml Eppendorf tubes containing 600µl of 2-propanol (Sigma-Aldrich, 
US). Sample tubes were inverted several times before pelleting the DNA by centrifugation at 
13,000 x g for 1 minute at room temperature. After decanting the supernatant, DNA pellets were 
washed once by adding 600µl of 70% ethanol solution (diluted in nuclease-free water, Ambion, 
Thermo Fisher Scientific, US), and centrifuging at 13,000 x g for 1 minute at room temperature. 
Sample supernatants were then decanted and DNA pellets air-dried for 15 minutes by inverting 
the tubes on clean tissue paper. DNA pellets were dissolved in 50µl of DNA Rehydration 
solution (10mM Tris-HCl, 1mM EDTA) by incubating at 4ºC overnight. The following day, 
samples were transferred to a -20ºC freezer for long-term storage. 
  The concentration of sample DNA was ascertained using the NanoDrop 2000 UV/Vis 
Spectrophotometer (Thermo Scientific). The spectrophotometer was first calibrated using DNA 
Rehydration Solution, before reading the absorbance of sample solutions at 260nm and 280nm 
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wavelengths to determine the DNA concentration (ng/µl). As a measure of sample purity, only 
samples with an A260/280 absorbance ratio of around 1.8 were kept for downstream analysis. 
 
2.3  QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (QRT-
PCR) 
2.3.1 RNA EXTRACTION AND QUANTIFICATION 
 Extraction of RNA from cell lines or strains was carried out using peqGOLD TriFast 
reagent (Peqlab) according to manufacturer's guidelines. Cell culture media was first aspirated 
from dishes containing 70-90% confluent cell monolayers growing in log-phase. Cell 
monolayers were washed once with pre-warmed 1X PBS to remove any traces of culture media, 
before 1ml of TriFast reagent was added to lyse the cells. After retro-pipetting several times, 
cell lysates were transferred into a sterile 1.5ml Eppendorf tube and incubated at room 
temperature for 5 minutes. Following the addition of 200µl of molecular biology-grade 
chloroform (Sigma, US), cell lysates were vortexed vigorously for 20 seconds. To enable 
phenol-chloroform phase separation, sample mixtures were incubated at room temperature for 5 
minutes and then centrifuged at 12,000 x g for 5 minutes at 4ºC. The aqueous-phase, containing 
the RNA, was carefully pipetted into a fresh 1.5ml Eppendorf tube containing 500µl of 2-
propanol. RNA was then precipitated by incubating samples on ice for 10-15 minutes. Samples 
were centrifuged at 12,000 x g for 10 minutes at 4ºC to pellet precipitated RNA. After decanting 
the supernatant, RNA pellets were washed twice with 75% ethanol (diluted in nuclease-free 
water, Ambion, Thermo Fisher Scientific, US) by gentle vortexing and centrifugation at 12,000 
x g for 10 minutes at 4ºC. After the final wash step, the ethanol solution was decanted and RNA 
pellets were air-dried by leaving tubes inverted for 5 minutes at room temperature. RNA pellets 
were then dissolved in 30-50µl of nuclease-free water (Ambion, Thermo Fisher Scientific, US) 
by incubating samples on ice for 30 minutes. For long-term storage, samples were transferred to 
a -80ºC freezer.  
 Sample RNA concentrations were determined using the NanoDrop 2000 UV/Vis 
Spectrophotometer (Thermo Scientific) as described for the quantification of DNA samples, 
except that the instrument was first calibrated using nuclease-free water. Only RNA samples 
with an A260/280  absorbance ratio of between 1.6-2.0, were kept for downstream gene expression 
analysis.   
2.3.2 ELIMINATION OF DNA FROM RNA EXTRACTS 
 Removal of contaminating DNA from RNA sample extracts was achieved using the 
Deoxyribonuclease I (DNAse I), Amplification Grade enzyme (Invitrogen, US). To each 
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reaction mixture containing 1µg of RNA, 1µl of 10X DNAse I Reaction Buffer and 1µl of 
(1U/µl) DNAse I enzyme was added, followed by nuclease-free water (Ambion, Thermo Fisher 
Scientific, US) to increase the final volume to 10µl. Solutions were then incubated at room 
temperature for 30 minutes. To de-activate the DNAse I enzyme, 1µl of 25mM 
Ethylenediaminetetraacetic acid (EDTA) was added before reaction mixtures were incubated at 
65ºC for 10 minutes.  
2.3.3 REVERSE TRANSCRIPTION OF RNA TO COMPLEMENTARY DNA (CDNA) 
 The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, US) was 
used to reverse transcribe 1µg of DNAse I-treated RNA into cDNA, according to manufacturer's 
guidelines. Reaction mixtures consisted of: 2µl 10X RT Buffer, 0.8µl 100mM deoxynucleotides 
(dNTPs), 2µl 10X RT Random Primers, 1µl MultiScribe® MuLV Reverse Transcriptase 
enzyme (50U/µl), 1µl RNAse OUT™ Recombinant Ribonuclease Inhibitor (40U/µl, Invitrogen, 
US) and 2.2µl of nuclease-free water (Ambion, Thermo Fisher Scientific, US). For larger 
amounts of starting RNA (2µg), reaction component volumes were scaled up accordingly. 
cDNA synthesis was carried out by incubating reaction mixtures at 25ºC for 10 minutes, 
followed by 37ºC for 120 minutes and then 85ºC for 5 minutes using a thermal cycler (DNA 
Engine Tetrad 2, MJ Research). Samples were then immediately stored at -20ºC, or an equal 
volume (20µl) of nuclease-free water was added to dilute the cDNA (1:1) prior to storage.   
2.3.4 GENE EXPRESSION ANALYSIS BY QRT-PCR 
 Gene expression levels were determined using an ABI Prism 7900HT Sequence 
Detection System (Applied Biosystems, US). Details of gene primer and probe sequences and  
the mRNA transcripts detected by each primer pair are detailed in Table 2.3. Reaction mixtures 
for all genes consisted of: 5µl‎ 10X‎ iTaq™‎Universal‎ SYBR® Green Supermix or Universal 
Probes Supermix (BioRad, US), 2µl undiluted or 1:1 diluted cDNA sample, gene primers 
with/without probes and nuclease-free water up to 10µl (Table 2.4). Reaction mixture 
components, aside from sample cDNA, were added to a sterile 1.5ml Eppendorf tube. After 
gentle vortexing, the reaction mixture was pipetted into wells of a 96-well microplate 
(MicroAmp® Optical 96-Well Reaction Plate, ABI, US). 2µl of cDNA sample was then added 
to appropriate wells before sealing microplates with optically-clear adhesive film (MicroAmp® 
Optical Adhesive Film, ABI, US). After centrifugation at 1000xg for 30 seconds at room 
temperature, microplates were loaded into the qRT-PCR thermal cycler. Exposure of the 
reaction mixture to light was minimized throughout the procedure. SDS 2.3 (ABI, US) software 
was used to set up thermal cycling parameters (Table 2.4),  assign appropriate detectors 
(SYBR
®
 or probe-labelled) and label wells with sample names. All samples for one gene were 
analysed on a single plate and every sample was analysed in triplicate. Non-Targeting Controls 
(NTC) containing nuclease-free water in place of cDNA were included for every gene analysed. 
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Where possible, positive and negative control samples for each target gene were included. To 
facilitate downstream quantification of target gene expression levels, the mRNA levels of one or 
more endogenous control genes (GAPDH, TOP1 and YWHAZ) were also determined using the 
same cDNA stock for each sample. 
Table 2.3 - Primer and probe sequences and transcript accession numbers 
Gene 
Primer 
Name 
Sequence (5'-3') 
Transcript (s) 
Accession No.* 
hTERT
1 
hTERT-F GAGCTGACGTGGAAGATGAGC 
- 
hTERT-R GGTGAACCTCGTAAGTTTATGCAA 
hTERT-Pr 
6-FAM-CACGGTGATCTCTGCCTCTGCTCTCC-
TAMRA 
GAPDH
1 GAPDH-F GAAGGTGAAGGTCGGAGT NM_001289746.1 
NM_002046.5 GAPDH-R GAAGATGGTGATGGGATTTC 
SETD2 
SETD2-F ATTGAGTTTTTCTTCCTCTTGTGAGAT 
NM_014159.6 
SETD2-R CCCAACCTAAGTTTCTGAGCTCTT 
SETD2-Pr 
6-FAM-CACATGTGGATGGCTTGCACTCATCA-
MGB 
FLJ/KIF9 
FLJ-F TGACAGTGCTTGGTGCCTTTC 
NR_033373.1 
FLJ-R CCATACTCGTTGCAAGGAGGA 
P21/CDK
N2A 
P21-F AGCATGGAGCCTTCG 
NM_001195132.1 
NM_000077.4 
NM_058197.4 P21-R ATCATGACCTGGATCGG 
BAP1 
BAP1-F AGAAATACTCACCCAAGGAG 
NM_004656.3 
BAP1-R TCCTTCTCTGGTCATCAATC 
PBRM1 
PBRM1-F ACGGAAAATCAACATGAGTG 
NM_018313.4 
PBRM1-R TGCCTTCATATTCTGCTTTC 
RASSF1 
RASSF1-F CTTGAACAAGGACGGTTC 
NM_001206957.1 
NM_170713.2 
NM_170714.1 
NM_007182.4 
NM_170712.2 RASSF1-R TGGGCAGGTAAAAGGAAG 
PARP3 
PARP3-F CTGGAAAGTAAACCAAGAAGG NM_005485.4 
NM_001003931.2 PARP3-R TCTCTGAGGCAAAGTAGATG 
P53 
P53-F N/A 
N/A 
P53-R N/A 
P16 
P16-F N/A NM_000077.4 
NM_001195132.1 P16-R N/A 
TOP1 
TOP1-F N/A 
N/A 
TOP1-R N/A 
YWHAZ 
YWHAZ-F N/A 
N/A 
YWHAZ-R N/A 
*Accession numbers obtained from the National Centre for Biotechnology Information (NCBI). 
1
hTERT and GAPDH primer sequences obtained from Ducrest et al., (2001). Abbreviations: F 
(Forward), R (Reverse), Pr (Probe), 6-FAM (Carboxyfluorescein), MGB (major groove binder), 
TAMRA (Carboxytetramethylrhodamine).  
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Table 2.4 - Primer-specific thermal cycling parameters and final reaction primer and probe 
concentrations 
Primer Source Sigma ABI 
Primer 
Design 
Other 
Gene Name 
PARP-3, PBRM1, RASSF1, 
BAP1, p21 
P16 
TOP1, 
YWHAZ 
hTERT*, GAPDH, 
SETD2,FLJ, p53 
Primer (µM) 0.45 0.9 0.3 0.3 
Probe (µM) - 0.25 - 0.15 
Thermal 
Cycling 
Parameters 
Step 1: 95ºC 30sec 
Step 2: (40cycles) 95ºC 15min, 
58ºC 30sec, 72ºC 15sec 
Step1: 95ºC 10min 
Step 2: (40cycles) 95ºC 15sec, 60ºC 1min 
*hTERT transcripts were amplified for 50 cycles.  
2.3.5 GENE EXPRESSION QUANTIFICATION 
 After completion of the thermal cycling program, sample amplification curves, and 
assigned baseline fluorescence and threshold values were inspected to confirm (i) consistency of 
cDNA quality across all samples, (ii) no detectable amplification of the NTC control, (iii) that 
appropriate threshold and baseline fluorescence values for each gene were assigned (iv) where 
possible, expected amplification curves of both positive and negative control samples. Cycle 
threshold values (Ct) were then imported into qbase
PLUS
 data analysis software program 
(Biogazelle). This software is designed to calculate the normalized relative quantities (NRQ) for 
each sample based on the Ct values obtained for target and endogenous control genes. 
NRQ values were calculated by qbase
PLUS
 software using the following formulae (adapted from 
Hellemans et al. 2007): 
1. Target gene normalization using a single endogenous control gene: 
 NRQ = E-ΔΔCt   =  
𝑬∆𝑪𝒕𝒆𝒏𝒅
𝑬∆𝑪𝒕𝒕𝒐𝒊
 
2. Target gene normalization using multiple endogenous control genes: 
 𝐍𝐑𝐐 =  
𝑬𝒕𝒐𝒊
∆𝑪𝒒,𝒕𝒐𝒊
√∏ 𝑬𝒆𝒏𝒅𝒊
∆𝑪𝒒,𝒆𝒏𝒅𝒊𝒇
𝒊=𝟏
𝒇
   =   
𝑹𝑸𝒕𝒐𝒊
𝒈𝒆𝒐𝒎𝒆𝒕𝒓𝒊𝒄 𝒎𝒆𝒂𝒏(𝑹𝑸𝒆𝒏𝒅)
 
E = amplification efficiency 
end = endogenous control gene 
toi = target gene of interest 
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All target and endogenous control genes included in this project were assumed to have a 100% 
amplification efficiency (E = 2).  
 
2.4 DETERMINATION OF TELOMERASE ACTIVITY 
2.4.1 PROTEIN EXTRACTION AND QUANTIFICATION 
 Cells growing in log-phase were harvested and counted using aforementioned methods. 
Following centrifugation, cell pellets were washed once with 1X PBS and immediately stored at 
-80ºC. After thawing on ice, cells were lysed by adding 200µl/10
5
-10
6
 cells of TRAPeze® 1X 
CHAPS Lysis Buffer (Chemicon®, Merck Millipore, DE) and thoroughly mixing several times 
before incubating on ice for 30 minutes. Cell lysates were then centrifuged at 12,000xg, for 20 
minutes at 4ºC. 20µl of each sample supernatant was set aside for protein quantification and the 
remainder aliquoted into multiple tubes and immediately stored at -80ºC.  
 The protein concentration of each sample was determined using the CB-X Protein 
Assay (G-Biosciences) according to manufacturer's guidelines. This colorimetric assay relies on 
the absorbance of the CB-X protein dye, which changes according to the amount of protein 
within each sample. Firstly, bovine serum albumin (BSA, 2mg/ml) was diluted in CHAPS 
buffer to produce a set of eight protein standards ranging from 0.05-2µg/µl. These were used to 
construct a calibration curve of absorbance values at 595nm for each protein standard (Fig 2.1). 
The linear trend line equation was used to determine the protein concentration of sample 
extracts. 
 
Figure 2.1 - Standard calibration curve of BSA protein (2mg/ml) diluted in CHAPS lysis buffer. 
 Samples were prepared for quantification, by first transferring 10µl of BSA standards or 
sample extracts to a 96-well microplate (Corning, US), followed by 200µl of CB-X Assay Dye. 
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Solutions were then incubated at room temperature for 5 minutes before loading the microplate 
into a spectrophotometer (xMark Microplate Absorbance Spectrophotometer, BioRad, US) and 
reading the absorbance at 595nm. Sample extracts and BSA standards were read in duplicate 
wells and each microplate was read three times in succession. The mean of six absorbance 
readings for each sample was then determined before subtracting the average background 
absorbance (CHAPS buffer only). These final values were used to construct a BSA standard 
curve and estimate protein concentrations of sample extracts (Fig. 2.1).  
2.4.2 TELOMERE REPEAT AMPLIFICATION PROTOCOL (TRAP) ASSAY 
 Telomerase activity was determined using an qRT-PCR-based TRAP assay protocol 
adapted from Wege et al. (2003). Reaction mixtures for each sample consisted of 12.5µl 10X 
iTaq™‎Universal‎SYBR® Green Supermix, 0.05µg/µl ACX primer, 0.1µg/µl TS primer (Table 
2.5), 250ng sample protein extract, and nuclease-free water to bring the total volume to 25µl. 
Protein extracts were thawed on ice and diluted to 62.5ng/µl using CHAPS lysis buffer. A stock 
solution containing all reaction mixture components except the protein sample, were loaded into 
96-well microplates (MicroAmp® Optical 96-Well Reaction Plate, ABI, US) followed by 
diluted protein extracts. A maximum of nine samples, twelve control samples and five standards 
were assayed on a single microplate at any one time. A serial dilution of telomerase-positive 
PC-3-hTERT protein extracts was carried out to generate a standard curve and enable 
quantification of telomerase activity within unknown samples. These consisted of five standards 
ranging from 400ng to 25ng protein, diluted in CHAPS lysis buffer. The 21NT breast cancer 
cell line was used as a telomerase-positive control and as an untreated wild-type control sample 
(Cuthbert et al. 1999, Ducrest et al. 2001, Szutorisz et al. 2003) and either HMEC 184 or 
HMEC 240L cell strains were used as normal  human controls. Negative controls for each 
sample were generated by heat-inactivating telomerase within aliquots of sample protein 
extracts at 85ºC for 10 minutes. An additional non-template control (NTC) consisting of 
CHAPS lysis buffer in place of protein sample, was also included. All samples, controls and 
standards were analysed in triplicate. After sealing with optical adhesive film (MicroAmp® 
Optical Adhesive Film, ABI, US), microplates were loaded into the ABI Prism 7900HT thermal 
cycler. The SDS 2.3 software program was used to set up a thermal cycling program consisting 
of an initial incubation step at 25ºC for 20 minutes to enable endogenous telomerase to elongate 
the TS primer substrate molecule, followed by PCR amplification of extended fragments at 
95ºC for 10 minutes and 35 cycles of 95ºC for 30 seconds and 60ºC for 90 seconds.   
Table 2.5 - Primer sequences used in the qRT-PCR TRAP assay 
Primer Name Sequence (5'-3') 
TS (Telomerase Substrate) AATCCGTCGAGCAGAGTT 
ACX (Anchored Return Primer) GCGCGG(CTTACC)3CTAACC 
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2.4.3 QUANTIFICATION OF TELOMERASE ACTIVITY 
 Once the thermal cycling program had completed, amplification plots of positive and 
negative control samples were first inspected before telomerase activity was quantified within 
sample extracts. Figure 2.2 shows typical amplification plots of control samples obtained from a 
single assay run, that demonstrate: (i) the absence of contaminating telomerase inhibitors within 
the reaction mixture (Figure 2.2A), (ii) that sample cross-contamination is unlikely to have 
occurred during assay set-up (Figure 2.2B) and (iii) a minimal degree of technical variation 
introduced by pipetting errors (Figure 2.2 A and C). From average Ct values of PC-3-hTERT 
protein standards, SDS 2.3 software was used to generate a standard curve plot (Fig 2.2C and D) 
and calculate the telomerase activity of unknown samples based on their Ct values. These values 
were exported and presented as a bar-graph with error bars showing the standard deviation of 
sample replicates.   
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Figure 2.2 - Representative amplification and standard curve plots of control samples and 
standards included in each qRT-PCR-based telomere repeat amplification protocol (TRAP) 
assay (SDS2.3). Baseline-corrected normalized fluorescence signals (ΔRn) of (A) Telomerase 
positive wild-type (21NT) and normal human (HMEC) control samples, (B) heat-treated 
samples and CHAPS-only NTC control (C) serial dilution standards of PC-3-hTERT protein 
extract. The green line shows the amplification threshold value. Image (D) A typical standard 
curve plot of Ct values obtained from PC-3-hTERT serial dilution standards. 
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2.5 GENE COPY NUMBER VARIATION (CNV) ANALYSIS  
 CNV analysis of target genes was carried out using pre-designed Taqman
®
 Copy 
Number Assay primers developed by ABI (Applied Biosystems, US), that detect and amplify 
specific 86-105bp intronic or exonic regions of SETD2 and FLJ gDNA sequences (Table 2.6). 
In order to normalize target gene copy number, assays were run in a duplex reaction with a 
ribonuclease P RNA component H1 (RNaseP) Taqman® Reference Assay. RNaseP is assumed 
to be present as two copies within each sample. To distinguish between target and reference 
sequences within a duplex qRT-PCR reaction, target gene copy number probe sequences are 
labelled with 5'FAM - 3'MGB and the reference gene probe sequences are labelled with 5'VIC - 
3'TAMRA. 
Table 2.6 - Details of the size and genomic region targeted by pre-designed CNV primers (ABI, 
US) 
Gene Name NCBI Location (Build 
37) 
Assay Reference 
Number 
Assay Gene 
Location 
Amplicon Length 
(bp) 
SUMF1 3p26.1c: 4,443,756 Hs06663284_cn Intron 7 81 
RAR-β 3p24.2a: 25,542,710 Hs01803834_cn Intron 2-Exon 3 106 
SETD2 
3p21.31: 47,057,898-
47,205,467 
Hs02774936_cn Exon 21 105 
Hs00431122_cn Exon 15 98 
Hs01027663_cn Intron 6-Exon 7 86 
Hs02852048_cn Exon 3 91 
Hs04751634_cn Intron 1 105 
FLJ  3p21.31: 47,243,557 Hs05895570_cn Intron 2 100 
PARP-3 3p21.2a: 51,979,562 Hs01428519_cn Exon7 85 
BAP1 3p21.1e: 52,439,941 Hs02357352_cn Intron9-Exon 10 108 
PBRM1 3p21.1e: 52,657,538 Hs06624309_cn Intron 14 108 
NA* 3p14.2b: 61,252,882 Hs06677725_cn - 111 
CADM2 3p12.1a: 85,911,377 Hs04769003_cn Intron 5 110 
RNaseP 
(Reference) 
14q11.2: 20,343,071 4403326 Exon 1 87 
Annotations: * NA (Not Applicable)  
 Reaction mixtures for each target gene consisted of 10µl of 2X Taqman
®
 Universal 
PCR Mastermix, 1µl of 20X Taqman
®
 Copy Number Assay, 1µl 20X Taqman
®
 Reference 
Assay, 4µl of 5ng/µl gDNA extracts and 4µl nuclease-free water up to a total volume of 20µl. 
Reaction mixtures without gDNA were first pipetted into wells of a 96-well microplate 
(MicroAmp
®
, ABI, US). Samples were analysed in triplicate and an NTC was included for each 
target gene analysed. The HMEC 184 cell strain was assumed to have two copies of every target 
gene analysed, and was used to calibrate gene copy number within all other samples. Following 
the addition of gDNA into appropriate wells, microplates were sealed with optical adhesive film 
(MicroAmp
®
, ABI, US) and centrifuged at 1000xg for 30 seconds at room temperature. After 
loading the microplate into the ABI Prism 7900HT Sequence Detection System, the following 
thermal cycling parameters were set up: 95
o
C for 10 minutes followed by 40 cycles of 95
o
C for 
15 seconds and 60
o
C for 1 minute. 
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 Raw amplification data was imported into the Copy Caller™ Software data analysis 
program, which calculates target gene copy number of each sample using the ΔΔCt method of 
relative quantification.  For each sample, the following calculations were applied: 
1. Normalization of target gene (t) with RNase P reference gene (r) within each well (w): 
(ΔCt)w= (Ct)t,w–(Ct)r,w 
 
2. The arithmetic mean of sample (s) ΔCt replicates (n): 
 μ(ΔCt)s =
𝛴𝑛 (𝛥𝐶𝑡)𝑤
𝑛
  
3. Calibration of sample ΔCt values relative to HMEC 184 ΔCt values (ΔΔCt): 
ΔΔCt‎=‎μ(ΔCt)s - μ(ΔCt)HMEC 184 
 
4. Fold change in amplification for each sample relative to HMEC 184 (RQ): 
RQ = 2
(-ΔΔCt) 
 
5. Calculated target gene copy number (CN): 
CN = 2 x RQ 
 
6. Calculated CN values obtained for each sample were then used to estimate target gene 
copy number:  
Calculated CN value Predicted Gene CN 
0 ≤‎CN < 0.5 0 
0.5 ≤‎CN < 1.5 1 
1.5 ≤‎CN‎<‎2.5 2 
2.5 ≤ CN < 3.5 3 
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2.6 CLONING 
2.6.1 TRANSFORMATION OF CHEMICALLY-COMPETENT E.COLI WITH PLASMID 
VECTORS 
 Plasmid constructs were transformed into OneShot
®
 TOP10 Chemically Competent 
E.coli (Invitrogen, US) according to manufacturer's guidelines. For each transformation 
reaction, one vial of OneShot
®
 TOP10 E.coli was removed from -80
o
C storage and thawed on 
wet-ice for around 30 seconds. 1-5µl of 10pg-100ng plasmid DNA was then added to the E.coli 
cell suspension and gently mixed before incubating on ice for 30 minutes. To heat-shock the 
E.coli cells, vials were placed inside a pre-warmed water bath and incubated at 42
o
C for 30 
seconds. Vials were immediately transferred to wet-ice for two minutes before adding 250µl of 
room-temperature S.O.C medium. Transformed E.coli were then incubated at 37
o
C for 1 hour 
on an orbital shaker at 200rpm. Using aseptic techniques, 20-200µl of bacterial suspension were 
spread onto 3-5 dishes containing pre-sterilized 4% high-salt Luria Bertani (LB) Agar (Sigma-
Aldrich, US) with 100µg/ml ampicillin. Dishes were then inverted and incubated overnight at 
37
o
C. The following day around 5-10 individual colonies were picked by gently scraping the 
surface of the plate with a sterile pipette tip and transferring into a Falcon tube containing 5ml 
of pre-sterilized room-temperature LB-Broth and 100µg/ml ampicillin. Bacterial suspensions 
were then returned to the orbital shaker and incubated at 37
o
C overnight at 200rpm. The 
following day, cultures were either stored at 4ºC for a maximum of five days, or were prepared 
for long-term storage as glycerol stocks. 
2.6.2 PREPARATION OF BACTERIAL GLYCEROL STOCKS 
 To create 25% glycerol stock solutions, 750µl of bacterial suspensions growing in log 
phase were transferred to fresh pre-sterilized Eppendorf tubes together with 250µl of pre-
sterilized 100% glycerol solution before gently mixing and storing immediately at -80
o
C. 
2.6.3 PROPAGATION OF TRANSFORMED E.COLI 
 Bacterial glycerol stock solutions were removed from -80
o
C and thawed on wet ice. 
Using aseptic techniques, 50µl of glycerol solution was used to inoculate Falcon tubes 
containing 5ml of pre-sterilized 2.5% LB-broth (high salt, Sigma, US) and 100µg/ml ampicillin. 
Bacterial cultures were then incubated at 37
o
C overnight in an orbital shaker at 200rpm. The 
following day, 0.5ml of bacterial culture was used to inoculate conical flasks containing 200ml 
of pre-sterilized 2.5% LB-broth and 100µg/ml ampicillin. Bacterial cultures were returned to the 
orbital shaker and incubated at 37
o
C overnight at 200rpm.  
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2.6.4 EXTRACTION AND PURIFICATION OF PLASMID DNA CONSTRUCTS FROM 
E.COLI 
 Plasmid constructs were extracted from E.coli using the QIAfilter Midi Plasmid 
Purification Kit (Qiagen, NL). First, bacterial cells were harvested by centrifugation at 5000xg 
for 15 minutes at 4
o
C. After decanting the supernatant, pellets were completely resuspended in 
10ml of Buffer P1 (50mM Tris-Cl pH 8, 10mM EDTA, 100µg/ml RNase A). Bacterial cells 
were then lysed by adding 10ml of Buffer P2 (200mM NaOH, 1% SDS), vigorously inverting 
tubes 4-6 times and incubating for 5 minutes at room temperature. To precipitate genomic 
DNA, 10ml of chilled neutralization buffer P3 (3M potassium acetate, pH 5.5) was added to 
lysate solutions and mixed by inverting tubes 4-6 times. Lysates were then transferred to 
QIAfilter Midi Cartridges and incubated at room temperature for 10 minutes. During this 
incubation period, QIAGEN-tips were equilibrated with 4ml of Buffer QBT (750mM NaCl, 
50mM MOPS, 15% isopropanol, 0.15% Triton® X-100). Plungers were then inserted into 
QIAfilter Midi tubes and the lysate filtered into equilibrated QIAGEN tips. Plasmid DNA binds 
to an anion-exchange resin as bacterial lysates pass through QIAGEN tips by gravity flow. To 
remove contaminating RNA from the resin, Buffer QC (1mM NaCl, 50mM MOPS, 15% 
isopropanol) was added to QIAGEN tips and allowed to clear by gravity flow. Elution of 
plasmid DNA from the resin was achieved by adding 5ml of Buffer QF (1.25M NaCl, 50mM 
Tris-Cl pH 8.5, 15% isopropanol) to QIAGEN tips and collecting eluates in 50ml Falcon tubes. 
Plasmid DNA was precipitated by adding 3.5ml of room-temperature isopropanol and by 
centrifuging the solution at 5000xg for 1 hour at 4
o
C. Sample supernatants were carefully 
decanted and DNA pellets were washed once with 2ml of 70% ethanol by centrifugation at 
5000xg for 1 hour at 4
o
C. After decanting supernatants, DNA pellets were air-dried for 5-10 
minutes and re-dissolved in nuclease-free water. DNA quality and final concentrations were 
ascertained using the NanoDrop 2000 UV/Vis Spectrophotometer (Thermoscientific, UK), as 
described in Chapter 2.2, before storing samples at -20ºC. 
 
2.7 TRANSFECTION OF TARGET GENES WITHIN THE 21NT CELL LINE 
2.7.1 TRANSFECTION PROCEDURE 
 Overexpression of target genes within the 21NT breast cancer cell line was achieved by 
transfection of plasmid DNA constructs consisting of target gene cDNA, using the TransIT
®
-
BrCa Transfection Reagent (Mirus) according to manufacturer's guidelines. This chemical-
based method of gene delivery into mammalian cells, relies on the formation of cationic 
lipopolyplexes consisting of polymers, lipids (present within transfection reagent mixture) and 
plasmid DNA, that are then taken up into cells by endocytosis. As a negative control, plasmid 
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constructs without target gene cDNA (empty vectors) were transfected into 21NT cells at the 
same time, using the identical procedure. 
 24 hours prior to transfection, 21NT cells were plated at 2.5x10
5
 cells/P60 dish and 
cultured  under normal growth conditions (Chapter 2.1.2, Table 2.2). The following day, cells 
were visualized under a light microscope to ensure that they were 60-80% confluent. To 
generate TransIT
®
-BrCa Transfection Reagent-plasmid DNA complexes, 500µl of Opti-MEM I 
Reduced Serum Medium (Invitrogen, US), 5µg of linearized plasmid DNA and 7.5µl of 
transfection reagent (1:1.5 ratio of plasmid DNA to transfection reagent) were mixed together in 
a sterile 1.5ml Eppendorf tube and incubated at room temperature for 25 minutes. The 
transfection reagent-DNA plasmid complexes were then added drop-wise to P60 dishes 
containing 21NT cells, which were gently agitated back-and-forth and side-to-side to ensure 
even distribution. Dishes were immediately returned to the incubator. 
2.7.2 TRANSFECTION EFFICIENCY 
 In order to determine the efficiency of target gene delivery using the above transfection 
reagent protocol, a GFP-labelled lentiviral vector construct (LNV-GFP) developed by my 
colleague Mr. Hassan Khonsari (PhD student supervised by Dr. Michael Themis, Brunel 
University London) was transfected into three individual P60 dishes of 21NT cells using the 
aforementioned procedure. 48 hours post-transfection, a Floid® Cell Imaging Station (Life 
Technologies, US) fluorescence microscope, was used to visualize cells and obtain at least three 
images of different areas of each dish at x20 magnification (Figure 2.3). The total number of 
cells and the number of green fluorescent cells, within three images/dish of LNV-GFP-
transfected 21NT cells was determined. The efficiency of gene delivery (transfection efficiency) 
was estimated by calculating the average proportion of cells displaying green fluorescence for 
all three images/dish. As shown in Figure 2.3, the overall transfection efficiency for this 
procedure was found to be around 20%.  
 
 
117 
 
 
Figure 2.3 - Determination of transfection efficiency. Representative fluorescence microscopy 
images (x20 magnification) of three individual P60 dishes of 21NT cells (seeded at 2.5 x 10
5
 
cells/dish) 48 hours after they were transfected with a lentiviral vector-green fluorescent 
protein (LNV-GFP) plasmid vector construct using the Mirus Transfection Reagent protocol. 
The proportion of green fluorescent cells was used to estimate the efficiency of gene delivery 
into 21NT cells using this method. Abbreviations: TE (transfection efficiency).  
 
2.7.3 COLONY FORMING UNIT (CFU) ASSAY 
 The aforementioned transfection procedure was used to transfect two P60 dishes of 
21NT cells; the first with control empty vector plasmids and the second with target gene 
plasmid constructs. 48 hours post-transfection, both dishes were passaged at a ratio of 1:8 into 
four P60 dishes. To select for 21NT cells that had undergone stable integration of plasmid 
DNA, dishes were maintained in complete culture medium supplemented with the appropriate 
selection antibiotics for two weeks. At this point, culture medium was aspirated and cells were 
washed once with pre-warmed sterile 1X PBS. In order to visualize and count the number of 
stable colonies present on each dish, cells were fixed with 5ml of 100% industrial methylated 
spirits (IMS) and stained with 3ml of Methyl Blue stain (Sigma Aldrich, US). The number of 
stable empty vector control and target gene colonies that arose following two weeks of 
antibiotic selection, was expressed as the mean ± SD of four dishes for each plasmid construct. 
A student's t-test was used to compare the mean number of stable empty vector control and 
target gene colonies that emerged.  
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2.8 STATISTICAL FORMULAE  
2.8.1 POPULATION DOUBLINGS (PD) 
 To monitor cell population growth, the following formula was used to calculate the 
number of times the cell population had doubled in size over a certain time period (Kumar et al., 
2014): 
  PD = [(log10C1)/(log102)] - [(log10C0)/(log102)] 
C1 = Final cell number 
C0 = Original cell number 
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CHAPTER 3 
3 THE USE OF MICROCELL-MEDIATED MONOCHROMOSOME 
TRANSFER (MMCT) TECHNIQUES TO DETERMINE THE EXISTENCE 
OF TELOMERASE REPRESSOR SEQUENCES LOCATED ON 
CHROMOSOMES 3 AND 17 WITHIN THE 21NT BREAST CANCER CELL 
LINE 
 
3.1 INTRODUCTION   
 The human telomerase enzyme has been found to be active within over 85% of human 
cancers, but is undetectable within the majority of normal human somatic tissues, (Kim et al., 
1994). It has been shown that the major rate-limiting factor for telomerase activity is the 
expression of the hTERT gene, which encodes the reverse transcriptase component of 
telomerase (Meyerson et al., 1997, Counter et al., 1998). This is supported by the finding that 
hTERT transcript molecules can only be detected within human cancer cell lines and not normal 
somatic cells (Ducrest et al., 2001). Therefore, changes in the regulation of hTERT gene 
transcription could be responsible for the observed telomerase activity within cancer cells.  
 Studies have shown that normal human somatic cells can undergo telomerase activation 
and immortalization in vitro (Counter et al., 1998, Ozer., 2000). Transfection of normal human 
fibroblasts with viral oncogenes has been found to extend the proliferative potential of cells 
beyond the replicative senescence barrier, due to the inhibition of important cell cycle 
regulatory proteins, p53 and pRb (Wright and Shay., 1992). Cells continue to divide for a 
further 20-30 population doublings (PD) until entering growth crisis. This is thought to be due 
to the continued erosion of telomeric sequences, which provokes substantial chromosomal 
instability and cell death (Chang et al., 2003). Rarely, a colony of immortal cells emerges from 
crisis, the majority of which display active telomerase. It has been hypothesized that telomerase 
reactivation occurs due to loss of an hTERT transcriptional repressor sequence(s) during cell 
crisis. There is evidence to show that cellular immortalization is an essential prerequisite for 
clonal evolution and malignant transformation of cells (Newbold et al., 1982, Counter et al., 
1998). As a result, cellular senescence pathways are thought to have evolved as a protective 
mechanism against immortalization and tumorigenesis.  
 The functional role of telomerase in cancer development, together with the observation 
that telomerase is active within the majority of human tumours and not within most normal 
human tissues, has led to the search for an effective strategy to inhibit telomerase activity in 
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cancer. One such approach involves the identification of important sequences responsible for 
regulating telomerase within normal human somatic cells that are functionally inactivated 
during cancer development. In this way, a greater understanding of the critical events that occur 
during carcinogenesis can be developed, and effective mechanisms of telomerase repression can 
be elucidated. Whole cell fusion of immortal human cell lines with normal human fibroblasts 
has been found to repress telomerase activity and restore limited growth potential, which shows 
that telomerase activity behaves like a recessive trait. (Pereira-Smith and Smith., 1983). In 
addition, cell fusion of two different parental immortal human cell lines (somatic genetic 
complementation) can also result in telomerase repression and growth arrest, which indicates 
that more than one event can occur during cancer development, that leads to hTERT 
deregulation and telomerase reactivation (Pereira-Smith and Smith, 1988).  
 In order to develop an effective strategy to study human gene function and narrow the 
search for genome sequences involved in normal cell growth regulation, Cuthbert et al., (1995) 
developed‎ a‎ library‎ of‎ human:‎ rodent‎monochromosomal‎ ‘donor’‎ hybrids,‎ representing‎ all‎ 22‎
normal human autosomes and the X-chromosome, maintained within a rodent fibroblast 
background. This hybrid panel provides a means of stable, functional gene transfer by 
facilitating the introduction of single, intact copies of normal human chromosomes into any 
mammalian recipient cell line. Each human chromosome copy originated from a normal human 
adult fibroblast cell strain, and was tagged with a selectable hygromycin-phosphotransferase 
(Hytk) fusion gene marker, to allow both positive and negative selection of hybrids following 
transfer into recipient cells. Cytogenetic characterization of each human: rodent hybrid, 
confirmed that human monochromosomes could be stably maintained within a rodent 
background, except chromosome 9, which underwent deletions on the short-arm. This was 
likely due to the presence of anti-proliferative genes, such as those encoded by the CDKN2 
locus (Cuthbert et al., 1995). 
 During an initial screen for telomerase regulatory sequences, introduction of a normal 
copy of human chromosome 3 was found to repress telomerase activity within a head and neck 
carcinoma cell line (Newbold., 1997). The same effect was observed following introduction of 
chromosome 3 into a primary breast carcinoma cell line (21NT). Up to 78% of chromosome 3 
hybrids were found to be telomerase repressed, compared with around 10% of hybrids 
containing chromosomes 8, 12 or 20 (Cuthbert et al., 1999). The majority of telomerase-
repressed chromosome 3 hybrids were found to enter delayed, permanent growth arrest, and 
display morphological features of senescence. Deletion mapping of chromosome 3 within 
telomerase-positive segregant hybrids, revealed two discreet regions of deletion on the short 
arm of chromosome 3 (3p21.3-p22 and 3p12-p21.1). These findings provided strong evidence 
that chromosome 3 harbours sequences that repress telomerase activity and inhibit the growth of 
breast cancer cells. 
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 Introduction of a normal copy of human chromosome 17 into a benzo(a)pyrene-
transformed MCF-10F human breast epithelial cell line, resulted in a significant reduction in 
telomerase activity and a 90% reduction in cell growth (Yang et al., 1999). Chromosome 17 is 
known to harbour the p53 tumour suppressor gene, which is ranked as the second most 
commonly mutated gene in breast cancer (Bamford et al., 2004). Several independent studies 
have shown that p53 can mediate hTERT transcriptional repression within breast, pancreatic and 
prostate cancer cells (Kusomoto et al., 1999, Xu et al., 2000, Shats et al., 2004). A reduction in 
hTERT transcription and telomerase activity was observed following activation of endogenous 
p53 within a breast carcinoma cell line, through sequestration of Sp1, a known transcriptional 
activator of hTERT (Xu et al., 2000). However, p53-mediated transcriptional repression of 
hTERT was found to be dependent on the presence of wild-type p53 within breast cancer cells. 
In support of this, transduction of wild-type p53 into pancreatic cells harbouring p53 mutations, 
resulted in hTERT transcriptional repression (Kusomoto et al., 1999). Shats et al., (2004), 
provided evidence of an alternative mechanism of hTERT repression in breast cancer cells, 
whereby p53 activates p21 and E2F proteins, which repress hTERT transcription through 
histone deacetylation. These observations provide evidence that multiple loss/mutation events 
can occur during breast carcinogenesis, that lead to hTERT de-repression and telomerase 
reactivation. The high frequency of p53 mutations in breast cancer (23%, Catalogue of Somatic 
Mutations in Cancer, COSMIC; Forbes et al., 2015), together with evidence demonstrating an 
important role of p53 in hTERT regulation, could suggest that loss of p53 function may be a 
common event in breast carcinogenesis that contributes to telomerase reactivation.  
 The 21NT cell line used within the study by Cuthbert et al., (1999), has been shown to 
possess a single insertion mutation within the p53 coding region, that results in a premature stop 
codon and non-functional p53 protein (Liu et al., 1994). Introduction of a normal copy of 
human chromosome 3 into this cell line has been shown to repress telomerase activity and 
restore a limited growth potential (see above) suggesting that at least two loss/mutation events 
could be responsible for hTERT deregulation. Therefore, in order to further understand whether 
multiple sequences could function to regulate telomerase activity within a single breast cancer 
cell line, the effect of introducing a single copy of human chromosomes 3 and 17 into the 21NT 
cell line, on the level of telomerase activity, was investigated. The same human: rodent 
monochromosome hybrid cell lines employed by Cuthbert et al., (1999) were used as donors of 
chromosomes 3 and 17 within this study, and telomerase activity was determined using a 
quantitative telomere-repeat amplification protocol (TRAP). In order to explore a relationship 
between telomerase activity and cell proliferation, the growth rate and replicative potential of 
hybrids was also examined. 
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3.2 MATERIALS AND METHODS 
3.2.1 MICROCELL-MEDIATED MONOCHROMOSOME TRANSFER (MMCT) 
PROCEDURE 
 The MMCT procedure was used to transfer human chromosomes 3 and 17 from human: 
rodent monochromosome donor hybrids A9-Neo3 and A9-Hytk17 donor hybrids, to the primary 
human breast cancer cell line, 21NT. First, donor hybrids A9-Neo3 and A9-Hytk17 were seeded 
in twelve 24cm
2
 flasks (Nunclon Surface, Nunc), at cell densities described in Table 3.1. Hybrid 
donor cells were maintained in DMEM (1X) and 20% FBS (Gibco, US) in the absence of 
selection antibiotics (Chapter 2.1.2.2). On the same day, 21NT cells were seeded at 1.5x10
6
 
cells/dish in two P100 cell culture dishes and maintained under normal growth conditions for 
three days (Chapter 2.1.2.1). 24 hours after seeding, colcemid was added to flasks containing 
A9-Neo3 and A9-Hytk17 donor hybrids at final concentrations detailed in Table 3.1. Flasks 
were then incubated at 37
o
C for 48 hours, to induce microcell formation. Exposure of cells to 
colcemid, inhibits the formation of cell spindles, leading to cell cycle arrest during metaphase. 
After prolonged exposure of cells to colcemid, cells attempt to re-enter the cell cycle and 
proceed to G1 phase. In the absence of complete mitosis, nuclear membranes form around 
single or small groups of chromosomes positioned randomly in the cell, leading to the formation 
of micronuclei (McNeill and Brown 1980).   
Table 3.1 Conditions used for micronucleation of human: rodent donor hybrid cells 
Human: Rodent Donor 
Hybrid 
Seeding Density/24cm
2
 
Flask 
Colcemid Concentration 
(µg/ml) 
A9-Hytk17 1.5x10
6 
0.075 
A9Neo3 1.25x10
6 
0.1 
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 After 48 hours, donor cells were observed under a microscope to confirm microcell 
formation (Figure 3.1A and B). Culture media was then aspirated and 30ml of pre-warmed 
cytochalasin B solution (10µg/ml, Sigma, US) was added to each flask. The cytochalasin B 
mycotoxin permeates micronucleated donor cells and inhibits the formation of cytoplasmic 
microfilaments, leading to 'out-pocketing' of micronuclei from the cell surface (Veomett et al., 
1974). Flasks were weighed and paired according to similar weights (±0.03g). Each well of a 6-
well rotor (6x250ml, Sigma, US), was filled with 75ml of pre-warmed (37ºC) water, before 
placing paired flasks in opposite wells of the rotor. Flasks were centrifuged at 9642xg for 1 hour 
and 10 minutes at 37ºC in Sigma laboratory centrifuges (6K15, Philip Harris). High-speed 
centrifugation facilitates complete extrusion of micronuclei from the cell cytoplasm, resulting in 
the production of individual microcells. These consist of micronuclei surrounded by a thin 
cytoplasmic layer. Following centrifugation, flasks were inspected for evidence of breakage and 
weighed to determine whether liquid had entered or left the flasks. If a difference in weight of 
Figure 3.1 - Representative photomicrographs of human: rodent monochromosome hybrid 
donor cells 48 hours after incubation with colcemid (x100 magnification). (A) A9-Neo3 hybrids 
incubated with 0.1µg/ml colcemid. (B) A9-Hytk17 hybrids incubated with 0.075µg/ml 
colcemid. Red arrows indicate micronucleated cells and adjacent images show an enlarged 
section of the original image, demonstrating the presence of micronucleated cells. 
A. 
B. 
A. 
B. 
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±0.02g was observed, flasks were immediately discarded. The majority of cytochalasin B 
solution was then decanted from each flask, leaving approximately 2ml behind. By tapping the 
sides of flasks, microcell pellets present in the bottom corners were resuspended into the 
residual solution. A sterile plugged Pasteur pipette was used to pool microcell suspensions from 
each flask into a single 50ml Falcon tube. Microcells were then pelleted by centrifugation at 
4500xg for 5 minutes at room temperature. Following aspiration of the supernatant, microcells 
were resuspended in 10ml of pre-warmed, serum-free DMEM (1X), for every six flasks 
originally harvested. Microcell suspensions were divided into 10ml aliquots, before being 
filtered through 8µm and 5µm polycarbonate filters (Nucleopore Track-Etch Membranes, 
Whatman®) to isolate microcells containing single chromosomes. Filtered 10ml aliquots were 
centrifuged at 4500xg for 5 minutes at room temperature. Following aspiration of the 
supernatant, microcell pellets were resuspended in 3ml of 100µg/ml phytohaemagglutinin 
(PHA-P), and pooled into one Falcon tube. A P100 culture dish containing 70-90% confluent 
21NT cells was then washed with pre-warmed, serum-free MEM-α‎(1X)‎three‎times.‎Microcell 
suspensions were then pipetted onto recipient 21NT cell monolayers and dishes were gently 
swirled before incubating at 37ºC for 25 minutes. As a negative control, another subconfluent 
P100 dish of 21NT cells, was subject to the same procedure except for the addition of 
microcells.  
 Following incubation, PHA-P solutions were aspirated before 1ml of polyethylene 
glycol solution (PEG) consisting of 42% PEG and 8% DMSO in serum-free DMEM (1X), was 
slowly added to the corner of the dish. The PEG solution was aspirated after exactly 1 minute 
and dishes were washed three times with serum-free MEM-α‎(1X).‎Each‎wash‎step‎consisted‎of‎
vigorous agitation for 1 minute, in order to remove as much of the PEG solution as possible. 
Complete culture medium was then added to the 21NT cell monolayer, before returning the dish 
to the incubator. The same procedure was also carried out for the negative control dish of 21NT 
cells. 24 hours later, dishes were passaged at a ratio of 1:10, and cultured in complete growth 
medium. Positive selection of 21NT-Neo3 and 21NT-Hytk17 hybrids, was carried out by 
supplementing culture media with 400µg/ml neomycin (G418) and 400U/ml hygromycin (hyg 
B) respectively. The presence of neomycin and hygromycin antibiotic resistance gene markers 
within donated human chromosomes 3 and 17 respectively, confer a selective growth advantage 
for 21NT cell hybrids containing introduced chromosome copies. These concentrations of 
antibiotic are cytotoxic to 21NT cells that do not gain a single copy of either exogenous 
chromosome following microcell-fusion. As expected, extensive cell death was observed 5-7 
days after the addition of appropriate selection antibiotics following fusion of 21NT cells with 
microcells containing tagged chromosomes 3 or 17.  
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 P100 dishes containing 21NT-HyTK17 and 21NT-Neo3 hybrids were incubated at 37ºC 
and 5% CO2 and re-fed with fresh complete culture medium containing selection antibiotics, 
every week for 3-4 weeks. Dishes were monitored regularly for the growth of hybrid cell 
colonies, which were either isolated and propagated on individual P35 cell culture dishes as 
described previously (Chapter 2.1.5), or harvested in situ for protein extraction. Hybrid colonies 
consisting of cells with vacuoles or an enlarged cytoplasm with very few mitotic cells, were 
harvested in situ.  
 Rarely, colonies of donor A9 donor hybrid cells were observed after approximately two 
weeks of selection, indicating that these cells had escaped the filtration step of the MMCT 
procedure. A9 donor cells were distinguishable from 21NT hybrids by their cellular morphology 
and growth pattern. On a single dish, they typically manifested as multiple, rapidly growing, 
dense colonies with several surrounding satellite colonies. As soon as contaminating A9 donor 
hybrids were identified, dishes were treated with hypoxanthine aminopterin thymidine (HAT, 
1X, Sigma, US). Aminopterin is an inhibitor of dihydrofolate reductase; a key enzyme in the de 
novo pathway of purine and pyrimidine nucleotide synthesis (Chung et al., 2001). Therefore in 
the presence of HAT, cells activate the salvage pathway of DNA synthesis in order to survive 
and continue replicating. The A9 fibroblast cell line used in the construction of human: rodent 
monochromosomal hybrids by Cuthbert et al., (1995), is deficient in the hprt gene, that encodes 
a critical enzyme involved in the salvage pathway; hypoxanthine-guanine 
phosporibosyltransferase (Cos et al., 1974). A9 donor cell growth arrest was observed 
approximately three days after HAT was added to the culture medium of affected dishes. This 
enabled further discrimination of 21NT hybrid colonies, that were able to survive and grow 
larger in size.  
 Transfer of human chromosome 17 from A9-Hytk17 donor hybrids to 21NT cells by 
MMCT, was carried out by our laboratory cell culture technician, Mrs. Alison Marriott. After 3-
4 weeks in selection, P100 dishes containing 21NT-Hytk17 colonies were provided to me. As 
described above, colonies were either picked and cultured as individual cell lines, or harvested 
in situ.   
 
3.2.2 TELOMERASE ACTIVITY OF 21NT-HYBRID AND 21NT CELL COLONIES 
 P35 dishes containing 70-90% confluent individual 21NT-Neo3 and 21NT-Hytk17 
hybrid cell clones, were harvested and either (i) counted as described previously (Chapter 2.1.6) 
or (ii) whole cell populations were pelleted without counting and immediately stored at -80ºC. 
For cell colonies that were counted, aliquots of 3x10
5
 cells were pelleted and stored at -80ºC. 
The remaining cell suspensions of a sub-set of hybrid colonies were re-established in P60 dishes 
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and maintained in complete medium with appropriate selection antibiotics, in order to determine 
cell growth rate and replicative potential.  
 Protein extraction and quantification of hybrid colony cell pellets was carried out as 
described previously (Chapter 2.4.1). A semi-confluent P35 dish reportedly yields an average of 
9x10
5
 cells (Corning, Life Sciences, US). Therefore, cell pellets harvested from P35 dishes with 
an unknown cell number, were lysed in 200µl of CHAPS buffer. The same volume was used to 
lyse cell pellets containing 3x10
5
 cells.   
 Lysis of hybrid colonies in situ, was carried out by first marking the position and size of 
the colony on the underside of the P100 dish with a permanent marker. After aspiration of 
culture media, hybrid colonies were washed once with pre-warmed 1X PBS. Cloning cylinders 
were then placed over colonies and fixed in place using pre-sterilized Vaseline (Chapter 2.1.5). 
50µl of CHAPs lysis buffer was then pipetted into each cloning cylinder and mixed thoroughly 
by retro-pipetting to cause complete cell lysis. Cell lysates were transferred into a sterile 
Eppendorf tube and subject to the same procedure for protein extraction and quantification as 
cell pellets. The qRT-PCR TRAP assay was used to quantify telomerase activity of all 21NT-
Neo3 and 21NT-Hytk17 hybrids generated (Chapter 2.4). 
 The clonal variation in telomerase activity of wild-type 21NT cells was determined by 
first seeding 21NT cells at 10
4
 cells/P100 dish. Nine cell colonies were picked using cloning 
cylinders (Chapter 2.1.5), and maintained as individual cell lines on P35 dishes. As soon as they 
were subconfluent, cells were harvested and pelleted. Following protein extraction and 
quantification, the telomerase activity of individual colonies was measured using the qRT-PCR 
TRAP assay, and quantified relative to the telomerized prostate cancer cell line (PC-3-hTERT, 
Chapter 2.1.2.1). 
 
3.2.3 CELL GROWTH AND REPLICATIVE POTENTIAL 
 As described above, a proportion of 21NT-Neo3 and 21NT-HyTK17 hybrid colonies 
were re-established in P60 culture dishes after 3.5x10
5
 cells were taken from cell suspensions 
for protein extraction and determination of telomerase activity. Remaining cells were re-
established in P60 dishes and maintained under normal growth conditions in appropriate 
selection antibiotics. At 70-90% confluence, the cell number was determined and 3.5x10
5
 cells 
were re-established on P100 dishes containing complete culture media. This procedure of serial 
sub-cultivation and cell counting was repeated a maximum number of five times, before 
colonies were cryo-preserved (Chapter 2.1.4). The same procedure was carried out using wild 
type 21NT cells.  
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 Hybrid colony and 21NT cell growth was assessed by calculating the total number of 
population doublings (PD) that had occurred between seeding 3.5x10
5
 cells and harvesting at 
70-90% confluence (Chapter 2.8.1). The cumulative PD(s) of each hybrid colony and 21NT 
cells was determined over five serial passages or until cell growth arrest was observed.  
 The PD/day for 21NT cells and hybrid colonies, was calculated by dividing the number 
of PD(s), by the number of days between passages. These values were then used to calculate the 
mean population doubling time (PDT), defined as the time taken (hours) for a cell population to 
double in size, for all hybrid colonies and the 21NT cell line.      
 
3.3 RESULTS AND DISCUSSION 
 In order to investigate whether normal human chromosomes 3 and 17 harbour 
sequences that repress telomerase within the primary breast cancer cell line 21NT, copies of 
both chromosomes present within human: mouse monochromosome hybrid donors A9-Neo3 
and A9-Hytk17 respectively, were transferred by MMCT into 21NT cells to generate 21NT-
Neo3 and 21NT-Hytk17 hybrid clones. Four independent MMCT experiments were carried out 
to generate two sets of 21NT-Neo3 and two sets of 21NT-Hytk17 hybrid colonies. A total of 
twenty-seven 21NT-Neo3 and sixteen 21NT-Hytk17 hybrid colonies were recovered (Table 
3.2). One 21NT-Neo3 and two 21NT-Hytk17 hybrid colonies entered growth arrest in situ 
following 3-4 weeks in selection. These hybrids demonstrated morphological features of 
senescence: large, granular cells, with an enlarged cytoplasm (Figure 3.2). However, the small 
proportion of in situ senescent hybrids observed following introduction of both chromosome 3 
and 17 (4% and 13% respectively), could indicate that it is a relatively uncommon occurrence, 
which is unrelated to the introduced chromosome copy. Due to the absence of actively dividing 
cells (Figure 3.2), these hybrid colonies were not picked, but were harvested in situ. Remaining 
21NT-Neo3 and 21NT-Hytk17 hybrids were picked and could be successfully re-established on 
individual P35 dishes.  
Table 3.2 - Summary of hybrid colonies generated and the number of colonies that senesced  
and entered growth arrest in situ. 
Hybrid Colony 
Number of colonies 
generated (per 10
6
 cells) 
Total 
Number of colonies that 
entered growth arrest in situ 
(IS) 
21NT-Neo3 
MMCT 1 11 (3.7) 
27 1 
MMCT 2 16 (5.3) 
21NT-Hytk17 
MMCT 1 6 (2) 
15 2 MMCT 2 9 (3) 
Abbreviations: IS (In situ) 
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 The frequency of 21NT-Hytk17 hybrid colonies recovered/10
6
 cells following MMCT-
mediated transfer of human chromosome 17, was considerably lower compared with the 
frequency of 21NT-Neo3 hybrid colonies recovered/10
6
 cells (Table 3.1). This could indicate 
the presence of a tumour suppressor sequence(s) on normal human chromosome 17 that inhibits 
the growth of 21NT cells. However, it is possible that there were differences in the number of 
micronucleated A9-Neo3 and A9-Hytk17 hybrids produced during the initial stages of the 
MMCT procedure, which could have led to downstream differences in the number of microcells 
obtained and the total number of hybrids generated.  
 
Figure 3.2 - Representative photomicrographs (magnification x100) of two 21NT-Hytk17 and 
one 21NT-Neo3 hybrid clone(s) harvested in situ, that displayed morphological characteristics 
of senescence including enlarged, granular cytoplasms, as indicated by red arrows.  
 
3.3.1 TELOMERASE ACTIVITY OF 21NT-NEO3 AND 21NT-HYTK17 HYBRID 
COLONIES 
 The next aim of this study was to examine the effect of introducing a normal copy of 
chromosome 3 and 17 into the 21NT cell line on telomerase activity. Telomerase activity of 
hybrid colonies was determined using a quantitative, real-time PCR-based TRAP assay 
procedure (qRT-PCR). This two-step assay works by first allowing endogenous telomerase 
within protein sample extracts to add a number of telomere repeat sequences (TTAGGG) to a 
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telomerase substrate molecule (TS). The second step involves PCR amplification and real-time 
detection of extended TS substrate molecules using an anchored return primer (ACX) and 
SYBR green nucleic acid dye. The ACX primer caps the 3' end of an extended telomerase 
product after one PCR cycle, and prevents further elongation of the same substrate in 
subsequent cycles. In this way, PCR-amplification of telomerase products reflects the number of 
active telomerase enzyme molecules within sample extracts, and is therefore proportional to the 
amplification signal generated.  
 All twenty-seven 21NT-Neo3 and fifteen Hytk17 hybrid clones recovered during this 
study were either lysed in situ, if cells displayed a senescent phenotype 3-4 weeks after selection 
(Figure 3.2), or harvested 1-2 weeks after actively dividing colonies were picked and 
propagated as individual cell lines (Chapter 3.2.2). Following protein extraction and 
quantification, telomerase activity of all hybrid colonies was determined. The level of 
telomerase activity exhibited by untreated parental 21NT cells was also determined. In addition, 
the telomerase activity of the early-passage normal human mammary epithelial cell (HMEC) 
strain 240L, derived from a reduction mammoplasty tissue sample (Garbe et al., 2009), was 
examined to determine the level of telomerase activity exhibited by normal breast epithelial 
cells. The HMEC 240L cell strain has been shown to enter growth arrest following 
approximately 15 population doublings (Garbe et al., 2009). The human prostate cancer cell line 
(PC-3-hTERT) over-expressing exogenous hTERT (via cDNA transfection) was also included, 
to quantify the telomerase activity of sample extracts and provide an additional telomerase-
positive control (Chapter 2.4.2). To determine the interclonal variability of telomerase activity 
within 21NT cells, single colonies were picked from a mass population of cells seeded at a low 
density, and propagated in individual P35 dishes. The telomerase activity of each colony was 
determined relative to PC-3-hTERT, and the standard deviation of the mean relative telomerase 
activity of all clones, was used to represent the interclonal variability. 
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Figure 3.3 - Telomerase activity within (A) 21NT-Neo3 and (B) 21NT-Hytk17 hybrid clones 
generated, expressed as a percentage of parental 21NT cells (100%, dotted line). A maximum of 
nine hybrid clones were analyzed across five separate assay runs and telomerase activity was 
calculated relative to the 21NT sample included in the same assay. Error bars for each hybrid 
colony represent the standard deviation (SD) of triplicate repeats. Mean ± SD telomerase 
activity of the most concentrated PC-3-hTERT standard from five assay runs, expressed as a 
percentage of 21NT cells is shown. 21NT sample error bars represent SD across all assay runs. 
(C) The telomerase activity of nine individual 21NT clones relative to PC-3-hTERT (100%), 
including the mean ±SD of all clones. (IS) denotes hybrid colonies that entered growth arrest in 
situ. Hybrid colonies picked from the same culture dish are labelled alphanumerically.  
 As shown in Figure 3.3, telomerase activity was detected within parental 21NT and 
telomerized PC-3-hTERT protein extracts, which have been shown to exhibit telomerase activity 
within previous studies (Cuthbert et al., 1999, Motevalli et al., 2014). The telomerase activity of 
the normal HMEC 240L cell strain was approximately 97% lower than the 21NT cell line 
(Figure 3.3). As shown in Figure 3.3C, the standard deviation from the mean telomerase activity 
exhibited by nine individual 21NT cell colonies, was found to be 23%. Therefore, 21NT-Neo3 
and 21NT-Hytk17 hybrid colonies exhibiting a greater than 23% change in telomerase activity 
relative to 21NT cells, were considered to be sufficiently different from the parental cells. 
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Table 3.3 - The proportion of 21NT-Neo3 and 21NT-Hytk17 hybrid colonies recovered that 
showed an increase or decrease in telomerase activity, outside the normal range of 21NT 
interclonal variability, including those that exhibited a greater than 90% reduction. 
 Telomerase Activity 
Hybrid Colony Increase by >SD of 
21NT clonal mean 
Decrease by >SD of 
21NT clonal mean 
≥90% reduction   
21NT-Neo3 15% (4/27) 78% (21/27) 11% (3/27) 
21NT-Hytk17 13% (2/15) 60% (9/15) 0% (0/15) 
The standard deviation of mean 21NT clonal telomerase activity was 23% (Figure 3.3C). 
Abbreviations: SD (Standard Deviation). 
  As shown in Table 3.3, the majority of 21NT-Neo3 (78%) and 21NT-Hytk17 (60%) 
hybrid colonies recovered were found to exhibit a reduction in telomerase activity relative to 
parental 21NT cells. None of the 21NT-Hytk17 hybrids recovered were found to display a 
greater than 90% reduction in telomerase activity relative to 21NT cells, compared with 11% of 
21NT-Neo3 hybrids. However, 4 out of 15 (27%) 21NT-Hytk17 hybrids demonstrated a marked  
(74-84%) reduction in telomerase activity (Figure 3.3B, 21NT-Hytk17 clones 4B, 7, 9A and 
11). A larger proportion of 21NT-Neo3 hybrids were found to display a greater than 50% 
reduction in telomerase activity, compared to 21NT-Hytk17 hybrids. However, similar 
proportions of 21NT-Neo3 and 21NT-Hytk17 hybrids exhibited an increase in telomerase 
activity relative to parental 21NT cells.   
 The results presented here demonstrate that the introduction of a normal human copy of 
chromosome 3 and 17 into the 21NT cell line results in a reduction in telomerase activity 
relative to parental 21NT cells, in the majority of cases. A larger proportion of 21NT-Neo3 
hybrids were found to exhibit a greater reduction in telomerase activity relative to parental 
21NT cells, than 21NT-Hytk17 hybrids.   
 
3.3.2 THE RELATIONSHIP BETWEEN 21NT-NEO3 AND 21NT-HYTK17 HYBRID 
PROLIFERATION AND TELOMERASE ACTIVITY 
 In order to investigate whether the observed reduction in telomerase activity within 
21NT-Neo3 and 21NT-Hytk17 hybrids is associated with a change in hybrid proliferation, the 
growth rate, division potential, and cellular morphology of a sub-set of 21NT-Neo3 and 21NT-
Hytk17 hybrid colonies was examined and compared with telomerase activity. Eleven 21NT-
Neo3 and six 21NT-Hytk17 hybrid colonies recovered from the first set of MMCT procedures 
carried out (Table 3.1), were re-established in culture after a cell sample was taken for protein 
extraction and analysis of telomerase activity. Hybrid colonies were then passaged a maximum 
number of five times to determine proliferative growth rate and potential. By counting the cells 
at each passage and re-seeding a fixed quantity of cells, the number of population doublings 
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(PD) that had occurred between each passage was ascertained (Chapter 2.8.1). Hybrid growth 
rate was determined by calculating the mean PD time over five passages. For comparison, the 
identical procedure was used to determine the growth rate of parental 21NT cells. 
Photomicrograph images of all hybrid colonies and 21NT cells were taken at regular intervals to 
monitor hybrid cell morphology. 
Table 3.4 - The frequency of 21NT-Neo3 and 21NT-Hytk17 hybrids that entered growth arrest 
or proliferated continuously  
Hybrid Colony 
Hybrids 
Analysed 
Growth 
arrest (IS) 
Growth arrest 
after picking 
Proliferated Continuously 
21NT-Neo3 11 9% (1/11) 27% (3/11) 
Normal GR 
27% 
(3/11) 
Reduced GR 
36% 
(4/11)  
21NT-Hytk17 6 33% (2/6) 17% (1/6) 
Normal GR 
17% 
(1/6) 
Reduced GR 
33% 
(2/6) 
Growth rate (GR) was determined as the mean PD time over five serial passages. A student's t-
test was used to compare the mean PD time of hybrid colonies with parental 21NT cells. The 
GR was considered to be significantly different if p>0.05. (IS) denotes hybrids that entered 
growth arrest in situ.  
 
Figure 3.4 - Average telomerase activity expressed as a percentage of wild-type 21NT cells 
(100%, dotted line), within 21NT-Neo3 and 21NT-Hytk17 hybrid clones that entered growth 
arrest (either in situ or after they were picked) or proliferated continuously for 12-15PD after 
they were picked. Error bars represent the standard error of the mean telomerase activity for 
each group. A student's t-test was used to compare the mean telomerase activity of hybrids that 
entered growth arrest with those that proliferated continuously. 
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 As shown in Table 3.4, 63% of 21NT-Neo3 hybrid colonies recovered from a single 
MMCT procedure, were found to proliferate continuously for 12-15 PD after they were picked, 
compared with 50% of 21NT-Hytk17 hybrids recovered. The majority of both continuously 
proliferating 21NT-Neo3 and 21NT-Hytk17 hybrids were found to display a significant 
reduction in growth rate compared to 21NT cells. 36% of 21NT-Neo3 and 50% of 21NT-
Hytk17 hybrids entered growth arrest either in situ, or after they were picked and cultured as 
individual cell lines. No 21NT-Neo3 and 21NT-Hytk17 hybrids exhibited an increase in growth 
rate compared with parental 21NT cells.  
  In 1999, Cuthbert and colleagues demonstrated a strong association between telomerase 
repression and induction of permanent growth arrest of 21NT-chromosome 3 hybrids. 
Therefore, in order to determine whether the proliferative fate of 21NT-Neo3 and 21NT-Hytk17 
hybrids was linked to telomerase activity, the mean telomerase activity levels exhibited by 
growth arrested and continuously proliferating hybrids were compared. As shown in Figure 3.4, 
21NT-Neo3 and 21NT-Hytk17 hybrids that entered growth arrest either in situ or after they 
were picked and propagated as individual cell lines, were found to display an average reduction 
of telomerase activity of 57% and 50% relative to wild-type 21NT cells respectively. On the 
other hand, 21NT-Neo3 and 21NT-Hytk17 hybrids that proliferated continuously after they 
were picked, showed either similar to or higher mean telomerase activity levels relative to wild-
type 21NT cells. Therefore, growth arrested 21NT-Neo3 and 21NT-Hytk17 hybrids show a 
marked, but not statistically significant, reduction in average telomerase activity compared with 
continuously proliferating hybrids. Consistent with Cuthbert et al., (1999), this could suggest a 
link between telomerase repression and induction of hybrid growth arrest within 21NT-Neo3 
and 21NT-Hytk17 hybrids.  
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Cellular Morphology and Telomerase Activity of 21NT-Neo3 and 21NT-Hytk17 Hybrids 
that Entered Growth Arrest 
Figure 3.5 - Analysis of 21NT-Neo3 and 21NT-Hytk17 hybrid colonies that emerged following 
two independent MMCT experiments and entered growth arrest either in situ or after they were 
picked and cultured as individual cell lines (A) Representative photomicrograph images of 
three 21NT-Neo3 and one 21NT-Hytk17 hybrid(s) that entered growth arrest after they were 
picked (magnification x100). (B) Telomerase activity of all hybrids that entered growth arrest 
both in situ (IS) or after they were picked, expressed as a percentage of wild type 21NT cells 
(21NT).  
 Cuthbert et al., (1999) found that 21NT-chromosome 3 hybrids that entered growth 
arrest displayed morphological and molecular features of senescence. Therefore, in order to 
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investigate the link between telomerase repression and induction of senescence pathways, the 
cellular morphology of 21NT-Neo3 and 21NT-Hytk17 hybrid clones that entered growth arrest 
was examined. Morphological features of senescence were observed within all four 21NT-Neo3 
hybrids that entered growth arrest: enlarged, flattened and vacuolated cells (Figure 3.2, Neo3-8 
and Figure 3.5, Neo3-3b, Neo3-5b, and Neo3-9). Out of these, 21NT-Neo3 hybrid colonies that 
entered growth arrest, one occurred in situ, two occurred within 2 weeks of picking (and before 
hybrid growth rate could be ascertained), and the remaining hybrid entered growth arrest 
following 6 PD after it was picked (Figure 3.5A, Clone Neo3-3b). Growth arrested 21NT-Neo3 
hybrids, exhibited a reduction in telomerase activity by an average of 57%, relative to parental 
cells (Figure 3.4).  
 Three out of six (50%) 21NT-Hytk17 hybrids recovered, were found to enter growth 
arrest (Table 3.4). Two 21NT-Hytk17 hybrids entered growth arrest in situ and displayed 
morphological features of senescence (Figure 3.2, Hytk17-4b and Hytk17-5). These hybrids 
also displayed a reduction in telomerase activity relative to parental 21NT cells. The remaining 
hybrid proliferated slowly for 2 PD before entering growth arrest, and was not found to display 
a significant difference in telomerase activity compared to parental 21NT cells (Figure 3.5B, 
Hytk17-4a). This particular hybrid did not exhibit features of senescence (Figure 3.5A, Hytk17-
4a), but cells appeared enlarged and vacuolated compared to parental 21NT cells (Figure 3.6A).  
Cellular Morphology, Mean Population Doubling Time and Telomerase Activity of 21NT-
Neo3 and 21NT-Hytk17 Hybrid Colonies that Proliferated Continuously 
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Figure 3.6 - Analysis of 21NT-Neo3 and 21NT-Hytk17 hybrid colonies that emerged following 
two independent MMCT experiments and proliferated continuously after they were picked and 
cultured as individual cell lines. Representative photomicrographs showing the cellular 
morphologies of (A) parental 21NT cells, (B) one 21NT-Neo3 and one 21NT-Hytk17 
continuously proliferating hybrid colony with similar growth rates to parental 21NT cells, (C) 
proliferating 21NT-Neo3 and 21NT-Hytk17 hybrid colonies with a significant reduction in 
growth rate compared with parental 21NT cells. The magnification (x40 or x100) is shown for 
each image. (D) The mean PD time over five serial passages and the relative telomerase 
activity of proliferating 21NT-Neo3 and 21NT-Hytk17 hybrid colonies. (*) denotes hybrids 
displaying a significant reduction in growth rate compared with parental 21NT cells.  
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 Over half of all continuously proliferating 21NT-Neo3 and 21NT-Hytk17 hybrids 
exhibited a significant reduction in growth rate compared with parental 21NT cells, which were 
found to proliferate with a mean PD time of 37 hours (Table 3.4 and Figure 3.6D). Out of seven 
(64%) continuously proliferating 21NT-Neo3 hybrids, three exhibited a similar growth rate and 
mean PD time to parental 21NT cells. These hybrids were also found to display a similar 
cellular morphology to parental cells (Figure 3.6B, Neo3-4b) and exhibited either similar to or 
increased levels of telomerase activity relative to 21NT cells (Figure 3.6D, Neo3-3a, Neo3-4b, 
Neo3-6). The remaining four proliferating 21NT-Neo3 hybrids displayed a significantly reduced 
growth rate compared to parental 21NT cells, and exhibited an up to four-fold higher level of 
telomerase activity, or a greater than 59% reduction. (Figure 3.6D, Neo3-1, Neo3-4a, Neo3-5a, 
Neo3-7). Three of these hybrid colonies were found to consist of both cells with senescent 
features, and those with a similar morphology to parental 21NT cells (Figure 3.6C, clone Neo3-
4a).  
 Fifty percent of 21NT-Hytk17 hybrids were found to proliferate continuously for five 
serial passages (Table 3.4). Out of these three hybrids, only one was found to display a similar 
growth rate and cellular morphology to parental 21NT cells (Figure 3.6B, Hytk17-2). This 
hybrid also exhibited an increase in telomerase activity relative to parental cells (Figure 3.6D). 
The remaining two hybrids demonstrated a significant reduction in growth rate, but unlike 
21NT-Neo3 hybrids, neither were found to exhibit morphological features of senescence (Figure 
3.6C, Hytk17-3). One of these hybrids demonstrated a 44% reduction in telomerase activity, 
whilst the remaining hybrid exhibited a similar level to parental 21NT cells (Figure 3.6D, 
Hytk17-1, Hytk17-3). 
 In order to investigate the relationship between telomerase activity and growth rate of 
proliferating 21NT-Neo3 and 21NT-Hytk17 hybrids, the mean PD time of all proliferating 
hybrids was plotted against relative telomerase activity. The Pearson Correlation Coefficient 
was used to determine the strength of the correlation between both variables. A negative 
correlation between relative telomerase activity and mean PD time was observed for both 
21NT-Neo3 and 21NT-Hytk17 hybrid colonies, indicating that a decrease in telomerase activity 
was associated with a decrease in hybrid growth rate (Figure 3.7A and B). A stronger 
correlation between telomerase activity and hybrid growth rate was observed for 21NT-Neo3 
compared with 21NT-Hytk17 hybrids.  
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Figure 3.7 - Scatter plots showing the relationship between the mean population doubling time 
and relative telomerase activity of continuously proliferating (A) 21NT-Neo3 and (B) 21NT-
Hytk17 hybrid clones. The Pearson Correlation Coefficient (r) was used to quantify the strength 
of the relationship between both variables. Hybrid Neo3-4a was omitted from the analysis. 
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3.4 SUMMARY 
 The bypass of normal barriers to proliferation and cellular immortalization are critical 
steps that have been thought to occur during the transformation of normal human somatic cells 
into tumour cells. The high level of telomerase activity observed within the majority of human 
tumours, but not within most normal cells, is thought to permit both cellular immortality and 
prevent induction of cellular senescence pathways, through maintenance of telomeric repeat 
sequences. Reactivation of telomerase activity is thought to occur due to the functional loss of 
hTERT transcriptional regulatory sequences during carcinogenesis. 
 Using the microcell-mediated monochromosome transfer (MMCT) technique and 
human: mouse monochromosomal hybrid panels, several independent studies have identified 
multiple chromosomes that are able to repress telomerase activity within different cancer types 
(Chapter 1.3.5.2.2.3, Oshimura and Barrett., 1997, Ducrest et al., 2002, Tanaka et al., 2005). 
Introduction of a normal copy of chromosome 3 into the 21NT breast cancer cell line and the 
RCC23 and KC12 renal cell carcinoma cell lines, has been shown to repress telomerase activity 
and induce senescence (Cuthbert et al., 1999, Ohmura et al., 1995, Tanaka et al., 1998 
respectively). Introduction of chromosomes 3 and 4 into the HeLa cervical carcinoma cell line 
and chromosomes 2 and 6 into the SiHa cervical carcinoma cell line, have also been found to 
repress telomerase activity (Backsch et al., 2001, Steenbergen et al., 2001, Uejima et al., 1995). 
These observations provide evidence that multiple telomerase repressor sequences can function 
within the same cancer cell line. Consistent with these observations, the results presented within 
my study showed that introduction of both chromosome 3 and 17 into the 21NT breast cancer 
cell line resulted in a significant reduction in telomerase activity (within 78% and 60% of 
hybrids respectively). In addition, 73% and 83% of chromosome 3 and 17-21NT hybrids 
respectively, either entered growth arrest and displayed morphological features of senescence, 
or exhibited a significant reduction in growth rate compared with parental 21NT cells. A 
reduction in telomerase activity was associated with a reduction in hybrid growth rate for both 
chromosome 3 and 17 hybrids.  
 Previously, Cuthbert et al (1999) found that 67%-78% of 21NT-chromosome 3 hybrids 
generated by MMCT-mediated transfer, displayed a greater than 90% reduction in telomerase 
activity compared to wild-type 21NT cells. By comparison, only 11% of 21NT-chromosome 8 
and 8% of 21NT-chromosome 20 hybrid colonies generated in the same study, exhibited a 
greater than 90% reduction in telomerase activity. These findings suggest that chromosome 3 
harbours sequences that repress telomerase activity within the 21NT cell line. Even though 78% 
of 21NT-chromosome 3 hybrids generated within my study were found to display a significant 
reduction in telomerase activity relative to wild-type 21NT cells, I found that only 11% of 
141 
 
hybrids exhibited a greater than 90% reduction in telomerase activity relative to wild-type 21NT 
cells, which contrasts findings presented by Cuthbert et al., (1999). 
 Cuthbert et al., (1999) found that 90% of 21NT-chromosome 3 hybrid colonies 
recovered from multiple MMCT procedures, entered delayed permanent growth arrest. The 
majority of these hybrids (~90%) displayed an increased mean PD time of 50 hours and 
proliferated for 10-12 PD (3-4 weeks in selection) before exhibiting a further reduction in 
growth rate prior to growth arrest. At this point, cells displayed morphological features of 
senescence. A small proportion (~10%) of 21NT-chromosome 3 hybrids that entered growth 
arrest, entered crisis following 15-18 PD (4-6 weeks in selection). After a prolonged crisis 
period, immortal variants emerged from approximately 40% of these hybrids, whilst the 
remaining hybrids remained in a state of permanent growth arrest. By comparison, all 21NT 
hybrid colonies containing a single copy of chromosomes 8, 12 or 20 that were recovered, 
proliferated with a similar growth rate to parental cells and did not display morphological 
features of senescence. In contrast to these findings, only 36% of 21NT-Neo3 hybrid colonies 
recovered from a single MMCT procedure within my study were found to enter growth arrest, 
while the remaining proliferated continuously for 12-15PD after they were picked and 
propagated as individual cell lines. However, growth arrested hybrids were found to display a 
marked reduction in telomerase activity relative to wild-type 21NT cells and continuously 
proliferating hybrids, which suggests that telomerase repression was associated with induction 
of growth arrest. The growth rate of the majority of these hybrids was not determined during 
this study, however most were found to enter growth arrest after a similar period of time in 
selection (4-6 weeks), as 21NT-chromosome 3 hybrids generated by Cuthbert et al. (1999). 
Only one 21NT-Neo3 hybrid was found to proliferate for approximately 9 weeks in selection 
prior to growth arrest, and displayed a significantly higher mean PD time of 109 hours. 
Similarly to Cuthbert et al. (1999), all 21NT-Neo3 hybrids that entered growth arrest within my 
study, were found to display morphological features of senescence.  
 Introduction of chromosome 3 into the RCC23 and KC12 renal cell lines, resulted in 
hybrids that exhibited undetectable levels of telomerase activity, which were found to enter 
growth arrest with shortened telomere lengths (Horikawa et al., 1998, Tanaka et al., 1998). 
Cuthbert et al., (1999) observed that the majority of chromosome 3 hybrids displayed a 
reduction in growth rate and entered growth arrest after 10-12 or 15-18 population doublings 
(PD), compared with hybrids recovered by Horikawa et al., (1998) and Tanaka et al., (1998), 
which exhibited longer division potentials of 31-41PD and 10-30PD prior to growth arrest. The 
number of population doublings that were found to occur prior to growth arrest may have been 
different within each study, due to the telomere length of the parental cell lines. For example, 
the 21NT and RCC23 cell lines have been found to have mean telomere restriction fragment 
lengths (TRF) of 3 and 6 kilobases (kb) respectively, and 21NT hybrids were found to enter 
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growth arrest within fewer population doublings, than RCC23 hybrids (Cuthbert et al., 1999, 
Horikawa et al., 1998). The number of PD(s) and mean telomere restriction fragment (TRF) 
lengths of chromosome 3 and 17-21NT hybrids that entered growth arrest within my study, 
were not ascertained due to an insufficient number of cells. The 21NT-chromosome 3 hybrids 
recovered within my study, entered growth arrest either in situ (3-4 weeks following microcell 
fusion), within two weeks of being picked, or following two serial passages after they were 
picked. Based on these observations, together with the lack of strong telomerase repression, it is 
unclear whether 21NT-chromosome 3 hybrids within my study, entered telomere length-
dependent growth arrest.  
   The findings presented within my study contrast those presented by Cuthbert et al., 
(1999) in that only 11% of 21NT-chromosome 3 hybrids were found to exhibit a 90% reduction 
in telomerase activity relative to wild-type 21NT cells and only 36% of hybrids were found to 
enter growth arrest. Interestingly, introduction of a normal copy of human chromosome 6 into 
the cervical cancer cell line (SiHa), carried out by two independent research groups, has also 
been shown to yield contrasting results (Steenbergen et al., 2001, Uejima et al., 1995). 
Steenbergen and colleagues, found that the majority of SiHa-chromosome 6 hybrids exhibited a 
significant reduction in the level of hTERT mRNA and telomerase activity. These hybrids were 
also found to enter growth arrest associated with progressive telomere shortening. On the other 
hand, introduction of chromosome 6 into the same cell line by Uejima et al., (1995), resulted in 
no observable effect on the telomerase activity, cellular morphology or growth potential of SiHa 
cells. Instead, introduction of normal copy of chromosome 2, was found to induce cellular 
senescence in 93% of hybrid colonies recovered. Both studies obtained hybrid donor cell lines 
containing a single copy of human chromosome 6 from two different human: mouse 
monochromosome donor libraries, which may have been responsible for the contrasting results 
observed. Human chromosomes within human: rodent monochromosome donors have been 
found to undergo structural rearrangements with host chromosomes (Tanabe et al. 2000). These 
observations demonstrate the importance of ensuring that human chromosomes maintained 
within human: rodent hybrid donor cell lines, are structurally intact before they are used as 
donors for functional gene transfer studies. Cytogenetic analysis of human monochromosomes 
within A9-Neo3 and A9-Hytk17 hybrid donor cell lines was not carried out during this study, 
therefore the structural integrity of these chromosomes was unknown prior to microcell fusion.  
 Alternatively, there is evidence to show that propagation of cell lines in culture for an 
extended period of time, are susceptible to genetic drift due to genetic instability, cross-
contamination with other cell lines or exposure to different culture conditions (Osborne et al., 
1987, Bahia et al., 2002). Differences in tumorigenicity, cloning efficiency and growth rate, 
have been observed within variants of the same cell line cultivated in different laboratories, 
which indicates that culture conditions have a substantial affect on the biological properties of 
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cells and may explain why conflicting results are sometimes obtained (Osborne et al., 1987). 
The 21NT primary breast cancer cell line, originally established by Band et al., (1990), has been 
cultivated for use in multiple in vitro studies at Brunel since the late 1990s. Therefore, it is 
possible that serial propagation of this cell line over an extended time period, may have resulted 
in genetic drift and selection of cells with different genetic abnormalities to early-passage cells. 
This may provide an explanation as to why introduction of a normal copy of human 
chromosome 3 into the 21NT cell line, did not result in the same phenotypic effect observed 
previously by Cuthbert et al., (1999). 
 Introduction of a normal copy of human chromosome 17 has been shown to cause cell 
growth inhibition of colorectal and breast cancer cells (Goyette et al., 1992, Negrini et al., 1994, 
Plummer et al., 1997, Yang et al., 1999) and growth suppression of peripheral neuroepithelial 
cells and prostate cancer cells (Lin et al., 1995, Yoshinori et al., 1995). Following transfer of 
chromosome 17 into MDA-MB-231 and MCF-7 breast cancer cells, no viable hybrids were 
found to possess chromosome 17p-arm material (Negrini et al., 1994). However, one 
proliferating MDA-MB-231 hybrid with chromosome 17q-arm material was found to exhibit 
reduced tumorigenicity in vivo. This suggests that distinct growth regulatory sequences may 
exist on both the p and q arm of chromosome 17.  Transfection of a wild-type p53 cDNA vector 
into these cell lines resulted in a 50% reduction in the number of colonies observed compared 
with a control vector, which suggested that p53 (located on 17p13.1) may have been responsible 
for mediating growth inhibition of both hybrids (Negrini et al., 1994). In contrast, Plummer et 
al., (1997) observed delayed growth arrest of MCF-7 cells following transfer of a chromosome 
17 fragment with a 17p13.1pter deletion, which indicated that p53 did not function as a tumour 
suppressor gene within this cell line. Only MCF-7 hybrids with 17q-arm material were found to 
enter growth arrest following 10-12PD, and deletion mapping of proliferating hybrids identified 
a putative tumour suppressor sequence localized to 17q24-q25. Similarly, transfer of 17q into 
the PPC-1 prostate cancer cell line was found to produce two hybrids, both of which exhibited a 
significant reduction in growth rate and reduced tumorigenicity in athymic nude mice 
(Yoshinori et al., 1995). This study also found that sequences within the 17q12-q22 
subchromosomal region mediated repression of tumorigenicity of PPC-1 prostate cancer cells. 
These observations suggest that multiple tumour suppressor sequences present on chromosome 
17, function to regulate the growth of human cells originating from different tissue types.  
  A putative mechanism by which chromosome 17 mediates cell growth inhibition was 
proposed by Yang et al., (1999), who observed strong telomerase repression and a 90% 
reduction in cell growth, following introduction of chromosome 17 into the benzo(a)pyrene-
transformed MCF-10F breast epithelial cell line. This study provided evidence to show that 
chromosome 17 may harbour sequences that regulate telomerase activity. In my study, 60% of 
21NT-chromosome 17 hybrids recovered, exhibited a significant reduction in telomerase 
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activity relative to wild-type 21NT cells, with 27% of hybrids displaying strong (74%-84% 
reduction) telomerase repression.  In addition 50% of hybrids entered growth arrest with a 50% 
average reduction in telomerase activity. The identification of a causal link between a reduction 
in telomerase activity and hybrid growth arrest was unclear, due to the lack of sufficient cell 
numbers to determine telomere lengths within 21NT-chromosome 17 clones. However, the 
majority of hybrids were found to either enter growth arrest, or display a significant reduction in 
growth rate, which provides additional evidence that chromosome 17 harbours sequences that 
inhibit/suppress the growth of breast cancer cells. The mechanisms by which these sequences 
mediate a tumour suppressive function and their relative positions along the chromosome, have 
yet to be fully elucidated. However, I have shown that at least two sequences are present within 
the genome that function to repress telomerase activity within the 21NT breast cancer cell line.  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
CHAPTER 4 
4 FUNCTIONAL INVESTIGATION OF THE 3P21-LINKED SEQUENCES, 
SETD2 AND FLJ, AS TELOMERASE REPRESSOR GENES IN BREAST 
CANCER CELLS 
 
4.1 INTRODUCTION 
 Repression of human telomerase activity and induction of cell growth arrest has been 
observed following introduction, of a normal copy of human chromosome 3 into the 21NT 
breast cancer cell line by MMCT (Cuthbert et al., 1999). The proposed mechanism by which 
chromosome 3 mediates this effect, is thought to be through transcriptional repression of the 
hTERT gene, which encodes the reverse transcriptase sub-unit of telomerase (Ducrest et al., 
2001). In support of this, telomerase-repressed 21NT-chromosome 3 hybrids have been found to 
contain less than 0.004 molecules/cell of immature intron-containing hTERT transcripts, 
compared with parental 21NT cells, which contain approximately 30-fold higher levels of 
hTERT molecules/cell (Ducrest et al., 2001). Interestingly, the same study also showed that 
telomerase-negative normal human lung fibroblasts (HLF) and SV40-transformed fibroblast 
cells, exhibited 50-1500 lower levels of spliced hTERT mRNA transcript molecules than 
telomerase-positive cancer-derived cell lines. This reinforces the link between hTERT 
expression and telomerase activity. Similarly, Horikawa et al., (1998) found that telomerase 
repression within RCC23-chromosome 3 renal cell carcinoma hybrids, was associated with a 
marked reduction in hTERT mRNA levels, which provides further evidence that hTERT 
regulatory sequences exist on chromosome 3. However, the recovery of telomerase-repressed 
hybrids produced by whole cell fusion of RCC23 and 21NT cells (i.e. somatic genetic 
complementation) indicates that more than one hTERT transcriptional repressor sequence may 
be present on chromosome 3 (Tanaka et al., 2005).   
 In order to determine whether chromosome 3-mediated hTERT repression within the 
21NT breast cancer cell line involves regulatory sequences that exist upstream of the hTERT 
transcription start site, Ducrest et al., (2001) transfected multiple hTERT-GFP (green 
fluorescent protein) reporter constructs containing 1.3-7.4kb of upstream 5'-hTERT flanking 
sequences into 21NT-chromosome 3 hybrids and parental cells. Despite observing a substantial 
reduction in immature pre-spliced hTERT mRNA levels, no difference in the level of GFP 
expression for all reporter constructs were found between 21NT-chromosome 3 hybrids and 
parental cells. These results indicate that regulatory sequences located up to 7.4kb upstream of 
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the hTERT transcription start site (TSS) may not be responsible for chromosome 3-mediated 
transcriptional repression. However, it is important to note that telomerase positive GM369 and 
telomerase-negative GM847 SV40-transformed fibroblast cell lines, expressing detectable and 
undetectable levels of hTERT transcripts respectively, also exhibited the same level of GFP 
expression following transfection with the same reporter constructs. This could signify the 
presence of important hTERT regulatory sequences further upstream or downstream of the 7.4kb 
region flanking the 5'-hTERT TSS, and which may be involved in chromosome 3-mediated 
repression.  
 In 2001, Ducrest and colleagues explored a putative link between chromosome 3-
mediated hTERT repression and the expression levels of c-Myc and c-Myc-target genes within 
21NT-chromosome 3 hybrids (Ducrest et al., 2001). Amplification of the c-Myc proto-oncogene 
has been found to occur within a 17-32% of primary breast cancers and is associated with more 
progressive disease (Nesbit et al., 1999). c-Myc over-expression has also been found to induce 
hTERT gene expression within normal human cells, and increase hTERT mRNA levels within 
telomerase-positive cancer cell lines (see Chapter 1.3.5.2.1.1, Takakura et al., 1999, Wu et al., 
1999). In contrast, the Mad protein has been found to repress hTERT transcription in normal 
human cells and competes with c-Myc for dimerization with Max proteins and binding to 
consensus sequences within the hTERT promoter (see Chapter 1.3.5.2.2.1, Oh et al., 2000). 
Taking these observations into account, Ducrest et al., (2001) observed similar mRNA and 
protein levels of c-Myc and its antagonist Mad within 21NT-chromosome 3 hybrids and 
parental cells. In addition, no difference between the mRNA levels of five c-Myc target genes 
(CAD, ODC, GADD45, eIF4E and LDHA) were observed between chromosome 3 hybrids and 
parental cells, providing evidence that sequences on human chromosome 3 do not mediate 
hTERT transcriptional repression through indirect regulation of the c-Myc pathway.  
  By determining the micrococcal nuclease (MNase) sensitivity pattern of chromatin 
incorporating genomic DNA 10kb upstream and 16kb downstream of the hTERT transcription 
start site, Szutorisz et al., (2003) explored the chromatin structure of this region within normal 
human cells and cancer cells. Two independent sites located within the first 1kb of the second 
intron of the hTERT gene, were found to be susceptible to MNase digestion within cancer cell 
lines expressing hTERT mRNA, but not within a normal human lung fibroblast or an alternative 
lengthening of telomeres (ALT)-positive SV40-transformed fibroblast cell line with 
undetectable hTERT mRNA levels. These results indicated that an 'open' chromatin 
conformation was associated with the presence of hTERT transcripts, which were detectable 
within cancer cells and not hTERT-negative normal human cells or ALT-positive cancer cells. 
Telomerase-positive (and hTERT-positive) 21NT cells were shown to exhibit a similar MNase-
sensitivity pattern to other hTERT-positive cancer cell lines, whereas two 21NT-chromosome 3 
hybrids were found to display the same digestion pattern as normal human fibroblasts. Szutorisz 
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et al., (2003) also discovered that 21NT-chromosome 3 segregants that had lost the 3p14.1-21.2 
region containing the putative telomerase-repressor sequence, exhibited an identical MNase-
sensitivity pattern to parental 21NT cells. However, not all 21NT segregant clones were found 
to re-express hTERT mRNA to the same level of parental cells, which could imply that a change 
in chromatin structure within the second intron of hTERT to an 'open' conformation, is 
necessary but insufficient to induce hTERT expression. These findings not only provided 
evidence of a causal relationship between chromatin structure and hTERT expression, but also 
demonstrated a possible mechanism by which the chromosome 3-encoded sequence mediates 
hTERT transcriptional repression. 
 Subsequent experiments, carried out by a research group led by Professor Newbold at 
Brunel University London, have focused on narrowing the search for an hTERT repressor 
sequence located on chromosome 3, that plays a functional role in chromatin remodelling. To 
identify a smaller region of chromosome 3 encompassing the repressor sequence, chromosome 
3 fragments generated by radiation exposure, were introduced into the 21NT cell line by MMCT 
(unpublished data). Following selection of hybrid colonies, analysis of hTERT mRNA levels 
was carried out and a single hTERT-repressed colony was identified. The chromosome 3 
fragment from this colony was transferred into an A9 mouse fibroblast cell line by MMCT and 
mapped using a series of polymorphic marker sequences spanning the length of human 
chromosome 3. The fragment was found to consist of discreet regions of chromosome 3 short-
arm (3p23, p21 and p11) and long-arm material (3q12 and q26). A single A9-chromosome 3 
fragment hybrid colony was found to have lost a 490kb sequence, which mapped to the 3p21.3 
region of chromosome 3. Frequent loss of this region was observed within segregant 21NT-
chromosome 3 hybrids that exhibited high levels of telomerase activity within the study by 
Cuthbert et al., (1999). Based on these observations, the 3p21.3 region was considered a strong 
candidate to harbour the putative hTERT repressor sequence.     
  The identified 490kb region of chromosome 3p21.3 encompassed six genes; TESSP2 
(testis serine protease 2), MYL3 (myosin light chain 3), PTHR1 (parathyroid hormone receptor 
1), CCDC12 (coiled-coil domain containing 12), NBEAL2 (neurobeachin-like 2) and SETD2 
(SET-domain containing 2), one pseudogene MRP63P3 (mitochondrial ribosomal protein 63 
pseudogene 3) and one non-coding RNA (ncRNA) FLJ (also known as KIF9-AS1). Out of these 
genes, SETD2 has been shown to function as an epigenetic regulator of gene transcription 
through histone H3 lysine 36 trimethylation (H3K36) (Sun et al., 2005). Levels of H3K36 
trimethylation have been found to increase within the coding regions of actively transcribed 
genes and SETD2 has been shown to be a direct binding partner of ser2/ser5 phosphorylated 
RNA polymerase II (RNA polII) in vitro and in vivo, which indicates a functional role of 
SETD2 in transcriptional elongation (Sun et al., 2005, Edmunds et al., 2007). 
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 A putative tumour suppressive role of SETD2 in breast cancer was suggested by Sarakbi 
et al., (2009), who showed that SETD2 mRNA levels within malignant breast cancer tissue were 
significantly lower than within normal breast tissue samples. Breast cancer samples derived 
from patients with more progressive disease were also found to have significantly lower levels 
of SETD2 mRNA than those who were disease-free for greater than 10 years. Similarly, SETD2 
mRNA levels were found to be significantly lower within tumour samples than matched 
adjacent non-cancerous tissue (ANCT) samples from 25 breast cancer patients (Newbold and 
Mokbel., 2010). Immunohistochemical staining for SETD2 protein expression also revealed 
higher protein levels within ANCT than tumour samples. These findings provided valuable 
evidence to show that SETD2 may function as a tumour suppressor in breast cancer.  
 The 490kb region of the chimeric chromosome 3 fragment was also found to possess 
the non-protein coding gene FLJ/KIF9-AS1 (referred to as FLJ from herein), which is 79.7kb in 
length and is located approximately 400bp upstream from the 5' coding region of SETD2. The 
final 16kb of the 3' FLJ genomic sequence is shared with part of the 3' coding region of KIF9 
(Kinesin family member 9). Unlike SETD2 and KIF9, FLJ is transcribed from the antisense 
DNA strand. According to current records, only one non-coding splice variant of FLJ has been 
identified, which is 4.9kb in length and consists of seven exons (NCBI and Ensembl). The 
biological role of FLJ has not yet been elucidated; however, it is possible that FLJ belongs to a 
group of long non-coding RNA (lncRNA) antisense sequences. It is thought that several 
thousands of lncRNA sequences are expressed within the human genome that are involved in 
regulating gene expression through alternative splicing, mRNA decay and chromatin 
remodelling, and which influence a wide range of cellular processes including cell cycle 
regulation, metabolism and migration (reviewed by Zhang et al., 2013). Much like protein-
encoding genes, deregulated lncRNAs have been implicated in different cancer types and have 
been found to exert either oncogenic or tumour suppressive functions (Gutschner et al., 2013, 
Mourtada Maarabouni et al., 2009, Zhang et al., 2013).  
 Independent studies have found that lncRNA sequences can bind to and guide 
chromatin remodelling complexes in cis and trans to regulate the expression of multiple genes 
involved in disease pathogenesis (Rinn et al., 2007, Gupta et al., 2011). The HOTAIR antisense 
long interfering (linc) RNA is transcribed from within the HOXC locus on 12q13.3 and is 
expressed at high levels within breast cancer metastases and some primary breast and colorectal 
tumours (Gupta et al., 2010, Kogo et al., 2011). The HOTAIR lincRNA was found to bind to 
the polycomb repressive complex 2 (PRC2) and repress the transcription of the tumour 
suppressor gene HOXD on 2q31.1 by mediating trimethylation of histone H3K27 (Rinn et al., 
2007). A subsequent study found that HOTAIR was responsible for global re-targeting of the 
PCR2 complex leading to transcriptional repression of other important tumour suppressor genes 
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to promote metastasis (Gupta et al., 2010). Therefore, lncRNAs can play important roles in the 
transcriptional regulation of many target genes through chromatin remodelling. 
 The aim of this study was to investigate the possible role of SETD2 and FLJ as tumour 
suppressor genes in breast cancer cells and to determine whether these candidate genes are 
involved in mediating transcriptional repression of hTERT within the 21NT breast cancer cell 
line.   
 
4.2 MATERIALS AND METHODS 
4.2.1 CHARACTERISATION OF BREAST CANCER CELL LINES AND HMEC CELL 
STRAINS 
 Eight breast cancer cell lines 21NT, 21MT, BT474, BT20, H5S78T, HCC1143, GI101 
and MCF-7 and one SV40-immortalized normal breast epithelial cell line MTSV, were cultured 
under normal growth conditions as detailed previously (Chapter 2.1.2). Pre-stasis normal human 
mammary epithelial cell strains HMEC 184, 240L and the post-stasis HMEC LONZA cell strain 
were cultured by my colleague Dr. Hemad Yasaei, and provided to me upon request as cell 
pellets derived from cells growing in log-phase. They were immediately stored at -80
o
C. 
4.2.1.1 SETD2, FLJ and hTERT gene expression analysis 
 Cell lines growing in log-phase, were cultured under normal growth conditions in P100 
dishes until sub-confluent. Cells were then harvested as described in Chapter 2.1.3 and pelleted 
by centrifugation at 15,000xg for 5 minutes and stored at -80
o
C. All cell lines/strains underwent 
RNA extraction, DNAseI-treatment and cDNA synthesis as detailed in Chapter 2.3. 
4.2.1.1.1 GeNorm™ Analysis  
 In order to quantify the expression levels of a target gene within a sample set, it is 
important to control for differences in starting cDNA concentrations, reaction enzyme 
efficiencies and the general level of transcriptional activity within each sample (Vandesompele 
et al., 2002). This can be achieved through normalization of target gene mRNA levels against 
an endogenous control gene that is expressed constitutively and at a stable level within all 
samples. In order to identify a suitable endogenous control gene that is stably expressed within 
the above samples, a geNorm kit (Primer Design) and the qBase
PLUS
 software package was used 
to determine the expression stability of seven endogenous control genes (Table 4.1). 
 cDNA samples were first diluted at a ratio of 1:10 with nuclease-free water. Reaction 
mixtures for each endogenous control gene consisted of: 1µl primer mix (300nM final 
concentration), 10µl‎of‎10X‎ iTaq™‎Universal‎SYBR® Green Supermix (BioRad, US), 4µl of 
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nuclease-free water and 5µl of diluted sample cDNA. Reaction mixtures without cDNA were 
first pipetted into wells of a 96-well microplate (MicroAmp
®
, ABI, US). 5µl of sample cDNA 
was then added to appropriate wells before sealing microplates with optical adhesive film 
(MicroAmp
®
, ABI, US). Following centrifugation at 1000xg for 30 seconds, sealed microplates 
were loaded into the ABI Prism 7900HT Sequence Detection System. Cell line/strain cDNA 
samples were analysed in duplicate and non-targeting controls (NTC) were included for each 
endogenous control gene analysed. Thermal cycling conditions for all genes apart from GAPDH 
consisted of an initial enzyme activation step for 10 minutes at 95
o
C, followed by 50 cycles of 
15 seconds at 95
o
C, 30 seconds at 50
o
C and 15 seconds at 72
o
C. The same thermal cycling 
conditions for GAPDH were used as outlined in Table 2.4, Chapter 2.3.4, except the number of 
amplification cycles was changed to 50.   
Table 4.1 - Details of the endogenous control genes evaluated for expression stability across 
HMEC strains and breast cancer cell lines 
Gene 
Symbol 
Name 
Genomic 
Location 
Function 
Β2M Beta-2-microglobulin 15q21-q22 
Serum protein associated with major 
histocompatability complex I. 
EIF2 
Eukaryotic translation 
initiation factor 2 
14q23.3 
Promotes binding of tRNA to ribosome to 
initiate protein synthesis. 
GAPDH 
Glyceraldehyde-3-
phosphate dehydrogenase 
12p13 
Oxidoreductase enzyme involved in 
carbohydrate metabolism. 
RPL13A Ribosomal protein L13a 19q13.3 
A component of the 60S ribosomal subunit 
involved in translation of mRNA into 
proteins. 
SDHA 
Succinate dehydrogenase 
complex, subunit A, 
flavoprotein (Fp) 
5p15 
Catalytic subunit of succinate-ubiquinone 
oxidoreductase involved in mitochondrial 
respiration. 
TOP1 Topoisomerase I 20q12-q13.1 
Catalyzes the breaking and rejoining of DNA 
strands during transcription. 
YWHAZ 
Tyrosine 3-
monooxygenase/tryptopha
n 5-monooxygenase 
activation protein, zeta 
8q23.1 
Interacts with phosphoserine-containing 
proteins to mediate signal transduction 
Information for each endogenous control gene was obtained from Vandesompele et al., (2002) 
and the NCBI database.  
 Amplification data was imported into the qbase
PLUS
 software package, which employs a 
unique analysis algorithm (Vandesompele et al., 2002) to determine the gene expression 
stability (M value) of each endogenous control gene within the sample set. This is achieved by 
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calculating the average pairwise variation of each endogenous control gene with all other 
control genes. Genes with high M-values therefore show the greatest pairwise variation and 
exhibit the least stable expression across all samples. Stepwise exclusion of highest scoring 
genes and re-calculation of new M-values for the remaining genes, distinguishes those with the 
lowest average pairwise variation and therefore the most stable expression. As shown in Figure 
4.1, TOP1 and YWHAZ were found to have the most stable expression across all samples 
analysed, and were therefore used to normalize expression levels of target genes SETD2, FLJ 
and hTERT. Target gene expression levels were determined using the same methods, primers, 
thermal cycling parameters and data analysis software package detailed in Chapter 2.3.4.  
Figure 4.1 - A line graph exported from qBase
PLUS
 showing the average expression stability 
(geNorm M) of seven endogenous control genes within all HMEC strains and breast cancer cell 
lines, following stepwise exclusion of the least stable endogenous control gene.    
 
4.2.2 SETD2 AND FLJ COPY NUMBER VARIATION (CNV) ANALYSIS 
 All breast cancer cell lines and normal HMEC strains were cultured under normal 
conditions until subconfluent before they were harvested, pelleted and stored at -80
o
C. Genomic 
DNA (gDNA) was extracted from cell lines and HMEC cell strains as outlined in Chapter 2.2. 
Sample DNA extracts were diluted to 5ng/µl using nuclease-free water. Gene copy number 
variation analysis of SETD2 and FLJ within breast cancer cell lines and normal HMEC strains 
was carried out as described in Chapter 2.5. Details of each pre-designed primer set (ABI, US) 
for SETD2 and FLJ are detailed in Table 2.6 (Chapter 2.5). The normal HMEC 184 cell strain 
was used to calibrate gene copy number within all samples. 
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4.2.3 OVER-EXPRESSION OF SETD2 WITHIN THE 21NT CELL LINE 
 The 8452bp-coding region of the human SETD2 gene was cloned into the pCMVNeo 
mammalian expression vector (OriGene) and subsequently transformed into One Shot® TOP10 
Chemically Competent E.coli (Invitrogen, US) by my colleague Dr. Terry Roberts. Frozen (-
80ºC) stock solutions of pCMVNeo and pCMVNeo-SETD2-transformed E.coli in 85% LB-
broth and 15% glycerol, were kindly provided to me upon request. 
 
 
 
 
 
 
 The pCMVNeo plasmid vector is 5838bp in length and contains a cytomegalovirus 
(CMV) early promoter sequence upstream of the multiple cloning site (MCS), which permits 
expression of inserted cDNA clones within mammalian cells (Figure 4.2). The downstream 
human growth hormone (hgh) poly A signal enables the production of mature mRNA 
sequences. Following transfection of the plasmid construct into mammalian cells, the presence 
of a neomycin resistance gene (Neo
r
) facilitates positive selection of cells that have undergone 
stable integration of the plasmid construct within the host genome.  
 Chemically competent OneShot
®
 TOP10 E.coli transformed with pCMVNeo and 
pCMVNeo-SETD2 plasmid constructs were propagated using the procedure described in 
Chapter 2.6.3. Plasmid DNA was extracted using the QIAfilter Midi Plasmid Purification Kit 
(Qiagen, NL) according to manufacturer's guidelines outlined in Chapter 2.6.4.     
4.2.3.1 Linearization of pCMVNeo and pCMVNeo-SETD2 vector constructs 
 Stable integration of plasmid vectors into host cell gDNA involves genetic 
recombination events. In order to reduce the risk of these events occurring within important 
regions required for the expression of cDNA in mammalian cells, both pCMVNeo and 
pCMVNeo-SETD2 plasmids were linearized by restriction enzyme digestion of a single targeted 
site. In order to identify a single restriction enzyme recognition sequence within a non-essential 
region of both plasmid constructs, plasmid sequences were entered into the NEBCutter software 
program (Posfai et al., 2005). This program can be used to detect many restriction enzyme 
cleavage recognition sites within any DNA sequence, and provide information about their 
relative positions within the sequence. pCMVNeo and pCMVNeo-SETD2 constructs were 
Figure 4.2 - Physical map of the pCMVNeo vector (OriGene), obtained from 
http://www.origene.com/assets/Documents/OTIProductManual-pCMVApplicationGuide.pdf  
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found to contain a single DraIII restriction site (Figure 4.3) that maps to the filamentous phage 
origin of replication known as f1 ori (Figure 4.2), which is not required for expression of 
SETD2 within mammalian cells.  
 
 
 
 
 Restriction enzyme reactions consisted of 50µg of plasmid DNA, 20µl of 10X 
CutSmart™ Buffer, 5µl of 20U/µl DraIII-HF® (High Fidelity) Restriction Enzyme and nuclease-
free water to a total volume of 200µl. The reaction mixture was then incubated at 37ºC for 2 
hours. Enzyme activity was inhibited by transferring samples to wet ice. To ensure complete 
digestion and linearization of circular plasmid DNA, the migration pattern of digested and 
undigested plasmid DNA was determined by gel electrophoresis. 250ng of plasmid DNA was 
added to wells of a 0.75% agarose gel made with 1X Tris-Borate-EDTA buffer (Sigma-Aldrich, 
US) and 0.5µg/ml ethidium bromide. After submerging in 1X TBE buffer, the gel was run at 60-
70V for around 1 hour 30 minutes. The TrackIt™ 1Kb Plus DNA Ladder (Invitrogen, US) was 
used to estimate DNA fragment size. Resolved DNA fragments were visualized using an 
Alphaimager under UV light. As expected, the supercoiled undigested plasmids migrated faster 
than DraIII-digested plasmids, indicating that the plasmid had been linearized (Figure 4.4). 
Expected fragment lengths were also observed for both pCMVNeo (5838bp) and pCMVNeo-
SETD2 (14,290bp) following digestion, which confirmed the presence of a single DraIII-
cleavage site within both plasmid constructs.    
Figure 4.3 - The position of DraIII restriction enzyme cleavage sites within pCMVNeo and 
pCMVNeo-SETD2 circular plasmid vector constructs (NEBcutter, Posfai et al., 2005).Grey 
arrows indicate open reading frames. 
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4.2.3.2 Phenol-chloroform extraction and ethanol precipitation of linearized 
plasmid DNA 
 Plasmid DNA was purified from the restriction digest reaction mixture using a phenol-
chloroform method of DNA extraction. Following the addition of 1 volume of phenol: 
chloroform (1:1) to plasmid DNA reaction mixtures, solutions were thoroughly mixed and 
centrifuged at 16,000xg for 5 minutes at room temperature. Upper aqueous phases were 
carefully transferred to fresh 1.5ml Eppendorf tubes and 1 volume of chloroform was added 
before mixtures were centrifuged at 16,000xg for 5 minutes. To ensure complete removal of 
contaminating proteins from the reaction mixture, the previous step was repeated once more. 
Purified DNA was precipitated by adding 0.1 volumes of 3M sodium acetate (Sigma, US) and 
2.5 volumes of 100% ethanol (Sigma, US), followed by incubation of samples at -80ºC for 1 
hour or -20ºC overnight. DNA was then pelleted by centrifugation at 16,000xg for 30 minutes at 
4ºC. DNA pellets were washed twice by adding 70% ethanol (diluted in nuclease-free water) 
and centrifuging at 16,000xg for 2 minutes at 4ºC. After carefully decanting sample 
supernatants, pellets were air-dried for 5-10 minutes before they were re-dissolved in nuclease-
free water. The DNA concentration was ascertained before storing samples at -20ºC. 
 
4.2.3.3 Transient transfection of pCMVNeo and pCMVNeo-SETD2 plasmids 
into the 21NT cell line 
 Transient transfection of SETD2 was carried out in order to examine the effect of short-
term SETD2 overexpression within the 21NT cell line. 24 hours prior to transfection, 21NT 
Figure 4.4 - Gel electrophoresis of DraIII-digested (B and C) and undigested circular (D 
and E) pCMVNeo and pCMVNeo-SETD2 vector constructs.  
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cells were seeded at 2.5x10
5
 cells/dish into thirty P60 dishes and maintained in complete culture 
media. 21NT cells were divided into three individual groups of ten dishes. The following day, 
one group of cells were transfected with a negative control empty vector pCMVNeo plasmid, 
while the second group were transfected with target pCMVNeo-SETD2 plasmid constructs, 
using the same methods described in Chapter 2.7.1. The remaining ten dishes of cells remained 
untreated and were maintained under normal growth conditions throughout the course of the 
experiment. 48 hours post-transfection, two dishes from each group were harvested, pelleted 
and stored at -80ºC for downstream analysis. This process was repeated every 24 hours for a 
further four days.  
4.2.3.4 Selection of stable 21NT-pCMVNeo and 21NT-pCMVNeo-SETD2 
transfection clones 
 In order to examine the long-term effect of SETD2 overexpression within the 21NT cell 
line, positive selection of 21NT cells that had undergone stable integration of plasmid vector 
constructs was carried out. 48 hours post-transfection with control pCMVNeo and target 
pCMVNeo-SETD2 constructs, P60 dishes containing 21NT cells were passaged at a ratio of 1:8 
into four P100 dishes, using methods described in Chapter 2.1.3. Cells were maintained in 
complete medium supplemented with 400µg/ml geneticin (G418) for approximately two weeks 
and monitored regularly for the emergence of stable colonies. 5-8 stable 21NT-pCMVNeo and 
21NT-pCMVNeo-SETD2 colonies were isolated at random and propagated as individual cell 
lines as described in Chapter 2.1.5. Colonies were maintained under antibiotic selection and 
propagated until three sub-confluent P100 dishes were obtained. Out of these, one dish of stable 
cells were harvested for cryopreservation (Chapter 2.1.4), and the remaining dishes were 
harvested, pelleted and stored at -80ºC for downstream analysis.  
 
4.2.3.5 Colony Forming Unit (CFU) assay 
 A CFU assay was carried out following transfection of pCMVNeo and pCMVNeo-
SETD2 plasmid constructs into the 21NT cell line to determine the effect of SETD2 over-
expression on cell growth as described in Chapter 2.7.3. 
 
4.2.4 TRANSFECTION OF FLJ INTO THE 21NT CELL LINE 
 The 2540bp transcript sequence of the non-coding FLJ (KIF9-AS1) gene, was cloned 
into the pCMVNeo expression vector described in Figure 4.2, and both control pCMVNeo and 
pCMVNeo-FLJ constructs were transfected into the 21NT cell line by Dr. T. Roberts. 
Cryopreserved aliquots of stable 21NT-pCMNeo and 21NT-pCMVNeo-FLJ cells were 
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provided to me upon request and were recovered using methods described in Chapter 2.1.4. 
Stable colonies were propagated in complete culture media supplemented with 400µg/ml G418. 
Subconfluent dishes of stable cell colonies growing in log-phase were harvested as described in 
Chapter 2.1.3 and pelleted by centrifugation at 15,000xg for 5 minutes, before immediately 
storing at -80ºC for downstream analysis. 
4.2.5 SIRNA-MEDIATED KNOCKDOWN OF SETD2 
 RNA-interference (RNAi) was used to determine the effect of transiently inhibiting 
SETD2 expression within a single hTERT-repressed 21NT-chromosome 3 hybrid colony 
(H3.5E). This was achieved by transfecting four pre-designed FlexiTube siRNA constructs 
(Qiagen, NL), that each target specific untranslated regions (UTRs) of the 8452bp SETD2 
transcript (Figure 4.5). As a non-targeting control, the AllStars siRNA Negative Control 
(Qiagen, NL) was also transfected into the H3.5E hybrid cell line. The transfection procedure 
and downstream analysis was carried out by both Dr. T. Roberts and myself. 
 
 
   
  
 On the day of transfection, three subconfluent P100 dishes of H3.5E cells growing in 
log-phase were harvested and counted using methods described in Chapter 2.1.6. An aliquot of 
1x10
6
 cells was pelleted by centrifugation and stored at -80ºC, to be used as an untreated control 
sample. The remaining cells were re-plated at 4.5x10
5
 cells/dish into P60 dishes. Following the 
addition of 1.3ml of complete medium supplemented with 400U/ml of hygromycin B 
(Calbiochem, DE), cells were incubated for three hours at 37ºC and 5% CO2. Each of the four 
FlexiTube SETD2 siRNA construct solutions were diluted to a final concentration of 250ng/µl 
in nuclease-free water, before transferring 6µl of each solution into a single sterile 1.5ml 
Eppendorf tube. The AllStars Negative Control siRNA mixture was also diluted to 250ng/µl in 
nuclease-free water. For each P60 dish of H3.5E cells to be tranfected, 1000ng of either AllStars 
or pooled FlexiTube SETD2 siRNA constructs were combined with 96µl of Opti-MEM I 
Figure 4.5 - A physical map of the SETD2 transcript sequence and the relative positions of 
UTR sequences targeted by four siRNA constructs developed by Qiagen, NL. Diagram 
obtained from:http://www.qiagen.com/gb/products/catalog/assay-technologies/rnai/flexitube-
sirna?catno=GS29072#geneglobe 
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Reduced Serum Medium (Invitrogen, US) and 20µl of HiPerfect Transfection Reagent. To 
enable the formation of transfection reagent-siRNA complexes, reaction mixtures were 
incubated at room temperature for 10 minutes. Transfection reagent-siRNA complexes were 
then added drop-wise onto cells, and dishes were gently swirled to ensure even distribution. 
Individual P60 dishes of H3.5E cells were transfected with either transfection reagent-FlexiTube 
SETD2 siRNA complexes or transfection reagent-AllStars Negative Control siRNA complexes. 
3 hours post-transfection, 2.8ml of complete medium supplemented with 400U/ml hygromycin 
B was added to each dish. Transfected cells were harvested, pelleted and stored at -80ºC for 
downstream analysis at 48, 72 and 96 hours post-transfection. 
 
4.2.6 GENE EXPRESSION ANALYSIS OF TREATED 21NT CELLS 
 21NT cells that had undergone transient or stable transfection of target gene-vector 
constructs and H3.5E hybrids transfected with small-interfering RNA (siRNA) molecules, 
underwent the same procedure of RNA extraction, DNAse I-treatment and cDNA synthesis as 
outlined in Chapter 2.3. Gene expression analysis of target genes SETD2, FLJ or hTERT was 
carried out using primer/probe concentrations and thermal cycling parameters described in 
Chapter 2.3.4. Target gene expression levels were normalized to the GAPDH endogenous 
control gene. The qbase
PLUS
 data analysis software program (Biogazelle) was used to calculate 
normalized relative quantities (NRQ) for each sample outlined in Chapter 2.3.5.   
 
4.2.7 DETERMINATION OF TELOMERASE ACTIVITY 
 Protein extraction and determination of telomerase activity within breast cancer cell 
lines, normal HMEC cell strains and stable 21NT transfection clones, was carried out using the 
same procedure described in Chapter 2.4. 
 
4.2.8  CHROMOSOME 3 ARM-SPECIFIC PAINTING BY FLUORESCENCE IN SITU 
HYBRIDIZATION 
4.2.8.1 Preparation of metaphase chromosomes and chromosome spreading 
 Cell monolayers growing in log-phase, were cultured under normal growth conditions 
until 70% confluent on P100 dishes. Cells were arrested in metaphase by adding colcemid 
(Sigma Aldrich, US) to a final concentration of 0.1µg/ml and incubating at 37ºC and 5% CO2 
for 2 hours. Cells were then harvested as described in Chapter 2.1.3, transferred to 15ml Falcon 
tubes and pelleted by centrifugation at 15,000xg for 5 minutes. Following aspiration of 
supernatants, cell pellets were resuspended in 10ml of 75mM pre-warmed (37ºC) hypotonic 
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potassium chloride (KCl) solution, to initiate nuclear swelling. Cell suspensions were then 
incubated at 37ºC for 15 minutes. To arrest hypotonic cell swelling and inhibit metabolic 
processes, 0.5ml of fresh fixative solution consisting of methanol: acetic acid (3:1), was added 
to cell suspensions and mixed by inverting the tube several times. Cells were then pelleted by 
centrifugation at 15,000xg for 5 minutes. Following aspiration of the supernatant, 1ml of 
fixative solution was added to cell pellets drop-wise along the side of tubes. Solutions were 
immediately vortexed to prevent cell clustering, before a further 9ml of fixative solution was 
added. Cell suspensions were then incubated at room temperature to 10 minutes, before 
centrifuging at 15,000xg for 5 minutes. The previous three steps were repeated twice more, 
before finally resuspending cell pellets in 1ml of fixative solution. 
 On the same day chromosome spreading was carried out by dropping 7µl of cell 
suspension onto clean 25 x 75 x 1mm poly-lysine-coated glass microscope slides (Menzel 
Glaeser). After complete evaporation of the fixative solution, slides were visualized under a 
phase contrast microscope to confirm the presence of chromosome spreads before proceeding to 
the next stage. Remaining cell suspensions were either stored at 4ºC for 1 month or at -20ºC for 
up to 1 year.  
4.2.8.2 Chromosome 3-specfic probe denaturation and hybridization 
 XCAP 3 short and long arm-specific partial chromosome 3 painting probes 
(Metasystems), labelled with green and red fluorochromes respectively, were used to visualize 
chromosome 3 structure within cell samples according to manufacturer's guidelines. For each 
slide to be analysed, 5µl of XCAP3 short arm and 5µl of XCAP3 long arm probe solutions were 
mixed together in a sterile microcentrifuge tube. The 10µl solution was then carefully spotted 
onto the centre of each slide and a 22 x 50mm borosilicate glass cover slip was placed over the 
top. Metaphase chromosomes and probe mixtures were denatured simultaneously by heating 
slides on a hotplate, pre-heated to 75ºC for 2 minutes. To facilitate probe hybridization, slides 
were incubated at 37ºC overnight in a humidified chamber. 
4.2.8.3 Post-hybridization washes, counterstaining and image capture 
 The following day, glass cover slips were carefully removed and slides were washed in 
pre-heated (72ºC) 0.4X saline-sodium citrate solution (SSC) for 2 minutes. Slides were then 
washed in 2X SSC solution for 30 seconds at room temperature, they were rinsed under tap 
water for a few seconds. Slides were then serially dehydrated by sequentially transferring 1ml of 
70%, 90% and 100% ethanol solution onto slide surfaces and incubating for 2 minutes at room 
temperature. Slides were left to air-dry for 2-3 minutes. metaphase chromosomes were 
counterstained by transferring 10µl of blue fluorescent DAPI (Vectashield) stain onto each 
slide, overlaying a 22 x 50mm borosilicate cover slip and incubating slides for 10 minutes at 
room temperature. The edges of cover slips were then sealed using rubber cement. 
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Chromosomes were visualized using a digital fluorescence microscope (Zeiss Axioplan 2 
Imaging) and images were taken at 100x magnification using an attached CCD camera 
(Photometrics) and the Smart Capture (Digital Scientific, UK) software package.    
 
4.3 RESULTS AND DISCUSSION 
4.3.1 EXPLORING THE FUNCTIONAL ROLE OF SETD2 AND FLJ IN BREAST 
CANCER CELLS 
 The initial aim of this study was to investigate the putative tumour suppressive role of 
target genes SETD2 and FLJ in breast cancer by examining their expression levels and allele 
copy number at the SETD2-FLJ genomic locus, within a panel of breast cancer cell lines and 
normal human mammary epithelial (HMEC) cell strains. To determine whether these genes may 
have suffered loss of function in connection with malignant transformation and/or telomerase 
activation, the relationship between SETD2 and FLJ expression levels, gene copy number and 
telomerase activity within breast cancer cell lines, was also examined. 
 The majority of breast cancer cell lines employed for the purposes of this study, were 
previously derived from seven female Caucasian patients aged between 36-74 years who were 
diagnosed with primary breast cancer (Chapter 2.1.2.1, Table 2.1). As shown in Table 4.2, the 
majority of breast cancer cell lines were derived from primary intraductal/invasive ductal 
carcinomas (IDC), most of which have also been found to harbour p53 mutations. The presence 
of somatic p53 mutations within breast tumours is associated with lower rates of disease-free 
survival (Pharoah et al., 1999). Over half of all breast cancer cell lines employed during this 
study were previously found to exhibit a tumorigenic phenotype, characterized by the ability to 
form tumours in nude mice (Table 4.2 and Chapter 2.1.2.1, Table 2.1). The H5S78T cell line is 
derived from a rare form of aggressive breast cancer known as carcinosarcoma, which is 
responsible for around 0.1% of all breast cancer cases and is associated with a poor prognosis 
(Hackett et al., 1977, Abbasi et al., 2012). H5S78T is the only non-tumorigenic cell line 
harbouring a p53 mutation within the entire panel (Table 4.2) The 21MT and MCF7 breast 
cancer cell lines were previously derived from the metastatic lung deposits of two female 
patients diagnosed with primary breast IDC and adenocarcinoma respectively (Band et al., 
1990, Soule et al., 1973). The 21MT cell line has been found to harbour the same p53 mutation 
as the matched primary tumour-derived cell line 21NT, from the same patient (Liu et al., 1994). 
In contrast to other breast cancer cell lines employed during this study, MCF7 has been found to 
harbour wild-type copies of p53 (Table 4.2). The BT474, 21NT and 21MT cell lines have been 
found to be HER2-positive (Kao et al., 2009, Band et al., 1990). HER2-positive breast cancers 
are associated with a poorer patient prognosis and a higher disease recurrence rate compared 
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with HER2-negative breast cancers (reviewed by Burstein, 2005). The MTSV cell line is a non-
tumorigenic SV40-immortalized luminal epithelial cell cultured from breast milk (Bartek et al., 
1990). 
Table 4.2 - Characteristics of all breast cancer cell lines employed during this study 
Breast 
Cancer Cell 
Line 
Breast 
Cancer 
Type 
Primary Tumour 
(PT)/Metastatic 
Deposit (MD) 
Tumorigenic 
(Y/N) 
p53 mutation 
status 
HER2/neu 
positive 
BT20 IDC PT Y MUT N 
BT474 IDC PT Y MUT Y 
GI101 IDC PT Y UD N 
HCC1143 IDC PT UD MUT N 
H5S78T CS PT N MUT N 
MCF7 AC MD N WT N 
MTSV* N/A N/A N N/A N/A 
21NT IDC PT Y MUT Y 
21MT IDC MD Y MUT Y 
The International Agency for Research on Cancer (IARC) TP53 Database 
(http://p53.iarc.fr/CellLines.aspx) was used to determine the p53 mutation status of the majority 
of breast cancer cell lines. The p53 mutation status of the H5S78T cell line was determined 
using the Universal Mutation Database, Edlund et al., (2012). Information for human epidermal 
growth factor receptor (HER2/neu) status of breast cancer cell lines was obtained from Kao et 
al., (2009), Band et al., (1990) and Hurst et al., (1993). Abbreviations: IDC 
(intraductal/invasive ductal carcinoma), CS (carcinosarcoma), AC (adenocarcinoma), MUT 
(mutation), WT (wild-type), UD (undetermined). * Denotes that MTSV is an SV40-immortalized 
breast luminal epithelial cell line. 
 Normal HMEC cell strains (184, 240L and LONZA) derived from breast reduction 
mammoplasty tissue of three Caucasian females aged between 19-21 years, were included as 
normal human controls within this study (Chapter 2.1.2.1, Table 2.1). HMEC 184 and 240L pre-
stasis cell strains were originally isolated and characterized by Dr. Martha Stampfer and 
colleagues at the Lawrence Berkeley National Laboratory, University of California. These cell 
strains have been found to enter stasis with a normal karyotype following 13-16 PD in 
continuous culture (HMEC Cell Bank, Stampfer., 2003, Garbe et al., 2009). The primary 
HMEC LONZA cell strain, developed by Lonza Group Ltd, has bypassed the stasis barrier 
(stage M0, p16-negative) to proliferation and enters replicative senescence (termed agonescence 
if p53 is functional) after approximately 15 PD in continuous culture. All HMEC strains used 
within this study were cultivated by my Brunel colleague Dr. H. Yasaei.  
4.3.1.1 SETD2 and FLJ gene expression analysis 
 The expression levels of candidate genes SETD2 and FLJ were first examined within all 
breast cancer cell lines and HMEC cell strains. Figure 4.6A shows that on average, breast cancer 
cell lines were found to exhibit significantly lower levels of SETD2 than HMEC cell strains (p = 
0.025). Six out of nine breast cancer cell lines examined, showed 40-80% lower SETD2 gene 
expression levels compared with HMEC strains and two out of nine breast cancer cell lines 
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exhibited a small reduction in relative SETD2 expression levels of 6%-7%. Only the single 
carcinosarcoma-derived cell line H5S78T, was found to display 27% higher SETD2 expression 
levels, relative to normal HMEC strains. Interestingly, the lowest SETD2 expression levels were 
observed within 21MT and MCF7 breast cancer cell lines derived from metastatic deposits. 
Similar levels of SETD2 expression were observed within the primary tumour-derived 21NT 
cell line and metastatic deposit-derived 21MT cell line from the same patient. This suggests that 
a reduction in SETD2 expression levels may occur at an early point during disease pathogenesis, 
prior to metastatic spread. The results presented here are consistent with those obtained by 
Sarakbi et al., (2009) and Newbold and Mokbel., (2010), which showed that breast cancer tissue 
samples were found to exhibit lower SETD2 gene expression levels compared with normal and 
matched adjacent non-cancerous tissue (ANCT) samples. Together, these data provide 
additional evidence to show that SETD2 may function as an important tumour suppressor gene 
in breast cancer. 
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Figure 4.6 - The normalized relative quantities (NRQ) of (A) SETD2 and (B) FLJ mRNA within 
a panel of nine breast cancer cell lines (blue) and three normal HMEC cell strains (red). NRQ 
values are expressed relative to the mean NRQ value of all samples. Error bars represent the 
standard error of the mean NRQ values from triplicate repeats for each sample. A student's t-
test was carried out on log-transformed NRQ values to compare mean SETD2 and FLJ gene 
expression levels of HMEC cell strains and breast cancer cell lines. (C) A scatter graph 
showing the relationship between SETD2 and FLJ expression levels within breast cancer cell 
lines (excluding BT474). The Pearson Correlation Coefficient (r) was used to quantify the 
strength of the relationship between both variables.   
 As shown in Figure 4.6B, a wide range in FLJ gene expression levels was observed 
within HMEC cell strains. In particular, the HMEC 184 cell strain was found to exhibit 
considerably lower FLJ expression levels compared with HMEC 240L or HMEC LONZA 
strains. Despite this observation, eight out of nine breast cancer cell lines examined exhibited 
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60-90% lower FLJ gene expression levels relative to HMEC cell strains. Upon exclusion of the 
HMEC 184 cell strain, breast cancer cell lines were found to exhibit significantly lower FLJ 
expression levels compared with normal HMECs (p = 0.021). The expression levels of FLJ 
within 21NT and 21MT cell lines were reduced by 60% and 76% respectively relative to HMEC 
strains 240L and LONZA, which indicates that, similarly to SETD2, a reduction in FLJ 
expression levels may occur at an early point during disease pathogenesis. Out of all breast 
cancer cell lines examined, only the BT474 cell line was found to exhibit higher FLJ expression 
levels relative to HMEC cell strains (Figure 4.6B). This particular cell line shares many features 
with other breast cancer cell lines examined (Table 4.2). Therefore, due to the unknown 
biological function of FLJ it is currently unclear as to why this particular cell line was found to 
exhibit high levels of FLJ expression relative to normal HMEC strains and other breast cancer 
cell lines. However, the results presented here demonstrate that the majority of breast cancer cell 
lines examined within this study, display lower expression levels of FLJ compared with normal 
HMEC strains, which would perhaps be expected of a novel putative tumour suppressor 
lncRNA gene in breast cancer. 
 In humans, SETD2 and FLJ genomic sequences are separated by a small, 393bp non-
transcribed DNA sequence, and are actively transcribed from opposing DNA strands and in 
opposite directions. Due to the observed reduction in both SETD2 and FLJ expression levels 
within breast cancer cell lines relative to normal HMEC strains, it is possible that the expression 
of these genes may be co-regulated, perhaps due to the presence of a shared promoter region. As 
shown in Figure 4.6A and B, normal HMEC cell strains do not appear to show any correlation 
between SETD2 and FLJ expression levels. Similarly, a very weak positive correlation between 
SETD2 and FLJ gene expression levels were observed within breast cancer cell lines (r = 0.2), 
suggesting that the expression of these genes may not be co-regulated. 
4.3.1.2 SETD2 and FLJ Copy Number Variation (CNV) Analysis 
 Molecular and cytogenetic profiling studies have shown that many different cancer 
types acquire somatic copy number alterations at whole chromosome arms or foci, some of 
which are thought to promote cancer development and progression through dysregulation of 
gene expression (Baudis., 2007, Beroukhim et al., 2010). Through parallel DNA copy number 
profiling and microarray gene expression analysis of primary breast tumours and cell lines, 
Pollack et al., (2002) found that at least 12% of gene expression variation could be directly 
linked to gene copy number alterations. Similar studies have identified recurrent regions of 
somatic copy number gains and losses that harbour functionally characterized oncogenes and 
tumour suppressor genes respectively (Baudis., 2007, Beroukhim et al., 2010). In breast cancer, 
amplification of a particular region of chromosome 17q is associated with the overexpression of 
the HER2/neu oncogene, which is thought to promote the growth of breast cancer cells through 
164 
 
activation of mitogenic signalling pathways (Slamon et al., 1987, Baerlund et al., 1997, Nahta 
et al., 2006). Based on these observations, copy number variation analysis may be a useful tool 
in the search for genes involved in cancer pathogenesis. 
 Independent studies have shown that allele loss within the short arm of chromosome 3 
occurs within 65-87% of breast cancer cell lines, tumour samples and around 45% of pre-
neoplastic lesions (Maitra et al., 2001, Chen et al., 1994, De Oliveira et al., 2012). This 
indicates that chromosome 3p loss is a common and early event in breast carcinogenesis, and 
could signify the presence of important tumour suppressor genes within this region. The most 
common site of allele loss in breast cancer has been found to occur within the 3p21.3 region 
(Maitra et al., 2001), which is known to harbour SETD2 and FLJ genes. 
 In order to determine whether the observed reduction in SETD2 and FLJ expression 
levels within breast cancer cell lines relative to normal HMECs may be linked to gene copy 
number loss, detailed copy number variation (CNV) analysis of the SETD2-FLJ genomic locus 
was carried out. The number of alleles present at six distinct genomic loci mapping to intronic 
and exonic sequences of SETD2 and FLJ was examined within the same panel of HMEC strains 
and breast cancer cell lines detailed previously. As shown in Figure 4.7, all HMEC strains were 
found to harbour two alleles at each loci, which indicates that this locus is present as two copies 
within normal human mammary cells. In contrast, only two out of nine breast cancer cell lines 
were found to harbour two alleles at each loci, while over half of breast cancer cell lines (5/9) 
were found to have undergone single copy number loss at all loci. Breast cancer cell lines that 
had undergone copy number loss were derived from patients with breast IDC and almost all had 
been previously found to exhibit a tumorigenic phenotype and harbour p53 mutations. However, 
the presence of two alleles at all loci within the BT20 cell line, implies that these features are 
not always associated with copy number loss at the SETD2-FLJ genomic locus. The remaining 
two breast cancer cell lines were found to have gained a single allele at the majority of loci 
examined, which included the rare carcinosarcoma-derived H5S78T cell line and the SV40-
immortalized MTSV cell line. This indicates that the SETD2-FLJ locus can also undergo copy 
number gain in breast cancer.  
 In order to examine the relationship between copy number variation and the gene 
expression levels of SETD2 and FLJ, breast cancer cell lines were grouped by gene copy 
number at the SETD2-FLJ genomic locus and the mean expression levels of both genes were 
calculated for each group. As shown in Figure 4.7B and C, significantly lower levels of both 
SETD2 and FLJ were observed within breast cancer cell lines that had undergone allele loss at 
this locus, compared with normal HMEC strains (p = 0.02 and p = 0.03 respectively). 
Interestingly, lower expression levels of both genes were also observed within breast cancer cell 
lines that had two alleles compared with HMEC cell strains and breast cancer cell lines with 
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only one allele at this locus. In addition, breast cancer cell lines that had undergone gene 
amplification at the SETD2-FLJ genomic locus, were found to exhibit substantially lower FLJ 
expression levels relative to HMEC strains (Figure 4.7C). These results indicate that copy 
number alterations at the SETD2-FLJ locus may be responsible for some, but not all cases of 
SETD2 and FLJ expression downregulation in breast cancer, and that alternative mechanisms of 
transcriptional silencing may be involved. These observations provide additional evidence that 
SETD2 and FLJ may function as important tumour suppressor genes in breast cancer. 
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Figure 4.7 - (A) Copy Number Variation (CNV) analysis of SETD2 and FLJ gene loci within 
nine breast cancer cell lines and three normal HMEC cell strains. The number of alleles at six 
genomic loci mapping to exonic and intronic regions of SETD2 and FLJ was determined as 
indicated above. An ideogram of chromosome 3 shows the relative positions of both target 
genes. The H5S78T cell line was found to harbour 3 alleles at 4/6 genomic loci examined and 
was therefore considered to have undergone copy number gain at this locus. Mean NRQ values 
of (B) SETD2 and (C) FLJ mRNA within HMEC cell strains and breast cancer cell lines 
grouped by overall copy number at the SETD2-FLJ gene locus. Error bars represent the 
standard error of the mean NRQ values for each group. A student's t-test was used to compare 
the log-transformed mean NRQ values of breast cancer copy number groups with mean HMEC 
NRQ values for both SETD2 and FLJ. 
◊
 and ᶲ denotes the exclusion of HMEC 184 and BT474 
from sample groups respectively. 
4.3.1.3 Telomerase activity within HMEC strains and breast cancer cell lines 
 The next aim of this study was to explore the relationship between SETD2 and FLJ 
gene expression levels and allele copy number variation at the SETD2-FLJ locus, with 
telomerase activity of breast cancer cell lines. As shown in Figure 4.8A, breast cancer cell lines 
were, as expected, found to exhibit significantly higher levels of telomerase activity compared 
with HMEC strains (p = 0.008). The highest levels of telomerase activity were observed within 
BT474, BT20 and 21NT breast cancer cell lines, derived from patients with breast IDC, which 
have been previously shown to exhibit a tumorigenic phenotype and harbour p53 mutations. In 
addition, BT474 and 21NT cell lines have been found to be HER2-positive, which may suggest 
that higher levels of telomerase activity are associated with a more aggressive disease 
phenotype. Breast cancer cell lines 21MT and MCF7, derived from metastatic deposits were 
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found to exhibit lower levels of telomerase activity compared to breast cancer cell lines derived 
from primary tumours.  
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Figure 4.8 - (A) Telomerase activity within HMEC cell strains and breast cancer cell lines 
relative to a telomerized prostate cancer cell line PC-3-hTERT. Error bars represent the 
standard deviation of the mean telomerase activity from triplicate repeats for each sample. A 
student's t-test was used to calculate the difference between mean telomerase activity of HMEC 
strain and breast cancer cell lines. Scatter plots showing the relationship between telomerase 
activity and (B) SETD2 NRQ values, (C) FLJ NRQ values and (D) allele copy number within 
the SETD2-FLJ locus within breast cancer cell lines examined. The Pearson Correlation 
Coefficient (r) was used to measure the strength of the correlation between variables.ᶲ denotes 
exclusion of the MTSV and H5S78T cell lines. (B) shows a strong positive correlation between 
SETD2 gene expression and telomerase activity levels within breast cancer cell lines, which 
suggests that SETD2 may function as a positive regulator of telomerase activity in breast 
cancer cells. 
 The relationship between SETD2 and FLJ expression levels with telomerase activity 
levels exhibited by breast cancer cell lines was then explored further. A very strong positive 
correlation was observed between telomerase activity and SETD2 gene expression levels within 
the majority of breast cancer cell lines examined (Figure 4.8B, r = 0.91). These observations 
contrast the hypothesis that SETD2 functions as a negative regulator of telomerase activity in 
breast cancer. On the other hand, no correlation between FLJ gene expression levels and 
telomerase activity was observed (Figure 4.8C, r = -0.021), which suggests that FLJ may not 
function as a regulator of telomerase in breast cancer.  
 A weak negative correlation was observed between allele copy number at the SETD2-
FLJ genomic locus and telomerase activity within breast cancer cell lines (Figure 4.8D, r = -
0.33). Due to the lack of association between SETD2 and FLJ gene expression levels and the 
number of alleles present at the SETD2-FLJ locus (Figure 4.7B and C), together with the 
observed relationship between SETD2 expression levels and telomerase activity, this 
observation does not indicate a functional link between either candidate gene and telomerase 
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activity within breast cancer cells. However, due to the frequency and extent of chromosome 3p 
loss in breast cancer (Maitra et al., 2001), it is likely that the observed change in copy number 
within the majority of breast cancer cell lines examined extends beyond the SETD2-FLJ gene 
locus. This would provide an explanation as to why a negative correlation was observed 
between SETD2-FLJ copy number and telomerase activity, but not between candidate gene 
expression levels and telomerase activity. Further investigation into the extent of chromosome 
3p loss within breast cancer cell lines and telomerase activity levels would be required in order 
to explore this possibility further.  
 
4.3.2 FORCED OVEREXPRESSION OF SETD2 WITHIN THE 21NT BREAST CANCER 
CELL LINE 
 The results presented in this Chapter so far are consistent with previous studies 
demonstrating a putative role of SETD2 as a tumour suppressor gene in breast cancer (Sarakbi et 
al., 2009, Newbold and Mokbel., 2010). Despite observing a positive correlation between 
SETD2 gene expression levels and telomerase activity within breast cancer cell lines (Figure 
4.8B), SETD2 was identified within a chimeric chromosome 3 fragment that caused telomerase 
repression when introduced into the 21NT breast cancer cell line (unpublished data, Newbold 
group). Results presented by Ducrest et al., (2001) and Szutorisz et al., (2003) demonstrating 
that the chromosome 3-encoded repressor sequence mediates telomerase repression through 
chromatin remodelling and silencing of the hTERT promoter, together with the known function 
of SETD2 as a histone methyltransferase enzyme, warranted further investigation into the 
functional role of SETD2 in telomerase regulation. In order to achieve this, the effect of forced 
SETD2 overexpression on hTERT gene transcription was examined within the 21NT cell line, 
known to exhibit telomerase repression and growth arrest following introduction of a normal 
copy of chromosome 3. The human SETD2 8452bp coding region was cloned into the 
pCMVNeo mammalian expression vector by Dr. T. Roberts. Both target gene pCMVNeo-
SETD2 and vector only pCMVNeo negative control plasmid constructs were linearized and 
transfected into the 21NT cell line using a chemical-based method of gene delivery.   
4.3.2.1 Stable overexpression of SETD2 within the 21NT breast cancer cell 
line 
 In order to examine the effect of stable long-term SETD2 overexpression on the 
transcriptional activity of hTERT and telomerase activity levels, 21NT cells transfected with 
negative control pCMVNeo and target gene pCMVNeo-SETD2 constructs were cultured in the 
presence of neomycin for two weeks to select for cells that had undergone stable integration of 
plasmid constructs. Two sets of five individual 21NT-pCMVNeo and 21NT-pCMVNeo-SETD2 
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transfection clones were isolated and propagated as individual cell lines, until sufficient cells 
were obtained for SETD2 and hTERT expression analysis.   
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Figure 4.9 - The normalized relative quantities (NRQ) of (A) SETD2 and (B) hTERT mRNA 
within stable 21NT-pCMVNeo (green) and 21NT-pCMVNeo-SETD2 (blue) colonies relative to 
the mean expression levels of two untreated 21NT cell samples (red). Error bars for stable 
clones represent the standard error of the mean NRQ values obtained from triplicate repeats for 
each sample. Error bars for the 21NT cell line represent the standard error of the mean NRQ 
values of two individual untreated 21NT samples included within the same assay. (C) 
Telomerase activity within stable 21NT-pCMVNeo and 21NT-pCMVNeo-SETD2 clones 
expressed as a percentage of untreated 21NT cells (100%). Error bars represent the standard 
error of the mean telomerase activity levels obtained from triplicate repeats for each sample.  
 Out of five stable 21NT-pCMVNeo-SETD2 stable clones, two clones were found to 
exhibit around 3-fold higher SETD2 expression levels relative to untreated 21NT cells (Figure 
4.9A, pCMV-SETD2 clones 2 and 5). These clones were found to display 80% and 20% lower 
expression levels of hTERT mRNA relative to untreated 21NT cells (Figure 4.9B). However, 
the same clones were found to exhibit either similar to or 4-fold higher levels of actual 
telomerase activity relative to untreated 21NT cells (Figure 4.9C). This suggests that the 
observed reduction in hTERT expression levels was insufficient to lead to telomerase repression 
within 21NT cells overexpressing SETD2. Out of all 21NT-pCMV-SETD2 stable clones, only 
clone 1 was found to exhibit substantially lower levels of telomerase relative to untreated 21NT 
cells (Figure 4.9C). This particular clone was found to display similar levels of SETD2 and 
hTERT expression relative to untreated 21NT cells, therefore repression of telomerase activity 
within this clone, does not appear to be linked to SETD2 expression or deregulation of hTERT 
transcription. It is formally possible that the pCMVNeo-SETD2 vector may have integrated into 
an important site responsible for post-transcriptional telomerase regulation.  
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 It is important to note that three out of five negative control 21NT-pCMVNeo stable 
clones were found to exhibit an 80% reduction or a 3-fold increase in hTERT expression levels 
relative to untreated 21NT cells (Figure 4.9B, pCMVNeo clones 3, 4 and 5). This could either 
suggest that the plasmid vector has integrated into important hTERT regulatory regions or, 
similar to telomerase activity, 21NT cells exhibit a normal degree of clonal variation in hTERT 
expression levels. Therefore, it is unclear whether the observed reduction in hTERT expression 
levels within stable 21NT-pCMVNeo-SETD2 clones is directly linked to SETD2 
overexpression. 
 The results presented here do not provide persuasive evidence to show that SETD2 may 
function as a negative transcriptional regulator of hTERT. It is possible that a greater than 3-fold 
higher level of SETD2 expression may be required to influence hTERT transcriptional activity. 
These findings also suggest that stable integration of pCMVNeo plasmid vector constructs 
influences hTERT expression regulation. Therefore, this particular plasmid vector may not be 
suitable for gene transfer studies to investigate hTERT transcriptional regulation.       
4.3.2.2 Transient overexpression of SETD2 within the 21NT cell line 
 In order to achieve high-level SETD2 overexpression and explore the possibility that 
higher levels of SETD2 expression may influence hTERT transcriptional activity, 21NT cells 
were transiently transfected with the pCMVNeo-SETD2 plasmid construct. The expression 
levels of SETD2 and hTERT were determined at 24-hour intervals, over a period of six days 
following transfection of 21NT cells with control pCMVNeo or pCMVNeo-SETD2 plasmid 
constructs. As shown in Figure 4.10A, 21NT cells transfected with pCMVNeo-SETD2 plasmid 
constructs maintained a greater than 10-fold higher level of SETD2 expression relative to 
untreated cells over the course of six days post-transfection. Unexpectedly, hTERT expression 
levels were found to be consistently higher within 21NT cells transfected with pCMVNeo-
SETD2 plasmids compared with both untreated and pCMVNeo-transfected 21NT cells at all 
time points, apart from Day 6 (Figure 4.10B). Additionally, a strong positive correlation was 
observed between SETD2 and hTERT gene expression levels within 21NT cells transiently 
transfected with pCMVNeo-SETD2 vector constructs (Figure 4.10C, r = 0.99). These results 
suggest that high levels of SETD2 expression may actually induce hTERT transcription within 
breast cancer cells. However, hTERT expression levels exhibited by 21NT cells transfected with 
control pCMVNeo plasmids, varied between 73% - 660% of untreated 21NT cells, which may 
reflect the normal degree of hTERT gene expression variation exhibited by 21NT cells. Taking 
this into account, high levels of SETD2 expression may either have no effect or a positive effect 
on hTERT transcriptional activity. These findings are consistent with the observed relationship 
between SETD2 expression levels and telomerase activity within breast cancer cell lines (Figure 
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4.8B), but contradict the hypothesis that SETD2 may function as a transcriptional repressor of 
hTERT.  
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Figure 4.10 - The normalized relative quantities (NRQ) of (A) SETD2 and (B) hTERT mRNA 
within 21NT cells 2-5 days following transient transfection of 21NT cells with pCMVNeo and 
pCMVNeo-SETD2 vector constructs, relative to untreated 21NT cells harvested on the same 
day. NRQ values represent the mean NRQ values of two samples harvested from each group on 
each day. Error bars show the standard error of the mean NRQ values for each duplicate 
sample (C) A scatter graph showing the relationship between SETD2 and hTERT gene 
expression levels within 21NT cells transiently transfected with the pCMVNeo-SETD2 plasmid. 
The Pearson Correlation Coefficient (r) was used to measure the strength of the correlation 
between SETD2 and hTERT expression levels. 
4.3.2.3 The effect of forced SETD2 expression on 21NT cell growth 
 The results obtained from transient SETD2 transfection within the 21NT cell line 
demonstrate that SETD2 may function as a positive transcriptional regulator of hTERT. Due to 
the important role of hTERT de-repression and subsequent telomerase re-activation in cancer 
development and progression, these results suggest that SETD2 may actually enhance 
tumorigenicity. These observations strongly contradict results presented in Figure 4.6A and by 
Sarakbi et al., (2009) and Newbold and Mokbel (2010), which provided evidence to show that 
SETD2 may exhibit a tumour suppressive function.  
 In order to understand the functional role of SETD2 in promoting/inhibiting breast 
cancer cell growth, the effect of stable SETD2 overexpression on the clonogenic survival of 
21NT cells was determined. To do this, the number of stable, neomycin-resistant cell colonies 
that arose two weeks following transfection of 21NT cells with control pCMVNeo and target 
gene pCMVNeo-SETD2 plasmid constructs was compared. As shown in Figure 4.11, the 
number of stable 21NT-pCMVNeo-SETD2 colonies was consistently and significantly higher 
than the number of stable 21NT-pCMVNeo colonies that arose following two weeks of 
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neomycin selection (p = 3x10
-4
). These results therefore suggest that SETD2 may enhance the 
clonogenic survival of breast cancer cells. 
  
 
Figure 4.11 - (A) Photographs of eight P60 dishes containing fixed and stained stable (i) 
control 21NT-pCMVNeo and (ii) target gene 21NT-pCMVNeo-SETD2 colonies that arose 
following two weeks of neomycin selection. (B) The mean number of 21NT-pCMVneo (green) 
and 21NT-pCMVNeo-SETD2 (blue) colonies present across four individual dishes for each 
plasmid construct. Error bars represent the standard deviation of the mean. A student's t-test 
was used to compare the mean of both groups. 
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4.3.3 KNOCKDOWN OF SETD2 EXPRESSION WITHIN A SINGLE 21NT-
CHROMOSOME 3 HYBRID CLONE (H3.5)  
 The findings presented so far, provide evidence to show that forced overexpression of 
SETD2 within the 21NT breast cancer cell line may induce hTERT expression and promote cell 
growth. However, the transfection method employed within this study may have induced non-
physiological levels of SETD2 expression. Therefore, the observed phenotype may not reflect 
the true function of SETD2 in vitro.    
 In order to explore the functional role of SETD2 in hTERT transcriptional regulation 
further, the effect of RNA-interference (RNAi)-mediated repression of SETD2 on hTERT 
expression was examined within a single telomerase-repressed 21NT-chromosome 3 hybrid 
clone (H3.5). This hybrid was generated from a previous MMCT experiment carried out in our 
laboratory by Mrs. Alison Marriott (Senior Cell Culture Technician), whereby a hygromycin 
phosphotransferase-thymidine kinase (Hytk) - tagged normal copy of human chromosome 3 was 
introduced into the 21NT cell line. H3.5 was initially characterized as telomerase-repressed but 
later underwent a crisis event whereby telomerase was re-activated by a step-change, generating 
an immortal variant. As a result, both pre-crisis (H3.5E) and post-crisis (H3.5L) forms of this 
hybrid clone were available for further characterization. 
4.3.3.1 Characterization of pre-crisis H3.5E and post-crisis H3.5L hybrid 
clones 
 In order to confirm previous observations demonstrating de-repression of hTERT and 
re-activation of telomerase activity following crisis, the expression levels of hTERT were 
examined within both pre-crisis (H3.5E) and post-crisis (H3.5L) forms of this hybrid clone. As 
shown in Figure 4.12, H3.5E hybrid clones exhibited an 88% reduction in hTERT expression 
levels relative to parental 21NT cells. This observation is consistent with findings by Ducrest et 
al., (2001), demonstrating that telomerase-repressed 21NT-chromosome 3 hybrids exhibit 
substantially lower levels of hTERT transcript molecules compared with telomerase-positive 
parental cells. By comparison, H3.5L hybrid cells were found to display 54% higher levels of 
hTERT expression compared to H3.5E cells, indicating that an increase in hTERT expression 
levels had occurred following the crisis event.  
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Figure 4.12 - Normalized relative quantities (NRQ) of hTERT mRNA within pre-crisis H3.5E 
and post-crisis H3.5L hybrid clones relative to parental 21NT cells. HMEC 184 was included as 
a negative control. NRQ values represent the mean NRQ of two independent qPCR runs for 
each sample and error bars represent the standard error of the mean. A student's t-test was 
used to compare mean NRQ values of samples.  
 As previously demonstrated by Cuthbert et al., (1999), allelotype analysis of 
chromosome 3 within telomerase-positive segregant 21NT-chromosome 3 hybrid clones, 
revealed two commonly deleted regions at 3p21.3-p22 and 3p12-21.1. These results provided 
evidence of a strong link between chromosome 3p deletions and the presence of active 
telomerase within 21NT-chromosome 3 hybrid clones. Taking these observations into account, 
the structure of chromosome 3 within pre-crisis H3.5E and post-crisis H3.5L hybrid clones was 
examined by fluorescence in situ hybridization (FISH).  
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Figure 4.13 - Representative fluorescence images (x100 magnification) of (A. i, ii) HMEC 184, 
(B. i, ii) 21NT, (C. i, ii) H3.5E and (D. i, ii) H3.5L cell lines/strain metaphase spreads 
hybridized with chromosome 3 p-arm (green) and q-arm (red)-specific probes and 
counterstained with DAPI (blue). White circles indicate  an extra chromosome 3 copy and white 
arrows indicate a consistent deletion of chromosome 3p observed within H3.5L hybrid 
metaphase spreads.   
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 HMEC 184, 21NT, H3.5E and H3.5L metaphase chromosomes were hybridized with 
fluorescently labelled chromosome 3 p-arm (green) and q-arm (red) specific probes. A 
minimum of five metaphase spreads were analysed for each cell line/strain. Representative 
images shown in Figure 4.13A indicate the presence of two intact copies of human chromosome 
3 within all HMEC 184 cell strain metaphase spreads. This provides a reference for normal 
chromosome 3 structure and confirms the specificity of the chromosome 3 painting probe. 
Representative images of 21NT metaphase chromosomes demonstrate the presence of two 
whole chromosome 3 copies and a chromosome 3q translocation, indicated by an additional q-
arm signal within another chromosome (Figure 4.13B). This was observed within five 
individual metaphase spreads. Similarly, FISH analysis of chromosome 3 structure within 21NT 
cells carried out by Cuthbert et al., (1999), also demonstrated the presence of two 
submetacentric chromosome 3 copies, a single translocation and small regions of chromosome 3 
material within two other chromosomes. Karyotypic analysis of 21NT cells within the study by 
Band et al., (1990), showed gross chromosomal rearrangements and aneuploidy. Together these 
results demonstrate that 21NT cells exhibit a high level of genetic instability, including 
structural changes in chromosome 3.  
 The presence of an additional whole chromosome 3 copy was observed within four out 
of seven pre-crisis H3.5E hybrid clone metaphase spreads, which confirms the existence of a 
single intact exogenous chromosome 3 copy introduced by MMCT within the majority of 
hybrids (Figure 4.13C). In contrast, all five post-crisis H3.5L metaphase chromosome spreads 
revealed a consistent deletion of the short-arm within a single copy of chromosome 3 (Figure 
4.13D). The remaining chromosome 3q fragment appears to have fused with endogenous 
chromosome material, demonstrated by the presence of DAPI signal at one end of the fragment. 
The observed difference in chromosome 3 structure between H3.5E and H3.5L hybrid clones, 
provides additional evidence of a functional link between chromosome 3 and hTERT gene 
regulation. These results also suggest that the hTERT regulatory sequence may be located on the 
short-arm of chromosome 3, which is consistent with findings by Cuthbert et al., (1999), 
Ducrest et al., (2001) and Szutorisz et al., (2003). 
 The presence of SETD2 within a chimeric chromosome 3 fragment, previously found to 
cause telomerase repression within the 21NT cell line, provided some evidence to show that this 
gene may function as a regulator of telomerase. The results presented here and by Cuthbert et 
al., (1999), demonstrate an important link between chromosome 3p loss, increased hTERT 
expression levels and telomerase re-activation. Therefore, in order to explore the possibility that 
the observed chromosome 3p loss and increase in hTERT expression levels within the post-crisis 
H3.5L hybrid also involved loss of SETD2 gene function, the expression levels and gene copy 
number were examined within pre-crisis H3.5E and post-crisis H3.5L hybrid clones.   
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Figure 4.14 - (A) Normalized relative quantities (NRQ) of SETD2 mRNA within pre-crisis 
H3.5E and post-crisis H3.5L hybrid clones relative to parental 21NT cells. NRQ values 
represent the mean of two independent qPCR runs for each sample and error bars represent the 
standard error of the mean. A student's t-test was used to compare log-transformed mean NRQ 
values of all samples. (B) Copy number variation analysis of the SETD2-FLJ genomic locus 
within HMEC 184, parental 21NT cells, H3.5E and H3.5L hybrid clones. The number of alleles 
at five genomic loci mapping to exonic and intronic regions of SETD2 and FLJ was determined 
as indicated above.  
 As shown in Figure 4.14A, a significant increase in SETD2 expression levels was 
observed within H3.5E hybrid clones compared with 21NT cells, which suggests that the 
introduction of a normal copy of chromosome 3 is associated with increased SETD2 expression 
levels. A significant reduction in SETD2 expression levels was observed within H3.5L hybrids 
compared with H3.5E hybrids, which suggests that the observed post-crisis chromosome 3p loss 
may have also involved loss of SETD2. In support of this, three out of five loci within the 
SETD2-FLJ genomic locus were present at two copies within the H3.5E hybrid, compared with 
only one out of five within the H3.5L hybrid, which indicates loss of chromosome 3p arm 
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material at the SETD2-FLJ genomic locus after the H3.5 clone entered crisis (Figure 4.14B). 
These results suggest that introduction of an intact copy of human chromosome 3 within the 
21NT cell line was associated with an increase in SETD2 expression and a reduction in hTERT 
expression levels. Following a crisis event, this hybrid clone underwent chromosome 3p loss 
involving the SETD2-FLJ genomic locus, which was associated with reduced levels of SETD2  
expression and increased hTERT expression. Overall, these findings provide evidence of a 
functional link between SETD2 and hTERT gene regulation. However, taking into account the 
effects of stable SETD2 overexpression on hTERT transcription levels and 21NT cell clonogenic 
survival described previously, it is possible that another chromosome 3p-encoded sequence may 
have been responsible for the observed telomerase repression within the H3.5E hybrid clone.  
4.3.3.2 Knockdown of SETD2 within the H3.5E hybrid clone 
 In order to explore further the putative functional link between SETD2 and 
transcriptional regulation of hTERT, the expression levels of both genes were examined 
following RNA interference (RNAi)-mediated inhibition of SETD2 expression within pre-crisis 
H3.5E hybrid clones. Hybrids were transfected with a mixture of SETD2-siRNA construct 
molecules, that target four distinct untranslated regions (UTRs) within the SETD2 transcript 
sequence. As a negative control, H3.5E cells were also transfected with a non-targeting (NT) 
mixture of siRNA molecules. Treated H3.5E cells were harvested for gene expression analysis 
at 24-hour intervals, 48-96 hours post-transfection with both constructs. As shown in Figure 
4.15A, a gradual reduction in SETD2 expression levels from 37% to 8% relative to untreated 
H3.5E hybrids, were observed 48 and 96 hours post-transfection with SETD2 siRNA molecules 
respectively. Unexpectedly, H3.5E hybrids transfected with NT-siRNA were found to exhibit a 
54% and 80% reduction in SETD2 expression levels relative to untreated cells, 72 and 96 hours 
post-transfection respectively (Figure 4.15A). This could suggest that the NT-siRNA constructs 
either directly or indirectly repressed the expression of SETD2, and therefore do not provide a 
reliable negative control. H3.5E hybrids transfected with SETD2-siRNA constructs were found 
to exhibit a similar level of hTERT expression relative to untreated cells, indicating that 
knockdown of SETD2 expression is not associated with an observable change in hTERT 
transcriptional activity (Figure 4.15B). These results failed to provide evidence supporting the 
notion that SETD2 may function as a transcriptional repressor of hTERT in breast cancer.  
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Figure 4.15 - Normalized relative quantities of (A) SETD2 and (B) hTERT mRNA 48-96 hours 
post transfection of H3.5E hybrid clones with non-targeting (NT, green) or a mixture of four 
SETD2-siRNA construct molecules (blue), relative to untreated (UT) H3.5E hybrids (red) 
harvested on the day of transfection. Error bars represent the standard error of triplicate 
repeats for each sample.  
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4.3.4 ANALYSIS OF A TWO STABLE 21NT-FLJ TRANSFECTION CLONES 
 The results presented so far provide no evidence to show that SETD2 may function as a 
hTERT transcriptional repressor. Therefore, the functional role of FLJ as a candidate repressor 
of hTERT was explored further. As demonstrated previously, breast cancer cell lines have been 
found to exhibit significantly lower levels of FLJ expression when compared with normal 
HMEC cell strains. Additionally, the majority of breast cancer cell lines employed during this 
study were found to have undergone allele loss that included the FLJ genomic locus. Similarly 
to SETD2, FLJ allele loss was observed within post-crisis H3.5L hybrids compared with pre-
crisis H3.5E hybrid clones (Figure 4.14B). As shown in Figure 4.16, H3.5E hybrid clones were 
found to display a significant increase in FLJ expression levels relative to untreated 21NT cells. 
In addition FLJ expression levels were found to be substantially reduced within H3.5L hybrids 
compared with H3.5E hybrids (Figure 4.16). These results indicate that chromosome 3p loss 
within post-crisis H3.5L hybrids may also be associated with loss of FLJ function. 
 
Figure 4.16 - Normalized relative quantities (NRQ) of FLJ mRNA within pre-crisis H3.5E and 
post-crisis H3.5L hybrid clones relative to parental 21NT cells. NRQ values represent the mean 
of two independent qPCR runs for each sample and error bars represent the standard error of 
the mean. A student's t-test was used to compare log-transformed mean NRQ values of all 
samples.  
 In order to explore a causal link between FLJ and hTERT gene regulation, the effect of 
forced FLJ overexpression on hTERT transcriptional activity within the 21NT cell was 
examined. After cloning the human FLJ open reading frame (ORF) into the pCMVNeo plasmid 
vector, my colleague Dr. T. Roberts transfected target pCMVNeo-FLJ and empty vector control 
pCMVNeo constructs into the 21NT cell line and cultured cells in the presence of neomycin to 
select for cells that had undergone stable integration of plasmid constructs. Individual 21NT-
pCMVNeo and 21NT-pCMVNeo-FLJ clones were isolated and propagated as individual cell 
lines. Aliquots of two 21NT-pCMVNeo and two 21NT-pCMVNeo-FLJ stable clones were 
provided to me for downstream analysis.       
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Figure 4.17 - Normalized relative quantities of (A) FLJ and (B) hTERT mRNA within two 
stable 21NT-pCMVNeo (orange) and two stable 21NT-pCMVNeo-FLJ (purple) clones relative 
to untreated 21NT cells. Error bars represent the standard error of the mean NRQ values from 
triplicate repeats for each sample. (C) Telomerase activity within all stable clones relative to 
untreated 21NT cells. The HMEC 240L sample was included as a negative control. Error bars 
represent the standard deviation of triplicate repeats for each sample.  
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 As shown in Figure 4.17A, stable 21NT-pCMVNeo-FLJ clones 1 and 2 were found to 
exhibit 1.6-fold and 21-fold higher FLJ expression levels relative to untreated 21NT cells 
respectively. Both 21NT-pCMVNeo-FLJ stable clones were found to display a 90% and 70% 
reduction in hTERT expression levels, which may indicate that FLJ could function as a 
transcriptional repressor of hTERT. In further support of this, 21NT-pCMVNeo-FLJ clones 
demonstrated a reduction in telomerase activity, outside of the normal range of clonal variation 
exhibited by 21NT cells (Chapter 3.3.1, Figure 3.3C). However, despite observing no change in 
FLJ expression levels within stable empty vector control 21NT-pCMVNeo clones 1 and 2, 
hTERT expression levels were found to be reduced by around 90% (Figure 4.17B). Similarly, 
both control 21NT-pCMVNeo clones displayed a similar reduction in telomerase activity as 
stable 21NT-pCMVNeo-FLJ clones, relative to untreated 21NT cells (Figure 4.17C), which 
indicates that the pCMVNeo vector construct alone influences hTERT expression. As previously 
shown in Figure 4.9C, two out of five stable empty vector control 21NT-pCMVNeo clones 
isolated during an investigation of SETD2 in hTERT transcriptional regulation, exhibited 80% 
lower hTERT expression levels relative to untreated 21NT cells. One stable 21NT-pCMVNeo 
clone also displayed 60% lower levels of telomerase activity compared with untreated 21NT 
cells (Figure 4.9C). These results demonstrate that the (empty) pCMVNeo vector consistently 
influences hTERT expression within the 21NT cell line. Therefore, further investigation is 
necessary to determine whether the observed reduction in hTERT expression levels and 
telomerase activity within 21NT cells, is linked to increased FLJ expression levels. However, it 
should be noted that neither 21NT-pCMVNeo or 21NT-pCMVNeo-FLJ stable clones exhibited 
a greater than 90% reduction in telomerase activity, which has been previously associated with 
growth arrest of 21NT-chromosome 3 hybrid clones in the study by Cuthbert et al., (1999). 
Therefore, it is likely that FLJ may not function as a transcriptional regulator of hTERT. 
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4.4 SUMMARY 
 Telomerase repression within 21NT breast cancer cells containing an exogenous intact 
copy of normal chromosome 3, was found to be due to transcriptional repression of the hTERT 
gene (Ducrest et al., 2001). The observed change in chromatin structure around intron 2 of the 
hTERT gene to a 'closed' state within 21NT-chromosome 3 hybrids, provided an important 
insight into the mechanism by which chromosome 3 may mediate hTERT transcriptional 
repression within breast cancer cells (Szutorisz et al., 2003). Subsequent studies that aimed to 
narrow the search for the chromosome 3-encoded hTERT repressor sequence, identified a 490kb 
region mapping to the 3p21.3 region, encompassing two putative candidate genes; a known 
histone methyltransferase enzyme (SETD2) and an uncharacterized long non-coding (lnc) RNA 
sequence (FLJ).  
 Consistent with findings presented by Sarakbi et al., (2009) and Newbold and Mokbel 
(2010), the results from my study demonstrate a putative tumour suppressor role of SETD2 in 
breast cancer. SETD2 gene expression levels were found to be significantly reduced within a 
panel of nine breast cancer cell lines relative to normal human mammary epithelial cell (HMEC) 
strains. By comparison, a greater proportion of breast cancer cell lines were found to exhibit 
lower levels of FLJ expression than SETD2, which provides indirect evidence of a putative 
novel lncRNA tumour suppressor gene in breast cancer. Similar levels of SETD2 and FLJ 
expression were observed within both primary tumour-derived and metastatic deposit-derived 
breast cancer cell lines, indicating that a reduction in both candidate gene expression levels 
occurs at an early point during disease pathogenesis and prior to metastatic spread. Interestingly, 
despite observing allele loss at the SETD2-FLJ genomic locus within over half of breast cancer 
cell lines examined, those harbouring two alleles at this locus also exhibited substantially lower 
levels of SETD2 and FLJ expression levels. Additionally, breast cancer cell lines with three 
alleles at this locus were also found to exhibit low FLJ expression levels. Therefore, copy 
number variation at the SETD2-FLJ locus does not account for all transcriptional deregulation 
of SETD2 and FLJ within breast cancer cells. 
 Independent sequencing studies and cohort analyses have identified SETD2 mutations 
within multiple cancer types, such as acute MLL-rearranged leukaemia (22%), high grade 
glioma (HGG, 15%), acute lymphoblastic leukaemia (ALL, 12%) and clear cell renal cell 
carcinoma (ccRCC, 11.6%) (Zhu et al., 2014, Fontebasso et al., 2013, Mar et al., 2014, Hakimi 
et al., 2013, respectively). Interestingly, SETD2 mutations have been identified within a panel 
of ccRCC cell lines that had undergone copy number loss within the 3p21 locus (Duns et al., 
2010). These mutations were found to disrupt SETD2 protein function either through 
introduction of premature stop codons, aberrant splicing or through single missense mutations 
within specific protein domains. A recent screen of somatic cancer mutations in protein lysine 
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methyltransferase (PKMT) enzymes revealed that there are 339 mutations within the SETD2 
gene; a large proportion of these are frame-shift and nonsense mutations that are predicted to 
confer loss of protein function (Kudithipudi and Jeltsch., 2014). According to current mutation 
data within the Catalogue of Somatic Mutations in Cancer (COSMIC) database, 1.72% of breast 
tumour samples harbour SETD2 mutations, all of which are derived from patients with invasive 
breast carcinoma (http://www.sanger.ac.uk/cosmic, Forbes et al., 2015). According to the same 
database, SETD2 mutations were not identified during a mutation screen of H5S78T, HCC1143, 
BT20 and BT474 breast cancer cell lines. The BT20 and H5S78T cell lines were found to 
harbour 2 and 3 alleles at the SETD2 genomic locus within my study respectively. These 
observations together with the low frequency of SETD2 mutations in breast cancer could 
suggest that other mechanisms of SETD2 loss of function may exist within breast cancer cells.  
 In support of the hypothesis that SETD2 may function as a regulator of hTERT, a single 
hTERT-repressed 21NT-chromosome 3 hybrid clone (H3.5E) was found to exhibit significantly 
higher levels of SETD2 expression than parental 21NT cells. In addition, two alleles were 
observed at multiple loci within the SETD2-FLJ genomic region of H3.5E hybrid cells, 
indicating that the exogenous copy of chromosome 3 was not only associated with hTERT 
repression but also with increased levels of SETD2 expression. This particular hybrid was 
reported to have entered crisis and a telomerase-positive hybrid cell colony was found to have 
emerged. Further characterization of the pre-crisis and post-crisis forms of this hybrid within 
my study, revealed an increase in hTERT expression levels and cytogenetic analysis 
demonstrated consistent loss of chromosome 3p material within a single copy of chromosome 3. 
These results are in agreement with findings presented by Cuthbert et al., (1999), Ducrest et al., 
(2001) and Szutorisz et al., (2003) demonstrating that a transcriptional repressor of hTERT is 
present on the short arm of chromosome 3. Copy number variation analysis demonstrated allele 
loss at the SETD2-FLJ genomic locus and expression levels of SETD2 were significantly 
reduced after the hybrid clone entered crisis. This provided further evidence that SETD2 may 
function as a hTERT repressor sequence. 
 Stable integration of pCMVNeo-SETD2 plasmid constructs into the 21NT cell line 
produced two stable clones overexpressing SETD2 to a similar level observed within hTERT- 
repressed pre-crisis H3.5 clones. Despite observing a substantial reduction in hTERT expression 
levels within one clone, telomerase activity was not found to be repressed within either stable 
clone. In fact, one clone was found to display almost 4-fold higher levels of telomerase activity. 
Similarly, transient high-level overexpression of SETD2 within 21NT cells, was consistently 
associated with increased levels of hTERT expression. In addition, siRNA-mediated knockdown 
of SETD2 expression within pre-crisis H3.5E hybrid cells, was not associated with any 
observable change in hTERT expression levels. The results presented within my study provide 
evidence to show that SETD2 does not function as a negative regulator of hTERT transcription 
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and is therefore unlikely to be responsible for telomerase repression in 3p monochromosomal 
hybrids. 
 In 2003, Smith et al., provided evidence to show that the telomerase enzyme may 
possess telomere-stabilization independent effects on promoting cell growth. An increase in 
cellular proliferation was observed within post-stasis HMEC strains ectopically expressing 
hTERT, but not normal HMEC controls, when both were cultured in a low-mitogen 
environment. The reduced dependency on extracellular growth factors, was thought to be due to 
the observed telomerase-dependent upregulation in the expression of genes involved in 
mitogenic signalling pathways, such as the epidermal growth factor receptor (EGFR). Apart 
from facilitating cellular immortality, telomerase may play additional roles in tumorigenesis. In 
my study, transient high-level SETD2 expression within 21NT cells was associated with 
increased hTERT expression levels. Similarly, a positive correlation between SETD2 and 
telomerase activity was observed within breast cancer cell lines. Interestingly, the number of 
stable 21NT-pCMVNeo-SETD2 clones that emerged following two weeks of neomycin 
selection was significantly higher than the number of stable empty vector control 21NT-
pCMVNeo stable clones that emerged. This suggests that overexpression of SETD2 may 
promote the growth of 21NT breast cancer cells. Taking into account the results presented by 
Smith et al., (2003) and the observed relationship between SETD2 and hTERT expression, it is 
possible that the observed increase in 21NT cell proliferation is due to increased hTERT 
expression levels. However, further investigation into a direct causal link between SETD2 and 
hTERT expression levels and cell growth is required.  
 Transcriptome profiling of a panel of 42 primary ccRCC tumour samples, revealed an 
association between SETD2 mutations and genome-wide aberrant RNA splicing defects 
affecting around 25% of all actively transcribed genes (Simon et al., 2014). This was found to 
be due to changes in chromatin accessibility and nucleosome positioning, which was thought to 
lead to the formation of alternative transcription start sites (TSS) and intron retention. A large 
proportion of deregulated transcripts affected known tumour suppressor genes and those 
involved in the DNA damage response (DDR) pathway. This demonstrates the important 
function that SETD2 plays in maintaining transcriptome stability within human cells, and 
provides an understanding of how loss of SETD2 function may promote tumorigenesis. It has 
recently been shown that knockdown of SETD2 within U2OS osteosarcoma cells, reduced 
histone H3 lysine 36 (H3K36) trimethylation marks and decreased the clonogenic survival of 
cells following treatment with DNA damage-inducing agents, compared with non-targeting 
controls (Pfister et al., 2014). The H3K36 trimethylation activity of SETD2 was found to be 
required for the recruitment of C-terminal binding protein interacting protein (CtlP) to sites of 
DNA double strand breaks (DSB) in order to facilitate repair and promote genomic stability in 
human cells. Expression of wild-type SETD2 through stable integration of doxycycline-
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inducible Tet operator-SETD2 constructs into U2OS cells, was found to increase H3K36 
trimethylation levels and rescue homologous recombination (HR) efficiency following 
knockdown of endogenous SETD2. In addition, overexpression of SETD2 to around 100-fold 
higher levels within MCF7 breast cancer cells, was found to increase the expression levels of 
p53 and specific downstream p53 target genes involved in apoptosis and cell cycle control (Xie 
et al., 2008). These studies demonstrate an important function of SETD2 in maintaining 
genomic stability through activation of DNA damage response pathways and DSB repair. 
However, the effect of reconstituting wild-type SETD2 expression on cancer cell growth was 
not reported within the Pfister et al., (2014) and Xie et al., (2008) studies. SETD2 gene 
expression analysis within my study demonstrated that both primary tumour and metastatic 
deposit-derived breast cancer cell lines exhibit low levels of expression, indicating that a 
reduction in SETD2 function may occur early in disease pathogenesis. Based on the function of 
SETD2 to maintain genomic stability, loss of SETD2 function within pre-neoplastic cells, may 
accelerate the acquisition of  somatic cancer mutations that drive tumorigenesis. This has been 
observed within hereditary non-polyposis coli (HNPCC), where inactivating mutations in DNA 
mismatch repair (MMR) genes hMLH1 or hMSH2, results in the accumulation of mutations in 
tumour suppressor and oncogenes leading to tumorigenesis (Lengauer et al., 1998).  
 The results of my study described in this chapter contrast with findings by Sarakbi et 
al., (2009) and Newbold and Mokbel (2010), demonstrating a putative tumour suppressor role 
of SETD2 in breast cancer. Sarakbi et al., (2009) compared SETD2 expression levels within 
breast tumour samples derived from patients with different breast cancer subtypes, tumour 
grades, clinical outcomes and clinicopathological features such as ER status, with normal breast 
tissue samples. Overall, malignant breast tumour samples were found to exhibit significantly 
lower levels of SETD2 mRNA than normal breast tumour samples. In addition, breast tumour 
samples derived from patients who developed local recurrence, metastases or died of breast 
cancer were found to exhibit significantly lower SETD2 expression levels than patients who 
were free of disease for greater than 10 years, which supports the role of SETD2 as a putative 
tumour suppressor gene. In contrast, my results are the first to demonstrate an association 
between increased SETD2 expression levels and an increase in 21NT breast cancer cell growth. 
The 21NT cell line is derived from a nuclear grade 3, primary IDC breast tumour from a 36-year 
old female, which had spread to three lymph nodes and the lungs (Band et al., 1990). This cell 
line has been shown to harbour a frame-shift mutation in p53, is HER2-positive and is negative 
for both ER and PgR receptors (Band et al., 1990, Liu et al., 1994). Using the Kaplan-Meier 
Plotter (KPM) program, which assesses the effect of 54,675 genes on the survival rates of over 
4,000 breast cancer patients, the effect of SETD2 expression on relapse-free survival (RFS) for 
breast cancer patients was examined (Gyorffy et al., 2010). Consistent with the findings 
presented by Sarakbi et al., (2009), breast cancer patients with low levels of SETD2 expression 
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show a significant reduction in RFS compared with patients with high SETD2 expression levels 
(Figure 4.18A). In complete contrast, high SETD2 expression levels within breast tumours that 
display similar characteristics to the 21NT cell line including, ER-negative and p53-mutant or 
ER-negative, PgR-negative and HER2-positive breast tumours, are associated with a 
significantly reduced RFS (Figure 4.18B and C). Therefore, increased SETD2 expression levels 
within a subset of breast tumours with certain molecular features is associated with reduced 
patient survival. The results presented within my study provide evidence to show that increased 
SETD2 expression within 21NT cells is associated with increased clonogenic survival and 
hTERT expression, which may promote tumour cell growth and survival. 
 
Figure 4.18 - Kaplan-Meier relapse-free survival (RFS) analysis depending on SETD2 
expression of (A) all breast cancer subtypes, (B) ER-negative breast cancers with p53 
mutations and (C) ER-negative, PgR-negative and HER2-positive breast cancer patients. Data 
and plots obtained from Kaplan-Meier Plotter (Gyorffy et al., 2010, 
http://kmplot.com/analysis/index.php?p=background). 
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 Based on the observed effect of SETD2 on hTERT transcriptional regulation, the 
putative function of FLJ to mediate transcriptional repression of hTERT was explored further. A 
significant increase in FLJ expression levels were observed within the hTERT-repressed pre-
crisis H3.5E hybrid clone. Following the crisis event, this hybrid displayed substantially lower 
levels of FLJ expression and had lost one allele at the FLJ genomic locus. These findings 
supported the hypothesis that FLJ may play a functional role in hTERT repression. Interestingly, 
stable overexpression of FLJ within parental 21NT cells was associated with a greater than 70% 
reduction in hTERT expression levels relative to untreated 21NT cells. However, a stable 21-
fold overexpression level of FLJ was only associated with a 30% reduction in telomerase 
activity compared with untreated controls. This suggests that FLJ may not have been 
responsible for the >90% reduction in telomerase activity observed within 21NT-chromosome 3 
hybrids generated in the study by Cuthbert et al., (1999). Importantly, stable 21NT-pCMVNeo 
empty vector control clones were found to exhibit a 90% reduction in hTERT expression and a 
36-70% reduction in telomerase activity relative to untreated 21NT cells, indicating that stable 
integration of the pCMVNeo vector alone influenced hTERT expression. Therefore, it is 
unlikely that the observed reduction in hTERT expression levels and telomerase activity within 
stable 21NT-pCMNeo-FLJ clones is associated with FLJ overexpression. These findings 
therefore suggest that FLJ does not function as a negative regulator of hTERT transcription or 
telomerase activity within the 21NT breast cancer cell line. 
 Based on the identification of SETD2 and FLJ within a chromosome 3-fragment 
previously found to cause telomerase repression within 21NT breast cancer cells, the aim of this 
study was to explore the functional role of these candidate genes in hTERT transcription 
regulation. Despite growing evidence of SETD2 as an important tumour suppressor gene in 
multiple cancer types, the results presented here suggest that SETD2 does not function as a 
negative transcriptional regulator of hTERT. In addition reconstitution of SETD2 expression 
within 21NT cells was found to have an unanticipated effect on cell growth, which requires 
further investigation. The findings presented within this study also identify a potentially novel 
tumour suppressor lncRNA (FLJ) in breast cancer localized to the 3p21.3 region. However, as 
with SETD2, FLJ does not appear to mediate transcriptional repression of hTERT within 21NT 
cells and, therefore, any role its loss of function may have in cancer development or progression 
remains to be elucidated. 
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        CHAPTER 5 
5 EXPLORING THE ROLE OF TUMOUR SUPPRESSOR GENES WITHIN 
THE CHROMOSOME 3P21.1-P21.3 REGION AS CANDIDATE 
REGULATORS OF TELOMERASE IN BREAST CANCER 
5.1 INTRODUCTION  
 As demonstrated by Cuthbert et al., (1999), introduction by MMCT of a normal copy of 
human chromosome 3 into the 21NT breast cancer cell line is associated with strong telomerase 
repression and induction of cellular senescence pathways. Deletion-mapping of chromosome 3 
within telomerase-positive segregant 21NT-chromosome 3 hybrids identified two regions that 
may harbour the putative telomerase repressor sequence, namely 3p21.3-p22 and 3p12-p21.1. 
Subsequent studies showed that the normal chromosome 3 copy mediates telomerase repression 
within 21NT cells through chromatin remodelling and transcriptional repression of the hTERT 
promoter (Ducrest et al., 2001, Szutorisz et al., 2003). Loss of heterozygosity (LOH) of 
chromosome 3p has been found to occur within 30-87% of primary breast tumour samples (Ali 
et al., 1989, Sato et al., 1991, Chen et al., 1994, Matsumoto et al., 1997, Martinez et al., 2001, 
Maitra et al., 2001, De Oliveira et al., 2012). Microsatellite and polymorphic marker mapping 
of chromosome 3p within these breast tumour samples revealed allele loss of multiple regions 
of chromosome 3p including 3p24-26, 3p25, 3p22-24, 3p21.3, 3p13-14.2 and 3p12. However, 
some studies have reported that the 3p21-p22 region is the most frequent site of LOH in breast 
cancer (Maitra et al., 2001, Martinez et al., 2001). In addition, around 36% of pre-neoplastic 
breast lesions have been found to undergo LOH within 3p21.3, which suggests that loss of this 
region is a frequent and early event in breast cancer development.  
 The findings presented within my study so far provide evidence to show that the 
chromosome 3p candidate telomerase repressor genes SETD2 and FLJ may not function as 
transcriptional regulators of hTERT (Chapter 4). These candidate genes are therefore unlikely to 
be responsible for the telomerase repression observed within 21NT-chromosome 3 hybrids in 
the Cuthbert et al., (1999) study. A review of relevant literature identified a novel set of 
candidate telomerase repressor genes that (i) are located close to or within the 3p21.3-p22 
region, (ii) have been previously implicated in breast cancer and (iii) have been shown to play a 
functional role in the epigenetic regulation of target gene transcription through chromatin 
remodelling. As a result, four candidate genes BAP1, RASSF1A, PBRM1 and PARP-3 were 
selected to investigate their putative role in hTERT transcription regulation. 
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5.1.1 BAP1 
  The BRCA1 associated protein-1 (BAP1) is a nuclear-localized, ubiquitin hydrolase 
enzyme that was originally identified during a yeast two-hybrid screen for Breast/Ovarian 
Cancer Susceptibility Gene (BRCA1)-interacting proteins (Jensen et al., 1998). In humans, 
BAP1 is localized to the 3p21.1 region, approximately 52.4Mb from the telomere of 
chromosome 3 (National Centre for Biotechnology Information, NCBI). BAP1 encodes a 729 
amino acid protein, containing an amino-terminal ubiquitin carboxy-terminal hydrolase (UCH) 
domain, BRCA1, BRC1-associated RING domain 1 (BARD-1), host cell factor-1 (HCF-1) and 
Yin Yang 1 (YY1) protein binding domains and nuclear localization signals (Jensen et al., 1998, 
Machida et al., 2009, Yu et al., 2010, reviewed by Carbone et al., 2013). BAP1 is expressed 
ubiquitously within multiple adult human tissues including normal breast tissue, with higher 
transcript levels observed within the testis, ovaries and placenta (Jensen et al., 1998).  
 According to a recent review of the TGCA (The Cancer Genome Atlas Network) and 
MSKCC (Memorial Sloan Kettering Cancer Centre) large-scale whole-exome sequencing 
studies, 6-12% of clear cell renal cell carcinoma (ccRCC) patients have been found to harbour 
BAP1 mutations, which are associated with poor cancer-specific survival (Hakimi et al., 2013). 
In addition, mutations within the UCH domain of BAP1 have been identified within lung 
cancers (Jensen et al., 1998). It has recently been shown that around 70% of germline BAP1 
mutation carriers develop malignancies at an early age, with 25% of these developing two or 
more types of malignancy (Carbone et al., 2013). The most common malignancies associated 
with germline BAP1 mutations are uveal melanoma (UVM) and mesothelioma, which are 
thought to characterize a novel germline BAP1 mutation-associated cancer syndrome. However, 
the incidence of other cancer types such as renal, lung, ovarian and breast cancers have also 
been reported within germline mutation carriers, which indicates that BAP1 may play a crucial 
role in preventing tumorigenesis within multiple tissues. BAP1 is located within a common site 
of loss of heterozygosity (LOH) within mesotheliomas, metastasizing uveal melanomas, breast, 
lung and renal carcinomas (reviewed by Angeloni., 2007, Carbone et al., 2013). Chromosome 
3p losses have been observed within pre-neoplastic lesions of the breast and lung, indicating 
that loss of BAP1 and other tumour suppressor genes within this region at an early point may 
facilitate cancer development (Maitra et al., 2001, Hung et al., 1995). In support of this, 
Stephens et al., (2012) identified BAP1 mutations as likely drivers of breast tumorigenesis 
during a mutation screen of 21,416 protein-coding genes within 100 breast cancer samples. By 
reconstructing the karyotypic evolution of the HCC1187 triple-negative ductal-breast carcinoma 
cell line, Newman et al., (2013) also found that a mutation of BAP1 had likely occurred at an 
early point during its evolution. These findings demonstrate that loss of BAP1 function may 
occur at an early point during the development of multiple cancer types, indicating that this gene 
may function as a critical tumour suppressor. 
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 In 1998, Jensen et al., observed a significant reduction in the number of cell colonies 
that emerged following co-transfection of MCF7 breast cancer cells with BAP1 and BRCA1 
compared with the number of colonies that emerged following transfection of BRCA1 alone or 
empty vector controls. Interestingly, Xiong et al., (2003) demonstrated that overexpression of 
wild-type BRCA1 was associated with repression of telomerase activity and progressive 
telomere shortening within the DU-145 prostate and T47D and HCC1937 breast cancer cell 
lines. This was found to be due to repression of the hTERT promoter activity, which was 
dependent on the amino terminal of BRCA1. Despite observing no change in c-MYC expression 
levels, BRCA1 overexpression was found to repress hTERT transcription, in part, through 
inhibition of c-MYC transcriptional activity (Xiong et al., 2003). These findings, together with 
the known interaction between BAP1 and the amino terminal-RING finger domain of BRCA1 
(Jensen et al., 1998) and the location of BAP1 within a chromosome 3p region that has been 
implicated in telomerase regulation in breast cancer (Cuthbert et al., 1999), suggests that there 
may be a putative link between BAP1 and hTERT transcriptional regulation.  
 Jensen et al., (1998) found that transfection of BAP1 alone was also associated with  
growth suppression of MCF7 cells, which indicates that aside from enhancing BRCA1-mediated 
growth suppression, BAP1 may exert other BRCA1-independent tumour suppressor functions in 
breast cancer. In support of this, Ventii et al., (2008) observed a 60% reduction in the number of 
cell colonies that emerged following overexpression of BAP1 within the BRCA1-deficient 
HCC1937 breast cancer cell line. Lentivirus-mediated expression of BAP1 within the NCI-H226 
non-small cell lung cancer (NSCLC) cell line, known to harbour a BAP1 mutation, was found to 
suppress cell growth in vitro and caused a significant reduction in tumour growth rate and 
overall volume in nude mice compared to negative controls. The tumour suppressor function of 
BAP1 was found to be dependent on the presence of functional deubiquitinating UCH and 
nuclear localization signal (NLS) domains, as transfection of recombinant BAP1 cDNA 
harboring mutations in either region did not confer a significant reduction in the growth of NCI-
H226 cells in vitro or in vivo.  
 Independent studies have shown that BAP1 is a chromatin-bound protein that forms 
complexes with transcription factors that are known to regulate the expression of target genes 
through chromatin remodelling including host cell factor-1 (HCF-1), additional sex combs-like 
1 and 2 (ASX1 and ASX2), histone acetyltransferase 1 (HAT1) and the histone H3 lysine 4 
demethylase KDM1B (Machida et al., 2009, Yu et al., 2010). Sheuermann et al., (2010) 
confirmed that BAP1 interacts with ASLX1 in human cells to form the Polycomb repressive 
deubiquitinase (PR-DUB) complex, which functions to deubiquitinate histone H2A. The 
Drosophila PR-DUB complex was found to exhibit the same function and was shown to bind to 
polycomb group response elements (PRE) within target polycomb group (PcG) gene promoters. 
Inactivation of the BAP1 orthologue calypso caused de-repression of PcG target HOX genes in 
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Drosophila, indicating that the de-ubiquitinating activity of PR-DUB is essential for mediating 
repression of target gene expression (Scheuermann et al., 2010). It is therefore possible that 
BAP1 may play an important role in repressing the expression of target genes in human cells 
through chromatin remodelling. 
 The HCF-1 binding motif (HBM) of BAP1 was found to bind to and de-ubiquitinate 
lysine residues within the Kelch domain of HCF-1 (Machida et al., 2009). Over-expression of 
the C91S BAP1 mutant, deficient in ubiquitin hydrolase activity, within MCF-10A and 
MCF12A breast epithelial cell lines was found to inhibit cell growth, whereas wild-type BAP1 
overexpression did not. This was thought to be due to the sequestration of BAP1-binding sites 
from endogenous wild-type BAP1 by the C91S mutant. Interestingly, transfection of C91S 
mutants containing a mutated HBM domain were not able to suppress MCF-10A cell growth, 
which indicates that the ability of BAP1 to bind to and de-ubiquitinate HCF-1 is essential for 
cell growth regulation in breast epithelial cells. HCF-1 has been found to interact with a variety 
of transcription factors such as E2F and Sp1 (Gunther et al., 2000, Knez et al., 2006) and 
chromatin remodelling enzymes including histone acetyltransferase (HAT) and 
methyltransferase (HMT) enzymes (Tyagi et al., 2007, Wysocka et al., 2003). It is thought that 
HCF-1 functions to activate or represses the expression of a wide variety of target genes 
involved in cell cycle progression by coordinating the recruitment of appropriate chromatin-
modifying complexes to gene promoters (Wysocka et al., 2003). RNA interference-mediated 
depletion of BAP1 within the U2OS osteosarcoma cell line was associated with an increase and 
decrease in the expression levels of genes involved in cell cycle control, DNA replication and 
repair, metabolism and survival, indicating that BAP1 may possess both activating and 
repressing functions (Yu et al., 2010). Of particular interest, several E2F target genes were also 
found to be deregulated as a result of BAP1 knockdown. It was recently shown that BAP1 
directly interacts with E2F-1 and E2F-4 transcription factors and it has been proposed that 
BAP1 may function to regulate E2F target gene expression through interaction with HCF-1 and 
E2F (Eletr and Wilkinson., 2012). Ectopic expression of the E2F-1 transcription factor has been 
found to repress the transcription of hTERT within HeLa and U2OS cancer cell lines through 
direct binding to Sp1 sites within the hTERT promoter (Won et al., 2002).  
 Based on the increased incidence of malignancy within germline BAP1 mutation 
carriers together with the observed growth suppression of breast and lung cancer cells upon 
overexpression of wild-type BAP1 in vitro, there is strong evidence to suggest that BAP1 plays a 
critical role in preventing tumorigenesis (Jensen et al., 1998, Ventii et al., 2008, reviewed by 
Carbone et al., 2013). BAP1 has been found to interact with multiple proteins that regulate the 
transcription of target genes through chromatin remodelling (Machida et al., 2009, Yu et al., 
2010). It is thought that BAP1 influences a wide range of cellular processes including cell cycle 
regulation, DNA damage repair and survival (Yu et al., 2010). The ubiquitin carboxy-terminal 
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hydrolase (UCH) domain and nuclear localization signals (NLS) have been found to be essential 
for mediating the tumour suppressive function of BAP1 (Ventii et al., 2008), however the 
precise mechanism by which BAP1 functions to suppress cancer cell growth is unknown. 
Taking into account the observed interaction between BAP1 and a known regulator of hTERT, 
together with the role of BAP1 as a transcriptional regulator and its location within a common 
region of loss associated with telomerase regulation (Cuthbert et al., 1999), an aim of this study 
was to explore a functional link between BAP1 and hTERT regulation in breast cancer cells. 
 
5.1.2 RASSF1A 
 Ras association domain family 1 (RASSF1) is a member of a Ras-association domain 
containing family of proteins, which have been shown to mediate cancer cell growth 
suppression through induction of pro-apoptotic signalling pathways (reviewed by Donninger et 
al., 2007).  The RASSF1 gene was originally identified by Damman et al., (2000) and is located 
within a common 120kb homozygous region of deletion within chromosome 3p21.3 in lung and 
breast cancer cells (Sekido et al., 1998). According to current records, the RASSF1 genomic 
locus encodes ten transcript variants, five of which are protein coding (Ensembl, Flicek et al., 
2014), which are produced by alternative splicing and promoter usage (Damman et al., 2000, 
Burbee et al., 2001). The RASSF1A transcript isoform is 1.8kbp in length and encodes a 340 
amino acid protein containing an N-terminal diacylglycerol (DAG) binding domain, a C-
terminal Ras-association domain and Sav/RASSf/Hpo (SARAH) protein interacting domain 
(Damman et al., 2000, Burbee et al., 2001, Donninger et al., 2007).  
 RASSF1A transcripts have been detected within a variety of normal human tissues and 
nonmalignant epithelial cell cultures, but are undetectable within 100% of SCLC cell lines, 65% 
of NSCLC cell lines, 62-65% of breast cancer cell lines and 49% of primary breast tumours 
(Damman et al.,  2000, Damman et al., 2001, Burbee et al., 2001). Loss of RASSF1A expression 
within these cancer types was found to be associated with CpG island hypermethylation within 
the RASSF1A promoter region. Subsequent studies showed that the RASSF1A promoter is 
frequently hypermethylated in over 30 different cancer types including ccRCC, hepatocellular, 
cervical, head and neck and testicular (reviewed by Agathanggelou et al., 2005 and Donninger 
et al 2007). Pan et al., (2005) found that 74% of tissue samples derived from primary 
nasopharyngeal carcinomas (NPC) harbored one or more RASSF1A mutations, the majority of 
which were missense. The same proportion of samples also showed complete RASSF1A 
promoter methylation, indicating that mechanisms of RASSF1A inactivation in human cancer 
involve copy number loss, epigenetic silencing and mutation. It is thought that RASSF1A is one 
of the most frequently inactivated genes in cancer, which demonstrates its importance as a 
tumour suppressor gene (Agathanggelou et al., 2005, Donninger et al., 2007). Independent 
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studies have shown that RASSF1A promoter hypermethylation in breast cancer patient tumour 
samples is associated with more progressive disease and poor disease-free survival, indicating 
that loss of RASSF1A may be a useful prognostic marker for breast cancer patients (Muller et 
al., 2003, Martins et al., 2011, Hagrass et al., 2013, Xu et al., 2012). 
  Loss of RASSF1A is thought to occur as an early event during breast tumorigenesis 
(Strunnikova et al., 2005, Dumont et al., 2009). Silencing of RASSF1A transcription was found 
to occur within proliferating human mammary epithelial cells (HMEC) with increasing passages 
due to elevated histone H3 deacetylation and lysine 9 trimethylation. HMECs that had 
overcome the stress-induced senescence barrier by silencing of p16
INK4A
, were then found to 
undergo DNA methylation at the RASSF1A promoter (Strunnikova et al., 2005). Similarly, 
variant HMEC cell strains (vHMEC), which are derived from a rare subpopulation of pre-
malignant and p16
INK4A
-silenced cells obtained from disease-free women, transduced with the 
Ha-RasV12 oncogene were found to exhibit characteristic features of malignancy including 
chromosomal instability, anchorage independent growth and increased levels of telomerase 
activity and RASSF1A promoter methylation (Dumont et al., 2009). However, these cells were 
not found to form tumours upon injection into mammary glands of immunocompromised mice, 
and were therefore considered to be non-tumorigenic. Increased levels of RASSF1A promoter 
methylation were also observed within other immortal, non-tumorigenic breast cancer cell lines 
and pre-malignant breast lesions (Dumont et al., 2009). These findings indicate that DNA 
methylation of the RASSF1A promoter region occurs at an early point during breast cancer 
development and coincides with telomerase re-activation and cellular immortalization; an 
essential pre-requisite for clonal evolution and malignant transformation (Newbold et al., 1982, 
Counter et al., 1998).      
 Forced overexpression of RASSF1A in nasopharyngeal, NSCLC, lung, prostate, renal 
and breast carcinoma cell lines is associated with a substantial reduction in clonogenic survival, 
malignant potential and tumorigenicity in vitro and in vivo, which demonstrates that RASSF1A 
is an important tumour suppressor gene in multiple cancer types (Damman et al., 2000, Burbee 
et al., 2001, Chow et al., 2004, Dreijerink et al., 2001, Kuzmin et al., 2002, Thaler et al., 2012). 
This is supported by the observation that Rassf1a knockout mice have been found to exhibit an 
increased propensity for spontaneous tumour development within the lungs, gastrointestinal 
tract, breast and immune system compared to heterozygous or wild-type mice (Tommasi et al., 
2005, van der Weyden et al., 2005).  
 RASSF1A has been shown to play a functional role in maintaining genomic stability 
through interacting with and stabilizing microtubules to facilitate spindle assembly and 
chromosome attachment during mitosis (Liu et al., 2003, Vos et al., 2004, Song et al., 2005, 
Donninger et al., 2007). rassf1a knockout mouse embryonic fibroblasts treated with the tubulin-
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depolymerizing agent nocodazole were found to lose microtubule structure, whereas treated 
mouse fibroblasts overexpressing rassf1a exhibited largely intact microtubule structures (Liu et 
al., 2003). The Ras-association domain of RASSF1A was found to be essential for mediating 
this effect. However, van der Weyden et al., (2005) demonstrated that rassf1a knockout mouse 
fibroblasts did not exhibit significant changes in cell cycle control or genomic stability 
compared to wild-type cells, but were instead found to be defective in pro-apoptotic signalling 
pathways (Baksh et al., 2005). Overexpression of RASSF1A within the MCF-7 breast cancer 
cell line was found to induce apoptosis, whereas knockdown of RASSF1A within the U2OS 
osteosarcoma cell line was found to inhibit death receptor induced apoptosis (Baksh et al., 
2005). Both Baksh et al., (2005) and Foley et al., (2008) showed that recruitment of RASSF1A 
and MOAP-1 (also known as MAP-1) to death receptors and subsequent activation of Bax, was 
essential for mediating death receptor-induced apoptosis.  
 Aside from playing a functional role in microtubule stabilization and pro-apoptotic 
signalling pathways, RASSF1A has also been found to modulate cell cycle progression 
(Shivakumar et al., 2002, Fenton et al., 2004, Thaler et al., 2009). RASSF1A has been found to 
interact with p120
E4F
; a transcription factor that mediates cell cycle inhibition through 
interaction with pRb, transcriptional repression of cyclin A and stabilization of cyclin-
dependent kinase inhibitors (CDKI) p21
Cip1/Waf1 
and p27
kip1
 (Fenton et al., 2004, Fajas et al., 
2000, Fajas et al., 2001, Fernandes et al., 1998). Shivakumar et al., (2002) found that 
RASSF1A-mediated growth inhibition of H1299 NSCLC cells in G1-phase of the cell cycle was 
associated with the inhibition of cyclin D1 protein accumulation and activation of pRb. 
Similarly, doxycycline-inducible RASSF1A expression within the A549 lung carcinoma cell line 
was associated with cell growth inhibition in G1 phase and cellular senescence, which was 
found to be due to p53-independent activation of the cyclin-dependent kinase inhibitor p21 
(Thaler et al., 2009). Both studies showed that expression of the human papillomavirus (HPV) 
E7 oncoprotein within H1299 and A549 lung cancer cell lines expressing exogenous RASSF1A, 
inhibited RASSF1A-mediated cell cycle arrest. The E7 viral oncoprotein is known to disrupt the 
interaction between pRb pocket proteins and E2F transcription factors, and has also been found 
to disrupt p53-mediated repression of hTERT by p21
 
(Farthing and Vousden., 1994, Shats et al., 
2004). Interestingly, overexpression of RASSF1A within MCF-7 breast cancer cells was 
associated with upregulation of p21
Cip1/Waf1 
and induction of senescence pathways.  
 p21 is part of the Cip/Kip family of cyclin dependent kinase (Cdk) inhibitors and targets 
cyclin E-Cdk2, cyclin D1-Cdk4 and cyclin D-Cdk6 complexes to regulate cell cycle progression 
through the G1 phase (reviewed by Shay and Roberts., 1995). Similar to the effect of RASSF1A 
overexpression on cell cycle inhibition within lung cancer cell lines (Shivakumar et al., 2002, 
Thaler et al., 2009), Niculescu et al., (1998) found that induction of p21
 
expression is associated 
with increased levels of active hypophosphorylated pRb protein levels and cell cycle arrest in 
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G1 phase. Hypophosphorylated pRb and associated pocket proteins p107 and p130, are known 
to mediate cell cycle inhibition through interaction with E2F transcription factors and repression 
of E2F-target gene expression (reviewed by Weinberg 1995, Hurford et al., 1997). Lai et al., 
(2001) found that pRb pocket protein-mediated transcriptional repression of E2F-target genes 
involves recruitment of histone deacetylases (HDAC) to mediate chromatin remodelling at gene 
promoters. Interestingly, interaction of E2F with pRb pocket proteins and recruitment of HDAC 
enzymes was found to be essential for p53-mediated transcriptional repression of hTERT 
expression through p21 in breast cancer cells (Shats et al., 2004). In further support of this, Won 
et al., (2004) found that the dynamic assembly and disassembly of E2F-pRb pocket protein-
HDAC complex members at the hTERT promoter during different phases of the cell cycle 
within normal human fibroblasts, is associated with changes in hTERT expression levels. Loss 
of E2F-pRb pocket protein-HDAC complex binding and hTERT de-repression was observed 
during S-phase of the cell cycle within IMR90 normal human fibroblasts. This is consistent with 
findings presented by Masutomi et al., (2003), demonstrating that hTERT expression levels and 
telomerase activity are elevated during S-phase of the cell cycle within normal human BJ, WI-
38 and TIF-3 fibroblasts. Disruption of pRb-pocket protein complex members by forced 
expression of the E7 viral oncoprotein led to de-repression of hTERT and telomerase activity 
(Won et al., 2004). These findings provide evidence of a functional link between cell cycle and 
hTERT regulation in normal human somatic cells through direct binding of E2F-pRb pocket 
proteins and recruitment of HDAC enzymes to the hTERT promoter.  
 Shivakumar et al., 2002 and Thaler et al., (2009) demonstrated that RASSF1A mediates 
cell cycle arrest and senescence of lung cancer cell lines through activation of pRb-dependent 
pathways. Taking into account what is currently known about pRb-mediated hTERT 
transcriptional regulation within normal human somatic cells, together with the relative timing 
of RASSF1A promoter methylation and telomerase re-activation during the early stages of breast 
tumorigenesis, the putative role of RASSF1A in hTERT transcriptional regulation within breast 
cancer cells was investigated within this study. It is important to note that overexpression of 
RASSF1A within the RCC23 renal cell carcinoma cell line was not found to be associated with 
repression of hTERT promoter activity (Tanaka et al., 2005). Similarly to MMCT-mediated 
introduction of normal human chromosome 3 into the 21NT cell line by Cuthbert et al (1999), 
activation of cellular senescence pathways and growth arrest of RCC23-chromosome 3 hybrids 
was associated with hTERT transcriptional repression and loss of telomerase activity (Ohmura 
et al., 1998). However, whole cell fusion of 21NT and RCC23 cells was found to produce 
telomerase-repressed hybrids, suggesting that distinct chromosome 3-encoded telomerase 
repressor genes may function to inhibit hTERT expression within breast and renal cancer cells 
(Tanaka et al., 2005). Therefore, these findings do not exclude the possibility that RASSF1A 
may function as a repressor of hTERT in breast cancer cells.    
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5.1.3 PBRM1/BAF180 
 The polybromo-1 (Pb1/PBRM1) gene, also known as BRG1-Associated Factor (BAF) 
180, is located within chromosome 3p21 and encodes a 1689 amino acid protein sequence 
containing six bromodomains (BD), two protein-protein interaction bromoadjacent homology 
domains (BAH) and a DNA-binding high mobility group (HMG) domain (Horikawa and 
Barrett, 2002). PBRM1 was originally identified during a screen of BRG1-associated protein 
factors within a variety of mammalian cell lines and forms part of the SWI/SNF (switch/sucrose 
non-fermentable) chromatin remodelling complex B, also known as PBAF (Wang et al., 1996). 
Mammalian SWI/SNF complexes contain either BRM or BRG1 ATPase enzymes together with 
around 8-10 BAF protein subunits, which function to actively reposition nucleosomes to 
regulate target gene expression, chromosome organization, DNA repair, replication and 
recombination (Wang et al., 1996, Reisman et al., 2009, Euskirchen et al., 2011). The presence 
of PBRM1 and BAF200 within the BRG1-containing PBAF complex distinguishes it from 
BRM-BAF and BRG1-BAF complexes which contain BAF250A (ARID1A) or BAF250B 
(ARID1B) (Nie et al., 2000, Lemon et al., 2001).  
 Protein bromodomains (BD) typically bind acetyl-lysine residues within histone tails 
and have been identified within yeast chromatin remodelling complexes (Horn and Peterson, 
2001). The six BDs of PBRM1 are thought to be responsible for targeting the PBAF complex to 
specific acetylated histone lysine residues to facilitate chromatin remodelling. However, studies 
have reported conflicting results for the specific histone acetyl-lysine binding sites of individual 
PBRM1-BDs (Chandrasekaran and Thompson, 2007, Charlop-Powers et al., 2010, reviewed by 
Brownlee et al., 2012). Using fluorescence anisotropy, Chandrasekaran and Thompson (2007) 
demonstrated that PBRM1-BDs bind preferentially to histone H3 lysine residues including 
H3K4Ac, H3K23Ac, H3K9Ac and H3K14Ac. In contrast, Charlop-Powers et al., (2010) found 
that each BD of PBRM1 bound to a different set of histone-acetyl lysine residues on histones 
H2, H3 and H4 including H3K36Ac, H2BK115Ac, H3K115Ac, H4K12Ac. These conflicting 
findings may be due to differences in the experimental methods employed, therefore the precise 
acetyl-lysine residues targeted by PBRM1-BDs remain unclear (Brownlee et al., 2012).  
 The yeast RSC (Remodels the Structure of Chromatin) complex is homologous to the 
human PBAF complex and has been found to play an essential role in mediating cell cycle 
progression during mitosis (Cao et al., 1997, Xue et al., 2000). Human PBAF has been found to 
be associated with chromosome kinetochores and spindle poles during prometaphase of the cell 
cycle, which suggests that PBAF may also be required for cell cycle progression (Xue et al., 
2000). PBRM1 has been found to interact with actin filaments and is therefore thought to be 
responsible for mediating actin-dependent chromosome positioning within the nucleus 
(Bettinger et al., 2004, reviewed by Thompson, 2009). Unlike other SWI/SNF complexes, the 
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PBAF complex has also been found to be required for ligand-dependent transcriptional 
activation by nuclear hormone-receptors, Sp1 and SREBP-1a, which demonstrates that the 
chromatin remodelling PBAF complex exhibits distinct functional roles in transcriptional 
regulation of specific target genes (Lemon et al., 2001).  
 Recent reviews of large-scale exome sequencing studies have found that SWI/SNF 
complex members are mutated in a high frequency (19%) of all human malignancies including 
ovarian (75%), hepatocellular (33-40%), gastric (32-36%), head and neck (11%) and breast 
cancer (9-11%) (Kadoch et al., 2013, Shain and Pollack, 2013). These studies have shown that 
the SWI/SNF complex is the most commonly mutated chromatin remodelling complex in 
human cancer and have found that individual protein subunits appear to be mutated more 
frequently in certain cancer types. This suggests that SWI/SNF complexes may exert tissue-
specific tumour suppressor functions. According to current COSMIC database records, PBRM1 
mutations have been detected within over sixteen different human tumour types and cancer cell 
lines, including kidney, biliary tract, breast and oesophageal, (www.cancer.sanger.ac.uk, Forbes 
et al., 2014). Exome sequencing of 257 renal cell carcinoma (RCC) tumour samples revealed 
that PBRM1 is the second most commonly mutated gene in RCC, with 41% of ccRCC samples 
harboring truncating mutations of PBRM1 (Varela et al., 2011). Consistent with these findings, 
around 70% of ccRCC tissue samples have been found to exhibit undetectable levels of PBRM1 
expression, which demonstrates that other mechanisms of functional inactivation may be 
present within cancer cells (Pawlowski et al., 2012). The same study also demonstrated a 
significant correlation between loss of PBRM1 expression and advanced tumour stage and poor 
patient survival compared with PBRM1-positive ccRCC patients. These findings demonstrate 
that loss of PBRM1 may play an important role in RCC disease pathogenesis. Xia et al., (2008) 
identified four truncating mutations within the bromodomains (BD) of PBRM1 in multiple 
breast cancer cell lines. The presence of PBRM1 mutations was correlated with loss of wild-type 
PBRM1 expression. In addition 48.1% of breast tumour samples were found to have undergone 
LOH at the PBRM1 genomic locus, which demonstrates that PBRM1 may also function as an 
important tumour suppressor gene in breast cancer (Xia et al., 2008). LOH of discreet regions of 
chromosome 3p is a frequent event in renal, breast and lung cancers (Zarbarovsky et al., 2002, 
Senchenko et al., 2004). Interestingly, despite the identification of PBRM1 mutations within 
renal and breast cancer cell lines (Varela et al., 2011, Xia et al., 2008), Sekine et al., (2005) 
found that NSCLC and SCLC cell lines with chromosome 3p LOH, do not exhibit loss of 
PBRM1 mRNA or protein levels. These findings indicate that PBRM1 may function as a tissue-
specific tumour suppressor gene.   
 Forced overexpression of PBRM1 within the PBRM1-deficient HCC1143 breast cancer 
cell line was associated with a significant increase in the number of cells in G1 phase-cell cycle 
arrest compared with empty vector controls (Xia et al., 2008). This was found to be partly due 
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to activation of the cyclin-dependent kinase inhibitor p21. A dosage-dependent increase in p21 
expression levels was observed following overexpression of PBRM1 within p53-deficient 
HCC1143 and SUM1315 breast cancer cell lines, which indicates that PBRM1 mediates p53-
independent induction of p21 expression. Endogenous PBRM1 was found to bind directly to the 
p21 promoter within MDA-MB-468 breast cancer cells, which express wild-type PBRM1 
mRNA. The same study also found that knockdown of PBRM1 within normal human breast 
epithelial MCF-10A cells treated with γ-irradiation or transforming growth factor β (TGF-β) 
abrogated induction of p21 expression and cell cycle arrest in G1 phase. p53-mediated 
transcriptional activation of p21 is essential for sustained cell growth arrest following γ-
irradiation-induced DNA damage (Bunz et al., 1998). On the other hand, members of the 
SMAD family of transcription factors have been found to be essential for TGF-β-mediated 
induction of p21 expression and cell growth arrest, independently of p53 (Datto et al., 1995, 
Pardali et al., 2000). Therefore, the findings presented by Xia et al.,(2008) demonstrate that 
PBRM1 may function as a critical tumour suppressor gene in normal mammary epithelial cells 
by mediating p21 transcriptional activation and cell cycle arrest in response to DNA damage 
and extracellular growth factor-induced signalling pathways. 
 Inactivation of p21 within normal human fibroblasts has been associated with an 
increase cellular lifespan and bypass of cellular replicative senescence pathways (Brown et al., 
1997). p21-deficient normal human fibroblasts were found to undergo continued telomere 
erosion until cells entered crisis, which demonstrates that p21 plays an important role in 
activating replicative senescence pathways in response to critical telomere shortening. 
Interestingly, knockdown of PBRM1 within normal human BJ fibroblasts has been associated 
with decreased basal and p53-induced levels of p21 expression, increased cellular proliferation 
and delayed induction of replicative senescence pathways (Burrows et al., 2010). Similarly, 
knockdown of another PBAF complex member BRD7 within normal human fibroblasts was 
also associated with decreased basal and p53-induced p21 expression levels, delayed replicative 
senescence and resistance to oncogene-induced senescence (OIS) pathways (Burrows et al., 
2010). These findings suggest that the PBAF complex may be involved in mediating cellular 
senescence pathways through transcriptional regulation of p21. In support of this, the histone 
acetyl-lysine binding bromodomain (BD) of BRD7 was found to be necessary for induction of 
p21 expression, which suggests that PBAF-mediated chromatin remodelling at the p21 promoter 
may be essential for transcriptional activation. Interestingly, gene expression profiling of normal 
human fibroblasts following knockdown of PBRM1 and treatment with the MDM2 inhibitor 
nutlin-3a showed that, in addition to p21, PBRM1 is involved in the transcriptional regulation of 
a specific subset of p53-target genes including MDM2 and DcR1 (Burrows et al., 2010). 
Together, the findings presented by Xia et al., (2008) and Burrows et al., (2010) demonstrate 
that PBRM1 mediates p53-dependent and independent activation of p21 expression in normal 
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human somatic cells and cancer cells and plays an important functional role in the induction of 
two critical tumour suppressor pathways; cell growth arrest and replicative senescence. 
However, knockdown of p21 within HCC1143 breast cancer cells overexpressing PBRM1 was 
only associated with a partial rescue of G1-phase cell cycle arrest (Xia et al., 2008). In addition, 
Burrows et al., (2010) demonstrated that aside from p21, PBRM1 regulates the transcription of 
multiple p53 target genes indicating that PBRM1 may exhibit other critical tumour suppressor 
functions in human cells. 
 Recently,  PBRM1 has been found to play important roles in maintaining genomic 
stability in human cells through mediating centromeric sister chromatid cohesion, DNA 
damage-induced transcriptional repression and non-homologous end joining (NHEJ) repair of 
DNA breaks (Brownlee et al., 2014, Karkarougkas et al., 2014). Targeted inactivation of 
cohesin complex proteins involved in mediating sister-chromatid cohesion during the cell cycle, 
has been linked to chromosomal instability and aneuploidy, which is thought to lead to 
tumorigenesis (Remeseiro et al., 2012, Solomon et al., 2011). Stable sh-RNA-mediated 
depletion of PBRM1 within the U2OS osteosarcoma cell line was associated with a reduction in 
sister chromatid cohesion, increased chromosome miss-segregation, and defective 
recombination-based DNA damage repair (Brownlee et al., 2014). Transfection of two PBRM1 
cDNA constructs harboring ccRCC-associated mutations within bromodomains 2 or 4 (BD2-
T232 and BD4-M538) (Varela et al., 2011), were unable to rescue sister-chromatid cohesion 
defects within shRNA-PBRM1 U2OS cells. These findings demonstrate an important role for 
PBRM1 in maintaining genome stability and preventing tumorigenesis through cohesion-
dependent functions such as sister chromatid exchange during mitosis and DNA damage repair. 
In a later study, the same group also demonstrated that PBRM1 and PBAF complex-mediated 
transcriptional repression of actively transcribed genes flanking euchromatic DNA double 
strand breaks, is important for efficient repair (Karkarougkas et al., 2014). In addition, increased 
levels of γ-H2AX foci were observed at early time points following irradiation of PBRM1, 
BRG1 or PBAF-depleted U2OS cells compared with controls, which indicates that the PBAF 
chromatin remodelling complex functions to promote repair at an early point following DNA 
damage. Similarly to Brownlee et al., (2014), transfection of cancer-associated PBRM1 mutants 
T232 and M538 within PBRM1-deficient cells were unable to rescue transcriptional repression 
or DNA repair defects. Therefore, aside from mediating cohesion-dependent functions, PBRM1 
promotes genomic stability by facilitating the efficient repair of DNA double strand breaks.    
 PBRM1 has been implicated in multiple tumour suppressor pathways including cell 
cycle arrest, replicative senescence, DNA damage repair and genome stability, which 
demonstrates that PBRM1 plays an important role in preventing tumorigenesis. As discussed in 
Chapter 5.1.2, induction of p21 expression has been found to be an essential for p53-mediated 
transcriptional repression of hTERT in breast cancer cells by E2F-pRB pocket protein-HDAC 
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complexes (Shats et al., 2004). As demonstrated by Burrows et al., (2010), PBRM1 functions as 
an important mediator of replicative senescence pathways through p53-dependent activation of 
p21 expression. In addition, PBRM1 was found to be important for p21 transcriptional 
activation and cell cycle arrest of breast cancer cells in response to TGF-β‎treatment‎(Xia‎et al., 
2008). It is thought that PBRM1 may cooperate with SMAD family protein members to activate 
p21 expression and mediate TGF-β-induced cell cycle arrest. Interestingly, TGF-β‎ has‎ been‎
found to repress hTERT promoter activity and telomerase activity within breast cancer cells 
(Yang et al., 2001). TGF-β‎may‎mediate‎hTERT transcriptional repression in cis through direct 
binding of SMAD3 to the hTERT promoter or in trans by SMAD3-mediated repression of the 
hTERT transcriptional activator c-Myc (Li et al., 2006). Taking these findings into account, the 
functional role of PBRM1 in hTERT expression regulation was investigated within this study.
  
5.1.4 PARP-3 
 Human PARP-3 belongs to a family of 17 poly(ADP-ribose) polymerase enzymes, 
which function to synthesize ADP-ribose polymers from Nicotinamide adenine dinucleotide 
(NAD) (reviewed by Aredia and Scovassi., 2014). PARP enzymes mediate the transfer ADP-
ribose polymers to specific amino acid residues of nuclear proteins to facilitate the assembly of 
functional protein complexes that regulate apoptosis, DNA replication, repair and gene 
transcription. PARP-3 (ARTD3) was originally discovered by Johnsson et al., (1999) during a 
search of the expressed sequence tag (EST) library for PARP-1 sequence-related proteins in 
humans. PARP-3 is located on chromosome 3p21.2 and encodes two major transcript isoforms, 
one of which contains an additional seven amino acids at the N-terminal (Augustin et al., 2003, 
Rouleau et al., 2007). Transcript variants 1 (PARP-3short) and 2 (PARP-3long) encode 60.1kDa 
and 61kDa proteins respectively and belong to the DNA-dependent sub-family of PARP 
enzymes, which catalyze mono(ADP-ribosyl)ation of target proteins (Rouleau et al., 2007, 
Gibson and Kraus., 2012). Structurally, PARP-3 proteins contain an N-terminal conserved 
WGR nucleic acid binding domain and a C-terminal mono(ADP-ribose) polymerase catalytic 
domain (Johansson., 1999, Augustin et al., 2003, Lehtiö et al., 2009).  
 Green-fluorescent protein-tagged PARP-3 expression within the human HeLa and 
SV40-transformed African green monkey COS-7 kidney cells, revealed that both PARP-3 
isoforms localize predominantly to the nucleus (Rouleau et al., 2007).  The same study also 
found that PARP-3 specifically interacts with components of the Polycomb group (group) 
complex including EZH2, Suz12, YY1, HDAC1 and HDAC2 and co-localize with many of 
these proteins at PcG bodies in vitro. This suggests that PARP-3 may be involved in 
transcriptional regulation of target genes through chromatin remodelling. Mass spectrometry 
analysis of co-immunoprecipitated proteins revealed that PARP-3 also interacts with multiple 
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components of DNA-damage repair pathways such as DNA-dependent protein kinase (DNA-
PKcs), Ku70, Ku80, PARP-1 and DNA ligases (Rouleau et al., 2007). The two major pathways 
that are involved in DNA DSB repair are homologous recombination (HR) and NHEJ (reviewed 
by Chapman et al., 2012). The DNA PKcs/Ku70/Ku80 complex interacts with DNA ligase IV 
to mediate DNA double strand break repair through non-homologous end-joining (NHEJ) 
pathways (Spagnolo et al., 2006). The Ku70-Ku80 heterodimer has been found to inhibit 5'-
DNA end resection and promote activation of the NHEJ repair pathway. Recently, Beck et al., 
(2014) demonstrated PARP-3 depletion was associated with a lack of Ku80 recruitment to sites 
of DSB and increased DNA end resection, which demonstrates that PARP-3 plays in important 
role in activating NHEJ-mediated DSB repair. Consistent with these findings, Boehler et al., 
(2010) demonstrated that PARP-3 accumulates at micro-irradiation-induced DNA damage sites 
within mammalian cells. ShRNA-mediated depletion of PARP-3 within normal human fetal 
lung MRC-5 fibroblast cells was not only associated with a higher frequency of spontaneous 
DNA strand breaks but also a significant delay in γ-H2AX foci clearance following X-
irradiation treatment compared to non-targeting controls (Boehler et al., 2010).  In the same 
year Rulten et al., (2010) found that PARP-3 is responsible for targeting the aprataxin and 
PNKP like factor (APLF) to sites of DNA breaks through histone H1 ribosylation, which 
facilitates DNA ligation during NHEJ.  
 Aside from playing an important functional role in mediating DNA damage repair, 
PARP-3 has also been implicated in regulating cell cycle progression (Augustin et al., 2003, 
Boehler et al., 2010). Overexpression of PARP-3 within HeLa cells was associated with an 
increase in the proportion of cells arrested in G1/S phase following treatment with DNA-
damage inducing agents, compared with empty vector controls which were arrested in G2/M 
(Augustin et al., 2003). PARP-3 has been found to associate with centrosomes and interact with 
the Nuclear Mitotic Apparatus (NuMA) protein and Tankyrase 1, which are involved in 
regulating microtubule dynamics during mitosis (Augustin et al., 2003, Boehlin et al., 2010, 
Radulescu and Cleveland., 2010). Knockdown of PARP-3 within normal lung MRC-5 
fibroblasts was associated with cell cycle arrest in metaphase and defects in spindle assembly, 
characterized by splayed microtubules and the presence of aberrant mitotic figures (Boehlin et 
al., 2010). In the presence of DNA, PARP-3 was found to cause direct ADP-ribosylation and 
stimulate Tankyrase 1-mediated ADP-ribosylation of NuMA. Therefore, it is thought that 
PARP-3 plays a functional role in cell cycle progression through mediating correct microtubule 
assembly during mitosis. 
 Interestingly, knockdown of PARP-3 within normal human lung fibroblasts has also 
been associated with increased sister telomere fusions and loss, demonstrating that PARP-3 may 
also function to maintain telomere stability (Boehlin et al., 2010). In 2007, Frias et al., 
investigated the relationship between telomerase activity and the expression levels of genes 
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involved in DNA damage repair pathways in non-small cell lung cancer (NSCLC) and found 
that tumour samples exhibiting high levels of telomerase activity also displayed significantly 
reduced levels of PARP-3 mRNA. Recently, transient overexpression of PARP-3 within the 
A549 lung adenocarcinoma cell line was associated with a significant reduction in telomerase 
activity 48 and 96 hours following transfection compared with empty vector controls. 
Moreover, shRNA-mediated depletion of PARP-3 within the human Saos-2 osteosarcoma cell 
line to around 40% of controls, was associated with a greater than two-fold increase in 
telomerase activity levels. This provides evidence to show that PARP-3 may function as a 
telomerase repressor gene in cancer. Taking these findings into account, together with the 
observation that PARP-3 resides within a common region associated with telomerase regulation 
in breast cancer (Cuthbert et al., 1999), the putative role of PARP-3 in telomerase regulation 
within breast cancer cells was investigated within this study. 
 
5.2 MATERIALS AND METHODS 
5.2.1 GENE COPY NUMBER VARIATION ANALYSIS (CNV) 
 Nine breast cancer cell lines, 21NT, 21MT, MCF-7, H5S78T, HCC1143, BT474, BT20, 
MTSV and GI101, were cultured under normal growth conditions (Chapter 2.1.2.1) until 
subconfluent before they were harvested, pelleted and stored at -80
o
C. Normal pre-stasis HMEC 
strains 184 and 240L and the post-stasis HMEC LONZA cell strain were cultured under normal 
growth conditions by my colleague Dr. H. Yasaei and were provided to me upon request as cell 
pellets derived from cells growing in log-phase. Genomic DNA (gDNA) was extracted from 
cell lines and HMEC cell strains as outlined in Chapter 2.2. Sample DNA extracts were diluted 
to 5ng/µl using nuclease-free water. Gene copy number variation (CNV) analysis of BAP1, 
PARP-3 and PBRM1 within breast cancer cell lines and normal HMEC strains was carried out 
as described in Chapter 2.5. Details of pre-designed CNV primer sets (ABI, US) for each gene 
are provided in Chapter 2.5, Table 2.6. The normal HMEC 184 cell strain was used to calibrate 
gene copy number within all samples. 
5.2.2 GENE EXPRESSION ANALYSIS 
 All breast cancer cell lines, normal HMEC strains and stable 21NT transfection clones 
were subjected to the same procedure of RNA extraction, DNAse I treatment and cDNA 
synthesis as described in Chapter 2.3. Using the appropriate primer sequences and thermal 
cycling parameters described in Table 2.3 and Table 2.4 (Chapter 2.3.4), BAP1, PBRM1, 
RASSF1A, PARP-3 and hTERT expression levels were examined using the same methods 
outlined in Chapter 2.3.4. As demonstrated in Chapter 4.2.1.1, GeNorm
™
 (Primer Design) 
analysis of normal HMEC strains and breast cancer cell lines demonstrated that the most 
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suitable endogenous control genes for examining target gene expression levels within this 
sample set were YWHAZ and TOP1. Therefore, target gene expression levels within normal 
HMEC strains and breast cancer cell lines, were normalized to YWHAZ and TOP1 expression. 
Target gene and hTERT expression levels within 21NT transfection clones were normalized to 
the GAPDH endogenous control. The qbase
PLUS
 (Biogazelle) data analysis software program 
was used to calculate normalized relative quantities (NRQ) of target gene mRNA for all samples 
as described in Chapter 2.3.5.  
5.2.3 TRANSFECTION OF TARGET GENES INTO THE 21NT BREAST CANCER CELL 
LINE 
 Overexpression of target genes BAP1, RASSF1A and PBRM1 within the 21NT breast 
cancer cell line was achieved by transfection of mammalian expression vector constructs 
containing target gene cDNA clones and associated empty vector controls (Table 5.1). 
Table 5.1 - Details of mammalian expression vectors used to overexpress BAP1, RASSF1A and 
PBRM1 within 21NT breast cancer cells 
Target gene 
Plasmid 
Vectors 
Accession 
Number 
Vector 
Size 
(bp) 
Source 
Selectable 
Marker 
BAP1 
Control pCMV6Neo - 5838 
OriGene, 
PCMV6NEO 
Neomycin 
Target 
pCMV6AC-
BAP1 
NM_004656 8442 
OriGene, 
SC320669 
RASSF1A 
Control 
pcDNA3.1/V5-
His-TOPO/LacZ 
- 8592 Invitrogen, US 
Neomycin 
Target 
pcDNA3.1(+)-
RASSF1A 
NM_007182.4 7273 
Professor 
Reinhard 
Damman
1
, 
(Damman et al., 
2000) 
PBRM1 
Control pBABE-puro - 5169 
Morgenstern and 
Land
2
., 1990, 
Addgene #: 1764 
Puromycin 
Target 
pBABE-puro-
BAF180 
NM_018313.4 10,130 
Professor Ramon 
Parsons
3
, Xia et 
al., (2008), 
Addgene #: 41078 
1
Intitute of Genetics, Justus-Liebig University Giessen, Germany, 
2
London Research Institute, 
Lincoln's Inn Fields, London, UK, 
3
Institute for Cancer Genetics, Columbia University, New 
York, USA. 
 The pCMV6AC-BAP1 and pcDNA3.1(+)-RASSF1A (the latter was a kind gift from 
Professor Reinhard Damman, Justus-Liebig University) plasmid constructs were received in the 
form of dried DNA samples, which were reconstituted in nuclease-free water (Ambion, Thermo 
Fisher Scientific, US) and transformed into OneShot
®
 TOP10 Chemically Competent E.coli 
(Invitrogen, US) as described in Chapter 2.6.1. The pCMV6Neo and pcDNA3.1/V5-His-
TOPO/LacZ empty vector plasmids were transformed into the same chemically-competent 
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E.coli cells by my colleague Dr. T. Roberts (Brunel University). These plasmids were provided 
to me upon request as frozen glycerol stock solutions (85% LB-Broth and 15% glycerol). The 
pBABE-puro and pBABE-puro-BAF180 plasmids were received as bacterial stabs of 
transformed E.coli. Using aseptic techniques, sterile pipette tips were used to recover the 
bacterial cells, which were then placed into Falcon tubes containing 5ml of pre-sterilized 2.5% 
LB-broth (high salt, Sigma, US) and 100µg/ml ampicillin. Bacterial cell suspensions were 
incubated overnight in an orbital shaker at 37
o
C and 200rpm. The following day, cultures were 
either stored at 4ºC for a maximum of five days or prepared for long-term storage. Glycerol 
stock solutions of all transformed E.coli cultures were created as described in Chapter 2.6.2. To 
obtain sufficient quantities of plasmid DNA for transfection purposes, bacterial cultures were 
propagated using the methods described in Chapter 2.6.3. Extraction and purification of plasmid 
DNA was achieved using the QIAfilter Midi Plasmid Purification Kit (Qiagen, NL) according 
to manufacturer's guidelines (Chapter 2.6.4).  
5.2.3.1 Restriction Digest of Target Gene Plasmid Vectors  
 In order to confirm the size of BAP1, RASSF1A and PBRM1/BAF180 target gene cDNA 
sequences within each of the plasmid vector constructs described in Table 5.1, plasmids were 
subject to restriction endonuclease digestion. For each target gene plasmid construct, restriction 
enzymes used to clone the cDNA into the vector backbone were used to release the cDNA insert 
sequence with reaction components described in Table 5.2. Restriction digest reaction mixtures 
were incubated at 37ºC for one hour before being transferred to wet-ice to inhibit enzyme 
activity. 250ng of plasmid DNA was added to wells of a 0.75% agarose gel made with 1X Tris-
Borate-EDTA buffer (Sigma-Aldrich, US) and 0.5µg/ml ethidium bromide (EtBr). To estimate 
the size of DNA fragments, the TrackIt
™
 1Kb Plus DNA Ladder (Invitrogen, US) was also 
loaded into a single well of each gel. After submerging in 1X TBE buffer, gels were run at 60-
70V for approximately 1 hour 30 minutes and resolved DNA fragments were visualized using 
an Alphaimager under UV light.  
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Table 5.2 - Restriction enzyme digest reaction conditions used to release target gene cDNA 
from plasmid vector backbones 
Plasmid Vector 
Cloning 
Sites (5'-
3') 
Vector 
Backbone 
(bp) 
cDNA Insert 
Sequence 
(bp) 
Restriction Digest Reaction 
Components* 
pCMV6AC-
BAP1 
EcoRI-
XhoI 
5802 2640 
1µg plasmid DNA, 1µl EcoRI-HF, 1µl 
XhoI-HF, 5µl NEB CutSmart
®
 Buffer, 
nuclease-free water. Total Volume: 
50µl 
pcDNA3.1(+)-
RASSF1A 
HindIII-
EcoRI 
5428 1845 
1µg plasmid DNA, 1µl HindIII-HF, 
1µl EcoRI-HF, 5µl NEB CutSmart
®
 
Buffer, nuclease-free water. Total 
volume: 50µl 
pBABE-puro-
BAF180
 
EcoRI-
EcoRI 
5169 4961 
1µg plasmid DNA, 1µl EcoRI-HF, 1µl 
NotI, 5µl NEBuffer EcoRI, nuclease-
free water. Total volume: 50µl 
* Restriction enzymes (20U/µl), NEB CutSmart
®
 Buffer (10X) and NEBuffer EcoRI (10X) were 
purchased from New England Biolabs (NEB).   
 As shown is Figure 5.1A and B, pCMV6AC-BAP1 and pcDNA3.1(+)-RASSF1A 
plasmid constructs were found to contain the expected target gene cDNA sequence lengths of 
2.6kbp and 1.8kbp respectively. The pBABE-puro plasmid and BAF180 cDNA sequence are 
very similar in size (Table 5.2). Therefore in order to distinguish DNA fragments following 
restriction digest of pBABE-puro-BAF180 with EcoRI (Figure 5.1Cii, Lane C), the NEBcutter 
software program (Posfai et al., 2005) was used to identify a different restriction enzyme that 
would cleave a single site within the vector backbone. As shown in Figure 5.1C, a single NotI 
restriction digest site was identified and used to confirm the BAF180 cDNA insert length of 
around 5kbp (Figure 5.1Cii, Lane D). 
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Figure 5.1 - Gel electrophoresis of DNA fragments following restriction digest of (A) 
pCMV6AC-BAP1 with XhoI and EcoRI, (B) pcDNA3.1(+)-RASSF1A with HindIII and EcoRI. 
(C) (i) Relative positions of NotI and EcoRI restriction sites determined using the NEBcutter 
software program and expected fragment lengths (Posfai et al., 2005). (ii) Gel electrophoresis 
of DNA fragments following digestion of pBABEpuro-BAF180 with EcoRI and NotI.  
5.2.3.2 Transfection of Plasmid Vector Constructs into the 21NT Cell Line 
 Overexpression of BAP1, RASSF1A and PBRM1(BAF180) within the 21NT breast 
cancer cell line was achieved by transfection of pCMV6AC-BAP1, pcDNA3.1(+)-RASSF1A, 
pBABE-puro-BAF180 and associated empty vector plasmids (Table 5.1) using the TransIT
®
-
BrCa Transfection Reagent (Mirus) as described in Chapter 2.7.1.  
5.2.3.3 Selection and Propagation of Stable Transfection Clones 
 In order to examine the long-term effect of forced BAP1, RASSF1A and PBRM1 target 
gene expression within the 21NT cell line, positive selection of 21NT clones that had undergone 
stable integration of target gene vector constructs was carried out. 48 hours post-transfection 
with target gene and empty vector control plasmids, P60 dishes of treated 21NT cells were 
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passaged at a ratio of 1:8 into four P100 dishes using methods described in Chapter 2.1.3. Cells 
were maintained in complete medium for two weeks supplemented with either 400µg/ml 
neomycin or 1µg/ml puromycin depending on the selectable marker present within the plasmid 
vector (Table 5.1). During this time, dishes were monitored regularly for the emergence of 
stable clones. At least five stable 21NT-target gene and five stable 21NT-empty vector control 
clones were isolated at random and propagated as individual cell lines as described in Chapter 
2.1.5. Once stable clones had reached sub-confluence on P35 dishes (passage 1), cells were 
harvested, counted (Chapter 2.1.6) and aliquots of 5x10
5
 cells were pelleted and immediately 
stored at -80ºC for downstream analysis of telomerase activity. The remaining cells were re-
plated on a P60 dish and were maintained in culture for cell growth analysis or propagated until 
three sub-confluent P100 dishes were obtained. At this point, one dish was harvested for 
cryopreservation (Chapter 2.1.4) and the remaining dishes were harvested, pelleted and stored at 
-80ºC for downstream analysis.  
5.2.3.4 Cell Growth Analysis 
 As described above, individual stable 21NT transfection clones that had reached sub-
confluence on P35 dishes (passage 1) were counted and an aliquot of 5x10
5
 cells were taken for 
downstream analysis of telomerase activity. The remaining cells were re-plated onto P60 dishes 
and were maintained in under normal growth conditions in the presence of appropriate selection 
antibiotics. At 70-90% confluence, cell number was ascertained (Chapter 2.1.6) and 5x10
5
 cells 
were re-established on P100 dishes containing complete culture media. This procedure of serial 
sub-cultivation was repeated a maximum number of five times before clones were 
cryopreserved (Chapter 2.1.4). Cell growth rate was assessed by calculating the total number of 
population doublings (PD) that had occurred between seeding 5x10
5
 cells and harvesting at 70-
90% confluence (Chapter 2.8.1). The same procedure was carried out for individual stable 
21NT-empty vector transfection clones and untreated 2NT cells.  
5.2.3.5 Colony Forming Unit (CFU) Assay  
 In order to determine the effect of stable BAP1, RASSF1A and PBRM1 expression on 
the clonogenic survival of 21NT cells, a colony forming unit (CFU) assay was carried out for 
each set of target genes and associated empty vector control plasmids (Table 5.1) as described in 
Chapter 2.7.3. 
5.2.3.6 Clone Size Estimation 
 To examine the effect of stable BAP1, RASSF1A and PBRM1 target gene expression on 
the growth rate of 21NT cells, the diameter of stable 21NT-target gene and associated 21NT-
empty vector control clones (Table 5.1) that emerged following two weeks of antibiotic 
selection was examined. Fixed and Methyl Blue-stained stable clones from the CFU assay were 
examined under a Zeiss Axioskop microscope (brightfield illumination). Photomicrographs of 
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10-18 individual 21NT-target gene and associated 21NT-empty vector control clones were 
taken at 2.5x magnification. As shown in Figure 5.2, a 10mm reticule was used to measure the 
diameter of each stable 21NT transfection clone. The clone diameter of all individual stable 
21NT-target gene and 21NT-empty vector control clones was recorded and the mean diameter 
(mm) ± SE of all stable clones for each transfected plasmid was calculated. A student's t-test 
was used to compare the mean clone diameter of each set of stable 21NT-target gene and 21NT-
empty vector control clones.   
 
Figure 5.2 - Estimation of stable clone diameter. Representative photomicrograph images at 
2.5x magnification of (A) 10mm reticule, (B) a single stable 21NT-pBABEpuro-PBRM1 clone 
fixed and stained with Methyl Blue. 
 
5.2.4 TELOMERASE ACTIVITY 
 To determine the effect of stable BAP1, RASSF1A and PBRM1 target gene 
overexpression on telomerase activity within 21NT cells, the level of telomerase activity was 
examined within stable 21NT-target gene and associated 21NT-empty vector control clones. 
Protein was extracted from aliquots of 2.5x10
5
 cells obtained from each stable clone at passage 
1 and quantified using the same methods described in Chapter 2.4.1. The Telomere Repeat 
Amplification Protocol (TRAP) assay was used to determine telomerase activity within all 
samples as described in Chapter 2.4.2. For each target gene examined, five stable 21NT-target 
gene clones and three stable 21NT-empty vector control clones were included in each assay. 
Telomerase activity was quantified as described in Chapter 2.4.3 and expressed as the mean ± 
SE of triplicate repeats for each sample relative to untreated wild-type 21NT controls.  
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5.3 RESULTS AND DISCUSSION 
5.3.1 CANDIDATE GENE COPY NUMBER VARIATION AND EXPRESSION ANALYSIS 
WITHIN NORMAL HMEC STRAINS AND BREAST CANCER CELL LINES 
 The initial aim of this study was to investigate a putative tumour suppressive function 
of the selected candidate genes BAP1, RASSF1A, PBRM1 and PARP-3 in breast cancer cells. To 
do this, candidate gene copy number variation (CNV) and expression levels were examined 
within the same panel of nine breast cancer cell lines and three HMEC strains employed within 
Chapter 4.3.1. Over half of breast cancer cell lines were found to have undergone allele loss 
within the SETD2-FLJ genomic locus. As shown in Figure 5.1, all four selected candidate genes 
are located within a 2.3Mb region within 3p21.1-21.3. Taking into account the high frequency 
of allele loss within the 3p21.3 region in breast cancer (Maitra et al., 2001, Martinez et al., 
2001), CNV analysis of selected candidate genes within breast cancer cell lines was carried out. 
According to the Database of Genomic Variants (DGV, MacDonald et al., 2013), copy number 
loss of RASSF1A has been observed within the genome of healthy individuals. The phenotypic 
consequence of this structural variation is unknown. However, according to the Database of 
Genomic Variation and Phenotype in Humans using Ensembl Resources (DECIPHER), 
loss/deletion of sequences involving the 3p21.31 region (including RASSF1) is associated with 
particular characteristics such as delayed speech and intellectual disability (Firth et al., 2009). 
Therefore, CNV analysis of the RASSF1A genomic locus within breast cancer cell lines could 
not be reliably determined within this study because matched normal tissue samples were not 
used to calibrate gene copy number alterations within breast cancer cell lines.    
 
Figure 5.3 - Graphical representation of the approximate positions of selected candidate genes 
RASSF1A, PARP-3, BAP1, PBRM1 within the 3p21.1-p21.3 region of human chromosome 3 
and their locations relative to the SETD2-FLJ genomic locus. Genomic coordinates of all 
candidate genes were obtained from the National Centre of Biotechnology Information (NCBI) 
database. 
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Table 5.3 - Candidate gene copy number (CN) variation analysis within normal HMEC strains 
and a panel of nine breast cancer cell lines 
Candidate Gene  
Normal 
HMEC Strains Breast Cancer Cell Lines 
Gene 
Distance 
from 
Telomere 
(Mb) 
2
4
0
L
 
L
O
N
Z
A
 
1
8
4
 
B
T
2
0
 
M
C
F
7
 
H
5
S
7
8
T
 
M
T
S
V
 
2
1
N
T
 
2
1
M
T
 
H
C
C
1
1
4
3
 
B
T
4
7
4
 
G
i1
0
1
 
SETD2 47.1 
+/+ +/+ +/+ +/+ +/+ 
+/+/
+ 
+/+/
+ 
+/- +/- +/- +/- +/- 
FLJ 47.2 
+/+ +/+ +/+ +/+ +/+ 
+/+/
+ 
+/+/
+ 
+/- +/- +/- +/- +/- 
PARP3 51.9 
+/+ +/+ +/+ +/+ +/+ 
+/+/
+ 
+/+/
+ 
+/- +/- +/- +/- +/- 
BAP1 52.4 
+/+ +/+ +/+ +/+ +/+ 
+/+/
+ 
+/+/
+ 
+/- +/- +/- +/- +/- 
PBRM1 52.6 
+/+ +/+ +/+ +/+ +/+ 
+/+/
+ 
+/+ +/- +/- -/- +/- +/- 
 
-/-  +/-  +/+  +/+/+ 
CN = 0  CN = 1  CN = 2  CN = 3 
 
 As shown in Table 5.3, breast cancer cell lines that initially demonstrated allele loss 
within the SETD2-FLJ genomic locus, were also found to have undergone copy number loss at 
PARP-3, BAP1 and PBRM1 loci. Based on the relative positions of each gene examined (Figure 
5.3), it is likely that the RASSF1A locus may have also undergone copy number loss within the 
same breast cancer cell lines. This suggests that a minimal 5.5Mb region within chromosome 
3p21.1-3p21.3, which encompasses five known tumour suppressor genes, was found to have 
undergone copy number loss within over half of breast cancer cell lines examined. Interestingly, 
the SV40-immortalized breast cell line MTSV and the HCC1143 breast cancer cell line were 
found to have undergone distinct copy number alterations within the PBRM1 locus compared 
with other loci examined. The HCC1143 breast cancer cell line has been found to harbour an 
intragenic homozygous deletion of PBRM1 involving exons 12-22 (Xia et al., 2008). The CNV 
primer set used to detect copy number alterations of PBRM1 within breast cancer lines 
employed in my study, were designed to detect a region within intron 14. These findings are 
therefore consistent with those presented by Xia et al., (2008) and may also indicate a 
particularly important tumour suppressive role of PBRM1 in breast cancer. In addition, copy 
number loss at all genomic loci was observed within both 21NT and 21MT cell lines, which are 
derived from primary breast tumour and metastatic deposits of the same patient respectively. 
This suggests that allele loss within the chromosome 3p21.1-p21.3 region may occur at an early 
point during breast tumorigenesis and prior to metastatic spread. The results presented here are 
consistent with previous studies demonstrating that chromosome 3p loss is a frequent and early 
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event in breast cancer (Ali et al., 1989, Sato et al., 1991, Chen et al., 1994, Matsumoto et al., 
1997, Martinez et al., 2001, Maitra et al., 2001 and De Oliveira et al., 2012). In addition, the 
results presented in Table 5.3, provide additional supporting evidence that RASSF1A, PARP-3, 
BAP1 and PBRM1 may function as important tumour suppressor genes in breast cancer. In order 
to explore the functional status of these candidate telomerase repressor genes further, the 
expression levels of BAP1, RASSF1A, PBRM1 and PARP-3 were examined within the same 
panel of breast cancer cell lines and compared with normal HMEC strains.  
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Figure 5.4 - Normalized relative quantities (NRQ) of candidate genes (A) BAP1, (B) RASSF1, 
(C) PBRM1 and (D) PARP-3 mRNA levels within a panel of nine breast cancer cell lines (blue) 
and three normal HMEC strains (red). NRQ values are presented relative to the mean NRQ 
value of all samples. Error bars represent the standard error of the mean NRQ values from 
triplicate repeats for each sample. A student's t-test was carried out on log-transformed NRQ 
values to compare mean candidate gene expression of HMEC strains with breast cancer cell 
lines. 
 Out of all candidate genes examined, only PBRM1 expression levels were found to be 
significantly reduced within the majority of breast cancer cell lines relative to normal HMEC 
strains. Six out of nine (67%) of breast cancer cell lines displayed a 43-90% reduction in 
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PBRM1 expression levels compared to normal HMEC strains (Figure 5.4). By comparison, only 
one (11%) breast cancer cell line showed a comparable level of BAP1 downregulation, while 
four (44%) showed the same level of reduction in RASSF1 and PARP-3 expression relative to 
normal HMEC strains. These findings provide evidence to show that PBRM1, RASSF1 and 
PARP-3 frequently undergo transcriptional repression within breast cancer cells and may 
therefore function as important tumour suppressor genes. However, it is important to note that 
the primers used to detect RASSF1A transcripts also detect other protein coding splice variants 
of the RASSF1 gene locus including isoforms B, C, D and H (Table 2.3, Chapter 2.3.4). 
Therefore, the expression levels shown in Figure 5.4B, do not represent the expression levels of 
the RASSF1A transcript isoform alone within cell lines/strains examined.  
 Interestingly, a sub-set of breast cancer cell lines including 21NT, 21MT and MCF-7 
were found to exhibit lower expression levels of all candidate genes relative to other breast 
cancer cell lines and normal HMECs. The 21NT and 21MT cell lines are derived from the same 
patient and are known to harbour a p53 mutation, are HER2-positive, have been previously 
shown to produce tumours when injected into nude mice (Table 4.2, Chapter 4.3.1) and were 
found have undergone copy number loss of all four candidate genes (Table 5.3). On the other 
hand, the MCF-7 cell line has been shown to harbour wild-type copies of p53, is non-
tumorigenic, HER2-negative and was not found to have undergone candidate gene copy number 
loss (Table 5.3). These findings suggest that silencing of tumour suppressor genes within the 
chromosome 3p21.1-21.3 region occurs within different molecular subtypes of breast cancer 
and provides further evidence that this region may possess important tumour suppressor genes. 
 21MT and MCF-7 cell lines are derived from the metastatic lung deposits of two 
individual breast cancer patients and were found to display a substantial reduction in PBRM1 
and RASSF1 expression levels relative to HMEC cell strains (Figure 5.4B and C). This could 
suggest that loss of PBRM1 and RASSF1 function may be associated with metastatic spread and 
more progressive disease. Low levels of PBRM1 were also observed within primary breast 
intraductal carcinoma-derived 21NT, HCC1143 and BT20 cell lines relative to normal HMEC 
strains (Figure 5.4C). Similarly, RASSF1 expression levels were also found to be markedly 
reduced within 21NT cells compared with HMEC strains (Figure 5.4B). These results therefore 
suggest that silencing of PBRM1 and RASSF1 expression may occur at an early stage during 
breast cancer development.  
 The H5S78T, BT474 and BT20 breast cancer cell lines were consistently found to 
exhibit higher candidate gene expression levels compared to other breast cancer cell lines and 
increased levels of BAP1, RASSF1 and PARP-3 expression relative to normal HMEC strains 
(Figure 5.4). A common feature shared by these breast cancer cell lines is the presence of a p53 
gene mutation (Table 4.3, Chapter 4.3.1). As shown in Table 5.3, H5S78T, BT20 and BT474 
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cell lines have been found to harbour three, two and one allele(s) at candidate gene loci 
respectively, which suggests that gene copy number loss is not always associated with reduced 
expression levels.  
 The H5S78T cell line was found to consistently display higher candidate gene 
expression levels relative to normal HMEC strains (Figure 5.4). As demonstrated in Table 5.3, 
this particular cell line was found to have undergone copy number gain at all loci examined, 
which may provide an explanation as to why the H5S78T cell line exhibited high levels of 
candidate gene expression. However, the SV40-immortalized MTSV cell line, which was found 
to harbour three alleles at the majority of loci examined (Table 5.3), exhibited substantially 
lower levels of RASSF1, PBRM1 and PARP-3 expression relative to normal HMEC strains 
(Figure 5.4B, C and D). These observations also suggest changes in gene copy number are not 
always associated with concomitant changes in gene expression levels. Other mechanisms of 
transcriptional silencing may function to inhibit the expression of important tumour suppressor 
genes within the 3p21.1-p21.3 region in breast cancer cells.  
 The results presented here demonstrate that the expression levels of several tumour 
suppressor genes localized to the 3p21.3-21.1 region are de-regulated in breast cancer, which 
can occur independently of gene copy number alterations. Out of all putative tumour suppressor 
genes examined, RASSF1, PBRM1 and PARP-3 gene expression levels were found to be 
substantially reduced within 44-67% of breast cancer cell lines employed during this study, 
which provides additional supporting evidence for the idea that these genes may function as 
important tumour suppressors in breast cancer cells. A high proportion of breast cancer cell 
lines were found to display similar to or higher levels of BAP1 expression relative to normal 
HMEC strains, which contradicts the hypothesis that this gene may function as a tumour 
suppressor in breast cancer. However, it is possible that other mechanisms of functional 
inactivation such as mutation, post-transcriptional or post-translational modification defects, 
may exist within breast cancer cell lines to abrogate the function of BAP1.  
 
5.3.2 BAP1 AS A CANDIDATE TELOMERASE REPRESSOR AND TUMOUR 
SUPPRESSOR GENE IN BREAST CANCER CELLS 
5.3.2.1 The effect of BAP1 overexpression on hTERT expression levels and 
telomerase activity within the 21NT cell line 
 Gene expression analysis of BAP1 within breast cancer cell lines and normal HMEC 
strains showed that this gene does not frequently undergo transcriptional repression within 
breast cancer cell lines. Independent studies have shown that reconstitution of wild-type BAP1 
expression suppresses the growth of breast cancer cells in vitro and lung cancer cells in vitro 
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and in vivo, which provides evidence that BAP1 may function as a powerful tumour suppressor 
gene in multiple cancer types (Jensen et al., 1998, Ventii et al., 2008). Therefore, the initial aim 
of this study was to determine whether BAP1 could play a functional role as a repressor of 
hTERT gene expression and telomerase activity in breast cancer by forced overexpression of 
BAP1 within the 21NT breast cancer cell line. 21NT cells were transfected with either negative 
control pCMVNeo or target gene pCMVNeo-BAP1 plasmid vector constructs and cultured in 
the presence of neomycin for two weeks to select for stable transfection clones. A total of five 
21NT-pCMVNeo and five 21NT-pCMVNeo-BAP1 transfection clones were isolated and 
propagated as individual cell lines.  
 As shown in Figure 5.5A, stable 21NT-pCMVNeo-BAP1 transfection clones were 
found to exhibit between 2-84 fold higher levels of BAP1 relative to untreated 21NT cells. 
These stable clones were also found to display either undetectable or a greater than 80% 
reduction in hTERT expression levels compared to untreated controls (Figure 5.5B). Similarly 
all stable 21NT-pCMNeo-BAP1 clones were found to exhibit a greater than 90% reduction in 
telomerase activity relative to untreated 21NT cells (Figure 5.5C). These findings on their own 
may appear to suggest that BAP1 may function as a repressor of hTERT and telomerase in 21NT 
cells. However, curiously, all stable negative control 21NT-pCMVNeo clones were also found 
to express 2-10 fold higher levels of BAP1 relative to untreated 21NT cells. Three out of five 
stable 21NT-pCMVNeo clones were found to display undetectable levels of hTERT, while two 
clones exhibited similar levels of hTERT expression to untreated 21NT cells (Figure 5.5B). In 
addition, a 67-89% reduction in telomerase activity was observed within three stable negative 
control 21NT-pCMVNeo clones relative to untreated controls (Figure 5.5C). These findings are 
consistent with those presented in Chapter 4.3.2, where transient and stable expression of the 
pCMVNeo plasmid vector within 21NT cells was associated with a consistent deregulation in 
hTERT expression and telomerase activity. This was thought to be due to insertional 
mutagenesis of important hTERT regulatory regions. It is therefore unclear whether exogenous 
expression of BAP1 is responsible for the observed reduction in hTERT expression and 
telomerase repression within stable 21NT-pCMVNeo-BAP1 clones. However, stable 
overexpression of BAP1 within 21NT cells was found to be associated with a greater and more 
consistent repression of hTERT transcription and telomerase activity compared with stable 
empty vector controls, which provides evidence to show that BAP1 may function as a negative 
regulator of hTERT (Figure 5.5).  
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Figure 5.5- Normalized relative quantities (NRQ) of (A) BAP1 and (B) hTERT mRNA within 
stable empty vector control 21NT-pCMVNeo (green) and target gene 21NT-pCMVNeo-
BAP1(blue) transfection clones relative to the mean ± SD NRQ values of three untreated 21NT 
cell samples (red). Error bars for stable transfection clones represent the standard error of the 
mean NRQ values obtained from triplicate repeats from each sample. (C) Telomerase activity 
within stable 21NT-pCMVNeo and 21NT-pCMVNeo-BAP1 transfection clones relative to 
untreated 21NT cells. Error bars represent the standard error of the mean telomerase activity of 
triplicate repeats for each sample. The HMEC 240L cell strain was included to represent a 
normal human control. 
5.3.2.2 The effect of stable BAP1 overexpression on 21NT cell growth and 
proliferative capacity   
 Introduction of a normal copy of human chromosome 3 into the 21NT cell line is 
associated with a greater than 90% reduction in telomerase activity and delayed permanent 
growth arrest following 10-12 or 15-18 population doublings (PD) within the majority of hybrid 
colonies (Cuthbert et al., 1999). The results presented above indicate that exogenous expression 
of BAP1 within the 21NT cell line is associated with a substantial and consistent decrease in 
hTERT mRNA levels and a greater than 90% reduction in telomerase activity. In order to 
examine the effect of BAP1 overexpression on the growth rate and replicative potential of 21NT 
cells, the cumulative population doublings (PD) and mean PD time of two stable negative 
control 21NT-pCMVNeo and two stable 21NT-pCMVNeo-BAP1 clones were examined over 
five serial passages.  
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C. Cellular morphology of untreated (UT) 21NT cells, stable 21NT-pCMVNeo and 21NT-
pCMVNeo-BAP1 transfection clones 
 
Figure 5.6 - (A) Cumulative number of population doublings (PD) of untreated 21NT cells, 
stable 21NT-pCMVNeo transfection clones 4 and 8 and stable 21NT-pCMVNeo-BAP1 
transfection clones 6 and 8 over five serial passages. (B) The mean PD time (hours) for all 
samples across five serial passages. A student's t-test was used to compare the means of sample 
groups (C) Representative photomicrograph images (x40 or x100 magnification) of untreated 
21NT cells, stable empty vector 21NT-pCMVNeo and 21NT-pCMVNeo-BAP1 transfection 
clones  
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 The cell growth rate of all stable transfection clones was examined after the clones were 
picked and had reached 90% confluence on individual P35 dishes (passage 1). Therefore, 
colonies had been in culture for 21-25 days prior to cell growth analysis. According to the 
calculated mean PD time of each individual colony (Figure 5.6B), 21NT-pCMVNeo clones 4 
and 8 and 21NT-pCMVNeo-BAP1 clones 6 and 8 were estimated to have undergone 
approximately 11-13 PD prior to analysis. As shown in Figure 5.6A and C, stable 21NT-
pCMVNeo-BAP1 clones 6 and 8 were found to proliferate continuously for a further 14 PD with 
no observable morphological features of senescence or cell growth arrest. This demonstrates 
that stable overexpression of wild-type BAP1 was not associated with induction of senescence 
pathways and permanent cell growth arrest of 21NT cells. However, both 21NT-pCMVNeo-
BAP1 clones 6 and 8 were found to display a moderately (but significantly) longer mean PD 
time of 53.1 and 46.5 hours respectively compared to untreated 21NT cells, which were found 
to exhibit a mean PD time of 37.1 hours (Figure 5.6B). As shown in Figure 5.5A, these clones 
were initially found to display 34 and 84-fold higher levels of BAP1 expression relative to 
untreated 21NT cells. Therefore, exogenous BAP1 expression within 21NT cells is associated 
with a significant reduction in cell growth rate. Stable control 21NT-pCMVNeo clones 4 and 8 
were also found to proliferate continuously for a further 15-16 PD and display a similar mean 
PD time as untreated 21NT cells (Figure 5.6A and B). These clones were initially found to 
exhibit 2-5-fold higher levels of BAP1 and a substantial reduction in hTERT expression levels 
and telomerase activity relative to untreated 21NT cells (Figure 5.5). Therefore, induction of 
endogenous BAP1 expression within 21NT cells was not associated with cell growth arrest or a 
reduction in growth rate. These results could also suggest that a greater than 5-fold increase in 
BAP1 expression levels may be required to suppress 21NT breast cancer cell growth. 
 The findings presented here so far show that 21NT-pCMVNeo-BAP1 transfection 
clones 6 and 8 were initially found to exhibit a greater than 90% reduction in telomerase activity 
but were also found to proliferate continuously for approximately 25-27 PD. Cuthbert et al., 
(1999) demonstrated that 21NT-chromosome 3 hybrids exhibiting a greater than 90% reduction 
in telomerase activity entered delayed permanent growth arrest, which was thought to be due to 
progressive telomere shortening and induction of cellular replicative senescence pathways. 
Therefore, in order to determine whether the observed levels of telomerase repression initially 
exhibited by 21NT-pCMVNeo-BAP1 clones 6 and 8 were maintained over the course of five 
serial passages, BAP1 expression levels and telomerase activity was examined at passages 1 and 
5. As shown in Figure 5.7A, stable 21NT-pCMVNeo-BAP1 transfection clones 6 and 8 were 
found to display substantially higher levels of BAP1 expression relative to untreated 21NT cells 
and negative control 21NT-pCMVNeo clones at passages 1 and 5, indicating that higher levels 
of BAP1 expression were maintained over five serial passages. However, BAP1 expression 
levels within 21NT-pCMVNeo-BAP1 clones 6 and 8 were found to be substantially lower in 
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absolute terms than initially observed (Figure 5.5A), which may reflect the inter-clonal 
variability of BAP1 expression exhibited by wild type 21NT cells. 
 As demonstrated within Figure 5.7B, both 21NT-pCMVNeo-BAP1 clones were found 
to exhibit approximately 85% lower levels of telomerase activity relative to untreated 21NT 
cells at passage 1, which is similar to initial findings presented in Figure 5.5C. Interestingly, 
both stable 21NT-pCMVNeo-BAP1 clones were found to display approximately three-fold 
higher levels of telomerase activity at passage 5 compared to passage 1, which indicates that 
telomerase repression was not maintained over the course of five serial passages. Later-passage 
stable 21NT-pCMVNeo-BAP1 clones were found to exhibit similar levels of telomerase activity 
to stable negative control 21NT-pCMVNeo clones (Figure 5.7B).    
 These findings demonstrate that forced overexpression of BAP1 within 21NT cells 
harboring a single copy of BAP1, is associated with transient telomerase repression within 
21NT cells. The observed increase in telomerase activity within later passage 21NT-pCMVNeo-
BAP1 clones may have prevented progressive telomere shortening and induction of cell growth 
arrest. Early-passage 21NT-pCMVNeo-BAP1 stable clones were found to display substantially 
lower levels of hTERT expression and telomerase activity compared to untreated 21NT cells and 
stable negative control 21NT-pCMVNeo clones (Figure 5.5B and C and Figure 5.7B), which 
suggests that BAP1 may function as a negative regulator of hTERT. It is possible that, in 
addition to BAP1, other co-factors or transcription factors may be required to maintain stable 
hTERT repression. Ultimately, these findings provide evidence to show that BAP1 is unlikely to 
be responsible for the strong telomerase repression and cell growth arrest observed within the 
majority of 21NT-chromosome 3 hybrids generated in the Cuthbert et al., (1999) study. 
However, these results suggest that BAP1 may function as an important component of a 
telomerase regulatory pathway.  
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Figure 5.7 - (A) Normalized relative quantities (NRQ) of BAP1 mRNA within two stable 21NT-
pCMVNeo and two 21NT-pCMVNeo-BAP1 transfection clones relative to three individual 
untreated 21NT cell samples (indicated by a dotted line) at passage 1 and following five serial 
passages. Error bars represent the standard error of the mean for triplicate repeats of each 
sample. (B) Telomerase activity within the same samples relative to untreated 21NT cells 
(indicated by a dotted line). Error bars represent the standard deviation of the mean for 
triplicate repeats of each sample.  
 Studies have shown that forced wild-type BAP1 overexpression within MCF-7 and 
HCC1937 breast carcinoma cell lines is associated with cell growth suppression (Jensen et al., 
1998, Ventii et al., 2008). As shown in Figure 5.6, overexpression of BAP1 within 21NT cells 
was associated with a significant reduction in cell growth rate compared with untreated controls. 
Therefore, in order to examine the effect of wild type BAP1 overexpression on the survival and 
proliferation of 21NT breast cancer cells, the number and size of stable negative control 21NT-
pCMVNeo and 21NT-pCMVNeo-BAP1 cell clones that emerged following two weeks of 
neomycin selection (post-transfection) was examined. As shown in Figure 5.8A and B, no 
significant difference was observed between the number of stable negative control 21NT-
pCMVNeo and 21NT-pCMVNeo-BAP1 cell clones that emerged, indicating that exogenous 
expression of BAP1 is not associated with changes in the clonogenic survival of 21NT cells. In 
contrast to results presented in Figure 5.6, both 21NT-pCMVNeo and 21NT-pCMVNeo-BAP1 
stable clones were found to display a similar average clone diameter, indicating that forced 
overexpression of BAP1 within the 21NT cell line is not associated with a significant change in 
colony cell growth (Figure 5.8C and D).   
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Figure 5.8 - (A) Photographs of P60 dishes containing fixed and stained stable (i) negative 
control 21NT-pCMVNeo and (ii) target gene 21NT-pCMVNeo-BAP1 colonies that emerged 
(post-transfection) following two weeks of neomycin selection. (B) The mean number of 
negative control (green) and BAP1 target gene (blue) stable colonies present across four 
individual P60 dishes for each plasmid construct. (C) Representative photomicrographs (2.5x 
magnification) of fixed and stained stable (i) 21NT-pCMVNeo and (ii) 21NT-pCMVNeo-BAP1 
clones that emerged following two weeks of neomycin selection. (D) The average diameter (mm) 
of 11-13 individual 21NT-pCMVNeo (green) and 21NT-pCMVNeo-BAP1 (blue) clones. Error 
bars represent the standard error of the mean number of clones/clone diameter for each group. 
A student's t-test was used to compare the mean of both groups.  
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5.3.3 RASSF1A AS A CANDIDATE TELOMERASE REPRESSOR AND TUMOUR 
SUPPRESSOR GENE IN BREAST CANCER CELLS 
5.3.3.1 The effect of RASSF1A overexpression on hTERT expression levels and 
telomerase activity within 21NT cells 
 The findings presented above provide some evidence to show that BAP1 may function 
as a transcriptional repressor of hTERT. However, it is unlikely that BAP1 is responsible for the 
observed telomerase repression and cell growth arrest within 21NT-chromosome 3 hybrids 
generated in the Cuthbert et al., (1999) study. Therefore, the functional role of RASSF1A as a 
candidate repressor of hTERT expression and telomerase activity within the 21NT breast cancer 
cell line was investigated. To do this, individual dishes of 21NT cells were transfected with the 
pcDNA3.1/V5-His-TOPO/LacZ (pcDNA) plasmid vector or a pcDNA3.1(+)-RASSF1A plasmid 
construct containing the human RASSF1A cDNA (pcDNA-RASSF1A, kindly provided by 
Professor Reinhard Damman, Justus-Liebig University). 48 hours following transfection, cells 
were cultured in the presence of neomycin for two weeks to select for stable clones. A total of 
five negative control 21NT-pcDNA and five target gene 21NT-pcDNA-RASSF1A clones were 
isolated and propagated as individual cell lines.      
 As shown in Figure 5.9A, three out of five stable 21NT-pcDNA-RASSF1A clones (1, 2 
and 3) were found to exhibit 8-55 fold higher levels of RASSF1 expression relative to untreated 
21NT cells. The remaining two 21NT-pcDNA-RASSF1A stable clones (4 and 5) were found to 
display similar levels of RASSF1A expression to negative control 21NT-pcDNA and untreated 
21NT cells. As shown in Figure 5.9B, four out of five 21NT-pcDNA-RASSF1A clones were 
found to exhibit a 62-97% reduction in hTERT expression levels relative to untreated controls; 
however only half of these clones were found to display increased levels of relative RASSF1A 
expression. 21NT-pcDNA-RASSF1A clone 2, which showed the highest level of RASSF1A 
expression relative to untreated controls, was found to exhibit a 9.5-fold increase in hTERT 
expression levels (Figure 5.9B). These findings demonstrate that forced overexpression of 
RASSF1A within 21NT cells is not always associated with a reduction in hTERT expression. 
Moreover, four out of five negative control stable 21NT-pcDNA clones were also found to 
exhibit a 63-87% reduction in hTERT expression levels relative to untreated controls. Therefore, 
the increase in RASSF1A expression was unlikely to have been responsible for the observed 
transcriptional repression of hTERT within 21NT-pcDNA-RASSF1A clones 1 and 3 (Figure 
5.9A and B).  
 Two out of five stable 21NT-pcDNA-RASSF1A clones (2 and 4) were found to exhibit a 
43-47% reduction in telomerase activity relative to untreated 21NT cells, while the remaining 
three clones displayed a similar level of telomerase activity to untreated 21NT cells and 
negative control 21NT-pcDNA stable clones (Figure 5.9C). 21NT-pcDNA-RASSF1A clone 2, 
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but not clone 4, was found to express substantially higher levels of RASSF1 expression (55-fold 
higher) relative to untreated controls and negative control 21NT-pcDNA stable clones (Figure 
5.9A). 21NT-pcDNA-RASSF1A clones 1 and 3, which were found to express over 8-fold higher 
levels of RASSF1 (Figure 5.9A) were found to exhibit no significant change in telomerase 
activity relative to untreated controls (Figure 5.9C), Therefore, consistent with the effect on 
hTERT transcription, forced overexpression of RASSF1 within 21NT cells is not always 
associated with a reduction in telomerase activity levels. These findings therefore provide some 
evidence to show that RASSF1A is unlikely to be responsible for the observed telomerase 
repression exhibited by 21NT-chromosome 3 hybrids within the Cuthbert et al., (1999) study. 
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Figure 5.9- Normalized relative quantities (NRQ) of (A) RASSF1 and (B) hTERT mRNA within 
stable empty vector control 21NT-pcDNA (green) and target gene 21NT-pcDNA-RASSF1A 
(blue) transfection clones relative to the mean ± SD NRQ values of three untreated 21NT cell 
samples (red). Error bars for stable transfection clones represent the standard error of the 
mean NRQ values obtained from triplicate repeats from each sample. (C) Telomerase activity 
within stable 21NT-pcDNA and 21NT-pcDNA-RASSF1A transfection clones relative to 
untreated 21NT cells. Error bars represent the standard error of the mean telomerase activity of 
triplicate repeats for each sample. The HMEC 240L cell strain was included to represent a 
normal human control. 
5.3.3.2 The effect of RASSF1A overexpression on the clonogenic survival and 
growth rate of 21NT cells 
 Around 62% of primary breast carcinomas have been found to undergo transcriptional 
repression of RASSF1A  through CpG island promoter hypermethylation (Damman et al., 2001). 
Transcriptional repression of RASSF1A is thought to occur at an early point during breast cancer 
development (Strunnikova et al., 2005, Dumont et al., 2009). Independent studies have shown 
that forced overexpression of RASSF1A within multiple tumour cell lines including NSCLC, 
prostate, lung, nasopharyngeal and breast and is associated with a significant reduction in cell 
colony formation, proliferation and tumorigenicity of cancer cells both in vitro and in vivo 
(Damman et al., 2000, Burbee et al., 2001, Chow et al., 2004, Dreijerink et al., 2001, Kuzmin et 
al., 2002, Thaler et al., 2012). 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
T
el
o
m
er
a
se
 A
ct
iv
it
y
 
Cell Line/Strain/Stable Clone 
C. Telomerase Activity within stable 21NT-pcDNA and 21NT-pcDNA-RASSF1A 
clones relative to an untreated control  
233 
 
 The 21NT primary breast cancer cell line was found to exhibit a 72% reduction in 
RASSF1 expression relative to normal HMEC strains and is also likely to have undergone copy 
number loss of a minimal 5.5Mb region within 3p21.1-21.3, which encompasses the RASSF1A 
genomic locus (Figure 5.4B and Table 5.3). Therefore, in order to examine the tumour 
suppressive properties of RASSF1A within the 21NT breast cancer cell line, the effect of forced 
wild-type RASSF1A overexpression on the clonogenic survival and proliferation of 21NT cells 
was investigated. To do this, 21NT cells were transfected with negative control pcDNA plasmid 
vectors or target gene pcDNA-RASSF1A constructs and the number and size of stable cell 
clones that emerged following two weeks of neomycin selection were compared.  
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Figure 5.10- (A) Photographs of P60 dishes containing fixed and stained stable (i) negative 
control 21NT-pcDNA and (ii) target gene 21NT-pcDNA-RASSF1A colonies that emerged (post-
transfection) following two weeks of neomycin selection. (B) The mean number of negative 
control (green) and RASSF1A target gene (blue) stable colonies present across four individual 
P60 dishes for each plasmid construct. (C) Representative photomicrographs (2.5x 
magnification) of fixed and stained stable (i) 21NT-pcDNA and (ii) 21NT-pcDNA-RASSF1A 
clones that emerged (post-transfection) following two weeks of neomycin selection. (D) The 
average diameter (mm) of 11-17 individual 21NT-pcDNA (green) and 21NT-pcDNA-RASSF1A 
(blue) clones. Error bars represent the standard error of the mean number of cell clones/clone 
diameter for each group. A student's t-test was used to compare the mean of both groups.  
 As shown in Figure 5.10A and B, no significant difference in the average number of 
stable negative control 21NT-pcDNA and target gene 21NT-pcDNA-RASSF1A clones was 
observed, which indicates that forced overexpression of RASSF1A is not associated with a 
significant decrease in the clonogenic survival of 21NT breast cancer cells. However, stable 
21NT-pcDNA-RASSF1A clones were found to exhibit a significant reduction in average clone 
diameter compared with negative control stable 21NT-pcDNA clones, which indicates that 
RASSF1A overexpression within 21NT cells is associated with a significant decrease in cell 
proliferation.  
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5.3.4 PBRM1 AS A CANDIDATE TELOMERASE REPRESSOR AND TUMOUR 
SUPPRESSOR GENE IN BREAST CANCER CELLS 
5.3.4.1 The effect of PBRM1 overexpression on hTERT expression levels and 
Telomerase Activity within 21NT cells 
 PBRM1 has been found to play an important functional role in the transcriptional 
regulation of basal and induced p21 expression within normal breast epithelial and cancer cells 
(Xia et al., 2008). Forced overexpression of PBRM1 within two PBRM1-mutant breast cancer 
cell lines has been associated with an increase in p21 protein levels (Xia et al., 2008). In 
addition, lack of PBRM1-mediated transcriptional activation of p21 was thought to have been 
responsible for the delayed induction of replicative senescence pathways observed following 
knockdown of PBRM1 within normal human fibroblasts (Burrows et al., 2010). p21 has been 
found to play an important functional role in the transcriptional repression of hTERT in breast 
cancer cells (Shats et al., 2004). Therefore, in order to determine whether an increase in PBRM1 
expression levels is associated with repression of hTERT expression and telomerase activity 
through induction of p21 expression, the effect of forced wild-type PBRM1 overexpression 
within the 21NT cell line was examined. To do this, 21NT cells were transfected with the 
puromycin-selectable, negative control pBABE plasmid vector or a pBABE-PBRM1 vector 
construct containing the 4961bp PBRM1 wild-type cDNA. Two days following transfection of 
plasmid vectors, cells were cultured in the presence of puromycin to select for stable clones. 
Following two weeks of puromycin selection, five stable empty vector 21NT-pBABE clones 
and six target gene 21NT-pBABE-PBRM1 clones were isolated and propagated as individual 
cell lines. 
 As shown in Figure 5.11A, stable 21NT-pBABE-PBRM1clones were found to exhibit 
2-11 fold higher levels of PBRM1 expression relative to untreated controls. By comparison, two 
out of five (40%) stable empty vector control 21NT-pBABE clones were found to display 
around 2-fold higher levels of endogenous PBRM1 expression. Therefore, five out of six (83%) 
21NT-pBABE-PBRM1 clones were found to display consistently higher PBRM1 expression 
levels than stable empty vector 21NT-pBABE clones. As shown in Figure 5.11B, all stable 
empty vector control and PBRM1-transfected 21NT clones were found to exhibit increased 
levels of p21 expression relative to untreated controls. However, on average, stable 21NT-
pBABE-PBRM1 clones were not found to exhibit significantly higher levels of p21 expression 
compared to stable empty vector 21NT-pBABE controls (p = 0.49, Figure 5.11B). As 
demonstrated in Figure 5.11A, the majority of stable 21NT-pBABE-PBRM1 clones were found 
to express substantially higher levels of PBRM1 expression relative to untreated 21NT cells and 
stable empty vector controls. Therefore, forced overexpression of wild-type PBRM1 within 
21NT cells is not associated with a significant increase in p21 expression levels compared to 
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empty vector controls. Despite these observations, a positive correlation between PBRM1 and 
p21 expression levels was observed within both stable empty vector 21NT-pBABE and 21NT-
pBABE-PBRM1 clones (r = 0.96 and r = 0.35 respectively, Figure 5.11C and D). Consistent 
with Xia., et al., (2008), these findings provide evidence to show that there may be a functional 
link between PBRM1 and p21 expression in breast cancer cells. However, these findings also 
indicate that forced overexpression of PBRM1 within 21NT cells is not associated with a 
significant induction of p21 expression compared to empty vector controls. This does not 
exclude the possibility that a greater than 11-fold increase in PBRM1 may be required to induce 
high levels of p21 expression. 
 Four out of six (67%) stable 21NT-pBABE-PBRM1 clones were found to exhibit a 
greater than 50% reduction in hTERT expression levels relative to untreated 21NT cells (Figure 
5.11E). Out of these, two (33%) displayed a greater than 90% reduction in relative hTERT 
expression levels. The remaining two (33%) 21NT-pBABE-PBRM1 clones displayed 3-4 fold 
higher levels of hTERT relative to untreated controls (Figure 5.11E). Interestingly, stable 21NT-
pBABE-PBRM1 clones that exhibited the highest levels of PBRM1 expression were also found 
to display higher levels of hTERT expression relative to untreated 21NT cells. 21NT-pBABE-
PBRM1 clones that exhibited a greater than 50% reduction in hTERT were found to display a 2-
7 fold increase in PBRM1 expression levels relative to untreated controls. These findings 
demonstrate that an increase in PBRM1 expression is not always associated with repression of 
hTERT transcription. Interestingly, the results presented in Figure 5.11F show that all stable 
21NT-pBABE-PBRM1 clones exhibited a 59-89% reduction in telomerase activity relative to 
untreated controls. However, stable empty vector 21NT-pBABE clones were also found to 
display a substantial reduction in telomerase activity. Therefore, it is unclear whether stable 
forced overexpression of PBRM1 was responsible for the reduction in telomerase activity 
observed within 21NT-pBABE-PBRM1 clones.  
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Figure 5.11 - Normalized relative quantities (NRQ) of (A) PBRM1 and (B) p21 mRNA within 
stable empty vector control 21NT-pBABE (green) and target gene 21NT-pBABE-PBRM1 (blue) 
transfection clones relative to the mean ± SD NRQ values of three untreated 21NT cell samples 
(red). The relationship between PBRM1 and p21 expression levels within (C) 21NT-pBABE and 
(D) 21NT-pBABE-PBRM1 clones, relative to untreated 21NT cells. The Pearson Correlation 
Coefficient (r) was used to quantify the strength of the relationship between both variables. (E) 
NRQ of hTERT mRNA within the same samples relative to mean ± SD NRQ values of three 
untreated 21NT cell samples. (F) Telomerase activity within stable 21NT-pBABE and 21NT-
pBABE-PBRM1 transfection clones relative to untreated 21NT cells. The HMEC 240L cell 
strain was included to represent a normal human control. Error bars represent the standard 
error of the mean NRQ value or telomerase activity of triplicate repeats for each sample.  
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Cellular morphology of untreated (UT) 21NT cells, stable 21NT-pBABE and 21NT-
pBABE-PBRM1 transfection clones 
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Figure 5.12- Representative photomicrographs (magnification x200) of untreated (UT) 21NT 
cells and a subset of stable control 21NT-pBABE and target gene 21NT-pBABE-PBRM1 clones. 
 Stable empty vector control 21NT-pBABE and target gene 21NT-pBABE-PBRM1 
clones were propagated in culture for around three weeks before they were cryopreserved. 
During this time none of the stable PBRM1-transfected 21NT clones were found to enter 
complete growth arrest. However, four out of six (67%) 21NT-pBABE-PBRM1 clones were 
found to contain cells exhibiting characteristic features of senescence including cytoplasmic 
enlargement, vacuolation and multinucleation (Figure 5.12). By comparison, stable empty 
vector 21NT-pBABE clone cells were found to exhibit a similar morphology to untreated 21NT 
cells. Interestingly, 21NT-pBABE clones 1 and 2, which were found to exhibit similarly low 
levels of telomerase activity relative to untreated cells as 21NT-pBABE-PBRM1 clones, were 
not found to contain cells that displayed features of senescence. This suggests that, independent 
of telomerase status, forced expression of wild-type PBRM1 within 21NT cells is associated 
with the appearance of cells exhibiting senescent features. 
5.3.4.2 The effect of PBRM1 overexpression on the clonogenic survival and 
growth rate of 21NT cells 
 Overexpression of wild-type PBRM1 within the PBRM1-deficient HCC1143 breast 
cancer cell line has been associated with a significant reduction in the number and size of stable 
PBRM1-transfected cell colonies compared to negative controls (Xia et al., 2008). Therefore, 
the effect of exogenous wild-type PBRM1 expression on the clonogenic survival and 
proliferation of 21NT cells was examined within this study. To do this, 21NT cells were 
transfected with empty vector pBABE plasmids or pBABE-PBRM1 constructs and cultured in 
the presence of puromycin for two weeks to select for stable clones. The number and size of 
puromycin-resistant stable 21NT-pBABE and 21NT-pBABE-PBRM1 cell clones that emerged 
was then examined.   
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 As shown in Figure 5.13A and B, the average number of stable 21NT-pBABE-PBRM1 
clones that emerged was significantly lower than the average number of 21NT-pBABE empty 
vector controls (p = 1.5x10
-5
*), which demonstrates that forced expression of wild-type PBRM1 
is associated with a significant decrease in the clonogenic survival and growth of 21NT breast 
cancer cells. However, surviving stable 21NT-pBABE-PBRM1 clones were found to display a 
similar average clone diameter to stable empty vector 21NT-pBABE clones (Figure 5.13C and 
D), which could suggest that a critical threshold of PBRM1 expression required for cell growth 
inhibition was not reached or the pBABE-PBRM1 plasmid construct did not remain intact upon 
stable integration within a proportion of 21NT-pBABE-PBRM1 clones. As outlined in Chapter 
4.2.3.1, genetic recombination events that occur during stable integration of plasmid DNA into 
the host genome, may involve important sites required for target gene expression within 
mammalian cells.  
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Figure 5.13- (A) Photographs of P60 dishes containing fixed and stained stable (i) negative 
control 21NT-pBABE and (ii) target gene 21NT-pBABE-PBRM1 colonies that emerged (post-
transfection) following two weeks of puromycin selection. (B) The mean number of negative 
control (green) and PBRM1 target gene (blue) stable colonies present across four individual 
P60 dishes for each plasmid construct. (C) Representative photomicrographs (2.5x 
magnification) of fixed and stained stable (i) 21NT-pBABE and (ii) 21NT-pBABE-PBRM1 
clones that emerged (post-transfection) following two weeks of puromycin selection. (D) The 
average diameter (mm) of 13 individual 21NT-pBABE (green) and 21NT-pBABE-PBRM1 (blue) 
clones. Error bars represent the standard error of the mean number of cell clones/clone 
diameters for each group. A student's t-test was used to compare the mean of both groups.  
 
5.4 SUMMARY 
5.4.1 BAP1 
 Independent studies have shown that the BAP1 de-ubiquitylase enzyme plays a tumour 
suppressor role in multiple cancer types including non-small cell lung cancer (NSCLC) and 
breast cancer (Jensen et al., 1998, Ventii et al., 2008). BAP1 mutations have been identified 
within these cancer types and are associated with poor cancer-specific survival in ccRCC 
patients (Hakimi et al., 2013). Germline BAP1 mutation carriers have an increased risk of 
developing mesothelioma, uveal melanoma and other malignancies including lung, breast and 
renal cancer, which demonstrates that this gene may play an important role in preventing 
tumorigenesis. BAP1 resides within a common region of loss of heterozygosity (LOH) in 
multiple cancer types including renal, lung and breast cancers (reviewed by Angeloni et al., 
2007). In support of this, the results presented within my study demonstrated that over half 
(56%) of breast cancer cell lines examined had undergone copy number loss involving the BAP1 
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genomic locus, while the remaining cell lines (44%) were found to harbour either two (22%) or 
three (22%) alleles. In contrast, over half (56%) of breast cancer cell lines were found to exhibit 
either similar or higher levels of BAP1 expression compared with normal HMEC strains. This 
demonstrates that changes in BAP1 gene copy number are not always associated with 
concomitant changes in gene expression levels. Only the MCF-7 breast cancer cell line was 
found to exhibit a substantial (60%) reduction in BAP1 expression levels. Interestingly, Jensen 
et al., (1998) found that the MCF-7 cell line does not harbour mutations in the open reading 
frame (ORF) of BAP1. However, forced overexpression of BAP1 within the MCF-7 cell line 
was associated with significant cell growth suppression, which indicates that high levels of 
BAP1 expression is associated with a powerful tumour suppressor effect even in the presence of 
endogenous wild-type BAP1 (Jensen et al., 1998). Northern blot analysis of BAP1 transcripts 
within 31 small cell lung cancer (SCLC) and 27 NSCLC cell lines showed that only two cell 
lines were found to display undetectable levels of BAP1 expression; one of which was due to 
the presence of a frameshift mutation within the BAP1 ORF leading to a truncated protein 
product. Similarly, during a screen of BAP1 mutations within breast, prostate, colorectal and 
gastric cancers, only one colon carcinoma-derived tumour sample was found to harbour a BAP1 
mutation, indicating that somatic BAP1 mutations are a rare occurrence in several cancer types 
including breast cancer (Je et al., 2012). The results presented within my study demonstrating 
that breast cancer cell lines exhibit similar or higher BAP1 expression levels relative to normal 
HMECs, suggest that transcriptional repression of BAP1 is uncommon in breast cancer cells. 
Interestingly, undetectable levels of BAP1 protein have been observed within RCC tumour 
samples harboring both mutant and wild-type copies of BAP1 (Pena-Llopis et al., 2012). 
Together, these findings suggest that loss of BAP1 function in cancer cells may involve post-
transcriptional processing defects or perhaps lack of transcriptional activators of BAP1.  
 BAP1 is a nuclear-localized chromatin-bound protein that forms multi-protein 
complexes with chromatin-modifying proteins and transcription factors (Machida et al., 2009, 
Yu et al., 2010). A common binding partner of BAP1 is Host Cell Factor-1 (HCF-1), which is 
known to regulate the expression levels of target genes involved in cell cycle control by 
recruiting chromatin modifying complexes to promoter regions.  BAP1 has been found to 
interact with and augment the cell growth suppressive effect of BRCA1; a previously identified 
hTERT repressor protein in breast cancer (Jensen et al., 1998, Xiong et al., 2003). BAP1 is 
located close to the 3p21.3-p22 region that is thought to harbour a powerful telomerase 
repressor sequence in breast cancer cells (Cuthbert et al., 1999). Therefore, a principle aim of 
my study was to investigate the putative role of BAP1 in hTERT regulation. I found that forced 
overexpression of BAP1 within the 21NT breast cancer cell line was associated with a greater 
than 80% reduction in hTERT expression levels and 85-90% reduction in telomerase activity 
relative to untreated controls. Stable BAP1-overexpressing clones were also found to exhibit a 
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greater reduction in hTERT expression and telomerase activity than empty vector controls, 
which demonstrates that BAP1 may play a functional role in regulating telomerase activity in 
breast cancer cells. Despite these observations, stable 21NT-pCMVNeo-BAP1 transfection 
clones were found to proliferate continuously for approximately 25-27 PD, without entering 
growth arrest or exhibiting morphological features of senescence. However, 21NT-pCMVNeo-
BAP1 clones were found to exhibit a significant reduction in cell growth rate compared with 
untreated 21NT cells, indicating that forced BAP1 overexpression is associated with 21NT cell 
growth suppression. Cuthbert et al., (1999) demonstrated that 21NT cells posses short mean 
telomere restriction fragment (TRF) lengths of 3 kilobases (kb) and introduction of a normal 
copy of chromosome 3 into the 21NT cell line was associated with a greater than 90% reduction 
in telomerase activity and cell growth arrest within 10-12 or 15-18 PD. By comparison, 
telomerase repression within RCC23-chromosome 3 hybrids was associated with cell growth 
arrest within 31-41 PD with a progressive reduction in mean TRF lengths from 6kb to 2.5kb 
(Horikawa et al., 1998). Therefore, following abolishment of telomerase activity, the number of 
PDs that occur prior to cell growth arrest appears to be dependent on mean telomere lengths 
within the parental cell line. Taking this into account, the telomerase-repressed stable 21NT-
pCMVNeo-BAP1 clones obtained within my study had therefore exceeded the number of PD 
that had occurred between telomerase repression and growth arrest of 21NT-chromosome 3 
hybrids within the Cuthbert et al., (1999) study. A comparison of early (14PD) and late passage 
(25-27 PD) stable 21NT-pCMVNeo-BAP1 clones revealed that telomerase activity had 
increased over progressive passages, to a similar level displayed by empty vector control stable 
clones. This is likely to have prevented progressive telomere shortening and induction of cell 
growth arrest pathways. BAP1 expression levels were substantially higher relative to untreated 
21NT cells within both early and late passage 21NT-pCMVNeo-BAP1 stable clones, therefore 
the observed increase in telomerase activity was unlikely to be due to changes in BAP1 
expression. 
 In a similar fashion to forced overexpression of BAP1 within 21NT breast cancer cells, 
in published work by others, stable overexpression of the BAP1 binding partner BRCA1, within 
DU-145 prostate cancer and T47D breast cancer cells was associated with a significant 
reduction in hTERT expression levels and telomerase activity (Xiong et al., 2003). Stable 
BRCA1-DU-145 and BRCA1-T47D transfection clones were also found to exhibit a reduction in 
cell growth rate and progressive telomere shortening from 3-3.3kb to 1.9kb and 2.3-4.0kb to 
2.0kb respectively. Interestingly, despite observing a significant reduction in telomere length, 
stable BRCA1-DU-145 and BRCA1-T47D clones were found to proliferate continuously without 
induction of cell growth arrest. Telomere length analysis of BRCA1-expressing DU145/BRCA1-
Tet-off cells, which express wild-type BRCA1 in the absence of tetracycline (TCN), showed that 
longer telomere lengths ranging from 2.3-6kb were lost within 3 days and maintained at 2.3kb 
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for around 31 days. A further reduction in mean TRF lengths to 1.8-2kb was observed at around 
60 days, with no signs of senescence or apoptosis. Therefore, expression of wild-type BRCA1 is 
associated with an initial period of rapid telomere erosion, followed by continued gradual 
telomere shortening without induction of cell growth arrest pathways. This was thought to either 
be due to the presence of residual levels of telomerase activity, or the presence of pRb and/or 
p53 mutations within parental cell lines (Xiong et al., 2003). BRCA1 was found to repress 
hTERT transcription through inhibition of c-Myc-mediated transcriptional activation of hTERT 
and also independently of c-Myc (Xiong et al., 2003). Similarly, Li et al., (2002) found that 
Nmi recruits BRCA1 to c-Myc and prevents c-Myc-mediated transcriptional activation of 
hTERT within breast cancer cells. Transfection of BRCA1 harboring mutations associated with 
hereditary breast cancer, failed to inhibit c-Myc induced hTERT transcriptional activation within 
the T47D breast cancer cell line. These findings indicate that BRCA1 may play an important 
tumour suppressor role in early in breast cancer development by preventing c-Myc induced 
activation of hTERT expression and telomerase activity.      
 Mean TRF lengths of stable 21NT-pCMVNeo-BAP1 transfection clones generated in 
my study were not ascertained. However, forced overexpression of BAP1 the 21NT breast 
cancer cell line was associated with a similar effect on hTERT expression levels, telomerase 
activity, cell growth and proliferative capacity as that resulting from stable overexpression of 
BRCA1 within prostate and breast cancer cell lines (Xiong et al., 2003). BAP1 is known to 
interact with the RING finger domain of BRCA1, which was found to be essential for BRCA1-
mediated hTERT-repression by Xiong et al., (2003). Therefore, it is possible that the repression 
of hTERT expression and telomerase activity observed within stable 21NT-pCMVNeo-BAP1 
clones in my study may be linked to BRCA1. This is supported by the finding that BAP1 has 
been found to enhance the cell growth suppressive effect of BRCA1 in breast cancer (Jensen et 
al., 1998) and BAP1 mutations have been found to occur early in breast tumorigenesis 
(Newman et al., 2013, Stephens et al., 2012). Needless to say, further investigation is necessary 
to establish a direct functional link between BAP1 and BRCA1-mediated hTERT transcriptional 
repression. 
 In conclusion, forced overexpression of BAP1 within the 21NT breast cancer cell line 
was not associated with any significant change in clonogenic survival, but was associated with 
an initial but unsustained repression of hTERT transcription and telomerase activity and 
continuous cellular proliferation at a significantly reduced growth rate. Due to the observed 
telomerase repression and induction of replicative senescence pathways within 21NT-
chromosome 3 hybrids generated by Cuthbert et al., (1999), the findings presented within my 
study suggest that BAP1 is unlikely to be responsible for mediating this effect. However, due to 
the observed similarities between these findings and those presented by Xiong et al., (2003), it 
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is possible that BAP1 may be linked to BRCA1-mediated hTERT transcriptional repression, 
which presents another possible tumour suppressive role of BAP1 in cancer. These findings also 
suggest that there may be multiple genes, including BAP1, located on the short arm of 
chromosome 3 that are functionally responsible for maintaining stable telomerase repression 
within normal human somatic cells. 
  
5.4.2 RASSF1A 
 The RASSF1 isoform A (RASSF1A) gene is one of the most frequently inactivated genes 
in human cancer (Agathanggelou et al., 2005, Donninger et al., 2007). RASSF1A mutations 
have been identified within nasopharyngeal carcinomas (Pan et al., 2005) but the most common 
mechanism of inactivation identified within over 30 different cancer types is CpG island 
promoter hypermethylation, which has been shown to correlate with loss of RASSF1A 
expression (Agathanggelou et al., 2005, Donninger et al., 2007, Damman et al., 2000, Burbee et 
al., 2001). The RASSF1 genomic locus is located within an overlapping homozygous 120kb 
region of deletion on chromosome 3p21.3 in three SCLC cell lines and one breast cancer cell 
line (Sekido et al., 1998). Independent studies have reported that 30%-69% of breast tumour 
samples and breast cancer cell lines exhibit allele loss within 3p21.3, which suggests that 
important tumour suppressor genes may be present within this region (Maitra et al., 2001, Chen 
et al., 1994, De Oliveira et al., 2012). Consistent with these findings, the results presented 
within my study show that 56% of breast cancer cell lines examined were found to have 
undergone consistent copy number loss of five genes spanning a 5.5Mb region within 3p21.1-
p21.3 (47.1Mb-52.6Mb from the telomere), which encompasses the RASSF1 locus. Allele loss 
within this region was found to have occurred within 21NT and 21MT breast cancer cells lines, 
which are derived from the primary breast tumour and metastatic deposit of the same patient 
respectively. This provides additional evidence to show that the 3p21.1-p21.3 region may have 
been lost at an early point during breast tumorigenesis and may harbour important tumour 
suppressor genes. According to the Database of Genomic Variants (DGV, MacDonald et al., 
2013), allele loss at the RASSF1 locus has been observed within normal healthy individuals. 
Within my study, three normal HMEC strains derived from reduction mammoplasty tissue 
samples of individual healthy female patients were used to calibrate gene copy number within 
breast cancer cell lines in the absence of matched normal tissue samples. Therefore, copy 
number alterations at the RASSF1 locus could not be determined. However, RASSF1 is located 
50.3Mb from the telomere, which is in the center of the putative 5.5Mb region of allele loss 
observed within over half of breast cancer cell lines examined. Therefore, it is likely that the 
RASSF1 genomic locus was lost along with neighbouring gene loci within each sample 
analyzed.  
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 Normal breast epithelial cells have been found to express both RASSF1A and RASSF1C 
transcript isoforms, which are under the control of independent promoters within the RASSF1 
locus (Damman et al., 2000, Damman et al., 2001, Burbee et al., 2001). RASSF1A and 
RASSF1C encode 340 and 270 amino acid proteins respectively (Damman et al., 2000). The last 
four exons are common to both RASSF1A and RASSF1C and encode the RAS-association (RA) 
domain. Unlike RASSF1C, RASSF1A encodes an N-terminal putative SH3 domain and a 
diacylglycerol/phorbol ester binding domain (DAG). Around 60% of breast cancer cell lines 
have been found to undergo RASSF1A CpG island promoter hypermethylation, which is 
strongly associated with complete loss of RASSF1A expression (Damman et al., 2001, Burbee et 
al., 2001). RASSF1A promoter methylation has been observed within pre-malignant breast 
lesions and immortal non-tumorigenic breast cancer cell lines, which indicates that loss of 
RASSF1A may drive breast tumorigenesis (Dumont et al., 2009). Unlike RASSF1A, RASSF1C 
transcripts have been detected within breast and lung cancer cell lines and has not been found to 
undergo CpG island promoter hypermethylation in NSCLC and SCLC cell lines (Damman et 
al., 2000, Damman et al., 2001, Burbee et al., 2001). It is therefore thought that the RASSF1A 
isoform, but not RASSF1C, functions as a critical tumour suppressor gene in breast cancer. 
However, Vos et al., (2000) found that 67% of transformed ovarian cell lines exhibited 
undetectable levels of RASSF1C expression. In addition, forced overexpression of RASSF1C 
was found to suppress the growth of transformed T-293 human embryonic kidney cells, which 
was thought to be due to induction of pro-apoptotic signalling pathways. Similarly, Li et al., 
(2004) found that RASSF1C suppressed the growth of KRC/Y renal cell carcinoma and LNCaP 
prostate cancer cell lines. Therefore, the RASSF1C isoform may harbour tissue-specific tumour 
suppressor functions.  
 The primer sequences used to examine the expression levels of RASSF1 within breast 
cancer cell lines and normal HMEC strains in my study, were designed to detect all known 
protein coding transcript isoforms A, B, C, D and H. Exon 1 is common to RASSF1 transcripts 
A, D and H, which suggests that these isoforms are likely to be under the control of the same 
promoter that has been found to be frequently hypermethylated in breast cancer cell lines 
(NCBI, Damman et al., 2000, Damman et al., 2001, Burbee et al., 2001). The RASSF1B isoform 
appears to be expressed only within normal haematopoietic cells (Damman et al., 2000). My 
results demonstrate that 44% of breast cancer cell lines examined exhibit a 52-72% reduction in 
RASSF1 expression levels relative to normal HMEC strains. Damman et al., (2001) and Burbee 
et al., (2001) did not observe any detectable levels of RASSF1A expression within breast cancer 
cell lines. In contrast, all breast cancer cell lines examined within my study showed detectable 
levels of RASSF1 expression. However, this is likely to be due to the presence of RASSF1C 
transcripts, which are detectable within breast cancer cell lines regardless of RASSF1A 
expression (Burbee et al., 2001). Therefore, it is possible that the observed reduction in RASSF1 
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expression levels within breast cancer cell lines in my study is associated with loss of RASSF1A 
expression. In support of this, Damman et al., (2000) and Damman et al., (2001) detected both 
RASSF1A and RASSF1C transcripts within the H5S78T breast carcinoma cell line, whereas the 
MCF-7 cell line was found to display RASSF1C but undetectable levels of RASSF1A 
expression. Consistent with these findings, the results presented within my study showed that 
H5S78T and MCF-7 breast cancer cell lines exhibited 257% and 40% RASSF1 expression levels 
relative to normal HMEC strains respectively. Therefore, it is likely that the 21NT, 21MT and 
MTSV cell lines, which exhibited a greater than 50% reduction in RASSF1 expression relative 
to normal HMEC strains, may have also undergone transcriptional silencing of RASSF1A. These 
findings therefore provide additional evidence that deregulation of RASSF1 is a frequent event 
in breast cancer cells. Independent studies have shown that RASSF1A promoter 
hypermethylation is associated with poor disease-free survival and more progressive disease 
(Muller et al., 2003, Martins et al., 2011, Hagrass et al., 2013, Xu et al., 2012). In support of 
these observations, I found that breast cancer cell lines derived from the metastatic deposits of 
two breast cancer patients (21MT and MCF-7), were among those that exhibited the lowest 
levels of RASSF1 expression relative to normal HMECs.  
 RASSF1 is located within the 3p21.3 region, which is thought to harbour a telomerase 
repressor sequence that may be lost in breast cancer cells (Cuthbert et al., 1999). In support of 
the hypothesis that RASSF1A may function as a putative telomerase repressor gene, variant 
HMEC (vHMEC) cells transformed with the Ha-Ras-V12 oncogene were found to exhibit 
increased levels of RASSF1A promoter methylation and telomerase activity (Dumont et al., 
2009). In addition, forced overexpression of RASSF1A within the A549 lung cancer cell line has 
been associated with cell cycle arrest and senescence, which was found to be mediated by 
increased p21 expression and activation of pRb (Thaler et al., 2009). p53-mediated 
transcriptional repression of hTERT in breast cancer cells has been found to be mediated by p21
 
and recruitment of the histone-modifying E2F-pRb-HDAC complex to the hTERT promoter 
(Shats et al., 2004). Szutorisz et al., (2003) demonstrated that the chromosome 3-encoded 
hTERT repressor sequence mediates transcriptional repression of hTERT through altering the 
chromatin state around intron 2. Within my study, forced overexpression of RASSF1A within 
the 21NT breast cancer cell line was not associated with consistent transcriptional repression of 
hTERT or a reduction in telomerase activity compared to untreated or empty vector controls. 
These findings are consistent with those presented by Tanaka et al., (2005), demonstrating that 
transfection of wild-type RASSF1A within the RCC23 renal cell carcinoma cell line was not 
associated with any observable change in hTERT promoter activity. Similarly to 21NT breast 
cancer cells, introduction of a normal copy of human chromosome 3 into RCC23 cells by 
MMCT was associated with hTERT transcriptional repression, a significant reduction in 
telomerase activity and cell growth arrest (Ohmura et al., 1998). Together, these findings 
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provide evidence to show that RASSF1A is unlikely to function as a transcriptional regulator of 
hTERT in breast or renal cancer cells. 
 Reconstitution of RASSF1A expression within RASSF1A-deficient lung, 
nasopharyngeal, kidney, prostate and breast cancer cell lines has been associated with 
significant cell growth inhibition and decreased tumorigenicity in vitro and in vivo (Damman et 
al., 2000, Burbee et al., 2001, Chow et al., 2004, Dreijerink et al., 2001, Kuzmin et al., 2002, 
Thaler et al., 2012). In my study, transfection of wild-type RASSF1A within the 21NT breast 
cancer cell line was not associated with any observable change in colony formation when 
compared to empty vector controls. However, a significant reduction in average colony size of 
stable 21NT-pcDNA-RASSF1A clones relative to empty vector controls was observed, which 
suggests that RASSF1A may suppress the proliferation but not the clonogenic survival of 21NT 
cells. These results contrast findings presented by similar studies demonstrating that RASSF1A 
overexpression within cancer cell lines is associated with a significant reduction in cell survival. 
Stable overexpression of RASSF1A within H1299 NSCLC cells was associated with 40-60% 
decrease in anchorage-dependent growth, a 90% reduction in anchorage-independent colony 
formation and a significant reduction in tumour formation in nude mice, compared with empty 
vector controls (Burbee et al., 2001). Interestingly, several stable RASSF1A overexpressing 
H1299 clones were found to proliferate well in vitro, but were found to exhibit a significant 
reduction in anchorage-independent growth, which demonstrates that RASSF1A may have 
multiple independent functions that suppress cancer cell growth and malignant potential. 
Therefore, based on the observed lack of cell growth inhibition within stable 21NT-pcDNA-
RASSF1A clones within my study, it would be interesting to determine whether overexpression 
of RASSF1A is associated with any changes in the tumorigenicity of 21NT cells.  
   
5.4.3 PBRM1 
 The polybromo-1 (PBRM1) protein member of the SWI/SNF complex B (PBAF) 
chromatin remodelling complex has been found to play important functional roles in regulating 
gene expression, cell cycle control, replicative senescence and more recently, genome stability 
in human cells (Xia et al., 2008, Burrows et al., 2010, Brownlee et al., 2014, Karkarougkas et 
al., 2014). PBRM1 mutations have been identified within a variety of cancer types including 
breast, stomach, urinary tract and is the second most commonly mutated gene in renal cell 
carcinoma (www.cancer.sanger.ac.uk, Forbes et al., 2014, Varela et al., 2011). Loss of PBRM1 
in RCC is also associated with advanced tumour stage and poor disease prognosis (Pawlowski 
et al., 2012). These findings demonstrate that PBRM1 may function as an important tumour 
suppressor gene in multiple tissue types. 
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  According to the COSMIC database, only 0.95% of 1156 breast carcinoma samples 
have been found to harbour PBRM1 mutations, the majority of which are missense mutations 
located within PBRM1 bromodomains BD3, BD4, BD5, BD6, the protein-protein interaction 
bromoadjacent homology domain 1 (BAH1) and the DNA-binding high mobility group (HMG) 
domain (Forbes et al., 2014). Out of 43 breast cancer cell lines, Xia et al., (2008) identified four 
truncating mutations within the bromodomains of PBRM1 of four samples (Xia et al., 2008). 
The presence of PBRM1 mutations within these cell lines was also associated with loss of 
PBRM1 expression. These findings demonstrate that PBRM1 mutations are uncommon in breast 
cancer and can occur within all three major functional domains. However, Xia et al., (2008) 
demonstrated that almost half (48%) of 52 paired breast tumour samples showed loss of 
heterozygosity at two sites flanking the PBRM1 genomic locus. Similarly, the results presented 
within my study showed that 56% of breast cancer cell lines examined were found to have 
undergone allele loss within the PBRM1 locus. In addition, PBRM1 copy number variation 
(CNV) analysis of the HCC1143 breast cancer cell line confirmed the results presented by Xia 
et al., (2008) demonstrating the presence of a homozygous deletion within PBRM1. 
Interestingly, two breast cancer cell lines (22%) were found to possess a different number of 
alleles at the PBRM1 genomic locus when compared with neighbouring gene loci situated 
upstream of PBRM1 (BAP1, PARP-3, FLJ and SETD2). The SV40-immortalized MTSV breast 
cell line was found to have gained a single allele at all loci examined apart from PBRM1, which 
was found to be present at two copies. Similarly, the HCC1143 breast cancer cell line showed 
loss of a single allele at all loci examined apart from PBRM1, which was not present within 
HCC1143 genomic DNA. This demonstrates that allele loss within the PBRM1 locus is a 
frequent event in breast cancer and provides additional evidence to show that PBRM1 may 
function as an important tumour suppressor gene.  
 The high frequency of allele loss at the PBRM1 locus in breast cancer cells suggest that 
gene copy number alterations may influence PBRM1 function. In support of this, PBRM1 
expression levels within breast cancer cell lines that had undergone allele loss at the PBRM1 
locus were, on average, significantly lower than normal human mammary epithelial cell 
(HMEC) strains. However, both MCF-7 and BT20 breast cancer cell lines, which harbour two 
PBRM1 alleles, were also found to exhibit a greater than 50% reduction in PBRM1 expression 
levels relative to normal HMEC strains. These findings suggest that both gene copy number loss 
and transcriptional repression may contribute to deregulation of PBRM1 in breast cancer cells. 
In contrast to the findings presented within my study, DeCristofaro et al., (2001) showed that 
21NT, BT474, BT20, H5S78T and MCF-7 breast cancer cell lines display similar protein levels 
of SWI/SNF complex A and B members, including PBRM1 to the human Jurkat leukemic T-
cell line. Only 2 out of 21 (9.5%) breast cancer cell lines, were found to exhibit significantly 
lower levels of PBRM1 protein compared to Jurkat T-cells, which suggests that the majority of 
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breast cancer cell lines may possess normal levels of PBRM1 protein. However, mammalian 
SWI/SNF complexes have been found to exhibit cell-type specific differences in protein sub-
unit composition and expression levels, which is thought to be due to tissue-specific SWI/SNF 
chromatin remodelling functions (Wang et al., 1996). Therefore, taking into account the 
frequency of PBRM1 allele loss and the observed transcriptional deregulation of PBRM1 within 
breast cancer cell lines, it is possible that PBRM1 protein levels may also be significantly 
reduced when compared with normal HMEC strains.   
  Depletion of PBRM1 within normal human fibroblasts has been associated with delayed 
induction of replicative senescence pathways and a reduction in the expression levels of 
multiple p53 target genes, including p21 (Burrows et al., 2010). Transient overexpression of 
PBRM1 within PBRM1-deficient HCC1143 breast cancer cell line has also been associated with 
induced p21 expression and cell cycle arrest in G1 phase. PBRM1 has been found to interact 
directly with the p21 promoter and mediate transcriptional activation in response to DNA 
damage-induced signalling pathways (Xia et al., 2008). p53 has been found to mediate 
transcriptional repression of hTERT within breast cancer cells through activation of p21 and 
recruitment of E2F-pRB pocket protein-HDAC chromatin remodelling complexes (Shats et al., 
2004). Interestingly, the chromsome-3 encoded telomerase repressor gene within telomerase-
repressed 21NT-chromosome 3 hybrid colonies has been found to mediate transcriptional 
repression of hTERT, in part, through chromatin remodelling at intron 2 of the hTERT promoter 
(Szutorisz et al., 2003). Taking these findings into account, the putative role of PBRM1 in 
regulating hTERT expression and telomerase activity through induction of p21 was investigated 
within my study. Consistent with Xia et al., (2008) a positive correlation between PBRM1 and 
p21 expression levels was observed within stable 21NT-PBRM1 transfection clones and empty 
vector controls. However, a 2-11 fold increase in stable PBRM1 expression within 21NT cells, 
was not associated with a significant increase in p21 expression levels compared to empty 
vector controls. Xia et al., (2008) demonstrated a substantial up-regulation in p21 protein 16-22 
hours following transient transfection of HCC1143 and SUM1315 breast cancer cell lines with 
wild-type PBRM1. It is possible that transient overexpression of PBRM1-plasmid constructs 
produced a greater than 11-fold increase in PBRM1 transcript levels within breast cancer cells in 
the Xia et al., (2008) study. Therefore, high levels of PBRM1 expression may be required to 
induce p21 transcription within breast cancer cells.  
 In my study, stable overexpression of PBRM1 was not associated with a consistent 
reduction in hTERT expression levels within 21NT cells. Despite observing a substantial decline 
in telomerase activity within stable 21NT-pBABE-PBRM1 transfection clones, empty vector 
controls were also found to display a similar decrease in telomerase activity levels relative to 
untreated 21NT cells. Therefore, it remains unclear whether PBRM1 functions as a regulator of 
hTERT transcription or telomerase activity in breast cancer cells. Four out of six (67%) stable 
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PBRM1-transfected 21NT clone populations contained cells that exhibited morphological 
features of senescence. However, none of the stable clone populations were found to enter 
complete growth arrest within around five weeks of continuous culture. Cuthbert et al., (1999) 
found that the majority of telomerase-repressed 21NT-chromosome 3 hybrids entered growth 
arrest around 3-5 weeks following MMCT-mediated transfer of a normal copy of chromosome 3 
into 21NT cells. Therefore, it is unlikely that PBRM1 is responsible for the observed telomerase 
repression and cell growth arrest of 21NT-chromosome 3 hybrids within the Cuthbert et al., 
(1999) study. 
  Forced overexpression of wild-type PBRM1 within the HCC1143 breast cancer cell 
line was associated with a significant reduction in the number and size of stable colonies that 
emerged following two weeks of antibiotic selection, compared to empty vector controls (Xia et 
al., 2008). This was found to be due, in part, to induction of p21 expression and cell cycle arrest 
in G1 phase. Using the same plasmid vector constructs as Xia et al., (2008), I found that forced 
overexpression of PBRM1 within the 21NT breast cancer cell line was also associated with a 
significant reduction in stable cell colony formation relative to empty vector controls. Further 
investigation would be necessary to establish whether PBRM1-associated 21NT cell growth 
inhibition was also due cell cycle arrest in G1 phase. These findings provide additional evidence 
in support of the idea that that PBRM1 functions as an important tumour suppressor gene in 
breast cancer cells.  
 
5.4.4 PARP-3 
 The human poly(ADP-ribose) polymerase enzyme PARP-3 has been implicated in 
multiple signalling pathways including DNA repair, cell cycle progression, telomere stability 
and has recently been shown to play a role in telomerase regulation (Boehler et al., 2010, Rulten 
et al., 2010, Beck et al., 2014, Augustin et al., 2003, Fernandez-Marcelo et al., 2014). Around 
10% of primary invasive breast tumour samples have been found to exhibit significantly lower 
levels of PARP-3 mRNA relative to normal breast tissue samples (Bieche et al., 2011). 
Underexpression of PARP-3 was also more frequently associated with a high histopathological 
tumour grade and the presence of oestrogen and progesterone receptors. Overall, the majority of  
invasive breast tumour specimens were found to display similar expression levels of PARP-3 to 
normal breast tissue, with only a small proportion (1.4%) exhibiting significant overexpression 
(Bieche et al., 2011). These findings suggest that a deregulation of PARP-3 expression occurs 
within a sub-set of invasive breast cancer cases and may be associated with more progressive 
disease. Within my study, 44% of breast cancer cell lines were found to exhibit a greater than 
70% reduction in PARP-3 mRNA levels relative to normal HMEC strains. These included the 
21NT and 21MT cell lines derived from the primary tumour and metastatic deposit of a patient 
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diagnosed with breast IDC, the MCF-7 metastatic breast adenocarcinoma cell line and the 
SV40-immortalized breast luminal epithelial cell line MTSV. Both metastatic deposit-derived 
21MT and MCF-7 cell lines were found to exhibit the lowest levels of PARP-3 expression, 
which is consistent with the findings presented by Bieche et al., (2011) demonstrating an 
association between PARP-3 underexpression and more progressive disease. The observed 
downregulation in PARP-3 expression within cell lines derived from primary breast tumours 
and metastatic deposits suggests that loss of PARP-3 expression may promote breast tumour 
development and progression.   
 Within my study, normal HMEC strains were found to exhibit a wide range of PARP-3 
expression levels. Johnsson et al., (1999) demonstrated that PARP-3 transcripts can be detected 
within multiple normal human tissues, however certain tissue types including the placenta and 
thymus exhibit particularly low levels of PARP-3 mRNA. Similarly, immunohistochemical 
analysis of Cynomolgous Monkey tissues demonstrated that PARP-3 exhibits a tissue and cell-
type specific expression pattern (Rouleau et al., 2009). High levels of PARP-3 expression were 
observed primarily within the ductal epithelial cells of the prostate, pancreas and salivary glands 
and moderately high levels within mammary secretory and ductal epithelial cells. In addition, 
high levels of PARP-3 protein were observed within well-differentiated cells compared with 
immature cells such as oocytes or spermatogenic cells. Due to the observed interaction between 
PARP-3 and members of the PcG complex (Rouleau et al., 2007), it was proposed that high 
levels of PARP-3 may be required to repress the transcription of  genes involved in early 
development (Rouleau et al., 2009). PARP-3 protein was undetectable within human (HeLa and 
A549) and monkey cell lines, which suggests that actively proliferating cells generally exhibit 
low levels of PARP-3 expression both in vitro and in vivo. Normal early-passage pre-stasis 
HMEC strains consist of a mixture of breast luminal, myoepithelial and progenitor epithelial 
cells (Garbe et al., 2012). With increasing passages, the proportion of multipotent progenitor 
and luminal epithelial cells within the population have been found to increase. Therefore, the 
variation in PARP-3 expression levels observed within normal HMEC strains within my study 
may be due to differences in the passage number and composition of immature progenitor and 
differentiated epithelial cell types that existed within the population at the time of analysis.  
 Within my study, PARP-3 gene copy number variation analysis of nine breast cancer 
cell lines revealed that 56% had undergone allele loss within this locus. The majority of these 
breast cancer cell lines were derived from primary breast IDC tumours known to harbour p53 
mutations. The remaining four breast cancer cell lines were found to harbour two alleles (22%) 
or three alleles (22%) and were derived from primary breast IDC, metastatic breast 
adenocarcinoma, primary breast carcinosarcoma and an SV40-immortalized luminal epithelial 
cell line. These findings demonstrate that allele loss within the PARP-3 genomic locus may be a 
frequent event in breast cancer. Interestingly, I found that PARP-3 gene copy number was loss 
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was not always associated with a reduction in mRNA levels. BT474, HCC1143 and GI101 
breast cancer cell lines harbouring only one PARP-3 allele were found to exhibit similar levels 
of PARP-3 expression to normal HMEC strains. Moreover, both MCF-7 and MTSV cell lines, 
which harbour two and three PARP-3 alleles respectively, were among those breast cancer cell 
lines exhibiting the lowest levels of PARP-3 expression. Therefore, PARP-3 copy number 
alterations in breast cancer are not always associated with changes in PARP-3 expression and 
other mechanisms of transcriptional repression may also be responsible for the observed 
deregulation in PARP-3 expression levels. However, these results demonstrate that PARP-3 
copy number loss is a frequent event in breast cancer, which is consistent with the notion that 
this gene may function as a tumour suppressor.     
 The presence of high levels of telomerase activity within NSCLC tumour samples has 
been associated with low levels of PARP-3 expression (Frias et al., 2007). Within my study, all 
breast cancer cell lines examined were found to possess detectable levels of telomerase activity 
(Chapter 4.3.1.3). Interestingly, apart from BT20, breast cancer cell lines exhibiting higher 
levels of telomerase activity than the telomerized PC3-hTERT cell line were found to have 
either lost one allele at the PARP-3 locus, or were found to exhibit low PARP-3 mRNA levels 
relative to normal HMEC strains. In addition, the H5S78T breast carcinosarcoma cell line, 
which was found to exhibit the highest levels of PARP-3 expression, also exhibited low levels 
of telomerase activity levels when compared to other breast cancer cell lines examined. 
However, in contrast to Frias et al., (2007), not all breast cancer cell lines exhibiting the highest 
levels of telomerase activity were found to display a considerable decrease in PARP-3 
expression levels relative to normal HMECs. The protein levels or functional status of PARP-3 
within breast cancer cell lines was not examined within this study, therefore there is insufficient 
evidence to show that high levels of telomerase activity are associated with loss of PARP-3 
function in breast cancer. However, within the majority of breast cancer cell lines examined, 
deregulation of PARP-3 due to gene copy number loss or reduced expression levels was found 
to be associated with higher levels of telomerase activity. 
 Transient overexpression of PARP-3 within A549 lung adenocarcinoma cells has been 
associated with a significant decrease in telomerase activity relative to empty vector controls 
(Fernandez-Marcelo et al., 2014). In addition, shRNA-mediated depletion of PARP-3 within 
Saos-2 osteosarcoma cells, was associated with a significant increase in telomerase activity 
compared with non-targeting controls. Consistent with these findings, recent preliminary 
experiments carried out by my colleague Dr. Terry Roberts at Brunel University, have 
demonstrated that stable overexpression of PARP-3 within the 21NT breast cancer cell line is 
associated with a reduction in hTERT expression levels when compared with empty vector 
controls (Dr. Terry Roberts, unpublished data). PARP-3 is located within the 3p21.2 region, 
which is close to the 3p21.3-p22 region that is thought to contain a telomerase repressor 
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sequence in breast cancer (Cuthbert et al., 1999). The results presented within my study show 
that the majority of breast cancer cell lines exhibiting higher levels of telomerase activity have 
either undergone allele loss within PARP-3 locus, or display a substantial reduction in PARP-3 
expression levels. In addition, Boehler et al., (2010) demonstrated that loss of PARP-3 within 
normal human lung fibroblasts was associated with spontaneous sister telomere fusions and 
loss, indicating that PARP-3 may play a functional role in maintaining telomere stability 
(Boehler et al., 2010). These observations, together with the findings presented by Fernandez-
Marcelo et al., (2014) and Dr. Roberts provide evidence to show that PARP-3 may function as a 
negative regulator of hTERT transcription in breast and lung cancer cells. Future experiments 
will aim to determine whether stable PARP-3 overexpression within the 21NT cell line is 
associated with telomerase repression and induction of cellular senescence pathways.  
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        CHAPTER 6 
6 INVESTIGATING CHROMOSOME 3P STRUCTURE DURING THE 
MULTI-STEP PROCESS OF NORMAL HUMAN MAMMARY 
EPITHELIAL CELL (HMEC) IMMORTALIZATION 
 
6.1 INTRODUCTION 
 The transformation of normal human somatic cells into fully malignant tumour cells is 
thought to be a multi-step process involving the acquisition of multiple genetic alterations that 
allow bypass of intrinsic barriers to uncontrolled and unlimited cell growth (reviewed by 
Newbold., 2002, Stampfer and Yaswen., 2002). Studies examining the immortalization of 
normal finite lifespan, human epithelial cells in vitro have identified mechanisms by which 
these cells are able to bypass intrinsic barriers to proliferation (Stampfer and Yaswen., 2002). 
Normal HMECs, derived from reduction mammoplasty tissues of healthy individuals, normally 
proliferate for around 15-45 population doublings (PD) before entering growth arrest termed 
stasis (Figure 6.1, Brenner et al., 1998, Romanov et al., 2001). At this point, cells display 
expression of senescence-associated β-galactosidase (SA-β-gal), are karyotypically normal and 
exhibit significantly increased expression levels of the cyclin-dependent kinase inhibitor 
(CKDI) p16
INK4A
 (Brenner et al., 1998). Romanov et al., (2001) demonstrated that pre-stasis 
HMECs do not express detectable levels of telomerase activity and telomere attrition prior to 
growth arrest is approximately 30bp/PD. Once the cells had reached stasis, mean telomere 
restriction fragment (TRF) lengths were around 6kbp, which would indicate that stasis is a 
telomere-length independent barrier. Furthermore, exogenous hTERT expression within pre-
stasis HMEC cells was not associated with stasis bypass or cellular immortalization in the 
majority of cases (Stampfer et al., 2000). Only one immortal hTERT-transduced pre-stasis 
HMEC clone emerged, which was found to have lost p16 expression. It is thought that stasis 
occurs in response to stressful stimuli, which leads to induction of p16 expression, inhibition of 
pRb phosphorylation and cell cycle arrest in G1 (Brenner et al., 1998, Stampfer and Yaswen., 
2002). In support of this, HMECs cultured in serum-free media proliferate continuously for only 
2-3 passages before displaying increased levels of p16 expression and entering growth arrest 
(Hammond et al., 1984).  
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Figure 6.1 - Model of the barriers to indefinite proliferation encountered by normal human 
mammary epithelial cells (HMEC) and how these are bypassed/overcome (adapted from 
Stampfer and Yaswen., 2003). Normal primary HMECs undergo 10-45 population doublings 
(PD) before entering the p16/pRb-mediated stress-associated senescence barrier known as 
stasis (M0). Loss of p16 function through mutation or promoter hypermethylation allows stasis 
bypass. Post-stasis HMECs continue to divide for 30-80PD until mean telomere lengths reach 
≤5kb. Cells then enter replicative senescence/agonescence (M1), where cells exhibit abnormal 
changes in chromosome structure. In the absence of functional p53, HMECs undergo further 
telomere shortening and enter crisis (M2), which is characterised by extensive genomic 
instability and cell death. Following a rare mutational/epigenetic event during crisis, telomere 
maintenence mechanisms are activated and immortal clones emerge. In the presence of 
functional p53, post-stasis HMECs can become immortalized through a process termed 
conversion, which is characterized by the gradual acquisition of telomerase activity and 
resistance to TGF-β-induced growth arrest. Abbreviations: TRF (Telomere Restriction 
Fragment), ALT (Alternative Lengthening of Telomeres), TGF-β (Transforming Growth Factor-
Beta). 
 Small subpopulations of proliferating cells have been found to emerge sporadically 
from senescent cultures of HMECs maintained in both serum-containing and serum-free media 
(Brenner et al., 1998). Unlike normal human mammary fibroblasts, spontaneous emergence 
from stasis occurs more frequently and is associated with loss of p16 expression (Huschtscha et 
al., 1998, Brenner et al., 1998, Romanov et al., 2001). A common mechanism of p16 silencing 
observed within post-stasis HMECs is CpG island promoter methylation. Treatment of these 
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cells with the demethylating agent 5-aza-2-deoxycytidine was found to be associated with re-
expression of p16 and induction of senescence pathways (Brenner et al., 1998). Loss of p16 is a 
frequent event in breast cancer, with around 50% of breast tumours exhibiting undetectable 
levels of p16 expression (Geradts and Wilson., 1996). In addition, variant HMECs (vHMECs), 
which possess hypermethylated and silenced p16 expression, have been observed within 
histologically normal mammary tissue sections derived from healthy women, indicating that 
post-stasis mammary epithelial cells are already present in vivo (Holst et al., 2003). These 
findings demonstrate that p16 is a key mediator of stress-associated stasis and that loss of p16 
expression and bypass of the stasis barrier may be an early event in breast carcinogenesis. 
 Post-stasis, p16-deficient HMECs also known as post-selection or extended life 
HMECs, have been found to proliferate for up to 80 PD before entering a second growth plateau 
known as replicative senescence or agonescence (Figure 6.1, Romanov et al., 2001, Stampfer 
and Yaswen., 2002). Despite the presence of cells positive for SA-β-gal, HMECs at this growth 
plateau exhibit significantly different characteristics from cells at stasis, including a 
heterogeneous morphology, higher proliferative index and increased cell death (Romanov et al., 
2001). During the second exponential growth phase, HMECs undergo progressive telomere 
shortening and exhibit mean TRF lengths of around 3.5kbp upon reaching the replicative 
senescence barrier. This is accompanied by increasing levels of genomic instability including 
chromosomal deletions, translocations, rearrangements, telomeric fusions and γ-H2AX foci 
(Romanov et al., 2001, Garbe et al., 2009). The major mediator of this proliferative barrier is 
p53, which activates DNA damage response pathways and cell growth arrest in response to 
critical telomere shortening (Stampfer and Yaswen., 2002). Garbe et al., (2007) found that post-
stasis HMECs transduced with the dominant-negative p53 suppressor element GSE22 entered 
crisis, characterized by massive cell death and mean TRF lengths of around 3.1kbp. As 
expected, untreated p53-postive controls were found to enter replicative senescence. Ectopic 
expression of hTERT within post-stasis HMECs is sufficient to bypass replicative senescence 
pathways and lead to immortal transformation (Stampfer et al., 2000). These findings 
demonstrate that both replicative senescence and crisis are important telomere length-dependent 
barriers to proliferation and the presence of p53 within post-stasis HMECs is associated with 
induction of viable cell growth arrest.  
 Spontaneous emergence of immortal cells from replicative senescence has never been 
found to occur in vitro (Stampfer and Yaswen., 2002). Studies have shown that abrogation of 
p53 function through introduction of specific dominant-negative p53 mutants or transduction 
with the SV40 Large T-Antigen is associated with the rare emergence of immortal clones from 
crisis (Gao et al., 1996, Gollahan and Shay., 1996, Van Der Haegen and Shay., 1993). 
Spontaneous immortalization from crisis has also been observed within HMECs derived from a 
patient with Li Fraumeni syndrome, which harbour germline mutations in p53 (Shay et al., 
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1994). However, stable transduction of post-stasis HMECs with the p53 inhibitor GSE22 was 
associated with weak or no telomerase activity both prior to and as cells entered crisis, which 
demonstrates that loss of p53 function alone is not sufficient for de-repression of endogenous 
telomerase activity and cellular immortalization (Garbe et al., 2007). It is thought that a rare 
mutational event occurs during crisis that is responsible for telomerase reactivation (Shay., 
1993).  
 Interestingly, Stampfer et al., (1997) demonstrated that loss of p53 is not a necessary 
event for the immortal transformation of HMECs. Following benzo(a)pyrene (BaP)-treatment of 
primary HMEC cultures, two immortal cell lines 184A1 and 184B5 emerged (Stampfer and 
Bartley., 1985). They were found to harbour functional p53 but possess numerous chromosomal 
aberrations including deletions and translocations and were found to be non-tumorigenic. Early-
passage 184A1 and 184B5 cultures maintained continuous, non-uniform growth, progressive 
telomere shortening and no detectable telomerase activity for around 10-30PD. Once mean TRF 
lengths had reached around 2kbp, some surviving cells were found to express low levels of 
telomerase activity and displayed a limited ability to maintain growth in the presence of TGF-β 
(Stampfer et al., 1997). TGF-β‎ induces‎ growth‎ arrest within normal human epithelial cells, 
whereas resistance to TGF-β‎ is‎ a‎ common‎ feature‎ of‎ malignant‎ carcinoma‎ cells‎ and‎ is‎
associated with invasive properties (Fynan and Reiss., 1993). Over subsequent passages, both 
telomerase activity levels and resistance to TGF-β were found to increase, until mass cultures 
exhibited uniform growth patterns and were fully immortalized. It is thought that critical 
telomere shortening within early passage, conditionally immortal HMECs 184A1 and 184B5, 
triggered a 'conversion' process whereby telomerase was re-activated gradually through an 
epigenetic mechanism. These findings contrast previous observations that telomerase re-
activation occurs as a rapid event due to a rare mutation during crisis (Shay et al., 1993). 
Therefore, normal human epithelial cells may possess several mechanisms of telomerase-
repression that prevent immortal transformation. Interestingly, transduction of 184A1 cells with 
the p53-inhibitor GSE22, was associated with a more rapid increase in hTERT expression, 
telomerase activity and TGF-β resistance compared with untreated controls (Stampfer et al., 
2003). Therefore, loss of p53 function is insufficient to induce telomerase reactivation, but 
instead may accelerate the acquisition of rare mutational events required for telomerase de-
regulation and immortal transformation. In support of this, early-passage immortal p53-deficient 
HMECs have been found to exhibit higher levels of genomic instability with further genomic 
aberrations observed over increasing passages, than conditionally immortal HMECs harbouring 
functional p53 (Stampfer et al., 2003). 
 Transduction of hTERT within post-stasis HMECs is sufficient for bypass of replicative 
senescence barriers and complete immortal transformation (Stampfer et al., 2000). In addition, 
telomerase-positive cancer cell lines have been found to express hTERT transcripts, whereas 
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telomerase-negative normal human primary lung fibroblasts do not (Ducrest et al., 2001). 
Therefore, deregulation of hTERT transcription may be the primary mechanism by which 
telomerase is reactivated as a rare event during crisis. As discussed in earlier Chapters, 
introduction of a normal copy of human chromosome 3 within the 21NT breast cancer cell line 
was associated with a 30-fold reduction in endogenous hTERT expression and strong telomerase 
repression (Cuthbert et al., 1999, Ducrest et al., 2001). Deletion mapping of telomerase-positive 
segregant 21NT-chromosome 3 hybrids identified two regions on the short arm of chromosome 
3 (3p21.3-p22 and 3p12-21.1) that may harbour putative hTERT repressor sequences (Cuthbert 
et al., 1999). Furthermore, LOH within chromosome 3p has been found to occur within 52-87% 
of breast tumour samples and 45% of pre-neoplastic breast lesions, which demonstrates that 
critical tumour suppressor genes may be located within this region that are lost as a frequent and 
early event during breast carcinogenesis (Matsumoto et al., 1997, Martinez et al., 2001, Maitra 
et al., 2001, Chen et al., 1994, De Oliveira et al., 2012). Taking these observations into account, 
the primary aim of this study was to investigate whether genomic deletions within chromosome 
3p coincide with de-repression of hTERT and telomerase re-activation during the immortal 
transformation of normal HMECs.   
 
6.2 MATERIALS AND METHODS 
6.2.1 CELL LINES/STRAINS 
 This study was carried out in collaboration with my colleague at Brunel University Dr. 
Hemad Yasaei, who was responsible for cultivating all HMEC cell strains, their derivatives and 
for generating immortal clones. The normal HMEC 184D strain (Stampfer and Bartley., 1984), 
derived from reduction mammoplasty tissue of a 21-year old female Caucasian patient was 
employed for the purposes of this study (Table 2.1, Chapter 2.1.2.1). To generate immortal 
clones, pre-stasis HMEC 184D cells were treated with nickel chloride (NiCl2) to silence p16 
expression and bypass the stasis barrier (Figure 6.2 - 184D-Ni). Nickel chloride is known to 
mediate its carcinogenic effects through DNA methylation and heterochromatization of genes 
(Lee et al., 1995). Finite lifespan, post-stasis 184D-Ni cells were then transfected with short-
hairpin RNA (shRNA) that targets p53 (a kind gift from Professor E. K. Parkinson). Following 
selection of stable transfection clones, cells were found to enter crisis. After 6-12 weeks, 
spontaneous immortal clones were found to emerge, which were isolated and propagated as 
individual cell lines (Figure 6.2 - 184D-Nip53sh clones 2.1, 2.3, 3.3, 6.1, 6.2 and 6.3). Non-
targeting control 184D-Ni cells entered replicative senescence and no immortal clones were 
found to emerge spontaneously. In addition, immortal 184D-p16sh and 184D-hT1 cell line 
derivatives were also employed for the purposes of this study (Figure 6.2). The 184D-hT1 cell 
line was derived through electroporation of pre-stasis HMEC 184D cell cultures with hTERT 
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cDNA plasmid vectors (Dr. Yasaei, unpublished data). Transfected cells were found to undergo 
non-clonal bypass of both stasis and replicative senescence barriers (Figure 6.2). The 184D-
p16sh cell line was derived from transduction of pre-stasis 184D cells, maintained in low serum 
and low stress medium, with shRNA targeting p16 (Garbe et al., 2014). Following stasis bypass, 
immortal 184D-p16sh clones were reported to have emerged from crisis (Figure 6.2). As a 
normal telomerase-negative control, the finite lifespan, pre-stasis HMEC 184D strain was used 
(Stampfer and Bartley., 1984). The 21NT cell line, which is derived from a primary intraductal 
carcinoma of the breast, was included within this study to represent a telomerase-positive 
malignant breast tumour cell line (Band et al., 1990). This cell line was cultivated by me using 
the methods and culture conditions described previously (Table 2.2, Chapter 2.1.2).  
 
Figure 6.2 - A model showing the derivation of HMEC 184D cell strains/lines used during this 
study. HMEC 184D (Stampfer and Bartley 1984), 184D-p16sh (Garbe et al., 2014) 184D-Ni, 
immortal p53sh clones and the immortalized 184D-hT1 cell line were cultivated by Dr. Yasaei 
at Brunel University. The HMEC 184D cell strain and immortal 184D-p16sh cell line was 
obtained directly from the Human Mammary Epithelial Cell (HMEC) Bank, Lawrence Berkeley 
Laboratory, University of California (http://hmec.lbl.gov/mindex.html). 
 All HMEC 184D strains and their derivatives were provided to me upon request as cell 
pellets obtained from mass cultures growing in log-phase. These were immediately stored at -
80ºC until required. 21NT cells growing in log-phase were cultured under normal growth 
conditions (Chapter 2.1.2) in P100 dishes until sub-confluent. Cells were then harvested using 
the methods described in Chapter 2.1.3 and pelleted by centrifugation at 15,000xg for 5 minutes 
before storing at -80ºC until required.  
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6.2.2 GENE EXPRESSION ANALYSIS 
 The expression levels of p16, p53 and hTERT were examined within finite lifespan pre-
stasis HMEC 184D, post-stasis 184D-Ni, immortal HMEC 184D derivatives (184D-p16sh, 
184D-hT1 and 184D-Nip53sh clones 2.1, 2.3, 3.3, 6.1, 6.2, 6.3) and the 21NT cell line. Sample 
cell pellets were removed from -80ºC and thawed on wet ice. All cell lines/strains underwent 
RNA extraction, DNAseI-treatment and cDNA synthesis using the methods described in 
Chapter 2.3. Using the appropriate primer sequences and thermal cycling parameters described 
in Table 2.3 and Table 2.4 (Chapter 2.3.4), the gene expression levels of p16, p53 and hTERT 
were examined as described in Chapter 2.3.4. Target gene expression levels were normalized 
against TOP1 and YWHAZ endogenous control genes. The qbase
PLUS
 (Biogazelle) data analysis 
software program was used to calculate normalized relative quantities (NRQ) of target gene 
mRNA for all samples as described in Chapter 2.3.5.  
 
6.2.3 COPY NUMBER VARIATION (CNV) ANALYSIS 
 Physical mapping of human chromosome 3p structure within finite lifespan HMEC 
184D strains, immortal derivatives and the 21NT breast cancer cell line was determined by 
CNV analysis of five annotated genes and one region (termed FHIT-prox henceforth)  spanning 
the length of chromosome 3p including, SUMF1, RAR-β, SETD2, PBRM1, FHIT-prox and 
CADM2 (Table 6.1). FHIT-prox is located at 3p14.2, which is approximately 1.4kbp 
downstream from FHIT.  
Table 6.1 - Details of target genes/region selected for physical chromosome 3p mapping by 
CNV analysis 
Gene Full Name 
NCBI Location: Distance from Telomere 
(Mb) 
SUMF1 Sulfatase modifying factor 1 3p26.1c: 4.4 
RAR-β Retinoic acid receptor-β 3p24.2a: 25.5 
SETD2 SET domain containing 2 3p21.31f: 47.1 
PBRM1 Polybromo-1 3p21.1e: 52.7 
FHIT-
prox 
Proximal to the fragile histidine 
triad 
3p14.2b: 61.3 
CADM2 Cell adhesion molecule 2 3p12.1a: 85.9 
Abbreviations: NCBI (National Centre for Biotechnology Information, 
http://www.ncbi.nlm.nih.gov/) 
 Sample cell pellets were first removed from -80ºC and thawed on wet ice. Genomic 
DNA (gDNA) was extracted from each sample as described in Chapter 2.2 and target gene CNV 
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analysis was carried out using pre-designed Taqman
®
 Copy Number Assay primers developed 
by ABI (Applied Biosystems, US) according to manufacturer's guidelines (Chapter 2.5). Details 
of gene primer sets used to determine target gene copy number are described in Table 2.6 
(Chapter 2.5). Normal pre-stasis HMEC 184D cell gDNA extracts was used to calibrate gene 
copy number within all samples. The Copy Caller™ Software data analysis program was used 
to calculate target gene copy number within all samples (Chapter 2.5).  
 
6.3 RESULTS 
6.3.1 CHARACTERIZATION OF HMEC 184D AND IMMORTAL DERIVATIVES 
 In order to determine whether changes in chromosome 3p structure occur during the 
immortal transformation of normal HMECs, the primary HMEC 184D cell strain together with 
post-stasis and immortal derivatives (cultivated and developed by my colleague Dr. Hemad 
Yasaei, Brunel University), were investigated (Table 6.2). These included pre-stasis and post-
stasis finite lifespan HMEC 184D cell strains, six immortal 184D-Nip53shRNA clones that had 
emerged from crisis following stable knockdown of p53, an immortal 184D cell line derived 
from transfection of pre-stasis 184D cells with hTERT and an immortal p16-shRNA treated 
184D cell line derivative (Figure 6.2 and Table 6.2). To generate immortal 184D-Nip53sh 
clones, pre-stasis HMEC 184D primary cultures had been treated with nickel chloride to induce 
epigenetic silencing of p16 and bypass the stasis barrier (Dr. Yasaei, unpublished data). 
Following treatment of finite lifespan 184-Ni cells with shRNA targeting p53, cells entered 
crisis and immortal clones were found to emerge at a frequency of around 2x10
-7
 (184D-
Nip53sh clones: 2.1, 2.3, 3.3, 6.1, 6.2, 6.3). According to recent data, these clones are 
telomerase positive and have been found to proliferate continuously for over 110 PD (Dr. 
Yasaei, unpublished data). It is thought that telomerase re-activation occurs due to a rare 
mutational event during cell crisis (Shay et al., 1993). However the findings presented by 
Stampfer et al., (1997) demonstrate that loss of p53 is not required for telomerase re-activation 
to occur and that p53-independent mechanisms of telomerase repression may exist within 
normal HMECs. Therefore, 184D-hT1 (Dr. Yasaei, unpublished data) and 184-p16sh (Garbe et 
al., 2014) cell line derivatives, which did not acquire an immortal phenotype through enforced 
abrogation of p53 function, were also employed for the purposes of this study. The 184D-p16sh 
cell line was found to emerge spontaneously from replicative senescence, whereas 184D-hT1 
was found to exhibit non-clonal bypass of both stasis and replicative senescence barriers (Figure 
6.2). The 21NT cell line, derived from a malignant primary intraductal carcinoma of the breast, 
was also included within this study. This particular cell line has been found to express hTERT 
transcripts (Ducrest et al., 2001, Szutorisz et al., 2003, Chapter 4.3.2) is telomerase positive 
(Cuthbert et al., 1999, Chapter 3.3.2) and was previously shown to have undergone allele loss of 
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a 5.5Mb region within 3p21.1-p21.3 (Chapter 5.3.1). Importantly, the 21NT cell line is thought 
to have lost a critical telomerase repressor gene on chromosome 3p, as introduction of a normal 
chromosome 3 copy by MMCT is associated with strong telomerase repression and induction of 
cell growth arrest (Cuthbert et al., 1999).  
Table 6.2 - A summary of HMEC cell strains, immortal derivatives and breast cancer cell lines 
employed for the purposes of this study 
Finite Lifespan Indefinite Lifespan 
Pre-Stasis 
HMEC 
Post-Stasis 
HMEC 
Immortal HMECs 
Malignant Breast 
Cancer Cell Line 
184D (P5) 
184D-Ni 
(P22) 
184D-Nip53sh clones: 2.1 (P34), 2.3 
(P34), 3.3 (P34), 6.1 (P34), 6.2 (P32), 6.3 
(P34) 
21NT (P45) 
  
184D-hT1 (P32) 
 
184D-p16sh (P32) 
Abbreviations: P (passage number) 
 To verify the stage of immortal transformation of each cell strain/line, the expression 
levels of p16, p53 and hTERT were examined. As shown in Figure 6.3A, the nickel-treated 
184D-Ni strain and all immortal 184D variants were found to exhibit either low or undetectable 
levels of p16 expression relative to pre-stasis 184D cells, which confirms that these cell 
strains/lines had bypassed the stasis barrier. Loss of p16 expression was also observed within 
the 21NT breast cancer cell line. All HMEC 184D-Nip53sh clones were found to exhibit a 
greater than 90% reduction in p53 expression relative to pre-stasis 184D and post-stasis 184D-
Ni cell strains (Figure 6.3B). Both 184D-p16sh and 184D-hT1 immortal cell lines were found to 
display similar to or higher levels of p53 relative to normal pre-stasis 184D cells, which 
suggests that p53 may be functional within these immortal 184D derivatives. The 21NT cell 
line, which is known to harbour a frameshift mutation within the coding region of p53 (Liu et 
al., 1994), was found to display a 67% reduction in p53 expression levels relative to the normal 
pre-stasis 184D cell strain (Figure 6.3B).  
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Figure 6.3 - Normalized relative quantities (NRQ) of (A) p16, (B) p53 and (C) hTERT mRNA 
within nickel chloride-treated post-stasis 184D-Ni cells, immortalized 184D-hT1, spontaneously 
immortalized 184-p16sh and 184D-p53sh clones and the 21NT breast cancer cell line relative 
to the pre-stasis primary 184D cell strain. NRQ values represent the mean ± standard error 
(SE) of triplicate repeats for each sample.   
 As shown in Figure 6.3C, all 184D-Nip53sh clones that emerged from crisis were found 
to exhibit substantially higher levels of hTERT expression relative to the normal pre-stasis 184D 
cell strain and the post-stasis 184D-Ni strain. This indicates that de-repression of endogenous 
hTERT expression had occurred following stable knockdown of p53 and emergence from crisis, 
and not following nickel chloride treatment of primary 184D cells and clonal bypass of stasis. 
Around 50-fold higher levels of hTERT expression were observed within immortal 184D-p16sh 
cells, which confirms that stable knockdown of p16 and clonal bypass of replicative senescence 
was associated with hTERT de-repression and immortal transformation of this cell line. As 
shown in Figure 6.3C, immortalized 184D-hT1 cells were found to display undetectable levels 
of hTERT expression. The primer sequences used to determine hTERT expression levels within 
this study were previously designed by Ducrest et al., (2001) to detect only pre-spliced 
immature hTERT transcript molecules by amplifying a region within the exon 2-intron 2 
boundary and therefore do not detect exogenous hTERT cDNA. The immortal 184D-hT1 cell 
line was derived from transduction of pre-stasis HMEC 184D cells with hTERT cDNA (Garbe 
et al., 2014). This accounts for the lack of pre-spliced hTERT mRNA expression within 184D-
hT1 cells and confirms that re-activation of endogenous hTERT did not occur during immortal 
transformation of this cell line.   
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6.3.2 PHYSICAL MAPPING OF CHROMOSOME 3P STRUCTURE AT DIFFERENT 
STAGES OF HMEC IMMORTAL TRANSFORMATION 
 To investigate changes in chromosome 3p structure during the immortal transformation 
of normal HMEC cells, copy number variation analysis (CNV) of five genes and one region 
proximal to the fragile histidine triad (FHIT) gene (FHIT-prox), which together span 
chromosome 3p12.1-26.1, were examined within the primary HMEC 184D strain, nickel 
chloride-treated post-stasis 184D-Ni cells, immortal 184D-Nip53sh clones, immortal 184D-hT1 
and 184Dp16sh derivatives and the primary breast carcinoma cell line 21NT.   
 As shown in Figure 6.4, both primary pre-stasis HMEC 184D and nickel chloride-
treated post-stasis 184D-Ni strains were found to harbour two alleles at all genomic loci 
examined, which suggests that gross structural changes in chromosome 3p did not occur 
following nickel chloride treatment of primary 184D cells and clonal bypass of stasis. 
Interestingly, four out of six (67%) immortal 184D-Nip53sh clones were found to have 
undergone allele loss at one or more genomic loci examined. This demonstrates that genomic 
deletions within chromosome 3p are a common event following functional inactivation of p53, 
clonal emergence from crisis, hTERT transcriptional derepression and acquisition of an 
immortal phenotype. However, two immortal 184D-Nip53sh clones (6.2 and 6.3) and the 
immortal 184D-p16sh and 184D-hT1 cell line derivatives were found to exhibit no change in 
allele number at all loci examined, compared to primary pre-stasis HMEC184D cells (Figure 
6.4). This demonstrates that immortal transformation through clonal bypass of crisis or 
replicative senescence barriers is not always associated with gross structural losses of 
chromosome 3p. However, these findings do not exclude the possibility that smaller structural 
alterations may have occurred in regions between each of the genomic loci examined in this 
study. Allele loss at all genomic loci was observed within malignant 21NT breast cancer cells, 
which suggests that this particular cell line has undergone gross structural losses of chromosome 
3p. Together these findings demonstrate that physical deletions of chromosome 3p occur as an 
early and frequent event during the immortal transformation of normal HMECs and are 
specifically associated with clonal bypass of the crisis barrier and de-repression of hTERT 
expression (Figure 6.3C). These findings are therefore also consistent with the notion that 
critical hTERT regulatory sequences may exist on chromosome 3p (Cuthbert et al., 1999, 
Ducrest et al., 2001, Szutorisz et al., 2003, Ohmura et al., 1995, Tanaka et al., 1998, Abe et al., 
2010). 
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Figure 6.4 - Copy number variation (CNV) analysis of six genes spanning the length of human 
chromosome 3p (3p12.1-p26.1) within pre- and post-stasis HMEC 184D strains, stable 
immortal 184D-Nip53sh clones, immortal 184D-p16sh and 184D-hT1 cell line derivatives and 
the 21NT breast cancer cell line. (A.) An ideogram of chromosome 3p shows the relative 
positions of each gene used to map chromosome 3p structure. (B.) A table showing the number 
of alleles present within cell lines/strains at each gene loci examined, relative to the pre-stasis 
HMEC 184D strain. 
  Recently, a high-density single nucleotide polymorphism (SNP) array (CytoSNP12, 
Illumina) was commissioned by my colleague Dr Yasaei to investigate genome-wide alterations 
in chromosome structure within the same set of finite lifespan HMEC 184D cell strains and 
immortal derivatives (Dr. Yasaei, unpublished data). As shown in Figure 6.5, the frequency and 
location of genomic losses and gains on chromosome 3p are largely consistent with those 
observed from the above CNV analysis of specific genes/regions spanning the length of 
chromosome 3p (Figure 6.4). SNP array analysis verified the incidence of genomic losses on 
A. 
B. 
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chromosome 3p within the same four immortal HMEC 184D-Nip53sh clones (Figure 6.5). 
These data also confirmed extensive allele loss of chromosome 3p within HMEC 184D-
Nip53sh clones 2.1 and 2.3 and 3.3. However, CNV analysis of 184D-Nip53sh clone 6.1 
identified allele loss within the RAR-β locus, which is located within 3p24.2 (Figure 6.4). SNP 
array analysis of the same sample revealed the presence of two discrete regions of deletion; 
3p14.2-p22.2 and 3p25.1-p26.2. The underlying cause of this inconsistent observation is 
unclear. However, as described in Table 6.2, gene expression and CNV analysis of this 
particular clone was carried out at passage number 34 (P34) whereas SNP array analysis was 
carried out at P36 (Dr. Yasaei, unpublished data). The identification of different structural 
alterations on chromosome 3p within later passage cells could indicate high levels genomic 
instability and evidence of clonal selection.  
  SNP array analysis demonstrated the absence of non-random structural alterations on 
chromosome 3 within post-stasis HMEC 184D-Ni cells, which confirmed that nickel chloride 
treatment and clonal emergence from stasis was not associated with any structural alterations on 
chromosome 3p. On the other hand, all 184D-Nip53sh clones were found to have undergone 
copy number gains and/or losses of multiple regions on chromosome 3. This indicates that 
genomic changes on chromosome 3 are specifically associated with clonal emergence from 
crisis and de-repression of hTERT expression (Figure 6.3C). Four (56%) 184D-Nip53sh clones 
displayed genomic losses on the long-arm (q-arm) of chromosome 3, the majority of which 
involved loss of a region localized to 3q29. In addition, copy number gain of multiple discrete 
regions on chromosome 3q was observed within 50% of immortal p53sh clones (Figure 6.5A). 
Similarly, the 21NT breast cancer cell line was found to have undergone copy number gain of 
the majority of chromosome 3q, which suggests that oncogenic sequences may exist within this 
region that promote malignant progression. However, the most common structural alteration 
that was found to occur on chromosome 3 within stable 184D-Nip53sh clones, was whole or 
partial loss of chromosome 3p (Figure 6.5A). Alignment of chromosome 3 within 184D-
Nip53sh clones 2.1, 2.3, 3.3 and 6.1 revealed a common region of deletion involving 3p14.2-
p22, which overlaps with commonly deleted regions that were thought to harbour a putative 
telomerase repressor sequence by Cuthbert et al., (1999) (Figure 6.5B). These findings could 
signify the presence of critical sequences within this region that prevent bypass of telomere 
length-dependent barriers to proliferation, such as hTERT regulatory sequences. However, SNP 
array analysis confirmed the absence of chromosome 3p losses within the two remaining 
immortal 184D-Nip53sh clones (6.2 and 6.3, Figure 6.5A), which demonstrates that large 
physical genomic deletions within this region are not always associated with hTERT repression 
and immortal transformation of normal HMECs.  
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Figure 6.5 - Single nucleotide polymorphism (SNP) array analysis of chromosome 3 within (A) 
pre- and post-stasis HMEC 184D strains, six immortal 184D-Nip53sh, the immortalized 184D-
hT1 cell line and the 21NT breast cancer cell line relative to the pre-stasis HMEC 184D strain. 
(B) Alignment of chromosome 3p deletions within four immortal 184D-Nip53sh clones 
(courtesy of Dr. Yasaei, unpublished data). Green and red boxes/lines indicate the positions of 
chromosome 3 allele gains and losses respectively. Grey highlighted regions indicate the 
absence of heterozygosity. SNP array analysis was carried out using the Illumina iScan, 
Infinium HD Bead Chip at Barts and the London School of Medicine and Dentistry. Data 
analysis was carried out by Dr. Yasaei  (Brunel University).   
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6.4 DISCUSSION 
 Around 70% of ductal carcinoma in situ (DCIS) and 100% of invasive breast lesions 
have been found to express telomerase activity, indicating that cellular immortalization is an 
early event that precedes the acquisition of malignant features (Umbricht et al., 1999). Normal 
human mammary epithelial cells (HMEC) have been found to encounter two distinct barriers to 
cellular immortalization in vitro; the stress-associated stasis barrier and the telomere 
dysfunction-associated replicative senescence barrier (Stampfer and Yaswen., 2002). Stasis 
bypass has been achieved in vitro through mutational or epigenetic silencing of p16 (Stampfer 
and Bartley., 1985, Romanov et al., 2001). Post-stasis or extended lifespan HMECs have been 
found to exhibit high levels of genomic instability due to progressive telomere shortening until 
cells enter replicative senescence (Romanov et al., 2001). Overcoming the second growth 
plateau is dependent on the immortal transformation of cells through de-repression of hTERT 
and reactivation of telomerase activity (Newbold., 2002). It is thought that high levels of 
genomic instability, as cells approach replicative senescence, give rise to rare errors that are 
responsible for telomerase reactivation. However, the mechanisms that mediate hTERT 
repression within normal HMECs and the specific genomic errors required for hTERT de-
repression during cellular immortalization remain obscure.  
 A common genomic alteration observed within up to 87% primary breast carcinomas is 
loss of heterozygosity (LOH) of the short arm of chromosome 3 (3p) (Matsumoto et al., 1997, 
Martinez et al., 2001, Maitra et al., 2001, Chen et al., 1994, De Oliveira et al., 2012). 45% of 
pre-neoplastic breast lesions have been found exhibit genomic losses on chromosome 3p, which 
indicates that this region harbours important tumour suppressor genes that are lost as an early 
event in breast carcinogenesis (Maitra et al., 2001). Using microcell-mediated 
monochromosome transfer (MMCT) techniques, Cuthbert et al., (1999) demonstrated that 
sequences present on the short arm of chromosome 3 (3p) may function to repress telomerase 
activity within breast cancer cells. These repressor sequences are thought reside within 3p21.3-
p22 and/or 3p12-p21.1. Subsequent studies showed that chromosome 3p-encoded sequences 
mediate strong telomerase repression and cell growth arrest through transcriptional silencing of 
hTERT (Ducrest et al., 2001, Szutorisz et al., 2003). In collaboration with my colleague Dr. 
Yasaei, an in vitro model of HMEC immortalization was used to investigate the timing, 
frequency and location of genomic losses on chromosome 3p. This particular model involved 
the generation of immortal transformants through abrogation of two relevant breast tumour 
suppressor genes; p16 and p53, that are transcriptionally silenced and mutated in approximately 
50% and 23% of breast cancers respectively (Geradts and Wilson., 1996, COSMIC database; 
Forbes et al., 2015). Together, our findings demonstrate that genomic losses on chromosome 3p 
are a frequent clonal event that coincides with de-repression of hTERT and emergence from 
crisis. Alignment of chromosome 3p deletions revealed a common region of deletion 
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encompassing 3p14.2-p22. Interestingly, this region partially overlaps both commonly deleted 
regions, 3p21.3-p22 and 3p12-p21.1, observed within segregant, telomerase positive 21NT-
chromosome 3 hybrids in the Cuthbert et al., (1999) study. Furthermore, this identified region 
also encompasses the 490kb region of deletion located within 3p21.31, which was previously 
thought to harbour a putative telomerase repressor sequence (Dr. T. Roberts, unpublished data). 
These findings therefore provide additional evidence to show that critical hTERT repressor 
sequences may be located on chromosome 3p that are lost during the immortal transformation 
of breast epithelial cells. Consistent with these observations, the presence of p53 mutations has 
been strongly associated with genomic deletions on chromosome 3p in breast cancer, which 
suggests that the co-incidence of these events may drive breast carcinogenesis (Deng et al., 
1996). A strong relationship between p53 mutations and chromosome 3p loss has also been 
observed in head and neck squamous cell carcinoma (HNSCC) and the combination of these 
events is associated with worse patient survival (Gross et al., 2014). Chromosome 3p LOH has 
been identified within pre-cancerous breast lesions in vivo (Deng et al., 1994, Moinfar et al., 
2000). Around 41% of mammary ductal intraepithelial neoplasia (DIN) lesions have been 
shown to undergo LOH within chromosome 3p14.2 (Moinfar et al., 2000). Furthermore, 60% of 
morphologically normal breast tissue samples obtained from regions adjacent to breast 
carcinomas have been found to harbour genomic losses within 3p22-p25 (Deng et al., 1996). 
These findings indicate that critical tumour suppressor genes located within chromosome 3p 
may be lost as an early event during breast carcinogenesis. 
 Functional inactivation of p53 within post-stasis extended lifespan HMEC cultures is 
associated with spontaneous emergence from crisis and has been shown to accelerate the 
acquisition of an immortal phenotype (Stampfer et al., 2003, Gao et al., 1996, Gollahan and 
Shay., 1996, Van Der Haegen and Shay., 1993). Continued proliferation of HMECs beyond the 
stasis barrier is associated with progressive telomere shortening resulting in gross chromosomal 
abnormalities including rearrangements, translocations, deletions and telomeric associations as 
cells approach replicative senescence (Romanov et al., 2001). Telomere shortening has been 
observed within histologically normal breast epithelium and within almost 80% of DCIS 
lesions, which provides evidence that telomere dysfunction may occur in vivo and early in 
breast carcinogenesis (Meeker et al., 2004). In addition, DCIS lesions have been found to 
exhibit  a greater number of cytogenetic abnormalities than pre-cancerous hyperplastic lesions 
(O'Connell et al., 1998). Higher levels of genomic instability have been observed within post-
stasis HMECs lacking functional p53 compared with those harbouring functional p53 (Stampfer 
et al., 2003). This has also been observed in primary breast cancers whereby abnormal p53 
protein expression is strongly associated with higher levels of genomic instability (Eyfjörd et 
al., 1995). For this reason, it is thought that inactivation of p53 may accelerate the acquisition of 
specific genomic errors required for hTERT de-repression and immortal transformation 
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(Stampfer et al., 2003). However, due to the presence of multiple genomic aberrations in early 
breast lesions in vivo and post-stasis HMECs in vitro, the specific errors responsible for 
immortal transformation are difficult to elucidate.  
 In order to narrow the search for genomic errors specific to cellular immortalization, 
Severson et al., (2014) carried out exome sequencing and copy number variation (CNV) 
analysis of benzo(a)pyrene (BaP)-treated post-stasis HMECs and two p53-functional immortal 
derivatives, which have not been found to exhibit high levels of initial and sustained genomic 
instability over continuing passages (Stampfer et al., 2003). These immortal derivatives 
emerged from replicative senescence and were found to acquire sufficient levels of telomerase 
activity to maintain telomere lengths through a gradual process termed conversion (Stampfer et 
al., 1997). Severson et al., (2014) found that post-stasis BaP-treated cells were found to harbour 
mutations within known cancer driver genes. Intriguingly, over 95% of mutations observed 
within immortal BaP-clones were also identified within post-stasis BaP-precursor cells, 
indicating that only a few additional mutations were associated with immortal transformation 
(Severson et al., 2014). Genes harbouring mutations that were predicted to influence protein 
function included NKRF (NFKB repressing factor), SORBS2 (sorbin and SH3 domain 
containing 2) and GLTSCR1L (Glioma tumour suppressor candidate region gene 1-like). 
However, none of the additional mutated genes were common to both immortal clones. 
Interestingly, a clear difference in the number of CNVs between post-stasis BaP-precursors and 
immortal derivatives were identified. Aside from genomic losses on chromosomes 6 and 12, one 
immortal BaP-clone was found to have undergone single copy deletions on chromosome 3p. 
These findings are consistent with those presented in this Chapter demonstrating that 
chromosome 3p loss is an early event in the immortal transformation of HMECs and is 
associated with telomerase reactivation.  
 In a recent study, Garbe et al., (2014) found that non-clonal immortal transformation of 
HMECs can be achieved by targeting both stasis and replicative senescence barriers directly 
through treatment with p16-shRNA and transduction of the c-MYC oncogene. Immortal 
derivatives were found to exhibit a normal karyotype and with none or few genomic 
abnormalities or CNVs. This demonstrates that gross genomic instability and specific losses on 
chromosome 3p are not absolute requirements for the immortal transformation of HMECs. 
Consistent with this findings, we observed no CNVs on chromosome 3p within the immortal 
184D-16sh cell line derivative during this study. Novak et al., (2009) observed an association 
between genome-wide DNA methylation changes and non-clonal bypass of senescence barriers, 
therefore epigenetic alterations are thought to be essential for immortal transformation (Garbe et 
al., 2014). Collectively, these observations do not eliminate the possibility that critical 
telomerase repressor sequences may exist on chromosome 3p within normal HMECs. Aside 
from genomic deletions and rearrangements, genes residing within the 3p14-3p21 region, 
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including FHIT and RASSF1A, have been found to undergo frequent hypermethylation in breast 
cancer (Buchagen et al., 1994, Zöchbauer-Müller et al., 2001, Damman et al., 2001). Therefore, 
investigating both genetic and epigenetic changes on chromosome 3p during the immortal 
transformation of HMECs, may narrow the search for critical telomerase regulatory sequences.  
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CHAPTER 7 
7 GENERAL DISCUSSION AND FUTURE WORK 
 Cellular immortality is one of the ten hallmarks of human cancer (Hanahan and 
Weinberg., 2011). Normal human somatic cells proliferate for a finite number of population 
doublings before entering a telomere length-dependent growth barrier termed replicative 
senescence (Hayflick and Moorhead., 1961, Hayflick., 1965). Overcoming this barrier is 
associated with the acquisition of telomere maintenance mechanisms, which permit indefinite 
growth (Newbold., 2002, Stampfer and Yaswen, 2002). There is strong evidence to show that 
cellular immortalization is an essential pre-requisite for malignant transformation of mammalian 
cells and therefore represents a critical step in human carcinogenesis (Newbold et al., 1982, 
Newbold and Overell., 1983) The predominant mechanism of telomere maintenance in human 
cancer is reactivation of telomerase activity, which is thought to be due to transcriptional de-
repression of the gene encoding the reverse transcriptase subunit of telomerase, hTERT 
(Newbold., 2002). The immortal transformation of normal human somatic cells in vitro has only 
been found to occur as a rare event following bypass of senescence barriers through treatment 
with chemical carcinogens, transduction of viral oncoproteins or direct functional inactivation of 
senescence effector proteins (Newbold., 2002, Stampfer and Yaswen., 2002). Therefore, 
stringent mechanisms of hTERT repression must exist within normal human somatic cells that 
are lost as a rare event during immortal transformation. 
 Telomerase repression and restoration of limited growth potential in human cancer cells 
has been achieved through somatic whole cell fusion with normal human cells or following the 
introduction of single normal human chromosomes by microcell-mediated monochromosome 
transfer (MMCT) (Pereira-Smith and Smith., 1983, Cuthbert et al. 1999, Ducrest et al., 2002). 
Monochromosomal hybrid studies have shown that human chromosomes 3, 4, 6, 7, 10 and 17 
harbour regulatory sequences that repress telomerase activity in different cancer types (see 
Chapter 1.3.5.2.2.3, reviewed by Ducrest et al., 2002, Tanaka et al., 2005). The available data 
indicate that no single chromosome represses telomerase activity within all cancer cell lines. 
Furthermore, there is some evidence to suggest that multiple sequences may be present on the 
same chromosome, which function to repress telomerase activity in different cancer types 
(Tanaka et al., 2005). This has led to the notion that telomerase regulation is tissue-specific and 
different telomerase regulatory sequences can be inactivated in different cancer types. However, 
it is unclear whether more than one mechanism of telomerase regulation may be inactivated 
within the same cancer type. To investigate this further, I carried out MMCT-mediated transfer 
of chromosome 3 and 17 into the 21NT primary breast cancer cell line, which had been 
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previously shown to undergo telomerase repression and growth arrest following introduction of 
chromosome 3 (Cuthbert et al., 1999). Chromosome 17 harbours the p53 tumour suppressor 
gene, which is mutated in around 23% of breast cancers and has also been shown to repress 
hTERT transcription within breast cancer cells (Shats et al., 2004, COSMIC database; Forbes et 
al., 2014). The majority of 21NT-chromosome 3 and 21NT-chromosome 17 hybrids were found 
to exhibit telomerase repression and were found to either enter growth arrest or display a 
significant reduction in cell growth rate. Consistent with these findings, Backsch et al., (2001) 
found that introduction of human chromosomes 3 and 4 into the HeLa cervical carcinoma cell 
line generated telomerase-repressed hybrids. This demonstrates that multiple telomerase 
regulatory sequences and pathways may function to repress telomerase activity within cells of 
the same cancer type. Importantly, this also raises the possibility that reconstitution of a single 
pathway may be sufficient to confer telomerase repression. 
 Aside from breast and cervical carcinoma cell lines, MMCT-mediated transfer of 
chromosome 3 into a head and neck carcinoma and two renal cell carcinoma cell lines, was 
associated with telomerase repression (Cuthbert et al.,1999, Backsch et al., 2001, Horikawa et 
al., Tanaka et al., 1998, Newbold., 1997). This suggests that chromosome 3 may harbour 
sequences that function to repress telomerase activity within multiple tissue types. Telomerase 
repression within 21NT-chromosome 3 hybrids was associated with loss of hTERT expression, 
but no changes in hTERT promoter activity (Ducrest et al., 2001). Similarly, introduction of 
chromosome 3 into the RCC23 renal cell carcinoma cell line by MMCT was also associated 
with strong hTERT repression. However, hTERT promoter activity was significantly reduced 
within RCC23-chromosome 3 hybrids compared to parental cells. The binding of an unknown 
repressor molecule to an E-box binding element positioned +22-27bp downstream of the hTERT 
transcription start site was found to be responsible for mediating hTERT repression within these 
hybrids. On the other hand, Szutorisz et al., (2003) found that introduction of chromosome 3 
into the 21NT breast cancer cell line was associated with targeted chromatin remodelling of two 
sites within intron 2 of hTERT. Therefore sequences present on chromosome 3 encode or 
regulate the expression of a direct E-box binding repressor molecule and an epigenetic regulator 
of hTERT, which may function as critical repressors of hTERT in different tissue types. 
 Deletion mapping of telomerase positive, segregant 21NT-chromosome 3 hybrids 
within the Cuthbert et al., (1999) study, identified two regions including 3p21.3-p22 and 
3p12.21.1, that may harbour telomerase repressor sequences. Subsequent studies involving the 
transfer of radiation-induced chromosome 3 fragments into 21NT breast cancer cells by MMCT 
identified a single fragment, which was found to repress hTERT expression (Dr. T. Roberts, 
personal communication of unpublished data). Following MMCT-mediated retrotransfer of this 
fragment back into mouse A9 fibroblast cells, sequence-tagged-site (STS) mapping of hybrid 
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clones demonstrated that it was a chimeric fragment containing regions of chromosome 3 short 
and long arm material (Chapter 4.1). A single A9-chromosome 3 fragment hybrid was found to 
have undergone deletion of a 490kb sequence, which maps to 3p21.3 approximately 47Mb from 
the telomere. Unfortunately, both intact and 490kb-deleted fragments could not be successfully 
re-introduced into the 21NT cell line to confirm that this region harboured the putative 
telomerase repressor sequence (Dr. T. Roberts, unpublished data). Nevertheless, this 490kb 
sequence is located within the 3p21.3-p22 region, which is thought to harbour a putative 
telomerase repressor sequence (Cuthbert et al., 1999). Furthermore, studies have shown that the 
3p21-p22 region is a frequent site of loss is heterozygosity (LOH) in breast cancer, which 
suggests the presence of important tumour suppressor genes (Maitra et al., 2001, Martinez et al., 
2001). Within the 490kb sequence, the SET domain-containing 2 (SETD2) gene and an adjacent 
long non-coding RNA sequence FLJ/KIF9, cloned by Dr. T. Roberts in our laboratory, were 
selected for further investigation. SETD2 has been shown to function as a genome-wide 
epigenetic regulator of gene transcription (Sun et al., 2005). In addition, SETD2 has been found 
to be expressed at significantly lower levels within breast cancer tissue relative to normal breast 
tissue samples (Sarakbi et al., 2009, Newbold and Mokbel., 2010).  
 In this project, I carried out gene copy number variation analysis (CNV) of six 
intronic/exonic regions within the SETD2-FLJ genomic locus and found that this region had 
undergone single copy deletion within the 21NT breast cancer cell line. Furthermore, a 
significant reduction in SETD2 and FLJ mRNA levels were observed within 21NT cells relative 
to normal human mammary epithelial (HMEC) strains, which is consistent with the notion that 
that the SETD2-FLJ locus may have undergone LOH within this cell line. CNV analysis of this 
locus within a single hTERT-repressed 21NT-chromosome 3 hybrid clone (H3.5E) and a 
telomerase-positive segregant derivative (H3.5L), that emerged following a crisis event, 
demonstrated that single copy deletions within the SETD2-FLJ genomic locus were associated 
with emergence from crisis and re-activation of hTERT expression. These findings provide 
some evidence to suggest that SETD2 and/or FLJ may play a functional role in hTERT 
repression within the 21NT breast cancer cell line. To investigate the direct effect of SETD2 on 
hTERT transcriptional activity, I transfected mammalian expression vectors containing the 
SETD2 coding region into 21NT cells and examined the effect of transient and stable SETD2 
expression on hTERT expression and telomerase activity. I found that a 3-245 fold increase in 
SETD2 expression was not associated with consistent repression of hTERT transcription or 
telomerase activity within 21NT cells. Furthermore, siRNA-mediated knockdown of SETD2 
within the hTERT repressed H3.5E hybrid clone was also not associated with an observable 
change in hTERT expression. These findings suggest that SETD2 is unlikely to function as a 
negative regulator of hTERT transcription within the 21NT breast cancer cell line. On the other 
hand, stable over-expression of FLJ within 21NT cells was associated with consistent repression 
281 
 
of hTERT expression and telomerase activity. However, curiously, stable empty-vector controls 
were also found to exhibit the same degree of hTERT and telomerase repression, which suggests 
that FLJ may not have been directly responsible for this phenotypic effect. These findings 
provide some evidence to show that SETD2 and FLJ may not function as critical regulators of 
hTERT within breast cancer cells, but clearly further work is needed to explain the unexpected 
result with the empty vector controls in the FLJ gene transfer experiment. 
 Continuing the search for telomerase repressor sequences localized to the 3p21-p22 
region, a review of the literature identified a set of four tumour suppressor genes that have been 
found to suppress breast cancer growth in vitro, and in some cases in vivo, and which have been 
functionally linked to the epigenetic regulation of target gene expression. These included the 
BRCA1 associated protein-1 (BAP1), Ras association domain family 1, transcript variant A 
(RASSF1A), polybromo-1 (Pb1/PBRM1/BAF180) and poly(ADP-ribose) polymerase family 
member 3 (PARP-3). These genes are located within the 3p21.1-p21.3 region, which is within 
or proximal to two discreet regions thought to harbour telomerase repressor sequences (Cuthbert 
et al., 1999). In order to investigate the functional status and tumour suppressive role of 
candidate genes within the 21NT breast cancer cell line and a panel of eight other telomerase 
positive breast cancer cell lines, I examined candidate gene copy number and mRNA levels. The 
majority of breast cancer cell lines, as well as 21NT, were found to have undergone allele loss at 
all candidate gene loci examined including the SETD2-FLJ locus. This suggests that single copy 
deletions of a minimal 5.5Mb region, localized to 3p21.1-p21.3 and encompassing known 
tumour suppressor genes, may be a frequent event in breast cancer cells. Apart from BAP1, the 
expression levels of RASSF1, PBRM1 and PARP-3 candidate genes were found to be 
substantially reduced within a large proportion of the selected breast cancer cell lines, relative to 
normal HMEC strains, which implies that tumour suppressor genes located within this region 
may frequently undergo LOH in breast cancer cells. Studies have shown that forced over-
expression of multiple genes localized to the 3p14.2-p21.3 region including BAP1, RASSF1A, 
PBRM1 and RAR-β2 is associated with significant inhibition of tumour cell growth in vitro 
through induction of cell growth arrest and senescence pathways (Burbee et al., 2001, Ventii et 
al., 2008, Jensen et al.,1998, Xia et al., 2008, Seewaldt et al., 1995). Consistent with these 
observations, I found that over-expression of RASSF1A and PBRM1 was associated with a 
significant decrease in colony size and clonogenic survival of 21NT breast cancer cells 
respectively. Furthermore, Ji et al., (2002) demonstrated that over-expression of wild-type 
FUS1, 101F6, NPRL2 and RASSF1A genes, which were found to be part of a homozygous 
region of deletion within 3p21.3 in lung and breast cancer cells, was associated with inhibition 
of lung tumour cell growth in vitro and in vivo through induction of apoptosis. Therefore, 
several genes localized to chromosome 3p appear to function to suppress tumour growth 
through a variety of mechanisms.  
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 In order to investigate the functional role of individual candidate genes in the 
transcriptional regulation of hTERT and telomerase activity, I transfected mammalian 
expression vectors containing cloned BAP1, RASSF1A and PBRM1 coding regions and 
associated empty vector controls into 21NT cells. hTERT expression and telomerase activity 
levels were then examined within individual 21NT clones that were stably over-expressing each 
candidate gene. Stable over-expression of PARP-3 within 21NT cells was carried out by Dr. T. 
Roberts in our lab. Interestingly, over-expression of both BAP1 and PARP-3 was associated 
with consistent repression of hTERT transcription within 21NT cells. However, telomerase 
activity levels within independent 21NT-BAP1 transfection clones were found to increase to a 
similar level as stable empty vector controls over progressive passages, indicating that over-
expression of BAP1 alone was insufficient to confer stable repression of telomerase or induction 
of cell growth arrest. The telomerase activity and replicative potential of stable 21NT-PARP-3 
transfection clones is currently under investigation in our lab by Dr. T. Roberts. These findings 
provide evidence to suggest that at least two sequences present on chromosome 3p may be 
required for complete repression of hTERT transcriptional activity within breast cancer cells. 
Consistent with these findings, Cuthbert et al., (1999) observed two discrete regions of deletion 
on chromosome 3p within segregant 21NT-chromosome 3 hybrids, which demonstrates that two 
repressor sequences may function to repress telomerase activity and loss of one repressor 
sequence may be sufficient to confer a degree of telomerase re-activation. Interestingly, primary 
breast tumours have been found to undergo discontinuous allele loss of multiple regions of 
chromosome 3p (Maitra et al., 2001). Other cytogenetic studies have shown that there may be at 
least two independent regions of deletion on chromosome 3p within breast tumours involving 
3p13-p14 and 3p24-26 as well as 3p21.3, which indicates that chromosome 3p harbours 
multiple tumour suppressor sequences that may be lost during breast carcinogenesis 
(Matsumoto et al., 1997, Chen et al., 1994). Reverse selection of 21NT-chromosome 3 hybrids 
that had lost the introduced chromosome 3 copy by ganciclovir (GCV) selection within the 
Szutorisz et al., (2003) study, was associated with restoration of an 'open' chromatin 
conformation around intron 2 of hTERT, but not associated with consistent re-activation of 
hTERT expression when compared to parental 21NT cells. Despite ensuring the absence of 
residual, exogenous chromosome 3p14.1-21.2 material within the majority of revertant clones, 
the presence of another repressor sequence outside of this region (perhaps within 3p21.2-p22) 
may have been responsible for the sustained repression of hTERT transcription. Therefore, it is 
possible that one chromosome 3p-encoded sequence functions to regulate the chromatin 
conformation around intron 2 of hTERT, while another sequence(s) may function to prevent 
binding of transcriptional activators of hTERT within or around this region. It would be 
interesting to explore the mechanisms by which BAP1 and PARP-3 function to repress hTERT 
transcription within 21NT cells and whether they function collectively to confer stable 
telomerase repression.  
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 Considering these observations, approaches to identify multiple sequences localized to 
chromosome 3p that function as transcriptional repressors of hTERT within the 21NT cell line, 
may improve our understanding of the mechanisms by which chromosome 3 mediates 
telomerase repression. Furthermore, in addition to protein-coding sequences, multiple non-
coding microRNA (miRNA) sequences on chromosome 3p have been found to undergo 
frequent copy number alterations and aberrant expression in breast cancer (Qian et al., 2012). In 
2009, Miura et al., demonstrated that over-expression of the RGM249 precursor miRNA 
sequence localized to chromosome 10p15.3, was associated with strong transcriptional 
repression of hTERT within A172 glioblastoma and HMc-Li7 hepatocellular carcinoma cell 
lines, which demonstrates that non-coding sequences may also function as critical regulators of 
hTERT. Therefore, approaches to identify regions on chromosome 3p associated with strong 
hTERT repression together with current genome mapping data, may facilitate the identification 
of a series of candidate regulatory sequences.  
 In 2010, Abe et al., used chromosome engineering to generate a variety of chromosome 
3 fragments lacking defined regions, to narrow the search for sequences on chromosome 3p that 
function to repress hTERT within the RCC23 renal cell carcinoma cell line. To achieve this, an 
intact chromosome 3 copy was first transferred by MMCT into chicken DT40 cells, which 
exhibit high homologous recombination frequencies. Together with a puromycin resistance 
gene, vector constructs containing sequences homologous to certain chromosome 3 regions 
were then transfected into DT40-chromosome 3 cells by electroporation to generate three 
selectable truncated fragments by homologous recombination; #3delp24-ter, #3delp22-pter and 
#3delp21.3-pter. Fragments were transferred by MMCT into RCC23 cells transfected with 
exogenous hTERT (RCC23-exohTERT) to permit ongoing proliferation. Both #3delp24-ter and 
#3delp22-pter fragments were found to repress endogenous hTERT expression, whereas RCC-
exohTERT clones containing #3delp21.3-pter fragment were found to exhibit the same level of 
endogenous hTERT expression as parental cells. Through STS-mapping of chromosome 3 
fragments, a 7Mb region within 3p21.3 was found to be responsible for the observed repression 
of endogenous hTERT. Therefore, by exploiting the high homologous recombination efficiency 
of chicken DT40 cells to generate various truncated chromosome 3 fragments lacking defined 
regions, Abe et al., (2010) has demonstrated a novel approach for mapping chromosomal 
regions responsible for hTERT repression. According to Abe et al., (2010), future studies aim to 
use this method to enable positional cloning of telomerase repressor sequences, which will then 
be inserted into a human artificial chromosome (HAC) vector. Unlike conventional gene 
delivery vectors, HACs have the capacity to incorporate large genomic loci together with 
associated regulatory elements to permit physiological expression of target genes within 
recipient cells (Reviewed by Oshimura et al., 2015). Furthermore, HAC vectors are maintained 
episomally, which prevents insertional mutagenesis of host genomic material. In 2009, Hoshiya 
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et al., demonstrated the potential therapeutic applications of HAC vectors by cloning the 2.4Mb 
human dystrophin gene into a HAC vector, which was stably maintained and expressed within 
chimeric mice. Therefore, chromosome engineering could be an effective approach for 
identifying and reconstituting critical hTERT repressor sequences within human cancer cells.  
 Some researchers argue that the identification of rare molecular events that occur to 
permit hTERT de-repression and telomerase re-activation within human carcinomas is difficult 
due to the high level of genomic instability exhibited by tumour cells (Garbe et al., 2014). It is 
thought that genomic instability caused by ongoing telomere shortening as cells approach 
replicative senescence, is responsible for generating errors required for telomerase re-activation 
as well as 'passenger' errors that are frequently observed within carcinomas (Garbe et al., 2007, 
Garbe et al., 2014). Therefore, the development of in vitro models of human epithelial cell 
immortalization have provided an alternative approach to understand the mechanisms by which 
hTERT becomes deregulated during human carcinogenesis. According to the current model, 
normal finite lifespan human mammary epithelial cells (HMEC) encounter two senescence 
barriers to indefinite proliferation; the stress-associated stasis barrier, and the telomere 
dysfunction-associated replicative senescence or crisis barrier (Stampfer and Yaswen., 2002). 
Overcoming the stasis barrier is associated with inactivation of the p16
INK4A
/pRb pathway and 
has been found to occur spontaneously in vitro (Huschtscha et al., 1998, Brenner et al., 1998, 
Romanov et al., 2001). On the other hand, spontaneous emergence from replicative senescence 
has never been found to occur in vitro (Stampfer and Yaswen., 2002). However, abrogation of 
p53 function within post-stasis HMECs is associated with the rare emergence of immortal 
clones from crisis (Gao et al., 1996, Gollahan and Shay., 1996, Van Der Haegen and Shay., 
1993).  
 In order to study the molecular events that occur during the early stages of HMEC 
immortal transformation, my Brunel colleague Dr. H. Yasaei, generated post-stasis and 
immortal variants of a single HMEC strain derived from reduction mammoplasty tissue of a 
healthy female patient. This was achieved by abrogating the function of critical effectors of 
stasis and replicative senescence barriers, p16 and p53. Immortal clones that emerged from 
crisis, were found to express hTERT transcripts and telomerase activity. Taking into account the 
findings presented by Cuthbert et al., (1999), demonstrating the presence of hTERT repressor 
sequences on chromosome 3p, I investigated structural alterations within this region at each 
stage of immortal transformation. By comparing the copy number variation (CNV) of six 
genomic loci/regions spanning 3p12.1-p26.1 within finite lifespan pre-stasis and post-stasis 
HMEC cell strains and immortal variants, I demonstrated that single copy allele loss on 
chromosome 3p is a frequent, clonal event that is specifically associated with emergence from 
crisis and hTERT de-repression. Subsequent high density, genome-wide single nucleotide 
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polymorphism (SNP) array analysis of the same samples confirmed the presence of single copy 
deletions on chromosome 3p and identified a minimal common region of deletion within 
3p14.2-p22 (Dr. H. Yasaei, personal communication of unpublished data). These findings 
demonstrate that allele loss on chromosome 3p may be an early event in breast tumorigenesis 
that is associated with immortal transformation. Consistent with the findings presented by 
Cuthbert et al., (1999), these results also provide additional evidence to suggest that critical 
hTERT regulatory sequences may be present on chromosome 3p. 
 The recent development of pathologically relevant models of HMEC immortal 
transformation that do not involve clonal bypass of senescence barriers, have demonstrated that 
high levels of genomic instability, including gene copy number losses on chromosome 3p, are 
not absolutely required for complete immortal transformation (Garbe et al., 2014). It is thought 
that in some instances, epigenetic changes may be responsible for de-regulation of hTERT 
expression during immortalization. Hypermethylation and silencing of tumour suppressor genes 
localized to chromosome 3p have been observed within pre-neoplastic breast lesions, non-
tumorigenic breast cancer cell lines and primary breast carcinomas, which demonstrates that 
epigenetic alterations within this region may occur early in breast carcinogenesis (Damman et 
al., 2001, Zöchbauer-Müller et al., 2001, Dumont et al., 2009). Therefore, it would certainly be 
of interest to investigate both global and chromosome 3-specific DNA methylation changes and 
altered histone modification patterns within in vitro models of HMEC immortalization.  
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7.1 SUMMARY AND CONCLUSION 
 De-repression of hTERT and telomerase re-activation is thought to be a critical event in 
human cancer development and is the predominant mechanism by which human tumour cells 
maintain their indefinite growth capacity. The functional inactivation of critical telomerase 
repressor sequences during the early stages of cancer development is thought to be responsible 
for telomerase re-activation and cellular immortalization. Gene transfer studies involving the 
introduction of single intact human chromosomes by microcell-mediated monochromosome 
transfer (MMCT) into human tumour cells demonstrate that multiple regulatory sequences exist 
throughout the genome, which may function to repress telomerase in a tissue-specific manner. 
Previously, our group has shown that transfer of normal chromosome 3 by MMCT into the 
21NT primary breast cancer cell line is associated with strong telomerase repression and cell 
growth arrest of the majority of hybrid clones (Cuthbert et al., 1999). Regulatory sequences 
responsible for the observed telomerase repression are thought to reside within 3p21.3-p22 and 
3p12-21.1. Subsequent studies have shown that chromosome 3p-encoded telomerase repressor 
sequences mediate their function through transcriptional repression of hTERT (Ducrest et al., 
2001). This was found to be due, in part, to chromatin remodelling at two sites within intron 2 
of hTERT (Szutorisz et al., 2003). In this project, I have shown that transfer of an intact copy of 
human chromosome 17, as well as chromosome 3, by MMCT into the 21NT breast cancer cell 
line is also associated with consistent repression of telomerase activity, which provides some 
evidence to suggest that multiple independent pathways of hTERT regulation may be inactivated 
within the same cancer type.  
 Attempts to achieve positional cloning of hTERT repressor sequences on chromosome 
3p, identified a single candidate gene SETD2 and a neighbouring long non-coding RNA 
sequence FLJ localized to 3p21.3 (Dr. Roberts, unpublished data). By examining the effect of 
forced SETD2 and FLJ expression within 21NT cells and the consequence of siRNA-mediated 
knockdown of SETD2 within a single hTERT-repressed 21NT-chromosome 3 hybrid, I have 
provided some evidence that neither candidate gene functions as a regulator of hTERT 
transcription. Interrogation of relevant literature identified a set four candidate telomerase 
regulatory genes including BAP1, RASSF1A, PBRM1 and PARP-3, located within the 3p21.1-
p21.3 region that have been shown to play a functional role in the epigenetic regulation of target 
gene transcription. Using mammalian expression vectors containing candidate gene cDNA, my 
colleague Dr. Roberts and I have demonstrated that forced over-expression of BAP1 and PARP-
3 within 21NT cells is associated with consistent, but not necessarily sustained, repression of 
hTERT transcription. Therefore, at least two sequences may be present on chromosome 3p that 
function together to regulate hTERT within breast cancer cells.  
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 Using an in vitro model of HMEC immortalization developed by my colleague Dr. 
Yasaei, I have shown that single copy deletions on chromosome 3p are a frequent clonal event 
that is specifically associated with hTERT de-repression and immortal transformation. 
Subsequent single nucleotide polymorphism (SNP) array analysis of immortal HMEC variants 
identified a minimal common region of deletion encompassing 3p14.2-p22 (Dr. Yasaei, 
unpublished data). These findings provide additional evidence to show that critical hTERT 
repressor sequences may be present on chromosome 3p, which may be lost as an early event 
during breast carcinogenesis.   
 Despite efforts to achieve positional cloning of critical hTERT repressor sequences in 
different cancer types, the key molecular players and mechanisms by which they function to 
repress hTERT transcription remain unclear. The development of innovative chromosome 
engineering techniques, together with pathologically relevant in vitro models of human 
epithelial cell immortalization, should advance our understanding of this fundamental aspect of 
human carcinogenesis and identify novel therapeutic targets for cancer prevention or treatment. 
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7.2 FUTURE WORK 
7.2.1 INVESTIGATING THE ROLE OF SETD2 IN BREAST CANCER 
7.2.1.1 Background 
 The histone 3 lysine 36 (H3K36) trimethyltransferase enzyme, SET domain containing 
2 (SETD2), has recently been shown to play a functional role in maintaining genome integrity 
in human cells by regulating homologous recombination (HR)-mediated repair of DNA double 
strand breaks (DSB) and DNA mismatch repair pathways (Pfister et al.,2014, Li et al., 2013). In 
addition, SETD2 has been found to interact with p53 in breast cancer cells and regulate the 
expression of genes involved in the DNA damage response pathway through nucleosome 
positioning and chromatin accessibility in clear cell renal carcinomas (ccRCC) (Xie et al., 2008, 
Simon et al., 2013). In 2009, Sarakbi and colleagues demonstrated that SETD2 mRNA levels 
are significantly lower within breast tumours than normal breast tissue samples and low levels 
of SETD2 expression are associated with more progressive disease (Sarakbi et al., 2009). 
Furthermore, SETD2 has been found to be mutated within a significant proportion (12%-22%) 
of multiple cancer types including acute mixed lineage-rearranged leukaemia (MLL) and clear 
cell renal carcinoma (ccRCC) (Zhu et al., 2014, Fontebasso et al., 2013, Mar et al., 2014, 
Hakimi et al., 2013). Loss of SETD2 function is associated with RNA processing defects, 
increased spontaneous mutation frequency, microsatellite instability and reduced HR-mediated 
repair of DSB, which may contribute to genetic instability and drive tumorigenesis (Pfister et 
al., 2014, Li et al.,2014, Simon et al.,2013). These studies provide evidence to suggest that 
SETD2 plays an important tumour suppressive role in human cells. 
   Taking the above observations into account, it was therefore surprising to find in my 
project work that forced overexpression of SETD2 within the oestrogen (ER) and progesterone 
receptor (PgR)-negative, HER2-positive breast cancer cell line 21NT, was associated with a 
significant increase in clonogenic survival when compared with empty vector controls (Chapter 
4.3.2.3). Furthermore, according to the Kaplan Meier Plotter (KPM) online survival analysis 
program, breast cancer patients with ER-negative, PgR-negative and HER2-positive tumours or 
ER-negative and p53-mutant tumours that express high levels of SETD2 mRNA, have 
significantly worse relapse free survival rates compared with those that display low levels of 
SETD2 expression (Chapter 4.4, Gyorffy et al., 2010). These findings are the first to suggest 
that SETD2 may play an oncogenic role in certain molecular subtypes of breast cancer.  
 Multiple anticancer strategies, such as ionizing radiation and chemotherapeutic agents, 
rely on the generation of toxic DNA lesions or DSBs within the genome of cancer cells in order 
to activate cell death signalling pathways (reviewed by Helleday., 2010). During S and G2 
phases of the cell cycle, these lesions can be substrates for HR-mediated repair (Saleh-Gohari 
and Helleday., 2004). HR-defective cancer cells can be sensitive to chemotherapeutic agents 
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that cause DNA replication stress, such as topoisomerase I/II inhibitors and antimetabolites, 
which are used for the treatment of HER2-positive, ER-negative breast tumours (Chapter 
1.2.5.3, Helleday, 2010). Conversely, genetic reversion of mutations and upregulation of genes 
involved in HR-mediated repair pathways, have been associated with resistance to replication 
stress-inducing anticancer agents. For instance, demethylation of the gene that encodes Fanconi 
anemia complementation group F (FANCF), which is involved in the FANC-BRCA DNA 
repair pathway, is associated with resistance to cisplatin in ovarian tumours (Taniguchi et al., 
2003). Independent studies have shown that SETD2 plays an important role in maintaining 
genome stability through the regulation of DNA repair pathways (Pfister et al., 2014, Li et 
al.,2014, Simon et al.,2013). It is therefore possible that the observed decrease in relapse-free 
survival rates within breast cancer patients with HER2-positive and hormone receptor-negative 
tumours that express high levels of SETD2 mRNA, could be linked to the more efficient repair 
of DNA lesions introduced by genotoxic anticancer agents. Future work would aim to determine 
whether SETD2 expression within HER2-positive, hormone receptor-negative breast tumours is 
a predictive marker of patient survival and response to chemotherapy and/or radiotherapy and 
investigate the molecular mechanism(s) by which SETD2 functions to confer decreased relapse-
free survival in breast cancer patients with this molecular subtype. 
7.2.1.2 Future Experimental Approaches 
 As shown in Chapter 4, stable overexpression of SETD2 within the tumorigenic, HER2-
positive and hormone receptor-negative 21NT breast cancer cell line is associated with a 
significant increase in clonogenic survival compared with empty vector controls. These 
preliminary findings suggest a putative oncogenic role of SETD2 in breast cancer cells. 
However they provide no evidence to show that higher SETD2 expression is associated with an 
increase in the tumorigenic potential of 21NT cells. One approach to investigate this further 
would be to generate mouse xenograft models of 21NT cell-derived tumours (as well as other 
HER2-positive, hormone receptor-negative breast tumours). By assessing tumour growth within 
immune-deficient, athymic nude mice following injection of stable 21NT-SETD2 and 21NT-
empty vector control transfection clones, it should be possible to examine the role of SETD2 on 
the tumorigenic potential of 21NT cells in vivo. In addition, the same mouse xenograft models 
could be employed to test the hypothesis that high SETD2 expression is associated with 
resistance to radiotherapy or chemotherapy and decreased survival, by examining the effect of 
SETD2 expression on tumour growth and host survival in response to treatment with genotoxic 
agents used currently in the treatment of HER2-positive, hormone receptor-negative breast 
tumours (e.g. radiation, cyclophosphamide and antimetabolites).  
 As demonstrated by Pfister et al., (2014), siRNA-mediated depletion of SETD2 within 
U2OS osteosarcoma cells is associated with a reduction in HR-mediated DNA damage repair 
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following irradiation compared with non-targeting controls. This was demonstrated by a 
reduction‎in‎replication‎protein‎A‎(RPA)‎and‎RAD51‎foci‎and‎delayed‎removal‎of‎γ-H2AX foci 
within SETD2-depleted cells. Therefore, in order to investigate whether the functional role of 
SETD2 as a regulator of HR-mediated DNA repair is associated with resistance to radiotherapy 
and/or chemotherapeutic agents for HER2-positive, hormone receptor-negative breast cancer 
cells, the effect of forced SETD2 expression on cell growth and the number of RAD51 and RPA 
foci formed following treatment of 21NT cells with irradiation and antimetabolites (e.g. 
methotrexate and fluorouracil) could be examined.  
 
7.2.2 NARROWING THE SEARCH FOR HTERT REPRESSOR SEQUENCES ON 
CHROMOSOME 3P IN BREAST CANCER CELLS 
7.2.2.1 Background 
 During the search for a sequence localised to human chromosome 3p that functions to 
regulate hTERT in breast cancer cells, I found that stable overexpression of BAP1 (3p21.1) 
within the 21NT breast cancer cell line was associated with a consistent but transient repression 
of telomerase activity (Chapter 5.3.2.1). In addition, stable overexpression of PARP-3 (3p21.2) 
has recently been associated with repression of hTERT transcription within the same breast 
cancer cell line (Dr. T. Roberts, unpublished data). These findings provide some evidence to 
suggest that multiple sequences localised to chromosome 3p may function to repress hTERT 
transcription and telomerase activity in breast cancer cells. In addition to the 21NT breast cancer 
cell line, a human head and neck carcinoma cell line, RCC23 and KC12 renal cell carcinoma 
(RCC) and the HeLa cervical carcinoma cell lines, introduction of a normal copy of human 
chromosome 3 into the HSC3 human oral squamous cell carcinoma cell line by microcell-
mediated monochromosome transfer (MMCT), has recently been found to produce hTERT-
repressed hybrids (Nishio et al., 2015, Cuthbert et al., 1999, Tanaka et al., 1998, Horikawa et 
al., 1999, Backsch et al., 2001). Consistent with the notion that multiple sequences regulate 
hTERT expression, whole cell fusion of HSC3 and RCC23 cell lines generated a series of 
hTERT-repressed hybrids, indicating that multiple telomerase regulatory sequences may be 
present on human chromosome 3. 
7.2.2.2 Future Experimental Approaches 
 In order to narrow the search for sequences on chromosome 3 that function to regulate 
hTERT in breast cancer cells, high resolution genome mapping techniques such as genotyping 
arrays or targeted genome sequencing technologies could be employed to identify, map and 
align common regions of deletion on chromosome 3 within a series of telomerase-positive, 
segregant 21NT-chromosome 3 hybrid clones and early-passage, immortal human mammary 
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epithelial cell (HMEC) clones that have emerged from crisis. As demonstrated in Chapter 6, 
single nucleotide polymorphism (SNP) array analysis of individual, immortal HMEC clones 
that had emerged from crisis following targeted abrogation of the critical effectors of stasis and 
replicative senescence (p16 and p53 respectively), revealed the presence of a common 33Mb 
region of deletion encompassing 3p14.2-p22 within four out of six clones (Chapter 6.3.2). 
Interestingly, this region is thought to harbour putative telomerase repressor sequences in breast 
and renal cell carcinoma cell lines (Cuthbert et al., 1999, Szutorisz et al., 2003, Horikawa et al., 
1998, Tanaka et al., 1998, Tanaka et al., 2005, Abe et al.,2010). The remaining two immortal 
clones were not found to have undergone genomic deletions on chromosome 3p. However, it is 
possible that these clones underwent small, discreet deletions, insertions or point mutations, that 
were not identified by the SNP array used in this study (Chapter 6.3.2). Therefore, in order to 
obtain a detailed map of structural alterations on chromosome 3p within these HMEC clones as 
well as prospective immortal, post-crisis HMEC clones or segregant 21NT-chromosome 3 
hybrids, the use of next generation DNA sequencing (NGS) technology or genotyping arrays 
that detect a greater number of markers (SNP, copy number variants and indels) should be 
considered. 
 An alternative approach to identify critical regulators of hTERT localised to human 
chromosome 3p in breast cancer cells would be to compare the expression levels of 
chromosome 3p-encoded genes within telomerase-repressed 21NT-chromosome 3 hybrids and 
telomerase-positive, segregant 21NT-chromosome 3 hybrids using transcriptome profiling 
technology. In 2011, Qi and colleagues compared the expression of around 22,000 transcripts 
by microarray analysis within telomerase-repressed and segregant, telomerase-positive B16F10-
human chromosome 5 microcell hybrids and parental mouse melanoma B16F10 cells (Qi et al., 
2011). This led to the identification of PITX1 as a repressor of hTERT promoter activity in 
mouse B16F10 and human A2058 melanoma cell lines. Using a similar approach, it may be 
possible to identify candidate hTERT repressor sequences in breast cancer cells by comparing 
the expression of genes localised to chromosome 3p in telomerase-positive segregant 21NT-
chromosome 3 hybrids and immortal, post-crisis HMEC clones, with telomerase-repressed 
21NT-chromosome 3 hybrids and pre-crisis HMECs. The recent identification of microRNA 
(miRNA) sequences that regulate hTERT within colorectal cancer (miR-21), head and neck 
squamous cell carcinoma (miR-512-5p) and gastric cancer (miR-1182, miR-1207-5p, miR-
1266) cells, would suggest that future comparative gene expression analyses should also 
incorporate known, non-protein coding sequences present on chromosome 3 (Li et al., 2015, 
Yang et al., 2015, Zhang et al., 2015, Chen et al., 2014). 
 To investigate the functional role of candidate regions or sequences localised to human 
chromosome 3p in the transcriptional regulation of hTERT in breast cancer cells, the DNA 
sequence of the region of interest could be cloned into a human artificial chromosome (HAC) 
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vector and introduced into telomerase-positive breast cancer cell lines and/or post-crisis HMEC 
clones by MMCT. Changes in hTERT transcription and telomerase activity within breast cancer 
cell lines or post-crisis HMECs following introduction of the candidate region, could then be 
examined relative to parental cell lines. HACs are exogenous, linear mini-chromosomes that 
possess functional centrosomes and artificial telomeres, and have the ability to replicate and 
segregate autonomously within the cell (reviewed by Oshimura et al., 2015). These vectors can 
be engineered using a telomere-associated chromosome fragmentation approach (top-down) or a 
de novo approach (bottom-up) using cloned chromosomal fragments. HAC vectors containing 
up to 10Mb of human DNA have so far been produced using both methods (Oshimura et al., 
2015).  
 With the aim of investigating the role of candidate sequences in the transcriptional de-
repression of hTERT during HMEC immortalization, targeted genome editing systems, such as 
the CRISPR/Cas9 system, could be utilised to inactivate specific candidate sequences on 
chromosome 3p within post-stasis, telomerase-negative HMEC cell strains. Recently, Weber 
and colleagues used the CRISPR/Cas9 system to carry out targeted mutagenesis of multiple 
sequences within adult mouse liver cells, in order to identify the genetic drivers of 
hepatocellular carcinoma and intrahepatic cholangiocarcinoma (Weber et al., 2015). The use of 
genome editing approaches to carry out targeted deletion of candidate sequences on 
chromosome 3 within telomerase-repressed, post-stasis HMECs, would confirm whether loss of 
these sequences is a critical event that confers transcriptional de-repression of hTERT and 
bypass of replicative senescence during the immortal transformation of normal HMECs. 
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